isoproterenol has been researched along with Cardiomegaly in 765 studies
Isoproterenol: Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on the heart, bronchi, skeletal muscle, alimentary tract, etc. It is used mainly as bronchodilator and heart stimulant.
isoprenaline : A secondary amino compound that is noradrenaline in which one of the hydrogens attached to the nitrogen is replaced by an isopropyl group. A sympathomimetic acting almost exclusively on beta-adrenergic receptors, it is used (mainly as the hydrochloride salt) as a bronghodilator and heart stimulant for the management of a variety of cardiac disorders.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Cardiac hypertrophy is accompanied by increased myocardial oxidative stress, and whether naringenin, a natural antioxidant, is effective in the therapy of cardiac hypertrophy remains unknown." | 8.31 | Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway. ( He, B; He, Y; Li, Y; Xia, T; Zeng, C; Zhang, C, 2023) |
| "Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 8.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
| " No studies were conducted earlier on the effects of (-) epicatechin (EC) on tachycardia, cardiac hypertrophy, and inflammation in MI." | 8.12 | Preventive effects of (-) epicatechin on tachycardia, cardiac hypertrophy, and nuclear factor- κB inflammatory signaling pathway in isoproterenol-induced myocardial infarcted rats. ( Ponnian, SMP, 2022) |
| " Rats were induced MI by isoproterenol (100 mg/kg body weight) and then treated with valencene and cardiac sensitive markers, cardiac hypertrophy, oxidative stress, markers of inflammation, nuclear factor- κB inflammatory pathway, and myocardial infarct size was estimated/determined." | 8.12 | Valencene post-treatment exhibits cardioprotection via inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size in isoproterenol-induced myocardial infarcted rats; A molecular study. ( Berlin Grace, VM; Shervin Prince, S; Stanely Mainzen Prince, P, 2022) |
| " In the present study, possible drug combinations were screened and the mechanism of the combinations against cardiac hypertrophy was examined within 1,8-cineole, β-caryophyllene, linalool, and β-pinene." | 8.12 | Combination of 1,8-cineole and beta-caryophyllene synergistically reverses cardiac hypertrophy in isoprenaline-induced mice and H9c2 cells. ( Bai, C; Li, Q; Liu, M; Ma, Q; Wei, C; Yu, L; Zhen, D, 2022) |
| "Gallic acid has been reported to mitigate cardiac hypertrophy, fibrosis and arterial hypertension." | 8.12 | Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg. ( Bai, L; Han, X; Jeong, MH; Kee, HJ, 2022) |
| "To study the effect of sinomenine (Sin) on isoproterenol (Iso, β-agonist)-induced cardiac hypertrophy (CH), we set up four mouse groups: control, Iso model, Iso+metoprolol (Met, β blocker) 60 mg/kg and Iso+Sin 120 mg/kg." | 8.02 | Protective effect of sinomenine on isoproterenol-induced cardiac hypertrophy in mice. ( Chen, J; Fang, P; Li, L; Tao, H; Zhang, C, 2021) |
| "Cardiac hypertrophy was induced in C57BL/6 mice by subcutaneous injection of isoproterenol (ISO) for two weeks." | 8.02 | Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol- induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice. ( Fan, W; Hu, Z; Wu, C; Wu, H; Wu, J; Wu, S; Wu, X; Yang, L; Yang, X; Zhang, B; Zhang, J, 2021) |
| " The study aims to understand the effect of arbutin on isoproterenol (ISO)-induced cardiac hypertrophy in mice." | 7.96 | Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice. ( Alavala, S; Jerald, MK; Mir, SM; Nalban, N; Sangaraju, R; Sistla, R, 2020) |
| " However, the therapeutic potential of PQQ for isoproterenol hydrochloride (Iso)‑induced cardiac hypertrophy has not yet been explored, at least to the best of our knowledge." | 7.96 | Pyrroloquinoline quinone attenuates isoproterenol hydrochloride‑induced cardiac hypertrophy in AC16 cells by inhibiting the NF‑κB signaling pathway. ( Dai, Z; Jin, Y; Shen, J; Wen, J; Zhao, X; Zhou, Y, 2020) |
| "A previous study by our group demonstrated a protective role of the neuropeptide secretoneurin (SN) in DL‑isoproterenol hydrochloride (ISO)‑induced cardiac hypertrophy in mice." | 7.96 | iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice. ( Chen, H; Jiang, W; Liu, X; Wu, M; Yu, C; Zhang, J, 2020) |
| "A rat model of cardiac hypertrophy was constructed by isoproterenol (ISO) intraperitoneal injection (i." | 7.96 | Songling Xuemaikang Capsule inhibits isoproterenol-induced cardiac hypertrophy via CaMKIIδ and ERK1/2 pathways. ( Fan, D; Pan, W; Qi, J; Tan, Y; Wu, J; Xu, W; Yu, J; Zhang, M, 2020) |
| " Long non-coding RNA myocardial infarction associated transcript (LncMIAT) is closely related to heart disease, and here, we were the first to discover that LncMIAT may act as an miR-144 sponge in isoproterenol-induced cardiac hypertrophy." | 7.96 | The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy. ( Bai, L; Chen, L; Fan, Y; Gan, M; Guo, Z; Hao, X; Jiang, D; Li, X; Shen, L; Tan, Y; Zhang, S; Zhu, L, 2020) |
| "Our results suggest that diazoxide blocks oxidative stress and reverses cardiac hypertrophy." | 7.96 | Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity. ( Araújo, MTS; Caldas, FRL; Coelho, BN; David, CEB; de Lacerda Alexandre, JV; Facundo, HT; Kowaltowski, AJ; Lucas, AMB; Ponte Viana, YI; Varela, ALN, 2020) |
| "To investigate the effect of acupuncture at PC6 on cardiac hypertrophy in isoproterenol (ISO)-treated mice." | 7.91 | Acupuncture at PC6 prevents cardiac hypertrophy in isoproterenol-treated mice. ( Du, Q; Guo, Y; Hou, Y; Yang, F; Zhang, M; Zhu, P, 2019) |
| "Rat and H9C2 cell models of cardiac hypertrophy were induced by isoproterenol and angiotensin II, respectively, followed by TUPS treatment." | 7.91 | Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition. ( Chen, Y; Liang, J; Pan, R; Wu, F; Wu, G; Wu, Z; Xu, W; Yan, W; Zhang, H; Zhang, K, 2019) |
| " As evident from the HW/BW ratio, HW/TL ratio, echocardiography, and histopathology, hypertrophic responses induced by isoproterenol (Iso; 5 mg/Kg body weight, subcutaneous) were blocked by Apo (10 mg/Kg body weight, intraperitoneal)." | 7.88 | Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat. ( Goswami, SK; Prasad, A; Saleem, N, 2018) |
| "To investigate the effect of dimethyl fumarate (DMF) on Toll-like receptor (TLR) signalling pathway in isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 7.88 | Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model. ( Ahmed, AA; Ahmed, AAE; El Morsy, EM; Nofal, S, 2018) |
| " The aim of the present study was to investigate the role of curcumin in regulating autophagy and mammalian target of rapamycin (mTOR) signaling in isoproterenol-induced cardiac hypertrophy and fibrosis in the rat." | 7.88 | Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. ( Li, CL; Liu, JX; Liu, R; Wang, JR; Yang, J; Zhang, HB, 2018) |
| "We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy." | 7.85 | Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017) |
| " Here, we investigated the effect of CaMKII inhibition in isoproterenol (ISO)-induced arrhythmias in hypertrophic mice." | 7.85 | CaMKII inhibition reduces isoproterenol-induced ischemia and arrhythmias in hypertrophic mice. ( Cheng, J; Feng, Y; Wang, Y; Wei, B, 2017) |
| " We investigated the role of Ca2+-mobilizing second messengers, NAADP and cADPR, in the cardiac hypertrophy induced by β-adrenergic stimulation by isoproterenol." | 7.83 | Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-Adrenergic Stimulation. ( Gul, R; Im, SY; Jang, KY; Kim, D; Kim, UH; Ko, JK; Lee, SH; Nam, TS; Park, DR; Shawl, AI, 2016) |
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 7.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "This study evaluates the protective effects of 7-hydroxycoumarin (7-HC) on dyslipidemia and cardiac hypertrophy in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 7.83 | Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats. ( Jagadeesh, GS; Nagoor Meeran, MF; Selvaraj, P, 2016) |
| "In this study, we evaluated ET effects on isoproterenol (ISO)-induced cardiac hypertrophy in female mice." | 7.81 | Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice. ( Li, J; Liu, J; Lu, P; Qi, Z; Ren, J; Tian, W; Yang, L; Zhu, M, 2015) |
| "We previously reported that Astragaloside IV (ASIV), a major active constituent of Astragalus membranaceus (Fisch) Bge protects against cardiac hypertrophy in rats induced by isoproterenol (Iso), however the mechanism underlying the protection remains unknown." | 7.81 | Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis. ( Lu, M; Luan, A; Tang, F; Wang, H; Yang, J; Yang, Y; Zhang, J; Zhang, S, 2015) |
| " The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 7.81 | Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. ( Al-Manee, RZ; Al-Oteibi, MM; Al-Rasheed, NM; Al-Shareef, SA; Hasan, IH; Mahmoud, AM; Mohamad, RA, 2015) |
| "This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy." | 7.81 | Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015) |
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 7.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| "We constructed a miRNA reporter imaging system to monitor miR-22 expression in isoproterenol-induced cardiac hypertrophy repetitively and noninvasively." | 7.80 | In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. ( Bu, L; Cheng, Z; Dong, D; Shen, B; Tu, Y; Wan, L; Yin, Z; Zhao, D, 2014) |
| "Our data suggest that tamoxifen produces beneficial effects on cardiac hypertrophy and hence may be considered as a preventive measure for cardiac hypertrophy." | 7.80 | Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. ( Desai, VJ; Patel, BM, 2014) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 7.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| " However, little is known about the role of Rapa in cardiac hypertrophy induced by isoproterenol and its underlying mechanism." | 7.80 | Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-κB activation. ( Cao, W; Chen, X; Chen, Y; Gao, Y; Liu, P; Yue, Z; Zeng, S; Zhang, L; Zou, J, 2014) |
| " Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury." | 7.79 | The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. ( Almeida, AP; Beiman, M; Carvalho, MB; Cohen, Y; Cojocaru, G; Ferreira, AJ; Ianzer, D; Marques, FD; Peluso, AA; Rotman, G; Santos, RA; Savergnini, SQ; Silva, GA, 2013) |
| "Although inadequate intake of essential nutrient choline has been known to significantly increase cardiovascular risk, whether additional supplement of choline offering a protection against cardiac hypertrophy remain unstudied." | 7.79 | Choline protects against cardiac hypertrophy induced by increased after-load. ( Du, Z; Wang, C; Wang, Y; Wu, J; Zhang, Y; Zhao, Y; Zhu, W, 2013) |
| "The present study aimed at using a proteomics based approach to: a) analyze and contrast the proteome of the healthy and isoproterenol induced hypertrophied hearts and b) identify potential biomarkers for diagnosis of cardiac hypertrophy." | 7.79 | A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. ( Banerjee, SK; Bhadra, MP; Chowdhury, D; Khatua, TN; Saxena, P; Tangutur, AD, 2013) |
| " This study aims to evaluate the protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and alterations in lipoproteins and electrocardiogram in isoproterenol-induced myocardial infarcted rats." | 7.79 | Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. ( Mainzen Prince, PS; Roy, SJ, 2013) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 7.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 7.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "To investigate the therapeutic effect of PI3Kgamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by Isoproterenol in rats." | 7.77 | [The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats]. ( Hu, XH; Jiang, W; Li, Y; Qing, Y; Song, LF; Tong, QY; Wu, XH, 2011) |
| "Isoproterenol-induced cardiac hypertrophy in mice has been used in a number of studies to model human cardiac disease." | 7.75 | Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. ( Errami, M; Galindo, CL; Garner, HR; Kumar, NM; Li, J; McCormick, JF; McIver, LJ; Olson, LD; Pham, TQ; Skinner, MA; Watson, DA, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 7.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Isoproterenol treatment of Brown Norway and Lewis rats (high and low plasma angiotensin-I-converting enzyme activity, respectively) results in similar cardiac hypertrophy but higher cardiac fibrosis in Brown Norway rats." | 7.74 | Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism. ( Copaja Soto, M; Díaz-Araya, G; Jalil, JE; Lavandero, S; Lijnen, P; Ordenes, GE; Paz Ocaranza, M; Saldaña, A; Valenzuela, R; Vio, C; Vivar Sanchez, R, 2008) |
| "Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy." | 7.74 | Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. ( Anderson, M; Larson, D; Moore, D, 2008) |
| "To study whether urotensin II (UII), a potent vasoconstrictive peptide, is involved in the development of cardiac hypertrophy and fibrogenesis of rats induced by isoproterenol (ISO)." | 7.74 | Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. ( Bu, DF; Li, YG; Liu, BG; Pang, YZ; Tan, XR; Tang, CS; Wang, DM; Wei, RH; Zhang, YG, 2007) |
| "Impaired leptin signalling in obesity is increasingly implicated in cardiovascular pathophysiology." | 7.73 | Leptin repletion restores depressed {beta}-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. ( Barouch, LA; Berkowitz, DE; Emala, CW; Gonzalez, DR; Hare, JM; Khan, SA; Lee, K; Minhas, KM; O'Donnell, CP; Phan, AC; Raju, SV; Saliaris, AP; Skaf, MW; Tejani, AD, 2005) |
| "To examine the negative regulation role of PTEN in isoproterenol-induced cardiac hypertrophy by testing the expression of PTEN mRNA and protein and to explore the effects of captopril (Cap) on PTEN expression." | 7.73 | [PTEN negatively regulates isoproterenol-induced cardiac hypertrophy and effects of captopril on PTEN expression]. ( Tian, Y; Wang, J; Yu, LJ; Zhou, YZ; Zhu, SJ, 2005) |
| "Gene expression of heparanase, matrix metalloproteinases (MMP)-2 and MMP-9 were examined in ventricles after chronic treatment with isoproterenol (ISO) induced cardiac hypertrophy in rats." | 7.73 | Induction of heparanase gene expression in ventricular myocardium of rats with isoproterenol-induced cardiac hypertrophy. ( Hara, Y; Hashizume, K; Ito, R; Kizaki, K; Mutoh, K; Okada, M; Yoshioka, K, 2005) |
| "The goal of this study was to investigate alterations of the endogenous opioid system in cardiac hypertrophy, to elucidate mechanisms of preproenkephalin (ppENK) gene expression, and to assess effects of endogenous opioids on myocardial contractility and atrioventricular conduction." | 7.73 | Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction. ( Eschenhagen, T; Griepentrog, J; Weil, J; Wenzel, U; Zimmermann, WH; Zolk, O, 2006) |
| " In addition, HRC null mice displayed a significantly exaggerated response to the induction of cardiac hypertrophy by isoproterenol compared to their wild-type littermates." | 7.73 | Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein. ( Black, BL; Cornelissen, I; Greene, SB; Heidt, AB; Jaehnig, EJ, 2006) |
| "Isoproterenol-induced cardiac hypertrophy is associated with increased expression of endothelial nitric oxide synthase in the aorta but without signs of improved endothelial function." | 7.73 | Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. ( Fecenkova, A; Gazova, A; Klimas, J; Krenek, P; Kroslakova, M; Kucerova, D; Kyselovic, J; Plandorova, J; Svec, P, 2006) |
| " However, its role in Isoproterenol-induced (Iso) cardiac hypertrophy has not been characterized so far and were focus of the current study." | 7.72 | Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy. ( Birkner, K; Braun, M; Pauke, B; Simonis, G; Strasser, RH, 2003) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 7.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and right ventricular (RV) weight." | 7.71 | Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. ( Leenen, FH; White, R; Yuan, B, 2001) |
| "The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 7.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 7.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| "It is well known that isoproterenol (ISO) a nonselective beta adrenoceptor agonist induces cardiac hypertrophy." | 7.68 | Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents. ( Hamaya, K; Isogai, Y; Kato, H; Mizokami, T; Namiki, A; Ogawa, K; Sanjo, J; Sasaki, H; Shimizu, M; Yagi, T, 1992) |
| "The reversal of the normal inhibitory action of angiotensin II is evidence of a unique alteration in the signal transduction of beta receptor stimulation and is of potential importance in defining the role of angiotensin II in cardiac hypertrophy." | 7.68 | Reversal of angiotensin II effect on the cyclic adenosine 3',5' monophosphate response to isoprenaline in cardiac hypertrophy. ( Rabkin, SW; Sunga, PS, 1991) |
| "To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8." | 7.68 | Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990) |
| "To assess the role of verapamil (VER)-sensitive calcium (Ca2+) channels in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175 g, N = 51) were divided into control (C) and ISO-treated (I) and VER (V1, 100 mg/L drinking water; V2, 10 mg/kg ip twice daily) and no-VER subgroups." | 7.68 | Verapamil does not prevent isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; Doss, LK, 1990) |
| "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0." | 7.67 | Development of isoproterenol-induced cardiac hypertrophy. ( Tang, Q; Taylor, PB, 1984) |
| "Cardiac hypertrophy was induced in adult female Wistar rats after 8 days of daily subcutaneous injections of isoproterenol (ISO)." | 7.67 | Regression of isoproterenol-induced cardiac hypertrophy. ( Tang, Q; Taylor, PB, 1984) |
| "Isoproterenol (IPR) administered to rats in a dose of 5 mg/kg for 4 days induces cardiac hypertrophy." | 7.67 | Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat. ( Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1985) |
| "Treatment of rats with the beta-adrenergic agonist isoproterenol results in cardiac hypertrophy, myocyte necrosis, and interstitial cell fibrosis." | 7.67 | Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. ( Benjamin, IJ; Cho, K; Clark, WA; Jalil, JE; Tan, LB; Weber, KT, 1989) |
| "Cardiac hypertrophy in adult rabbits was induced by subcutaneous injection of isoproterenol." | 7.67 | Phosphorylation of ribosomal and ribosome-associated proteins in isoproterenol-induced cardiac hypertrophy. ( Lee, JC; Pickett, S, 1985) |
| "The left ventricular function of 23 patients with essential hypertension was investigated during infusion of isoproterenol (ISP)." | 7.67 | [Left ventricular function in essential hypertension during isoproterenol infusion]. ( Hirota, K; Kajino, H; Kawarabayashi, T; Murai, K; Nishikimi, T; Oku, H; Takeda, T; Takeuchi, K; Yasuda, M; Yoshimura, T, 1985) |
| "The left ventricular function of patients with essential hypertension was examined during exercise and isoproterenol (ISP) infusion echocardiography." | 7.67 | Cardiac function of patients with essential hypertension during exercise and isoproterenol infusion. ( Komatsu, H; Murai, K; Nishikimi, T; Oku, H; Takeda, T; Takeuchi, K; Yasuda, M, 1987) |
| "Administration of a single high dose or multiple low doses of isoproterenol (ISO) to rats induces myocardial necrosis and cardiac hypertrophy." | 7.67 | Quantification of myocardial necrosis and cardiac hypertrophy in isoproterenol-treated rats. ( Brinkman, CJ; Knufman, NM; van der Laarse, A; Vliegen, HW, 1987) |
| "Chronic administration of isoproterenol (ISO) produces hypertrophy of the rat heart and tibialis muscle." | 7.66 | Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle. ( Deshaies, Y; Leblanc, J; Willemot, J, 1981) |
| "Daily administration of d,l isoproterenol-HCl (5 mg/kg) in rats for periods of 14-21 days results in marked cardiac hypertrophy and a decrease in cardiac actomyosin ATPase activity." | 7.66 | Characterization of the decreased ATPase activity of rat cardiac actomyosin in isoproterenol-induced cardiac hypertrophy. ( Inchiosa, MA; Pagano, VT, 1979) |
| "Initial and transient increases in the basal levels of cyclic GMP in the heart were noted prior to cardiac hypertrophy in rats administered isoproterenol." | 7.66 | Alterations in activities of cyclic nucleotide systems and in beta-adrenergic receptor-mediated activation of cyclic AMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. ( Brackett, NL; Kuo, JF; Tse, J, 1978) |
| "Isoproterenol (IPR) administered to rats in a dose of 5 mg/kg for seven days induces cardiomegaly." | 7.65 | Experimental cardiac hypertrophy induced by isoproterenol in the rat. ( Csáky, L; Szabó, J; Szegi, J, 1975) |
| "The effect of the beta-blocking agents propranolol and oxprenolol on isoproterenol-induced cardiac hypertrophy has been investigated in the rat." | 7.65 | Prevention of isoproterenol-induced cardiac hypertrophy by beta-blocking agents in the rat. ( Csáky, L; Nosztray, K; Szabó, J; Szegi, J, 1976) |
| " Cardiac hypertrophy was induced by isoproterenol treatment." | 7.65 | Studies on adenosine triphosphatase activity of rat cardiac myosin in isoproterenol-induced cardiac hypertrophy. ( Nosztray, K; Szabó, J; Szöör, A, 1977) |
| "Cardiac hypertrophy was induced by subcutaneous injections with isoproterenol (5 mg/kg b." | 5.91 | Calanus oil attenuates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress. ( Abdellatif, SY; Elsharkawy, SH; Fares, NH; Mahmoud, YI, 2023) |
| "In cases of heart failure, cardiac hypertrophy may be caused by the upregulation of G-protein-coupled receptor kinase 2 (GRK2)." | 5.91 | GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress. ( Ding, L; Gao, D; Li, W; Li, X; Liu, J; Niu, X, 2023) |
| "Pathological cardiac hypertrophy is a major cause of heart failure, and there is no effective approach for its prevention or treatment." | 5.91 | Trim65 attenuates isoproterenol-induced cardiac hypertrophy by promoting autophagy and ameliorating mitochondrial dysfunction via the Jak1/Stat1 signaling pathway. ( Deng, H; Jiang, Z; Liu, H; Liu, X; Ren, Z; Tian, Z; Wu, Z; Zhou, Z, 2023) |
| "Cardiac hypertrophy was induced in rats by subcutaneous injection of isoproterenol (ISO, 1." | 5.91 | JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit. ( Cai, SD; Feng, GS; Guo, Z; Hu, YH; Javaheri, A; Li, Q; Li, ZZ; Liang, LY; Liu, PQ; Lu, J; Luo, WW; Valenzuela Ripoll, C; Wang, L; Wang, QQ; Wu, ZK; Zhang, JG, 2023) |
| "The cardiac mitochondrial damage and cardiac hypertrophy pathways are intimately associated with the pathology of myocardial infarction (MI)." | 5.91 | Protective effects of β-caryophyllene on mitochondrial damage and cardiac hypertrophy pathways in isoproterenol-induced myocardial infarcted rats. ( Ponnian, SMP; Stanely, SP; Yovas, A, 2023) |
| "Pirfenidone is a promising agent for the treatment of idiopathic pulmonary fibrosis and has recently proven to exert inhibitory effects on the inflammatory response." | 5.72 | Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway. ( Cao, Q; Chen, Z; Huang, X; Lai, H; Ouyang, X; Tao, Y; Wang, S; Wang, Y; Yang, L; Zhou, H, 2022) |
| "Protocatechuic acid treatment reversed these effects." | 5.62 | Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1-Sp1-PKCγ axis. ( Bai, L; Han, X; Jeong, MH; Kee, HJ; Kee, SJ; Zhao, T, 2021) |
| "Rats were injected with ISO to induce cardiac hypertrophy and treated with MCP." | 5.62 | Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway. ( Li, AY; Li, Y; Liu, WZ; Liu, XC; Song, QH; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y; Zhou, WW, 2021) |
| "Cardiac hypertrophy is considered to be a leading factor in heart function-related deaths." | 5.56 | UBE3A alleviates isoproterenol-induced cardiac hypertrophy through the inhibition of the TLR4/MMP-9 signaling pathway. ( Cao, Y; Chen, J; Gu, B; Gu, S; Jin, Y; Jin, Z; Li, X; Li, Y; Ma, L; Ning, Z; Tian, J; Tu, J; Wang, Z, 2020) |
| "Recent data show that cardiac hypertrophy contributes substantially to the overall heart failure burden." | 5.56 | STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. ( Ke, Q; Liu, B; Liu, F; Mei, Y; Su, H; Sun, X; Tan, W, 2020) |
| "Cardiac hypertrophy is an independent risk factor of many cardiovascular diseases." | 5.56 | Cymbopogon Proximus Essential Oil Protects Rats against Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis. ( Abdel-Kader, MS; Albaqami, FF; Alharthy, KM; Althurwi, HN; Salkini, MA, 2020) |
| "Cardiac hypertrophy is an adaptive response to stress, in order to maintain proper cardiac function." | 5.56 | Imine stilbene analog ameliorate isoproterenol-induced cardiac hypertrophy and hydrogen peroxide-induced apoptosis. ( Bhadra, MP; Bhukya, CK; Chakrabarti, M; Manchineela, S; Mendonza, JJ; Naini, R; Nallari, P; Raut, GK; Reddy, VD; Suresh, Y; Venkateshwari, A, 2020) |
| "Potential early markers for cardiac hypertrophy as APBB1, GOLGA4, HOOK1, KATNA1, KIFBP, MAN2B2, and SLC16A1 are also reported." | 5.56 | Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase. ( de Jesus, ICG; Figueiredo, HCP; Gómez-Mendoza, DP; Guatimosim, S; Kjeldsen, F; Lemos, RP; Parreira, RC; Pinto, MCX; Resende, RR; Rezende, CP; Santos, AK; Verano-Braga, T, 2020) |
| "Piperine pretreatment significantly prevented these changes in ISO treated group." | 5.56 | The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity. ( Aliev, G; Beeraka, NM; Chubarev, VN; Dhivya, V; Gavryushova, LV; Huang, CY; Mikhaleva, LM; Minyaeva, NN; Tarasov, VV; Viswanadha, VP, 2020) |
| "Cardiac hypertrophy is the underlying cause of heart failure and is characterized by excessive oxidative stress leading to collagen deposition." | 5.56 | Targeting the Nrf2/ARE Signalling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis. ( Chakrapani, LN; Kalaiselvi, P; Kishore Kumar, SN; Mohan, T; Ravi, DB; Singh, A; Srinivasan, A; Varadharaj, S; Velusamy, P, 2020) |
| "Here, cardiac hypertrophy was induced by injection of l-thyroxine or ISO in SD rats." | 5.51 | AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway. ( Hu, X; Li, T; Liu, J; Ou-Yang, Q; Wang, L; Xie, X, 2019) |
| "PPAR-γ is an inhibitor of cardiac hypertrophy (CH) signaling pathways." | 5.51 | Hesperidin regresses cardiac hypertrophy by virtue of PPAR-γ agonistic, anti-inflammatory, antiapoptotic, and antioxidant properties. ( Arya, DS; Bhargava, P; Bhatia, J; Khan, SI; Malik, S; Verma, VK, 2019) |
| "However, its potential effect on cardiac hypertrophy remains unclear." | 5.51 | Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. ( Bi, X; Hong, H; Lu, J; Wang, J; Ye, J; Yu, Y; Yuan, J; Zhang, Y, 2019) |
| "Plantamajoside (PMS) is an active component extracted from Herba Plantaginis, which is a traditional Chinese medicine, and many biological activities of PMS have been reported." | 5.51 | Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway. ( Hou, M; Liu, Y; Pin, L; Shang, L; Shun, M; Zhang, Y; Zhong, X; Zhu, S, 2019) |
| "To evaluate the roles of KLF15 in cardiac hypertrophy, we generated transgenic mice overexpressing KLF15 of KLF15 knockdown mice and subsequently induced cardiac hypertrophy." | 5.46 | KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling. ( Du, Y; Gao, L; Guo, Y; Liu, X; Shang, D, 2017) |
| "The development of cardiac hypertrophy is a complicated process, which undergoes a transition from compensatory hypertrophy to heart failure, and the identification of new biomarkers and targets for this disease is greatly needed." | 5.46 | Alterations in NO/ROS ratio and expression of Trx1 and Prdx2 in isoproterenol-induced cardiac hypertrophy. ( Pistolozzi, M; Shi, X; Su, H; Sun, X; Tan, W, 2017) |
| "Cardiac hypertrophy was induced by ISO (5mg/kg/day s." | 5.46 | Proteomic analysis of the protective effects of aqueous bark extract of Terminalia arjuna (Roxb.) on isoproterenol-induced cardiac hypertrophy in rats. ( Ahmad, S; Goswami, SK; Jahangir Alam, M; Kumar, S; Maulik, SK; Prabhakar, P; Sharma, M, 2017) |
| "Long-lasting cardiac hypertrophy results in the loss of compensation by cardiomyocytes which could ultimately develop into heart failure." | 5.43 | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-κb pathway. ( Ai, JQ; Chang, YX; Chen, L; Gao, XM; Gao, YH; Mao, HP; Niu, ZC; Wang, XY, 2016) |
| "ISO-caused cardiac hypertrophy accompanying with a significant decrease in autophagy activity." | 5.43 | SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. ( Cai, Y; Chen, S; Gao, S; Hong, H; Li, H; Li, M; Li, Z; Liu, C; Liu, P; Liu, Z; Lu, J; Sun, D; Ye, J, 2016) |
| "Whether DFMO attenuates cardiac hypertrophy through endoplasmic reticulum stress (ERS) is unclear." | 5.43 | Endoplasmic Reticulum Stress is Involved in DFMO Attenuating Isoproterenol-Induced Cardiac Hypertrophy in Rats. ( Jin, L; Li, B; Lian, J; Lin, Y; Liu, J; Wang, J; Xiao, W; Zhang, X; Zhou, L, 2016) |
| "Gallic acid pretreatment attenuated concentric cardiac hypertrophy." | 5.43 | Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. ( Cho, JY; Choi, SY; Jeong, MH; Jin, L; Kee, HJ; Kim, GR; Lin, MQ; Piao, ZH; Ryu, Y, 2016) |
| " In conclusion, the present study indicated that chronic use of KATP channel agonists following cardiac hypertrophy can attenuate ventricular remodeling and upregulate the expression level and spatial distribution of Cx43." | 5.42 | Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist. ( Gu, J; Guo, Z; Hao, YY; Sun, JM; Wang, AL; Wang, CM; Xie, YJ, 2015) |
| "Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative, anti-tumour and neuroprotective properties." | 5.42 | Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. ( Arbiser, JL; Bonner, MY; Gius, D; Gupta, MP; Jones, DP; Kim, G; Pillai, VB; Raghuraman, H; Samant, S; Sundaresan, NR; Walker, DI, 2015) |
| "Results showed that ISO-induced cardiac hypertrophy was enhanced in CM Klf4 KO mice compared with control mice." | 5.40 | Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity. ( Hayashi, M; Horimai, C; Yamashita, M; Yoshida, T, 2014) |
| "Vitexin is a flavone glycoside isolated from the leaf of Crataeguspinnatifida Bunge, the utility of which has been demonstrated in several cardiovascular diseases." | 5.39 | Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways. ( Du, ZM; Hang, PZ; Lu, CC; Qi, JC; Wang, C; Wang, Y; Wu, JC; Wu, JW; Xu, YQ; Zhang, Y, 2013) |
| "Tanshinone IIA is a lipid-soluble pharmacologically active compound extracted from the rhizome of the Chinese herb Salvia miltiorrhiza, a well-known traditional Chinese medicine used for the treatment of cardiovascular disorders." | 5.37 | Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. ( Cai, B; Chen, N; Dong, D; Li, J; Li, X; Liu, Y; Lu, Y; Shan, H; Tan, X; Wang, G; Wang, X; Yang, B; Yang, F; Zhang, P, 2011) |
| "ISO-induced cardiac hypertrophy and Erk1/2 activation in Pak-1-KO/ISO were attenuated when the selective Erk1/2 inhibitor FR180204 was administered." | 5.37 | Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. ( Chernoff, J; Ke, Y; Knezevic, I; Lei, M; Monasky, MM; Sheehan, KA; Solaro, RJ; Taglieri, DM; Wang, X; Wolska, BM, 2011) |
| "Isoproterenol treatment significantly reduced 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid formation and significantly increased their corresponding 8,9-, and 14,15-dihydroxyeicosatrienoic acid and the 20-hydroxyeicosatetraenoic acid metabolite." | 5.35 | Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. ( Aboutabl, ME; El-Kadi, AO; Zordoky, BN, 2008) |
| "Isoproterenol (ISO) was given to C57BL mice with or without ARB (olmesartan) treatment and to AT1aR(-/-) mice by a subcutaneously implanted osmotic mini-pump for 11 days at a rate of 15 mg/kg/day." | 5.34 | Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. ( Abe, Y; Fujisawa, Y; Kimura, S; Nagai, Y; Nishiyama, A; Ohmori, K; Zhang, GX, 2007) |
| "Cardiac hypertrophy is often associated with an increased sympathetic drive, and both in vitro and in vivo studies have demonstrated the development of cardiomyocyte hypertrophy in response to either alpha- or beta-adrenergic stimulation." | 5.32 | Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition. ( Camihort, G; Camilión de Hurtado, MC; Cingolani, HE; Console, GM; Dumm, CG; Ennis, IL; Escudero, EM; Seidler, RW, 2003) |
| "Isoproterenol was continuously administered to rats at a rate of 2." | 5.30 | Cardiac beta-adrenergic signaling pathway alteration in isoproterenol-induced cardiac hypertrophy in male Sprague-Dawley rats. ( Hakamata, N; Hamada, H; Nakamura, H; Ohsuzu, F, 1997) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 5.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "Indapamide-treated animals had significantly greater myocardial cAMP concentrations than control animals." | 5.29 | Effect of indapamide on cyclic adenosine 3',5'-monophosphate signal transduction system in isolated adult rat cardiomyocytes from normal myocardium and cardiac hypertrophy. ( Rabkin, SW, 1993) |
| " IPR administered to euthyroid rats in a dosage of 5 mg/kg/day for 4 days induced cardiomegaly." | 5.27 | Study of the factors influencing cardiac growth. I. Comparison of cardiomegaly induced by isoproterenol in euthyroid and thyroidectomized rats. ( Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1984) |
| "Cardiac hypertrophy is accompanied by increased myocardial oxidative stress, and whether naringenin, a natural antioxidant, is effective in the therapy of cardiac hypertrophy remains unknown." | 4.31 | Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway. ( He, B; He, Y; Li, Y; Xia, T; Zeng, C; Zhang, C, 2023) |
| "Protocatechuic acid (3,4-dihydroxybenzoic acid) prevents oxidative stress, inflammation and cardiac hypertrophy." | 4.31 | Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase. ( Bai, L; Han, X; He, X; Jeon, MJ; Jeong, MH; Jeong, SM; Kee, HJ; Kee, SJ; Kim, SH; Zhou, H, 2023) |
| " No studies were conducted earlier on the effects of (-) epicatechin (EC) on tachycardia, cardiac hypertrophy, and inflammation in MI." | 4.12 | Preventive effects of (-) epicatechin on tachycardia, cardiac hypertrophy, and nuclear factor- κB inflammatory signaling pathway in isoproterenol-induced myocardial infarcted rats. ( Ponnian, SMP, 2022) |
| "In vitro models of vasoconstriction, atrium, and in vivo models of invasive blood pressure measurement and isoproterenol (ISO) induced cardiac hypertrophy in rats were used to understand underlying mechanistic by LC-MS/MS based dynamic metabolomics analysis of the serum and heart samples to be investigated the effect of ethanolic extract of C." | 4.12 | Metabolomics based mechanistic insights to vasorelaxant and cardioprotective effect of ethanolic extract of Citrullus lanatus (Thunb.) Matsum. & Nakai. seeds in isoproterenol induced myocardial infraction. ( Ahmedah, HT; Al-Huqail, AA; Bigiu, N; Chicea, LM; Irimie, M; Marc Vlaic, RA; Moga, M; Pop, OL; Saqib, F; Wahid, M, 2022) |
| " Rats were induced MI by isoproterenol (100 mg/kg body weight) and then treated with valencene and cardiac sensitive markers, cardiac hypertrophy, oxidative stress, markers of inflammation, nuclear factor- κB inflammatory pathway, and myocardial infarct size was estimated/determined." | 4.12 | Valencene post-treatment exhibits cardioprotection via inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size in isoproterenol-induced myocardial infarcted rats; A molecular study. ( Berlin Grace, VM; Shervin Prince, S; Stanely Mainzen Prince, P, 2022) |
| " In the present study, possible drug combinations were screened and the mechanism of the combinations against cardiac hypertrophy was examined within 1,8-cineole, β-caryophyllene, linalool, and β-pinene." | 4.12 | Combination of 1,8-cineole and beta-caryophyllene synergistically reverses cardiac hypertrophy in isoprenaline-induced mice and H9c2 cells. ( Bai, C; Li, Q; Liu, M; Ma, Q; Wei, C; Yu, L; Zhen, D, 2022) |
| "Gallic acid has been reported to mitigate cardiac hypertrophy, fibrosis and arterial hypertension." | 4.12 | Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg. ( Bai, L; Han, X; Jeong, MH; Kee, HJ, 2022) |
| "Cardiac hypertrophy was modeled in H9c2 cells treated with isoproterenol (ISO) to assess the effects of Shenge San (, SGS) on cell viability and mitochondrial membrane potential." | 4.12 | Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes. ( Duan, Z; Jianmei, Y; Jiawei, LI; Lingyan, Z; Min, C; Yihong, W; Youhua, W, 2022) |
| "To study the effect of sinomenine (Sin) on isoproterenol (Iso, β-agonist)-induced cardiac hypertrophy (CH), we set up four mouse groups: control, Iso model, Iso+metoprolol (Met, β blocker) 60 mg/kg and Iso+Sin 120 mg/kg." | 4.02 | Protective effect of sinomenine on isoproterenol-induced cardiac hypertrophy in mice. ( Chen, J; Fang, P; Li, L; Tao, H; Zhang, C, 2021) |
| " In this study, we observed the high expression of MBNL1 in cardiac tissue and peripheral blood of an isoproterenol (ISO)-induced cardiac hypertrophy mouse model." | 4.02 | MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo. ( Liang, C; Luo, Y; Xu, Y; Zhang, T, 2021) |
| "Cardiac hypertrophy was induced in C57BL/6 mice by subcutaneous injection of isoproterenol (ISO) for two weeks." | 4.02 | Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol- induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice. ( Fan, W; Hu, Z; Wu, C; Wu, H; Wu, J; Wu, S; Wu, X; Yang, L; Yang, X; Zhang, B; Zhang, J, 2021) |
| " The study aims to understand the effect of arbutin on isoproterenol (ISO)-induced cardiac hypertrophy in mice." | 3.96 | Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice. ( Alavala, S; Jerald, MK; Mir, SM; Nalban, N; Sangaraju, R; Sistla, R, 2020) |
| " In a mouse model of isoproterenol-induced cardiac injury, TPGS is not able to affect cardiac remodeling, however combination of vitamin E TPGS and Apelin counteracts myocardial apoptosis, oxidative stress, hypertrophy and fibrosis." | 3.96 | In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin. ( Blanzat, M; Boal, F; Cassel, S; Cinato, M; Dejugnat, C; Jimenez, T; Kunduzova, O; Leme Goto, P; Loi, H; Marsal, D; Merachli, F; Santin, Y; Todua, N; Tronchere, H; Vons, B, 2020) |
| " However, the therapeutic potential of PQQ for isoproterenol hydrochloride (Iso)‑induced cardiac hypertrophy has not yet been explored, at least to the best of our knowledge." | 3.96 | Pyrroloquinoline quinone attenuates isoproterenol hydrochloride‑induced cardiac hypertrophy in AC16 cells by inhibiting the NF‑κB signaling pathway. ( Dai, Z; Jin, Y; Shen, J; Wen, J; Zhao, X; Zhou, Y, 2020) |
| "A previous study by our group demonstrated a protective role of the neuropeptide secretoneurin (SN) in DL‑isoproterenol hydrochloride (ISO)‑induced cardiac hypertrophy in mice." | 3.96 | iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice. ( Chen, H; Jiang, W; Liu, X; Wu, M; Yu, C; Zhang, J, 2020) |
| "The anti-hypertrophy effect of TMYX was validated in isoproterenol-induced cardiac hypertrophy model in C57BL/6 mice." | 3.96 | High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3. ( Baruscotti, M; Guo, R; Liu, H; Liu, N; Wang, Y; Zhang, H; Zhang, J; Zhao, L, 2020) |
| "A rat model of cardiac hypertrophy was constructed by isoproterenol (ISO) intraperitoneal injection (i." | 3.96 | Songling Xuemaikang Capsule inhibits isoproterenol-induced cardiac hypertrophy via CaMKIIδ and ERK1/2 pathways. ( Fan, D; Pan, W; Qi, J; Tan, Y; Wu, J; Xu, W; Yu, J; Zhang, M, 2020) |
| " We determined that the knockout of WWP2 specifically in myocardium decreased the level of PARP1 ubiquitination and increased the effects of isoproterenol (ISO)-induced PARP1 and PARylation, in turn aggravating ISO-induced myocardial hypertrophy, heart failure, and myocardial fibrosis." | 3.96 | Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling. ( Cao, L; Qian, H; Sun, Y; Wu, S; Zhang, N; Zhang, Y, 2020) |
| "Isoproterenol (ISO)-induced heart failure is a standardized model for the study of beneficial effects of various drugs." | 3.96 | Angiotensin (1-7) and Apelin co-therapy: New strategy for heart failure treatment of rats. ( Gholampour, Y; Javanmardi, K; Soltani Hekmat, A; Tavassoli, A, 2020) |
| " Long non-coding RNA myocardial infarction associated transcript (LncMIAT) is closely related to heart disease, and here, we were the first to discover that LncMIAT may act as an miR-144 sponge in isoproterenol-induced cardiac hypertrophy." | 3.96 | The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy. ( Bai, L; Chen, L; Fan, Y; Gan, M; Guo, Z; Hao, X; Jiang, D; Li, X; Shen, L; Tan, Y; Zhang, S; Zhu, L, 2020) |
| "Our results suggest that diazoxide blocks oxidative stress and reverses cardiac hypertrophy." | 3.96 | Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity. ( Araújo, MTS; Caldas, FRL; Coelho, BN; David, CEB; de Lacerda Alexandre, JV; Facundo, HT; Kowaltowski, AJ; Lucas, AMB; Ponte Viana, YI; Varela, ALN, 2020) |
| "To investigate the expression changes of miRNAs (miR199a-5P, miR206, miR133a-3P, miR499-5P) in rat model of cardiac hypertrophy induced by isoproterenol (ISO), and to explore the main signal pathways and molecular mechanisms which related to that with the way of bioinformatics." | 3.91 | [Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy]. ( Gong, W; Li, C; Liu, CQ; Liu, R; Wu, XC; Xiong, HR; Zhao, Y; Zheng, ZW; Zhou, J, 2019) |
| "To investigate the effect of acupuncture at PC6 on cardiac hypertrophy in isoproterenol (ISO)-treated mice." | 3.91 | Acupuncture at PC6 prevents cardiac hypertrophy in isoproterenol-treated mice. ( Du, Q; Guo, Y; Hou, Y; Yang, F; Zhang, M; Zhu, P, 2019) |
| "Rat and H9C2 cell models of cardiac hypertrophy were induced by isoproterenol and angiotensin II, respectively, followed by TUPS treatment." | 3.91 | Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition. ( Chen, Y; Liang, J; Pan, R; Wu, F; Wu, G; Wu, Z; Xu, W; Yan, W; Zhang, H; Zhang, K, 2019) |
| "The objective of this study was to investigate the effect of astaxanthin on isoproterenol (ISO)-induced myocardial infarction and cardiac hypertrophy in rats." | 3.88 | Astaxanthin Prevented Oxidative Stress in Heart and Kidneys of Isoproterenol-Administered Aged Rats. ( Alam, MA; Alam, MN; Hossain, MM; Mamun, MAA; Rahman, MM; Reza, HM; Subhan, N; Ulla, A, 2018) |
| " As evident from the HW/BW ratio, HW/TL ratio, echocardiography, and histopathology, hypertrophic responses induced by isoproterenol (Iso; 5 mg/Kg body weight, subcutaneous) were blocked by Apo (10 mg/Kg body weight, intraperitoneal)." | 3.88 | Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat. ( Goswami, SK; Prasad, A; Saleem, N, 2018) |
| "To investigate the effect of dimethyl fumarate (DMF) on Toll-like receptor (TLR) signalling pathway in isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 3.88 | Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model. ( Ahmed, AA; Ahmed, AAE; El Morsy, EM; Nofal, S, 2018) |
| "The effects of diazoxide on cardiac hypertrophy and miR-132 expression were characterized in adult rats and in cardiomyocytes." | 3.88 | Protective Action of Diazoxide on Isoproterenol-Induced Hypertrophy Is Mediated by Reduction in MicroRNA-132 Expression. ( Carrillo, ED; García, MC; Hernández, A; Narasimhan, G; Sánchez, JA, 2018) |
| " The aim of the present study was to investigate the role of curcumin in regulating autophagy and mammalian target of rapamycin (mTOR) signaling in isoproterenol-induced cardiac hypertrophy and fibrosis in the rat." | 3.88 | Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR. ( Li, CL; Liu, JX; Liu, R; Wang, JR; Yang, J; Zhang, HB, 2018) |
| " Cardiac hypertrophy of mice was elicited by isoproterenol (ISO) infusion (40 mg/kg per day for 14 days)." | 3.85 | Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy. ( Chen, XH; Ding, YY; Li, JM; Liu, Y; Lu, XL; Pan, XC; Tong, YF; Wang, Y; Zhang, HG, 2017) |
| "This study aimed to exploit the potential therapeutic value of palmatine in treatment of cardiac hypertrophy and the underlying molecular mechanism." | 3.85 | Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats. ( Liu, Y; Peng, W; Xu, Z; Yuan, Y, 2017) |
| "We previously reported a genetic analysis of heart failure traits in a population of inbred mouse strains treated with isoproterenol to mimic catecholamine-driven cardiac hypertrophy." | 3.85 | Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice. ( Karma, A; Lusis, AJ; Rau, CD; Ren, S; Romay, MC; Santolini, M; Tuteryan, M; Wang, JJ; Wang, Y; Weiss, JN, 2017) |
| " Here, we investigated the effect of CaMKII inhibition in isoproterenol (ISO)-induced arrhythmias in hypertrophic mice." | 3.85 | CaMKII inhibition reduces isoproterenol-induced ischemia and arrhythmias in hypertrophic mice. ( Cheng, J; Feng, Y; Wang, Y; Wei, B, 2017) |
| " We investigated the role of Ca2+-mobilizing second messengers, NAADP and cADPR, in the cardiac hypertrophy induced by β-adrenergic stimulation by isoproterenol." | 3.83 | Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-Adrenergic Stimulation. ( Gul, R; Im, SY; Jang, KY; Kim, D; Kim, UH; Ko, JK; Lee, SH; Nam, TS; Park, DR; Shawl, AI, 2016) |
| "This study was aimed to investigate the possible inhibitory effects of aliskiren (ALS) and/or carvedilol (CAV) on CaMKIIδ isoforms expression in experimental cardiac hypertrophy." | 3.83 | Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model. ( Abdel Baky, NA; Al-Mohanna, F; Bin-Dayel, AF; Fadda, LM; Mohammad, RA, 2016) |
| "This study evaluates the protective effects of 7-hydroxycoumarin (7-HC) on dyslipidemia and cardiac hypertrophy in isoproterenol (ISO) induced myocardial infarction (MI) in rats." | 3.83 | Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats. ( Jagadeesh, GS; Nagoor Meeran, MF; Selvaraj, P, 2016) |
| " Isoproterenol (ISO) was used to induce cardiac hypertrophy in Wistar rats." | 3.83 | Suppression of calcium‑sensing receptor ameliorates cardiac hypertrophy through inhibition of autophagy. ( Li, H; Lin, Y; Liu, L; Shi, S; Tian, Y; Wang, C; Wang, L; Xi, Y; Xu, C; Zhang, W; Zhao, Y, 2016) |
| " In a cardiac specific transgenic mouse model, it was observed that overexpression of hHole specifically in heart attenuated cardiac hypertrophy and fibrosis induced by isoproterenol (ISO), with blunted transcriptions of ERK1/2, total ERK1/2 proteins and phosphorylated ERK1/2 (p-ERK1/2) levels." | 3.83 | Cardiac Specific Overexpression of hHole Attenuates Isoproterenol-Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling. ( Cao, L; Chen, F; Dai, G; Deng, Y; Fan, X; Jiang, Z; Li, Y; Liu, X; Luo, S; Mo, X; Peng, X; Shi, Y; Wan, Y; Wang, X; Wang, Y; Wu, X; Xu, W; Ye, X; Yuan, W; Zeng, Q; Zhang, S; Zhou, J; Zhu, X, 2016) |
| " We have previously reported that APS could inhibit isoproterenol-induced cardiac hypertrophy." | 3.83 | Protective effects of Astragalus polysaccharides against endothelial dysfunction in hypertrophic rats induced by isoproterenol. ( Han, R; Hu, J; Lu, M; Mei, M; Tang, F; Wang, H; Xu, C, 2016) |
| " Consistently, TβRIII expression was substantially increased in transverse aortic constriction (TAC)- and isoproterenol-induced mouse cardiac hypertrophy in vivo and in isoproterenol-induced cardiomyocyte hypertrophy in vitro." | 3.83 | Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through β-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II. ( Chu, W; Ding, XQ; Dong, CJ; Ji, Y; Li, H; Li, YC; Li, YY; Liu, MT; Lou, J; Song, SY; Sun, F; Yu, CJ; Zhang, LL; Zhang, ZR; Zhao, D, 2016) |
| " β-AR overstimulation with associated cardiac hypertrophy and increased vasoconstrictor response to phenylephrine in aorta were modeled in rats by 7-day isoproterenol treatment." | 3.83 | Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue. ( Alonso, MJ; Clerici, SP; Davel, AP; Jaffe, IZ; Palacios, R; Rossoni, LV; Vassallo, DV; Victorio, JA, 2016) |
| " Here, we determined whether North American ginseng can modulate the deleterious effects of the β-adrenoceptor agonist isoproterenol on cardiac hypertrophy and function using in vitro and in vivo approaches." | 3.83 | North American ginseng (Panax quinquefolius) suppresses β-adrenergic-dependent signalling, hypertrophy, and cardiac dysfunction. ( Gan, XT; Huang, CX; Karmazyn, M; Lui, EM; Rajapurohitam, V; Tang, X; Xue, J, 2016) |
| "Using the β-adrenergic agonist isoproterenol as a specific pathological stressor to circumvent the problem of etiologic heterogeneity, we performed a genome-wide association study for genes influencing cardiac hypertrophy and fibrosis in a large panel of inbred mice." | 3.81 | Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice. ( Avetisyan, R; Lusis, AJ; Martin, L; Rau, CD; Ren, S; Romay, MC; Wang, J; Wang, Y, 2015) |
| "In this study, we evaluated ET effects on isoproterenol (ISO)-induced cardiac hypertrophy in female mice." | 3.81 | Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice. ( Li, J; Liu, J; Lu, P; Qi, Z; Ren, J; Tian, W; Yang, L; Zhu, M, 2015) |
| "We previously reported that Astragaloside IV (ASIV), a major active constituent of Astragalus membranaceus (Fisch) Bge protects against cardiac hypertrophy in rats induced by isoproterenol (Iso), however the mechanism underlying the protection remains unknown." | 3.81 | Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis. ( Lu, M; Luan, A; Tang, F; Wang, H; Yang, J; Yang, Y; Zhang, J; Zhang, S, 2015) |
| " The present study was designed to investigate the effect of pretreatment with SIM on isoproterenol (ISO)-induced cardiac hypertrophy in rats." | 3.81 | Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway. ( Al-Manee, RZ; Al-Oteibi, MM; Al-Rasheed, NM; Al-Shareef, SA; Hasan, IH; Mahmoud, AM; Mohamad, RA, 2015) |
| "This study aimed to explore the effects of puerarin on autophagy in cardiac hypertrophy." | 3.81 | Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy. ( Chen, M; Huang, Z; Li, Y; Liu, B; Liu, P; Luo, C; Ou, C; Wu, Z; Zhang, J, 2015) |
| " Therefore, it is important to examine whether fenofibrate would modulate the cardiac P450 and its associated arachidonic acid metabolites and whether this modulation protects against isoproterenol-induced cardiac hypertrophy." | 3.80 | Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy. ( Althurwi, HN; El-Kadi, AO; Elshenawy, OH, 2014) |
| "We constructed a miRNA reporter imaging system to monitor miR-22 expression in isoproterenol-induced cardiac hypertrophy repetitively and noninvasively." | 3.80 | In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging. ( Bu, L; Cheng, Z; Dong, D; Shen, B; Tu, Y; Wan, L; Yin, Z; Zhao, D, 2014) |
| " Transgenic (TG) mice with cardiomyocyte-specific overexpression of mitofilin were generated, and cardiac hypertrophy was introduced by transverse aortic constriction (TAC) or chronic infusion of isoproterenol (ISO)." | 3.80 | Overexpression of mitofilin in the mouse heart promotes cardiac hypertrophy in response to hypertrophic stimuli. ( An, XZ; Chen, HZ; Li, H; Liu, DP; Liu, G; Luo, YX; Xu, J; Zhang, R; Zhang, Y, 2014) |
| " The present study investigated whether CaR played a role in cardiac fibroblast proliferation and extracellular matrix (ECM) secretion, both in cultured rat neonatal cardiac fibroblasts and in a model of cardiac hypertrophy induced by isoproterenol (ISO)." | 3.80 | Calcium sensing receptor promotes cardiac fibroblast proliferation and extracellular matrix secretion. ( Dong, S; Fu, S; Li, T; Lu, F; Wang, L; Wu, J; Xu, CQ; Yang, F; Yu, X; Zhang, T; Zhang, WH; Zhang, X; Zhao, Y; Zheng, D; Zhong, X, 2014) |
| "Our data suggest that tamoxifen produces beneficial effects on cardiac hypertrophy and hence may be considered as a preventive measure for cardiac hypertrophy." | 3.80 | Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy. ( Desai, VJ; Patel, BM, 2014) |
| " This study investigated whether melatonin prevents LV remodeling and improves survival in isoproterenol-induced heart failure." | 3.80 | Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure. ( Adamcova, M; Bednarova, KR; Celec, P; Gajdosechova, L; Hrenak, J; Kamodyova, N; Krajcirovicova, K; Simko, F; Zorad, S, 2014) |
| " Most importantly, we found that epicardial application of resiniferatoxin largely prevented the elevated left ventricle end-diastolic pressure, lung edema, and cardiac hypertrophy, partially reduced left ventricular dimensions in the failing heart, and increased cardiac contractile reserve in response to β-adrenergic receptor stimulation with isoproterenol in CHF rats." | 3.80 | Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure. ( Cornish, KG; Rozanski, GJ; Wang, HJ; Wang, W; Zucker, IH, 2014) |
| " However, little is known about the role of Rapa in cardiac hypertrophy induced by isoproterenol and its underlying mechanism." | 3.80 | Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-κB activation. ( Cao, W; Chen, X; Chen, Y; Gao, Y; Liu, P; Yue, Z; Zeng, S; Zhang, L; Zou, J, 2014) |
| " The aim of this study was to investigate whether nebivolol has additional effects on β-adrenoceptor-mediated functional responses along with morphologic and molecular determinants of cardiac hypertrophy compared with those of metoprolol, a selective β1-adrenoceptor blocker." | 3.79 | Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage. ( Altan, VM; Arioglu-Inan, E; Balligand, JL; Esfahani, H; Kayki-Mutlu, G; Ozakca, I; Ozcelikay, AT, 2013) |
| " To investigate whether it would be beneficial in a cardiac failure model with down-regulated SERCA2a levels, we made a cardiac hypertrophy model using isoproterenol infusion (1." | 3.79 | Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats. ( Mitsuyama, S; Obata, K; Takaki, M; Takeshita, D; Zhang, GX, 2013) |
| " Herein, we examined the effects of this peptide on isoproterenol (ISO)-induced cardiac remodeling and myocardial infarction (MI) injury." | 3.79 | The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats. ( Almeida, AP; Beiman, M; Carvalho, MB; Cohen, Y; Cojocaru, G; Ferreira, AJ; Ianzer, D; Marques, FD; Peluso, AA; Rotman, G; Santos, RA; Savergnini, SQ; Silva, GA, 2013) |
| "Although inadequate intake of essential nutrient choline has been known to significantly increase cardiovascular risk, whether additional supplement of choline offering a protection against cardiac hypertrophy remain unstudied." | 3.79 | Choline protects against cardiac hypertrophy induced by increased after-load. ( Du, Z; Wang, C; Wang, Y; Wu, J; Zhang, Y; Zhao, Y; Zhu, W, 2013) |
| " miR-22-null hearts blunted cardiac hypertrophy and cardiac remodeling in response to 2 independent stressors: isoproterenol infusion and an activated calcineurin transgene." | 3.79 | MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress. ( Chen, J; Hu, X; Huang, ZP; Kataoka, M; Seok, HY; Wang, DZ; Zhang, Z, 2013) |
| "Calcitriol (CAL), an active form of vitamin D, plays a vital role in controlling cardiac hypertrophy and heart failure." | 3.79 | Cardioprotective effect of calcitriol on myocardial injury induced by isoproterenol in rats. ( Cheng, S; Wang, X; Yang, Y; Zhu, Y, 2013) |
| " To determine the role of these domains during β-adrenergic-induced cardiac hypertrophy, we stressed the mice with isoproterenol." | 3.79 | AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to β-adrenergic-induced cardiac hypertrophy. ( Burmeister, BT; Carnegie, GK; Conklin, BR; Hsiao, EC; Huang, Y; Salomonis, N; Scott, MJ; Spindler, MJ; Srivastava, D, 2013) |
| " Rats were pretreated with p-coumaric acid (8 mg/kg body weight) daily for a period of 7 days and then injected with isoproterenol (100mg/kg body weight) on 8th and 9th day to induce myocardial infarction." | 3.79 | Preventive effects of p-coumaric acid on cardiac hypertrophy and alterations in electrocardiogram, lipids, and lipoproteins in experimentally induced myocardial infarcted rats. ( Roy, AJ; Stanely Mainzen Prince, P, 2013) |
| "The present study aimed at using a proteomics based approach to: a) analyze and contrast the proteome of the healthy and isoproterenol induced hypertrophied hearts and b) identify potential biomarkers for diagnosis of cardiac hypertrophy." | 3.79 | A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats. ( Banerjee, SK; Bhadra, MP; Chowdhury, D; Khatua, TN; Saxena, P; Tangutur, AD, 2013) |
| "In Wistar rats, cardiac hypertrophy and heart failure were induced by subcutaneous injection of isoproterenol (Iso)." | 3.79 | Role of the calcium-sensing receptor in cardiomyocyte apoptosis via the sarcoplasmic reticulum and mitochondrial death pathway in cardiac hypertrophy and heart failure. ( Dong, S; Fu, SB; Leng, X; Li, H; Lu, FH; Ren, H; Xu, CQ; Zhang, WH; Zhang, X; Zhao, YJ; Zhong, X, 2013) |
| "In PKA inhibitor peptide transgenic mice, chronic isoproterenol failed to induce cardiac hypertrophy, fibrosis, and myocyte apoptosis, and decreased cardiac function." | 3.79 | Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling. ( Ai, X; Chen, X; Fu, Q; Gao, E; Gao, H; Ge, XJ; Jin, J; Kunapuli, SP; Li, Y; Makarewich, C; Szeto, C; Tang, A; Tang, M; Wang, F; Wang, J; Xiang, KY; Zeng, C; Zhang, X; Zhou, L, 2013) |
| " This study aims to evaluate the protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and alterations in lipoproteins and electrocardiogram in isoproterenol-induced myocardial infarcted rats." | 3.79 | Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats. ( Mainzen Prince, PS; Roy, SJ, 2013) |
| "Herein, we studied the cross talk between 5-HT(2B) receptor blocker (SB-204741) and GSK-3β inhibitor (SB-216763) in isoproterenol-induced cardiac hypertrophy for 28 days." | 3.78 | Phosphorylation of Akt/GSK-3β/eNOS amplifies 5-HT2B receptor blockade mediated anti-hypertrophic effect in rats. ( Al-Attas, OS; Arya, DS; Bharti, S; Chauhan, SS; Hussain, T; Singh, R, 2012) |
| "The responses of AMP-activated protein kinase (AMPK) and Ornithine decarboxylase (ODC) to isoproterenol have been examined in H9c2 cardiomyoblasts, AMPK represents the link between cell growth and energy availability whereas ODC, the key enzyme in polyamine biosynthesis, is essential for all growth processes and it is thought to have a role in the development of cardiac hypertrophy." | 3.78 | Evidence that AMP-activated protein kinase can negatively modulate ornithine decarboxylase activity in cardiac myoblasts. ( Caldarera, CM; Campana, G; Cetrullo, S; Flamigni, F; Gottardi, D; Guarnieri, C; Passariello, CL; Pignatti, C; Stefanelli, C; Tantini, B; Zini, M, 2012) |
| "Cardiac hypertrophy was induced by a chronic infusion of isoproterenol (ISO) 15 mg/kg/day for 3 weeks in human apoB transgenic mice (n = 9) and in non-transgenic wild-type mice (n = 10)." | 3.78 | Overexpression of apolipoprotein B attenuates pathologic cardiac remodeling and hypertrophy in response to catecholamines and after myocardial infarction in mice. ( Borén, J; Lindbom, M; Omerovic, E; Råmunddal, T; Shao, Y; Täng, MS, 2012) |
| "Persistent β-adrenergic receptor stimulation with isoproterenol is associated with cardiac hypertrophy as well as cardiac synthesis of angiotensin II." | 3.78 | Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1. ( Ballesteros, S; Cachofeiro, V; Davel, AP; de las Heras, N; Lahera, V; Martín-Fernández, B; Miana, M; Rossoni, LV; Valero-Muñoz, M; Vassallo, D, 2012) |
| " However, Mstn-/- mice responded better to isoproterenol stress tests with greater increases in fractional shortening and ejection fraction-differences that were again more apparent in females and which are consistent with physiological cardiac hypertrophy." | 3.78 | The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism. ( Garikipati, DK; Jackson, MF; Luong, D; Nelson, OL; Rodgers, BD; Stanton, JB; Vang, DD, 2012) |
| " Physical training was considered a physiological condition, while isoproterenol-induced hypertrophy, myocardial infarction and DOCA-salt model of hypertension were used as pathological models of heart injury." | 3.78 | The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli. ( Almeida, PW; Braga, VB; Campagnole-Santos, MJ; Coutinho, DC; Dias-Peixoto, MF; Ferreira, AJ; Gomes Filho, A; Greco, L; Guatimosim, S; Lima, RF; Melo, DS; Melo, MB; Santos, RA, 2012) |
| "Although spironolactone and telmisartan are reported to reduce the risk of morbidity and death, direct studies on their effects on isoproterenol-induced cardiac hypertrophy are scanty." | 3.78 | Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy. ( Goyal, BR; Mehta, AA, 2012) |
| "Cardiac hypertrophy was induced in wild-type and IL-10 knockout mice by isoproterenol (ISO) infusion." | 3.78 | Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. ( Barefield, D; Ghosh, AK; Gupta, R; Hoxha, E; Kishore, R; Krishnamurthy, P; Lambers, E; Mackie, A; Qin, G; Ramirez, V; Sadayappan, S; Singh, N; Thal, M; Verma, SK, 2012) |
| "It is well known that the two chemical compounds endothelin-1 (ET-1) and isoproterenol (ISO) can individually induce cardiac hypertrophy through G protein-coupled receptors in cardiomyocytes." | 3.77 | Endothelin-1- and isoproterenol-induced differential protein expression and signaling pathway in HL-1 cardiomyocytes. ( Hong, HM; Kabir, MH; Lee, C; Oh, E; Song, EJ; Yoo, YS, 2011) |
| " Accordingly, we tested the hypothesis that blocking the E2F1-mediated signal transduction pathway prevents cardiac hypertrophy by treating E2F1 knockout mice (E2F1-/-) with either isoproterenol (ISO) or Angiotensin II (ANG)." | 3.77 | The role of E2F1 in the development of hypertrophic cardiomyopathy. ( Hoit, BD; Lee, HG; Liner, A; Richardson, SL; Smith, MA; Wolfram, JA; Zhu, X, 2011) |
| "To investigate the therapeutic effect of PI3Kgamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by Isoproterenol in rats." | 3.77 | [The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats]. ( Hu, XH; Jiang, W; Li, Y; Qing, Y; Song, LF; Tong, QY; Wu, XH, 2011) |
| " Isolated myocytes from overexpressing lines showed increased Ca(2+) transients and arrhythmias in response to endothelin-1 stimulation." | 3.76 | The IP3 receptor regulates cardiac hypertrophy in response to select stimuli. ( Bers, DM; Blatter, LA; Bodi, I; DeSantiago, J; Domeier, TL; Lorenz, JN; Maillet, M; Mikoshiba, K; Molkentin, JD; Nakayama, H, 2010) |
| " We found that, in the left ventricle, Gal-3 1) enhanced macrophage and mast cell infiltration, increased cardiac interstitial and perivascular fibrosis, and causes cardiac hypertrophy; 2) increased TGF-beta expression and Smad3 phosphorylation; and 3) decreased negative change in pressure over time response to isoproterenol challenge, ratio of early left ventricular filling phase to atrial contraction phase, and left ventricular ejection fraction." | 3.75 | N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin. ( André, S; Carretero, OA; D'Ambrosio, M; Gabius, HJ; Liao, TD; Liu, YH; Peng, H; Rhaleb, NE; Sharma, U, 2009) |
| " Importantly, administration of the PDE1 inhibitor IC86340 attenuated cardiac hypertrophy induced by chronic isoproterenol infusion in vivo." | 3.75 | Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy. ( Abe, J; Beavo, JA; Blaxall, BC; Cai, Y; Chen, YF; Florio, V; Li, JD; Miller, CL; Nagel, DJ; Oikawa, M; Rybalkin, SD; Wojtovich, AP; Xu, H; Xu, X; Yan, C, 2009) |
| "Isoproterenol-induced cardiac hypertrophy in mice has been used in a number of studies to model human cardiac disease." | 3.75 | Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure. ( Errami, M; Galindo, CL; Garner, HR; Kumar, NM; Li, J; McCormick, JF; McIver, LJ; Olson, LD; Pham, TQ; Skinner, MA; Watson, DA, 2009) |
| "A recent clinical study has shown that carvedilol has a significantly more favorable effect than metoprolol on survival rate in patients with heart failure." | 3.74 | Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers. ( Asari, K; Hanada, K; Kawana, J; Mita, M; Ogata, H; Saito, M, 2008) |
| "Isoproterenol treatment of Brown Norway and Lewis rats (high and low plasma angiotensin-I-converting enzyme activity, respectively) results in similar cardiac hypertrophy but higher cardiac fibrosis in Brown Norway rats." | 3.74 | Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism. ( Copaja Soto, M; Díaz-Araya, G; Jalil, JE; Lavandero, S; Lijnen, P; Ordenes, GE; Paz Ocaranza, M; Saldaña, A; Valenzuela, R; Vio, C; Vivar Sanchez, R, 2008) |
| "Isoproterenol (Iso) was a clinical therapeutic that is now used as a research means for the induction of cardiac hypertrophy." | 3.74 | Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis. ( Anderson, M; Larson, D; Moore, D, 2008) |
| "To study whether urotensin II (UII), a potent vasoconstrictive peptide, is involved in the development of cardiac hypertrophy and fibrogenesis of rats induced by isoproterenol (ISO)." | 3.74 | Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol. ( Bu, DF; Li, YG; Liu, BG; Pang, YZ; Tan, XR; Tang, CS; Wang, DM; Wei, RH; Zhang, YG, 2007) |
| "The aim of the present study was performed to determine whether a novel histone deacetylase (HDAC) inhibitor, N-(2-aminophenyl)-4-{[benzyl(2-hydroxyethyl)amino]methyl} benzamide (K-183), prevents a reversible cardiac hypertrophy induced by isoproterenol and improves left ventricular (LV) dysfunction in rats." | 3.74 | Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts. ( Kitagawa, Y; Nakajima-Takenaka, C; Shimizu, J; Takaki, M; Tamura, Y; Taniguchi, S; Uesato, S, 2007) |
| " We studied the response to acute isoproterenol in SUR2 null mice as a model of acute adrenergic stress and found that the episodic coronary vasospasm observed at baseline in SUR2 null mice was alleviated." | 3.74 | Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress. ( Chalupsky, K; Earley, JU; Kakkar, R; Makielski, JC; McNally, EM; Shi, NQ; Smelley, M; Stoller, D, 2007) |
| "Homo- and heteroplasmic mitochondrial DNA (mtDNA) mutations were observed and identified in an isoproterenol-induced rabbit model of cardiac hypertrophy." | 3.74 | Does strong hypertrophic condition induce fast mitochondrial DNA mutation of rabbit heart? ( Han, IY; Joo, H; Kang, SW; Kim, E; Kim, T; Kim, YW; Lee, JH; Thu, VT; Youm, JB, 2008) |
| "This study aimed to quantify the effect of cardiac hypertrophy induced with isoprenaline and caffeine on reflex regulation of renal sympathetic nerve activity by the arterial and cardiopulmonary baroreceptors." | 3.74 | Impact of cardiac hypertrophy on arterial and cardiopulmonary baroreflex control of renal sympathetic nerve activity in anaesthetized rats. ( Aherne, CM; Buckley, MM; Flanagan, ET; Johns, EJ; Lainis, F; Sattar, M, 2008) |
| "Impaired leptin signalling in obesity is increasingly implicated in cardiovascular pathophysiology." | 3.73 | Leptin repletion restores depressed {beta}-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy. ( Barouch, LA; Berkowitz, DE; Emala, CW; Gonzalez, DR; Hare, JM; Khan, SA; Lee, K; Minhas, KM; O'Donnell, CP; Phan, AC; Raju, SV; Saliaris, AP; Skaf, MW; Tejani, AD, 2005) |
| "To examine the negative regulation role of PTEN in isoproterenol-induced cardiac hypertrophy by testing the expression of PTEN mRNA and protein and to explore the effects of captopril (Cap) on PTEN expression." | 3.73 | [PTEN negatively regulates isoproterenol-induced cardiac hypertrophy and effects of captopril on PTEN expression]. ( Tian, Y; Wang, J; Yu, LJ; Zhou, YZ; Zhu, SJ, 2005) |
| "Gene expression of heparanase, matrix metalloproteinases (MMP)-2 and MMP-9 were examined in ventricles after chronic treatment with isoproterenol (ISO) induced cardiac hypertrophy in rats." | 3.73 | Induction of heparanase gene expression in ventricular myocardium of rats with isoproterenol-induced cardiac hypertrophy. ( Hara, Y; Hashizume, K; Ito, R; Kizaki, K; Mutoh, K; Okada, M; Yoshioka, K, 2005) |
| "The goal of this study was to investigate alterations of the endogenous opioid system in cardiac hypertrophy, to elucidate mechanisms of preproenkephalin (ppENK) gene expression, and to assess effects of endogenous opioids on myocardial contractility and atrioventricular conduction." | 3.73 | Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction. ( Eschenhagen, T; Griepentrog, J; Weil, J; Wenzel, U; Zimmermann, WH; Zolk, O, 2006) |
| " A novel PARP inhibitor (L-2286) was tested in a rat model of chronic heart failure following isoproterenol-induced myocardial infarction." | 3.73 | PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway. ( Deres, P; Gallyas, F; Halmosi, R; Hanto, K; Hideg, K; Kalai, T; Kulcsar, G; Palfi, A; Sumegi, B; Szabados, E; Szereday, Z; Toth, A; Toth, K, 2006) |
| " In addition, HRC null mice displayed a significantly exaggerated response to the induction of cardiac hypertrophy by isoproterenol compared to their wild-type littermates." | 3.73 | Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein. ( Black, BL; Cornelissen, I; Greene, SB; Heidt, AB; Jaehnig, EJ, 2006) |
| "Isoproterenol-induced cardiac hypertrophy is associated with increased expression of endothelial nitric oxide synthase in the aorta but without signs of improved endothelial function." | 3.73 | Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy. ( Fecenkova, A; Gazova, A; Klimas, J; Krenek, P; Kroslakova, M; Kucerova, D; Kyselovic, J; Plandorova, J; Svec, P, 2006) |
| " However, its role in Isoproterenol-induced (Iso) cardiac hypertrophy has not been characterized so far and were focus of the current study." | 3.72 | Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy. ( Birkner, K; Braun, M; Pauke, B; Simonis, G; Strasser, RH, 2003) |
| " We tested the hypothesis that this ACE gene polymorphism determines the extent of cardiac fibrosis induced by isoproterenol (Iso) in the rat." | 3.72 | Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats. ( Carreño, JE; Díaz-Araya, G; Jalil, JE; Lavandero, S; Muñoz, D; Ocaranza, MP; Riveros, JP, 2004) |
| "These findings indicated that celiprolol attenuates cardiac myocyte hypertrophy both in vitro and in vivo and halts the process leading from hypertrophy to heart failure." | 3.72 | Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice. ( Asakura, M; Asano, Y; Asanuma, H; Hori, M; Kim, J; Kitakaze, M; Kitamura, S; Liao, Y; Minamino, T; Ogai, A; Sanada, S; Shintani, Y; Takashima, S; Tomoike, H, 2004) |
| "By mimicking sympathetic stimulation with chronic isoproterenol perfusion in vivo, we found that mice developed a cardiac hypertrophy, which was prevented by exposure to the 5-HT2B receptor antagonists SB206553 or SB215505 or in 5-HT2B receptor-knockout mice." | 3.72 | Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts. ( Callebert, J; Etienne, N; Jaffré, F; Launay, JM; Maroteaux, L; Monassier, L; Nebigil, CG; Sarre, A, 2004) |
| " ECG-telemetered TG mice had significantly more arrhythmias than wild-type (WT) littermate controls at baseline, and arrhythmias were additionally increased by isoproterenol." | 3.71 | Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy. ( Anderson, ME; Colbran, RJ; Dzhura, I; Olson, EN; Passier, R; Roden, DM; Temple, J; Trimble, R; Wu, Y; Zhang, R; Zhang, W, 2002) |
| "To study the alterations of myocardial taurine transport function, taurine transporter (TAUT), and cysteine sulfinate decarboxylase (CSD) mRNA as well as effect of exogenous taurine in rats with isoproterenol (ISO)-induced cardiomegaly." | 3.71 | Dysfunction of myocardial taurine transport and effect of taurine supplement in rats with isoproterenol-induced myocardial injury. ( Bu, DF; Du, JB; Gao, L; Jiang, HF; Pang, YZ; Qi, YF; Shi, YR; Tang, CS, 2002) |
| "The role of renin-angiotensin-aldosterone system in cardiac remodelling was studied in isoproterenol-induced cardiac hypertrophy in rats." | 3.71 | Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats. ( Casis, O; Echevarria, E; Espiña, L; Gallego, M; Iriarte, MM; Vegas, L, 2001) |
| "To assess the possible contribution of the circulatory and cardiac renin-angiotensin system (RAS) to the cardiac hypertrophy induced by a beta-agonist, the present study evaluated the effects of isoproterenol, alone or combined with an angiotensin I-converting enzyme inhibitor or AT(1) receptor blocker, on plasma and LV renin activity, ANG I, and ANG II, as well as left ventricular (LV) and right ventricular (RV) weight." | 3.71 | Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system. ( Leenen, FH; White, R; Yuan, B, 2001) |
| " Isovolumetric left ventricle preparations of rats with cardiac hypertrophy (H; N = 10) induced by isoproterenol administration showed higher DPmax (174 +/- 14 mmHg) than control (C; N = 8) animals (155 +/- 12 mmHg) or rats with regression (R; N = 8) of hypertrophy (144 +/- 11 mmHg)." | 3.70 | Developed pressure data may provide misinformation when used alone to evaluate systolic function in isovolumetric left ventricle preparations. ( Murad, N; Tucci, PJ, 1999) |
| "The in vivo signal transduction pathway, responsible for isoproterenol-induced cardiac hypertrophy or remodeling, remains to be clarified." | 3.70 | Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling. ( Izumi, Y; Kim, S; Komatsu, R; Omura, T; Takemoto, Y; Takeuchi, K; Yoshikawa, J; Yoshiyama, M, 1999) |
| "We tested the hypothesis that changes in phosphorylation of the sarcoplasmic reticulum (SR) protein, phospholamban (PIB) and myofibrillar proteins troponin I (TnI) and C protein are responsible for the decreased relaxant response to isoproterenol in cardiac hypertrophy and failure induced by ascending aortic banding in rats." | 3.70 | Altered phosphorylation of sarcoplasmic reticulum contributes to the diminished contractile response to isoproterenol in hypertrophied rat hearts. ( Belu-John, Y; Morgan, JP; Silverman, M; Strömer, H; Szymanska, G, 1999) |
| "We tested the hypothesis that increasing myocardial cyclic GMP would attenuate cyclic AMP induced positive inotropy and O2 consumption, in part, through changes in cyclic AMP and that renal hypertension-induced cardiac hypertrophy (HYP) would alter this relationship." | 3.70 | Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts. ( Leone, RJ; Scholz, PM; Straznicka, M; Weiss, HR, 2000) |
| "The role of angiotensin II (ANG II) in the development of isoproterenol (Iso)-induced cardiac hypertrophy was examined in rats." | 3.69 | Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats. ( Abassi, ZA; Cuda, G; Golomb, E; Keiser, HR; Panchal, VR; Stylianou, M; Trachewsky, D, 1994) |
| "Chronic infusion of isoproterenol (Iso) in rats results in cardiac hypertrophy via incompletely understood mechanisms." | 3.69 | Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart. ( Boluyt, MO; Crow, MT; Eschenhagen, T; Lakatta, EG; Long, X; Mende, U; Schmitz, W, 1995) |
| "The aim was to investigate changes in cardiac transforming growth factor beta 1 (TGF-beta 1), fibronectin, and collagen types I and III mRNA levels in isoprenaline induced cardiac hypertrophy, and the effects of delapril, an angiotensin converting enzyme inhibitor, and TCV-116, an angiotensin II type 1 receptor antagonist, on this hypertrophy." | 3.69 | Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system. ( Iwao, H; Kim, S; Omura, T; Takeda, T; Takeuchi, K, 1994) |
| " This conclusion is strengthened by the observation that hypertrophic hearts from volume-overloaded rats had similar amounts of cardiac hypertrophy to the hearts from the hypertensive rats, without a change in flow, coronary vascular resistance or ischaemic sensitivity, whereas the hearts from isoproterenol-treated rats had lower ischaemic sensitivity and coronary vascular resistance." | 3.69 | Sensitivity to ischaemic ATP breakdown in different models of cardiac hypertrophy in rats. ( Harmsen, E; Leenen, FH; Ruzicka, M; Schoemaker, R; Yu, J, 1994) |
| "The force-interval relationship, systemic evaluation of changed contractile force and calcium sensitivity of the myofilaments were investigated using small trabecular muscle from hearts with isoproterenol-induced cardiac hypertrophy." | 3.69 | Altered contractile function in isoproterenol-induced hypertrophied rat heart. ( Tang, L; Taylor, PB, 1996) |
| " Cardiac hypertrophy was induced by daily subcutaneous injection of isoproterenol (0." | 3.69 | Force-frequency response in isoproterenol-induced hypertrophied rat heart. ( Gao, W; Tang, L; Taylor, PB, 1996) |
| "Two experimental models of cardiac hypertrophy (chronic thyroxine or isoprenaline treatment of adult rats) were compared 24 h and five weeks after the agent was last given." | 3.68 | Functional changes in the right and left ventricle during development of cardiac hypertrophy and after its regression. ( Cihák, R; Kolár, F; Ostádal, B; Pelouch, V; Procházka, J; Widimský, J, 1992) |
| "It is well known that isoproterenol (ISO) a nonselective beta adrenoceptor agonist induces cardiac hypertrophy." | 3.68 | Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents. ( Hamaya, K; Isogai, Y; Kato, H; Mizokami, T; Namiki, A; Ogawa, K; Sanjo, J; Sasaki, H; Shimizu, M; Yagi, T, 1992) |
| "The DNA synthesis has been studied in the conductive system (CS) myocytes, compared to that in atrial and ventricular myocytes: 1) in the left ventricular myocardial infarction induced in two- and three-week-old and adult rats, 2) after isoproterenol injections to adult rats and mice, and 3) in the hypertrophied human heart." | 3.68 | [The capacity for reactive DNA synthesis of the myocytes in the heart conduction system in experimental and clinical myocardial pathology]. ( Erokhina, IL, 1992) |
| " The effects of isoproterenol (ISP) and chemical sympathectomy (6-hydroxydopamine treatment) on myocardial beta-receptors were also investigated in 10 and 24 week-old SHRS and WKY to examine the effects of hypertension and aging on receptor regulation." | 3.68 | Effects of aging and drugs on myocardial beta-adrenergic receptors in M-SHRSP and SHRSP. ( Ikawa, H; Suzuki, A, 1991) |
| "The reversal of the normal inhibitory action of angiotensin II is evidence of a unique alteration in the signal transduction of beta receptor stimulation and is of potential importance in defining the role of angiotensin II in cardiac hypertrophy." | 3.68 | Reversal of angiotensin II effect on the cyclic adenosine 3',5' monophosphate response to isoprenaline in cardiac hypertrophy. ( Rabkin, SW; Sunga, PS, 1991) |
| "To evaluate the effect of nitrendipine on cardiac hypertrophy and inotropic response to isoproterenol in two-kidney, one-clip (2K,1C) renovascular hypertension, male Wistar rats (n = 56) were divided into a clipped group (K) (n = 28) and a sham group (S) (n = 28)." | 3.68 | Improvement of cardiac contractile response to beta-adrenergic stimulation in normal and two-kidney, one-clip hypertensive rats treated with nitrendipine. ( Fontan, M; Gallo, A; Gómez Llambi, H; Mazzadi, A; Taquini, CM, 1991) |
| "The effects on ventricular function of calcium channel blockers and isoproterenol were studied in isovolumically beating perfused control rabbit hearts and in hearts subjected to a double pressure plus volume overload studied at the early phase of heart failure." | 3.68 | Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart. ( Crozatier, B; el Houda Bouanani, N; Ezzaher, A; Hittinger, L; Su, JB, 1991) |
| "To determine the effects of aging and concentric hypertrophy on the reserve of the left ventricle (LV), 36 patients with hypertension (HT), 22 with hypertrophic cardiomyopathy (HCM) and 25 age-matched normal subjects (N) were studied by isoproterenol (ISP) infusion echocardiography." | 3.68 | Left ventricular reserve of the hypertrophied heart in patients with systemic hypertension and hypertrophic cardiomyopathy--relation to age and left ventricular relative wall thickness. ( Chou, HT; Fukuzaki, H; Yokota, Y, 1990) |
| "To assess the role of dietary sodium in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175g n = 65) were divided into control (C) and ISO-treated (I) and three dietary sodium subgroups; low (8." | 3.68 | Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; DeVenny, MF; Doss, LK; Grizzle, WE, 1990) |
| "Previous studies from our laboratory, have demonstrated that 21 days after unclipping the decrease in arterial pressure (AP) was followed by a regression of cardiac hypertrophy (CH) and a normalization of contractile response to Isoproterenol (I) stimulation in two kidney one clip (2K1C) hypertension." | 3.68 | [Effect of alpha methyldopa on heart in renovascular hypertension]. ( Fontan, M; Gallo, A; Gómez Llambi, H; Kuraja, I; Massadi, A; Taquini, CM, 1990) |
| "Cardiac hypertrophy and failure were induced in male Wistar rats by daily administration of 5 mg/kg isoproterenol for three weeks." | 3.68 | Ultrastructural and electrophysiological alterations during the development of catecholamine-induced cardiac hypertrophy and failure. ( Lévai, G; Mészáros, J, 1990) |
| "To assess the role of verapamil (VER)-sensitive calcium (Ca2+) channels in the regional development and pathogenesis of isoproterenol (ISO)-induced cardiac hypertrophy, male Fischer rats (150-175 g, N = 51) were divided into control (C) and ISO-treated (I) and VER (V1, 100 mg/L drinking water; V2, 10 mg/kg ip twice daily) and no-VER subgroups." | 3.68 | Verapamil does not prevent isoproterenol-induced cardiac hypertrophy. ( Allard, MF; Bishop, SP; Doss, LK, 1990) |
| "Three models of cardiac hypertrophy (aortic constriction, application of isoproterenol, daily injections of triiodothyronine) were characterized in haemodynamic and in metabolic terms." | 3.67 | Correlation between haemodynamic and metabolic changes in three models of experimental cardiac hypertrophy. ( Zimmer, HG, 1984) |
| "The development of cardiac hypertrophy was studied in adult female Wistar rats following daily subcutaneous injections of isoproterenol (ISO) (0." | 3.67 | Development of isoproterenol-induced cardiac hypertrophy. ( Tang, Q; Taylor, PB, 1984) |
| "Cardiac hypertrophy was induced in adult female Wistar rats after 8 days of daily subcutaneous injections of isoproterenol (ISO)." | 3.67 | Regression of isoproterenol-induced cardiac hypertrophy. ( Tang, Q; Taylor, PB, 1984) |
| "The present study was carried out to determine the beta-receptor subtype responsible for the hypertrophy and dysfunction of parotid glands in rats chronically treated with isoproterenol (ISP)." | 3.67 | Hypertrophy and dysfunction of parotid gland induced by chronic stimulation of beta 1-adrenergic receptors. ( Ohshika, H; Suzuki, Y, 1985) |
| "Isoproterenol (IPR) administered to rats in a dose of 5 mg/kg for 4 days induces cardiac hypertrophy." | 3.67 | Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat. ( Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1985) |
| "The beta-adrenergic system has been explored in cardiac hypertrophy (CH) by combining an in vitro study of the inotropic effect of isoproterenol (ISO) and of forskolin (FSK) and binding assays using radioactive pindolol." | 3.67 | Beta-adrenergic system is modified in compensatory pressure cardiac overload in rats: physiological and biochemical evidence. ( Callens-el Amrani, F; Chevalier, B; Mansier, P; Swynghedauw, B, 1989) |
| "Cardiac hypertrophy was induced in adult female Wistar rats following 12 days of daily subcutaneous injections of isoproterenol (ISO)." | 3.67 | Effect of catecholamine-induced cardiac hypertrophy on the force-interval relationship. ( Churchill, D; Helbing, RK; Rourke, S; Taylor, PB, 1989) |
| "Isoproterenol treatment leads to endomyocardial fibrosis with muscle fibers encircled by fibrillar collagen." | 3.67 | Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment. ( Abrahams, C; Jalil, JE; Janicki, JS; Pick, R; Weber, KT, 1989) |
| "Treatment of rats with the beta-adrenergic agonist isoproterenol results in cardiac hypertrophy, myocyte necrosis, and interstitial cell fibrosis." | 3.67 | Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis. ( Benjamin, IJ; Cho, K; Clark, WA; Jalil, JE; Tan, LB; Weber, KT, 1989) |
| "Cardiac hypertrophy in adult rabbits was induced by subcutaneous injection of isoproterenol." | 3.67 | Phosphorylation of ribosomal and ribosome-associated proteins in isoproterenol-induced cardiac hypertrophy. ( Lee, JC; Pickett, S, 1985) |
| "The left ventricular function of 23 patients with essential hypertension was investigated during infusion of isoproterenol (ISP)." | 3.67 | [Left ventricular function in essential hypertension during isoproterenol infusion]. ( Hirota, K; Kajino, H; Kawarabayashi, T; Murai, K; Nishikimi, T; Oku, H; Takeda, T; Takeuchi, K; Yasuda, M; Yoshimura, T, 1985) |
| "The left ventricular function of patients with essential hypertension was examined during exercise and isoproterenol (ISP) infusion echocardiography." | 3.67 | Cardiac function of patients with essential hypertension during exercise and isoproterenol infusion. ( Komatsu, H; Murai, K; Nishikimi, T; Oku, H; Takeda, T; Takeuchi, K; Yasuda, M, 1987) |
| "Administration of a single high dose or multiple low doses of isoproterenol (ISO) to rats induces myocardial necrosis and cardiac hypertrophy." | 3.67 | Quantification of myocardial necrosis and cardiac hypertrophy in isoproterenol-treated rats. ( Brinkman, CJ; Knufman, NM; van der Laarse, A; Vliegen, HW, 1987) |
| "Cardiac hypertrophy was induced in adult female Wistar rats by daily subcutaneous injections of isoproterenol (0." | 3.67 | Catecholamine induced cardiac hypertrophy. ( Helbing, RK; Tang, Q; Taylor, PB, 1987) |
| "In this work, we compared the electrophysiological and metabolic parameters of a volume overload model of cardiac hypertrophy (aorto-caval fistula) with those of two other models of hypertrophy (aortic stenosis and isoproterenol pretreatment)." | 3.67 | [Absence, in the hypertrophied rat heart caused by aortocaval fistula, of several metabolic and electrophysiological changes seen in other models of hypertrophy]. ( Aussedat, J; Kreher, P; Thollon, C; Verdetti, J, 1985) |
| "In response to norepinephrine or isoproterenol, dogs with pressure overload cardiac hypertrophy showed depressed contractility and myocardial lactic acid production when compared to normal dogs." | 3.66 | A differential effect of ouabain and beta-agonists on contractility and lactic acid production in the hypertrophied heart. ( Ellison, DM; Newman, WH, 1980) |
| " In all three models of experimentally induced cardiac hypertrophy, the enhancement of myocardial adenine nucleotide biosynthesis was potentiated by ribose." | 3.66 | Studies on the hexose monophosphate shunt in the myocardium during development of hypertrophy. ( Ibel, H; Steinkopff, G; Zimmer, HG, 1980) |
| "Cardiac hypertrophy, induced in rats by either tri-iodothyronine or isoproterenol, administered daily for 7 days, was monitored using several parameters." | 3.66 | Protein synthesis in the early stages of cardiac hypertrophy. ( Clarke, K; Ward, LC, 1983) |
| "During the past 5 years, we have seen six patients who met inclusion criteria of exertional palpitations, reproducible treadmill (TM) provocable ventricular tachycardia (VT), and performance of electrophysiologic (EP) studies including isoproterenol (ISO) infusion." | 3.66 | Exercise provocable right ventricular outflow tract tachycardia. ( Ashley, WW; Bauernfeind, RA; Palileo, EV; Petropoulos, AT; Rosen, KM; Strasberg, B; Swiryn, S, 1982) |
| "6) activity were studied in hypertrophic heart of spontaneously hypertensive rats as well as in the heart of Wistar rats during the development and regression of cardiac hypertrophy induced by isoproterenol administration." | 3.66 | Polyamine levels and diamine oxidase activity in hypertrophic heart of spontaneously hypertensive rats and of rats treated with isoproterenol. ( Desiderio, MA; Perin, A; Sessa, A, 1983) |
| "Two different conditions responsible for cardiac hypertrophy in the rat were investigated: the first one is isoproterenol-induced myocardial infarct, the second is exposure to hypoxia (0." | 3.66 | Myocardial hypertrophy in the rat. Correlation between two experimental models. ( Cacciapuoti, AA; Chiariello, M; Condorelli, M; Ferro, G; Genovese, A, 1980) |
| "The main biochemical features of protein synthesis in the myocardium are described as well as several metabolic alterations that occur during the very early stages in three models of cardiac hypertrophy resulting from pressure overload in vivo and in vitro, application of a high dose of isoprenaline and repeated daily administration of triiodothyronine." | 3.66 | Early metabolic alterations during the development of experimentally induced cardiac hypertrophy. ( Gerlach, E; Zimmer, HG, 1980) |
| "Chronic administration of isoproterenol (ISO) produces hypertrophy of the rat heart and tibialis muscle." | 3.66 | Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle. ( Deshaies, Y; Leblanc, J; Willemot, J, 1981) |
| "Cardiac hypertrophy was induced in rabbits by injecting either thyroxine or isoprenaline or by surgically constricting the abdominal aorta." | 3.66 | The relationship between fibrosis and lactate dehydrogenase isoenzymes in the experimental hypertrophic heart of rabbits. ( Cameron, AJ; Revis, NW, 1978) |
| "Daily administration of d,l isoproterenol-HCl (5 mg/kg) in rats for periods of 14-21 days results in marked cardiac hypertrophy and a decrease in cardiac actomyosin ATPase activity." | 3.66 | Characterization of the decreased ATPase activity of rat cardiac actomyosin in isoproterenol-induced cardiac hypertrophy. ( Inchiosa, MA; Pagano, VT, 1979) |
| "Cardiac hypertrophy was induced in rabbits by subcutaneous injection of thyroxine or isoprenaline or by surgically constricting the abdominal aorta." | 3.66 | Metabolism of lipids in experimental hypertrophic hearts of rabbits. ( Cameron, AJ; Revis, NW, 1979) |
| "Initial and transient increases in the basal levels of cyclic GMP in the heart were noted prior to cardiac hypertrophy in rats administered isoproterenol." | 3.66 | Alterations in activities of cyclic nucleotide systems and in beta-adrenergic receptor-mediated activation of cyclic AMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy. ( Brackett, NL; Kuo, JF; Tse, J, 1978) |
| " Analysis of ventricular weight to body weight ratio indicates that isoproterenol was a more effective stimulus of hypertrophy if given during the dark period, when the rat is most active, than when administered during the light hours." | 3.65 | A diurnal rhythm of incorporation of L-[3H] leucine in myocardium of the rat. ( Meyer, DK; Rau, E, 1975) |
| "Isoproterenol (IPR) administered to rats in a dose of 5 mg/kg for seven days induces cardiomegaly." | 3.65 | Experimental cardiac hypertrophy induced by isoproterenol in the rat. ( Csáky, L; Szabó, J; Szegi, J, 1975) |
| "The effect of the beta-blocking agents propranolol and oxprenolol on isoproterenol-induced cardiac hypertrophy has been investigated in the rat." | 3.65 | Prevention of isoproterenol-induced cardiac hypertrophy by beta-blocking agents in the rat. ( Csáky, L; Nosztray, K; Szabó, J; Szegi, J, 1976) |
| " Cardiac hypertrophy was induced by isoproterenol treatment." | 3.65 | Studies on adenosine triphosphatase activity of rat cardiac myosin in isoproterenol-induced cardiac hypertrophy. ( Nosztray, K; Szabó, J; Szöör, A, 1977) |
| " Cardiomegaly has been produced in rats by sideropenic anaemia, by isoprenaline or thyroxine or by the application of both drugs, by artificial increase in resistance to blood flow and by long-term adaptation to hypoxia and physical stress." | 3.65 | The growth of the muscular and collagenous parts of the rat heart in various forms of cardiomegaly. ( Bartosová, D; Chvapil, M; Korecký, B; Poupa, O; Rakusan, K; Turek, Z; Vízek, M, 1969) |
| "Cardiac hypertrophy was induced by subcutaneous injections with isoproterenol (5 mg/kg b." | 1.91 | Calanus oil attenuates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress. ( Abdellatif, SY; Elsharkawy, SH; Fares, NH; Mahmoud, YI, 2023) |
| "In cases of heart failure, cardiac hypertrophy may be caused by the upregulation of G-protein-coupled receptor kinase 2 (GRK2)." | 1.91 | GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress. ( Ding, L; Gao, D; Li, W; Li, X; Liu, J; Niu, X, 2023) |
| "Pathological cardiac hypertrophy is a major cause of heart failure, and there is no effective approach for its prevention or treatment." | 1.91 | Trim65 attenuates isoproterenol-induced cardiac hypertrophy by promoting autophagy and ameliorating mitochondrial dysfunction via the Jak1/Stat1 signaling pathway. ( Deng, H; Jiang, Z; Liu, H; Liu, X; Ren, Z; Tian, Z; Wu, Z; Zhou, Z, 2023) |
| "Cardiac hypertrophy is associated with increased translation." | 1.91 | OGFOD1 modulates the transcriptional and proteomic landscapes to alter isoproterenol-induced hypertrophy susceptibility. ( Harris, M; Kennedy, LM; Murphy, E; Rodriguez, R, 2023) |
| "Cardiac hypertrophy was induced in rats by subcutaneous injection of isoproterenol (ISO, 1." | 1.91 | JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit. ( Cai, SD; Feng, GS; Guo, Z; Hu, YH; Javaheri, A; Li, Q; Li, ZZ; Liang, LY; Liu, PQ; Lu, J; Luo, WW; Valenzuela Ripoll, C; Wang, L; Wang, QQ; Wu, ZK; Zhang, JG, 2023) |
| "The cardiac mitochondrial damage and cardiac hypertrophy pathways are intimately associated with the pathology of myocardial infarction (MI)." | 1.91 | Protective effects of β-caryophyllene on mitochondrial damage and cardiac hypertrophy pathways in isoproterenol-induced myocardial infarcted rats. ( Ponnian, SMP; Stanely, SP; Yovas, A, 2023) |
| "Pathological cardiac hypertrophy is a characteristic feature in many cardiovascular diseases (CVDs)." | 1.72 | Aloin alleviates pathological cardiac hypertrophy via modulation of the oxidative and fibrotic response. ( Kulhari, U; Kumar, A; Kundu, S; Mugale, MN; Murty, US; Ram, C; Sahu, BD; Syed, AM, 2022) |
| "However, the anti-cardiac hypertrophy effects of TFLF in vivo and the underlying mechanisms remain to be elucidated." | 1.72 | Smilax glabra Roxb. flavonoids protect against pathological cardiac hypertrophy by inhibiting the Raf/MEK/ERK pathway: In vivo and in vitro studies. ( Cai, Y; Cai, Z; Fu, D; Liu, J; Tu, J; Wang, D; Xu, S; Zhou, J, 2022) |
| "Pirfenidone is a promising agent for the treatment of idiopathic pulmonary fibrosis and has recently proven to exert inhibitory effects on the inflammatory response." | 1.72 | Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway. ( Cao, Q; Chen, Z; Huang, X; Lai, H; Ouyang, X; Tao, Y; Wang, S; Wang, Y; Yang, L; Zhou, H, 2022) |
| "Hypertrophic cardiomyopathy is a major cause of mortality worldwide." | 1.72 | Cardioprotective Effect of Polymyxin-B and Dantrolene Combination on Isoproterenol-Induced Hypertrophic Cardiomyopathy in Rats, via Attenuation of Calmodulin-Dependent Protein Kinase II. ( Bhatt, LK; Shaikh, F, 2022) |
| "In vivo, cardiac hypertrophy was established by subcutaneous injection of isoprenaline (6 mg/kg·day) in C57BL/6 mice for 7 consecutive days." | 1.72 | Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics. ( Bao, G; Gao, C; Guo, X; Han, B; Hu, H; Jiang, X; Liu, M; Ma, W; Zhang, K; Zhao, Z, 2022) |
| "Protocatechuic acid treatment reversed these effects." | 1.62 | Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1-Sp1-PKCγ axis. ( Bai, L; Han, X; Jeong, MH; Kee, HJ; Kee, SJ; Zhao, T, 2021) |
| "Rats were injected with ISO to induce cardiac hypertrophy and treated with MCP." | 1.62 | Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway. ( Li, AY; Li, Y; Liu, WZ; Liu, XC; Song, QH; Sun, JH; Xu, GR; Yang, HX; Zhang, C; Zhang, Y; Zhou, WW, 2021) |
| "Isoprenaline-induced cardiac hypertrophy can deteriorate to heart failure, which is a leading cause of mortality." | 1.62 | Vasonatrin peptide, a synthetic natriuretic peptide, attenuates myocardial injury and oxidative stress in isoprenaline-induced cardiomyocyte hypertrophy. ( Chang, P; Chen, W; Wang, J; Wang, X; Yu, J; Zhang, J; Zhang, X; Zhu, X, 2021) |
| "Cardiac hypertrophy is considered to be a leading factor in heart function-related deaths." | 1.56 | UBE3A alleviates isoproterenol-induced cardiac hypertrophy through the inhibition of the TLR4/MMP-9 signaling pathway. ( Cao, Y; Chen, J; Gu, B; Gu, S; Jin, Y; Jin, Z; Li, X; Li, Y; Ma, L; Ning, Z; Tian, J; Tu, J; Wang, Z, 2020) |
| "Recent data show that cardiac hypertrophy contributes substantially to the overall heart failure burden." | 1.56 | STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways. ( Ke, Q; Liu, B; Liu, F; Mei, Y; Su, H; Sun, X; Tan, W, 2020) |
| "However, its mechanism of action in cardiac hypertrophy has not been fully explained." | 1.56 | LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis. ( Liang, C; Luo, Y; Xu, Y; Zhang, T, 2020) |
| "A rat model of cardiac hypertrophy was induced by isoproterenol treatment (5 mg·kg-1·day-1) for 4 weeks, with or without ALS treatment at 20 mg·kg-1·day-1." | 1.56 | Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways. ( Guo, D; Liu, H; Zhao, Z, 2020) |
| "Cardiac hypertrophy was induced in the zebrafish following a pretreatment with erythromycin (ERY), and the onset and reconciliation of disease by YDR were determined using a treadmill electrocardiogram, heart anatomy analysis, C-reactive protein release, and platelet aggregation time-analysis." | 1.56 | Application of Zebrafish Model in the Suppression of Drug-Induced Cardiac Hypertrophy by Traditional Indian Medicine Yogendra Ras. ( Balkrishna, A; Bhattacharya, K; Rustagi, Y; Varshney, A, 2020) |
| "Cardiac hypertrophy is an independent risk factor of many cardiovascular diseases." | 1.56 | Cymbopogon Proximus Essential Oil Protects Rats against Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis. ( Abdel-Kader, MS; Albaqami, FF; Alharthy, KM; Althurwi, HN; Salkini, MA, 2020) |
| "Pathological cardiac hypertrophy is ultimately accompanied by cardiomyocyte apoptosis." | 1.56 | Taurine attenuates isoproterenol-induced H9c2 cardiomyocytes hypertrophy by improving antioxidative ability and inhibiting calpain-1-mediated apoptosis. ( Hu, J; Li, W; Lin, S; Lyu, Q; Wu, G; Yang, J; Yang, Q, 2020) |
| "Cardiac hypertrophy is an adaptive response to stress, in order to maintain proper cardiac function." | 1.56 | Imine stilbene analog ameliorate isoproterenol-induced cardiac hypertrophy and hydrogen peroxide-induced apoptosis. ( Bhadra, MP; Bhukya, CK; Chakrabarti, M; Manchineela, S; Mendonza, JJ; Naini, R; Nallari, P; Raut, GK; Reddy, VD; Suresh, Y; Venkateshwari, A, 2020) |
| "Potential early markers for cardiac hypertrophy as APBB1, GOLGA4, HOOK1, KATNA1, KIFBP, MAN2B2, and SLC16A1 are also reported." | 1.56 | Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase. ( de Jesus, ICG; Figueiredo, HCP; Gómez-Mendoza, DP; Guatimosim, S; Kjeldsen, F; Lemos, RP; Parreira, RC; Pinto, MCX; Resende, RR; Rezende, CP; Santos, AK; Verano-Braga, T, 2020) |
| "Memantine treatment reduced the expression of cardiac TNF-α in comparison to Iso group." | 1.56 | Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies. ( Abbaszadeh, S; Jannesar, K; Malekinejad, H; Soraya, H, 2020) |
| "Piperine pretreatment significantly prevented these changes in ISO treated group." | 1.56 | The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity. ( Aliev, G; Beeraka, NM; Chubarev, VN; Dhivya, V; Gavryushova, LV; Huang, CY; Mikhaleva, LM; Minyaeva, NN; Tarasov, VV; Viswanadha, VP, 2020) |
| "Cardiac hypertrophy is the underlying cause of heart failure and is characterized by excessive oxidative stress leading to collagen deposition." | 1.56 | Targeting the Nrf2/ARE Signalling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis. ( Chakrapani, LN; Kalaiselvi, P; Kishore Kumar, SN; Mohan, T; Ravi, DB; Singh, A; Srinivasan, A; Varadharaj, S; Velusamy, P, 2020) |
| "It was found that SMYAD could regulate cardiac hypertrophy and fibrosis makers' mRNA levels in vitro and vivo." | 1.56 | Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure. ( Chen, Y; Jiang, Y; Yao, X; Zhang, F; Zhang, X; Zhao, Y; Zhu, L, 2020) |
| "The nuclear HMGB1 may prevent from cardiac hypertrophy, whereas its exogenous protein is proven to induce hypertrophic response." | 1.51 | PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy. ( Guo, Z; Li, Q; Li, ZM; Liu, PQ; Lu, J; Sun, SY; Wang, LP; Wang, PX; Yang, HW; Ye, JT, 2019) |
| "Here, cardiac hypertrophy was induced by injection of l-thyroxine or ISO in SD rats." | 1.51 | AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway. ( Hu, X; Li, T; Liu, J; Ou-Yang, Q; Wang, L; Xie, X, 2019) |
| "PPAR-γ is an inhibitor of cardiac hypertrophy (CH) signaling pathways." | 1.51 | Hesperidin regresses cardiac hypertrophy by virtue of PPAR-γ agonistic, anti-inflammatory, antiapoptotic, and antioxidant properties. ( Arya, DS; Bhargava, P; Bhatia, J; Khan, SI; Malik, S; Verma, VK, 2019) |
| "However, its potential effect on cardiac hypertrophy remains unclear." | 1.51 | Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway. ( Bi, X; Hong, H; Lu, J; Wang, J; Ye, J; Yu, Y; Yuan, J; Zhang, Y, 2019) |
| "Plantamajoside (PMS) is an active component extracted from Herba Plantaginis, which is a traditional Chinese medicine, and many biological activities of PMS have been reported." | 1.51 | Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway. ( Hou, M; Liu, Y; Pin, L; Shang, L; Shun, M; Zhang, Y; Zhong, X; Zhu, S, 2019) |
| "Cardiac fibrosis was induced in C57BL/6 mice by subcutaneously injecting isoproterenol." | 1.51 | SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition. ( Fan, XF; Gong, YS; Han, LP; Li, X; Liu, ZH; Wang, X; Zhang, Y, 2019) |
| "Understanding the relationship between cardiac hypertrophy induced oxidative injuries and supporters of endogenous reparatory machinery will help in establishing the beneficial role of adequate antioxidant supplementation." | 1.48 | Comparative study of the antioxidant properties of monocarbonyl curcumin analogues C66 and B2BrBC in isoproteranol induced cardiac damage. ( Bogdanov, J; Bogdanova-Popov, B; Gagov, H; Gjorgievska, E; Hadzi-Petrushev, N; Ilievska, J; Kamkin, A; Krajoska, J; Mitrokhin, V; Mladenov, M; Sopi, R, 2018) |
| "To evaluate the roles of KLF15 in cardiac hypertrophy, we generated transgenic mice overexpressing KLF15 of KLF15 knockdown mice and subsequently induced cardiac hypertrophy." | 1.46 | KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling. ( Du, Y; Gao, L; Guo, Y; Liu, X; Shang, D, 2017) |
| "ISO-induced cardiac hypertrophy, characterized by an increase in the heart weight/body weight ratio, CSA and ventricular wall thickness." | 1.46 | Specific α7 nicotinic acetylcholine receptor agonist ameliorates isoproterenol-induced cardiac remodelling in mice through TGF-β1/Smad3 pathway. ( Fang, HL; He, X; Li, DL; Liu, JJ; Lu, Y; Sun, L; Wang, S; Wei, XL; Yang, YH; Yu, XJ; Zang, WJ; Zhang, N; Zhao, M, 2017) |
| "Pathological cardiac hypertrophy used to be elucidated by biomechanical, stretch-sensitive or neurohumoral mechanisms." | 1.46 | Senescence as a novel mechanism involved in β-adrenergic receptor mediated cardiac hypertrophy. ( Chen, L; Li, Z; Shi, D; Sun, R; Sun, Y; Xiong, K; Xue, L; Zhang, Y; Zhu, B, 2017) |
| "The development of cardiac hypertrophy is a complicated process, which undergoes a transition from compensatory hypertrophy to heart failure, and the identification of new biomarkers and targets for this disease is greatly needed." | 1.46 | Alterations in NO/ROS ratio and expression of Trx1 and Prdx2 in isoproterenol-induced cardiac hypertrophy. ( Pistolozzi, M; Shi, X; Su, H; Sun, X; Tan, W, 2017) |
| "Cardiac hypertrophy was induced by ISO (5mg/kg/day s." | 1.46 | Proteomic analysis of the protective effects of aqueous bark extract of Terminalia arjuna (Roxb.) on isoproterenol-induced cardiac hypertrophy in rats. ( Ahmad, S; Goswami, SK; Jahangir Alam, M; Kumar, S; Maulik, SK; Prabhakar, P; Sharma, M, 2017) |
| "While Huntington's disease (HD) is classified as a neurological disorder, HD patients exhibit a high incidence of cardiovascular events leading to heart failure and death." | 1.43 | Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease. ( Colwell, CS; Coppola, G; Fishbein, MC; Gao, F; Ghiani, CA; Jordan, MC; Park, S; Roos, KP; Schroeder, AM; Wang, HB, 2016) |
| "However, early detection of cardiac hypertrophy is difficult by the currently used non-invasive method and new approaches are in urgent need for efficient diagnosis of cardiac malfunction." | 1.43 | Speckle Tracking Based Strain Analysis Is Sensitive for Early Detection of Pathological Cardiac Hypertrophy. ( An, X; Bai, Y; Li, H; Lu, Z; Song, Y; Wang, J; Xiao, H; Zhang, Y, 2016) |
| "To evaluate the role of miR-99a in cardiac hypertrophy, we assessed the expression of miR-99a in hypertrophic cardiomyocytes induced by isoprenaline (ISO)/angiotensin-II (Ang II) and in mice model of cardiac hypertrophy induced by transverse aortic constriction (TAC)." | 1.43 | Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy. ( Bai, J; Ding, L; Gu, R; Li, Q; Li, R; Wang, B; Wang, L; Xie, J; Xu, B, 2016) |
| "Long-lasting cardiac hypertrophy results in the loss of compensation by cardiomyocytes which could ultimately develop into heart failure." | 1.43 | Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-κb pathway. ( Ai, JQ; Chang, YX; Chen, L; Gao, XM; Gao, YH; Mao, HP; Niu, ZC; Wang, XY, 2016) |
| "ISO-caused cardiac hypertrophy accompanying with a significant decrease in autophagy activity." | 1.43 | SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy. ( Cai, Y; Chen, S; Gao, S; Hong, H; Li, H; Li, M; Li, Z; Liu, C; Liu, P; Liu, Z; Lu, J; Sun, D; Ye, J, 2016) |
| "Whether DFMO attenuates cardiac hypertrophy through endoplasmic reticulum stress (ERS) is unclear." | 1.43 | Endoplasmic Reticulum Stress is Involved in DFMO Attenuating Isoproterenol-Induced Cardiac Hypertrophy in Rats. ( Jin, L; Li, B; Lian, J; Lin, Y; Liu, J; Wang, J; Xiao, W; Zhang, X; Zhou, L, 2016) |
| "The study of the mechanisms leading to cardiac hypertrophy is essential to better understand cardiac development and regeneration." | 1.43 | Loss of Mouse P2Y6 Nucleotide Receptor Is Associated with Physiological Macrocardia and Amplified Pathological Cardiac Hypertrophy. ( Balligand, JL; Beauloye, C; Boeynaems, JM; Clouet, S; Communi, D; Daskalopoulos, EP; Di Pietrantonio, L; Esfahani, H; Horckmans, M; Lemaire, A; Vanorlé, M, 2016) |
| "Gallic acid pretreatment attenuated concentric cardiac hypertrophy." | 1.43 | Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity. ( Cho, JY; Choi, SY; Jeong, MH; Jin, L; Kee, HJ; Kim, GR; Lin, MQ; Piao, ZH; Ryu, Y, 2016) |
| " In conclusion, the present study indicated that chronic use of KATP channel agonists following cardiac hypertrophy can attenuate ventricular remodeling and upregulate the expression level and spatial distribution of Cx43." | 1.42 | Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist. ( Gu, J; Guo, Z; Hao, YY; Sun, JM; Wang, AL; Wang, CM; Xie, YJ, 2015) |
| "Pathologic cardiac hypertrophy is one of the leading causes of sudden death from cardiac disease and involves a complex network of bio-signaling mechanisms." | 1.42 | N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy. ( DaSilva, JN; Fernando, P; Moreau, S; Valdivia, A, 2015) |
| "Pretreatment with zingerone prevented hyperlipidaemia and cardiac hypertrophy, by virtue of its antihyperlipidaemic, antihypertrophic, and reducing properties in isoproterenol-induced myocardial infarcted rats." | 1.42 | Antihyperlipidaemic, antihypertrophic, and reducing effects of zingerone on experimentally induced myocardial infarcted rats. ( Hemalatha, KL; Stanely Mainzen Prince, P, 2015) |
| "Here, the roles of NOR1 in cardiac hypertrophy induced by isoprenaline and the underlying molecular mechanisms were investigated." | 1.42 | The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1. ( Feng, XJ; Gao, H; Gao, S; Huang, XY; Li, H; Li, Z; Liu, M; Liu, PQ; Lu, J; Wang, JJ; Ye, JT; Zou, J, 2015) |
| "Honokiol (HKL) is a natural biphenolic compound derived from the bark of magnolia trees with anti-inflammatory, anti-oxidative, anti-tumour and neuroprotective properties." | 1.42 | Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3. ( Arbiser, JL; Bonner, MY; Gius, D; Gupta, MP; Jones, DP; Kim, G; Pillai, VB; Raghuraman, H; Samant, S; Sundaresan, NR; Walker, DI, 2015) |
| "In an in vivo model of cardiac hypertrophy, expression of MITF and the BRG1 subunit of the SWI/SNF complex increased coordinately in response to pressure overload." | 1.42 | MITF interacts with the SWI/SNF subunit, BRG1, to promote GATA4 expression in cardiac hypertrophy. ( de la Serna, IL; Joe, B; Kumarasamy, S; Liu, L; Mehta, G; Walsh, A; Williams, K; Wu, J, 2015) |
| "Cardiac hypertrophy is an independent risk factor for cardiovascular disease and its subsequent progression to heart failure represents a major cause of morbidity and mortality in the world." | 1.40 | Chlorogenic acid prevents isoproterenol-induced hypertrophy in neonatal rat myocytes. ( Feng, J; Li, J; Li, P; Li, X; Li, Y; Shen, D; Song, R; Tang, X; Wo, D; Yan, H; Zhang, J, 2014) |
| "Cardiac hypertrophy was induced in mice either by isoproterenol administration or by aortic constriction." | 1.40 | Erbin is a negative modulator of cardiac hypertrophy. ( Borg, JP; Dagan, N; Foo, RS; Gilon, D; Golomb, E; Kay, G; Marchetto, S; Oppenheim, A; Rachmin, I; Razin, E; Smith, Y; Tshori, S, 2014) |
| "All mice were 10 weeks of age." | 1.40 | Gestational hypertension and the developmental origins of cardiac hypertrophy and diastolic dysfunction. ( Armstrong, DW; Johri, AM; Matangi, MF; Meens, JA; Pang, SC; Tse, MY; Ventura, NM; Wong, PG, 2014) |
| "Pathological cardiac hypertrophy induced by increased sympathetic drive can subsequently lead to congestive heart failure, which represents the major cause of morbidity and mortality worldwide." | 1.40 | Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades. ( Dai, H; Jia, G; Liu, X; Liu, Z; Wang, H, 2014) |
| "Results showed that ISO-induced cardiac hypertrophy was enhanced in CM Klf4 KO mice compared with control mice." | 1.40 | Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity. ( Hayashi, M; Horimai, C; Yamashita, M; Yoshida, T, 2014) |
| "NAC may suppress ISO-induced cardiac hypertrophy by down-regulating the expression of activated-CaMKII, and by reducing the level of oxidative stress originated from mitochondria and NADPH oxidase pathways." | 1.39 | [Oxidative stress and calcium/calmodulin-dependent protein kinase II contribute to the development of sustained β adrenergic receptor-stimulated cardiac hypertrophy in rats]. ( Chai, HJ; Li, R; Liu, B; Liu, YL; Qu, YY; Zhang, L, 2013) |
| "Also HRC-null mice exhibited severe cardiac hypertrophy, fibrosis, pulmonary edema and decreased survival after TAC." | 1.39 | Targeted ablation of the histidine-rich Ca(2+)-binding protein (HRC) gene is associated with abnormal SR Ca(2+)-cycling and severe pathology under pressure-overload stress. ( Bers, DM; Cha, H; Chen, S; Cho, C; Franzini-Armstrong, C; Ginsburg, KS; Han, P; Hong, S; Jin, S; Kim, DH; Kranias, EG; Lee, H; Oh, JG; Park, CS; Park, I; Park, WJ; Singh, VP; Wang, HS, 2013) |
| "Vitexin is a flavone glycoside isolated from the leaf of Crataeguspinnatifida Bunge, the utility of which has been demonstrated in several cardiovascular diseases." | 1.39 | Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways. ( Du, ZM; Hang, PZ; Lu, CC; Qi, JC; Wang, C; Wang, Y; Wu, JC; Wu, JW; Xu, YQ; Zhang, Y, 2013) |
| "Heart failure was induced by isoprenaline s." | 1.39 | Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure. ( Cai, Z; Chen, C; Cianflone, K; Duan, Q; Gong, W; Ni, L; Wang, DW; Wang, X; Yan, M, 2013) |
| "Cardiomyocytes treated with hypertrophy agonists displayed rapid and transient activation of the intrinsic-mediated cell death pathway, characterized by elevated levels of caspase 9, followed by caspase 3 protease activity." | 1.39 | Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy. ( Abdul-Ghani, M; Brunette, S; Dick, SA; Fernando, P; Megeney, LA; Putinski, C; Stiles, R, 2013) |
| "Cardiac hypertrophy is associated with a switch towards increased glucose metabolism and decreased fatty acid metabolism." | 1.39 | Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux. ( Baines, CP; Douglas, DL; Krenz, M; McCommis, KS, 2013) |
| "Oxidative stress has been implicated in cardiac hypertrophy and in its transition to heart failure." | 1.39 | Desmodium gangeticum (Linn.) DC. exhibits antihypertrophic effect in isoproterenol-induced cardiomyoblasts via amelioration of oxidative stress and mitochondrial alterations. ( Pangayarselvi, B; Prathapan, A; Raghu, KG; Sankar, V, 2013) |
| "In addition, induction of cardiac hypertrophy by ISO caused remarkable induction in CT-1 mRNA and protein expression levels by approximately 3." | 1.39 | Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection. ( Al-Mazroua, HA; Al-Rasheed, NM; Korashy, HM, 2013) |
| "Cardiac hypertrophy is controlled by a complex signal transduction and gene regulatory network, containing multiple layers of crosstalk and feedback." | 1.38 | Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy. ( Acton, ST; Bass, GT; Dang, ST; Katikapalli, A; Ryall, KA; Saucerman, JJ; Taylor, BE, 2012) |
| "Rats were cold acclimated to induce cardiac hypertrophy and increase cardiac LPL." | 1.38 | Cardiac lipoprotein lipase activity in the hypertrophied heart may be regulated by fatty acid flux. ( Caldwell, GM; Hauton, D, 2012) |
| " These findings provide insight into the apparent loss of cardioprotection after menopause and suggest that caution is warranted in the long-term use of aromatase inhibitors in the setting of breast cancer prevention." | 1.38 | Estrogens mediate cardiac hypertrophy in a stimulus-dependent manner. ( Haines, CD; Harvey, PA; Leinwand, LA, 2012) |
| "Therefore, we can conclude that cardiac hypertrophy led to a reduced sensitivity of baroreflex control of RSNA." | 1.38 | Baroreflex control of renal sympathetic nerve activity in mice with cardiac hypertrophy. ( Abreu, GR; Balarini, CM; Cabral, AM; Gava, AL; Meyrelles, SS; Peotta, VA; Vasquez, EC, 2012) |
| "Isoproterenol (2 mg/kg, IP) was administered daily for 7 days." | 1.37 | An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats. ( Almeida, AP; Caliari, MV; Ferreira, AJ; Irigoyen, MC; Jacoby, BA; Marques, FD; Melo, MB; Nadu, AP; Santos, RA; Silva, GA; Sinisterra, RD; Sousa, FB; Souza, LE, 2011) |
| "Tanshinone IIA is a lipid-soluble pharmacologically active compound extracted from the rhizome of the Chinese herb Salvia miltiorrhiza, a well-known traditional Chinese medicine used for the treatment of cardiovascular disorders." | 1.37 | Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway. ( Cai, B; Chen, N; Dong, D; Li, J; Li, X; Liu, Y; Lu, Y; Shan, H; Tan, X; Wang, G; Wang, X; Yang, B; Yang, F; Zhang, P, 2011) |
| "ISO-induced cardiac hypertrophy and Erk1/2 activation in Pak-1-KO/ISO were attenuated when the selective Erk1/2 inhibitor FR180204 was administered." | 1.37 | Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A. ( Chernoff, J; Ke, Y; Knezevic, I; Lei, M; Monasky, MM; Sheehan, KA; Solaro, RJ; Taglieri, DM; Wang, X; Wolska, BM, 2011) |
| "In vivo, cardiac hypertrophy was induced by injection of ISO (5 mg." | 1.36 | KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways. ( Chen, IJ; Dai, ZK; Hsu, JH; Liou, SF; Liu, CP; Wu, BN; Wu, JR; Wu, PJ; Yeh, JL, 2010) |
| "To prevent cardiac hypertrophy and heart failure, it is necessary to identify and characterize molecules that may regulate the hypertrophic program." | 1.36 | miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy. ( Li, PF; Long, B; Wang, K; Zhou, J, 2010) |
| "No differences in cardiac hypertrophy were obtained by 7-day ISO infusion in 4- to 6-week-old conventional cGKI-KO and CTR mice." | 1.36 | Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes. ( Beavo, JA; Hofmann, F; Leiss, V; Loga, F; Lukowski, R; Rybalkin, SD, 2010) |
| "Chronic isoproterenol (ISO)-induced cardiac hypertrophy was inhibited in wild-type mice and AT1aR(-/-) mice treated with the ARB Candesartan (CV11974)." | 1.36 | Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors. ( Kimura, S; Matsuyoshi, H; Murao, K; Obata, K; Takaki, M; Yu, X; Zhang, GX, 2010) |
| "Isoprenaline-induced cardiac hypertrophy was associated with increased expression of beta myosin heavy chain, which was also prevented by Ro5-4864." | 1.36 | Peripheral benzodiazepine receptor ligand Ro5-4864 inhibits isoprenaline-induced cardiac hypertrophy in rats. ( Dinda, AK; Enjamoori, R; Jaiswal, A; Kumar, S; Maulik, SK; Seth, S, 2010) |
| "Hdac3-Tg mice did not develop cardiac hypertrophy at 3 months of age, unlike previously reported Hdac2-Tg mice." | 1.35 | Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy. ( Epstein, JA; Lu, MM; Trivedi, CM; Wang, Q, 2008) |
| "Isoproterenol treatment significantly reduced 5,6-, 8,9-, 11,12-, and 14,15-epoxyeicosatrienoic acid formation and significantly increased their corresponding 8,9-, and 14,15-dihydroxyeicosatrienoic acid and the 20-hydroxyeicosatetraenoic acid metabolite." | 1.35 | Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats. ( Aboutabl, ME; El-Kadi, AO; Zordoky, BN, 2008) |
| "Atorvastatin treatment of NaCl-infused rats had only marginal effects." | 1.35 | Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects. ( Ehmke, H; El-Armouche, A; Eschenhagen, T; Grimm, M; Höppner, G; Schmechel, A; Schwoerer, AP, 2009) |
| "However, the role of RALT in cardiac hypertrophy remains unclear." | 1.35 | Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling. ( Bian, ZY; Cai, J; Ghosh, AK; Li, A; Li, H; Shen, DF; Tang, QZ; Yan, L; Yang, L; Yang, Q; Yang, XC; Yi, FF, 2009) |
| "In isoprenaline-treated rats, cardiac hypertrophy and dysfunction were found." | 1.35 | Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin. ( Cheng, YS; Dai, DZ; Dai, Y, 2009) |
| "Sodium houttuyfonate can inhibit myocardial hypertrophy in mouse and rat models by restricting the activity of the sympathetic nervous system and decreasing the levels of angiotensin II and endothelin-1 in ventricular tissue." | 1.35 | Effect of sodium houttuyfonate on myocardial hypertrophy in mice and rats. ( Chen, CX; Gao, JP; Gu, WL; Lü, J; Wang, Y, 2009) |
| "Cardiac hypertrophy is associated with a reduction in the contractile response to beta-adrenergic stimulation, and with re-expression of foetal genes such as beta-myosin heavy chain (MHC)." | 1.35 | Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain. ( Pandya, K; Porter, K; Rockman, HA; Smithies, O, 2009) |
| "Cardiac hypertrophy is accompanied by maladaptive cardiac remodeling, which leads to heart failure or sudden death." | 1.35 | miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy. ( Gao, J; Jiao, J; Li, PF; Lin, Z; Murtaza, I; Wang, K, 2009) |
| "Voluntary exercise training resulted in cardiac hypertrophy, the heart weight to body weight ratio being significantly greater in trained compared with sedentary animals." | 1.35 | Voluntary exercise-induced changes in beta2-adrenoceptor signalling in rat ventricular myocytes. ( Billeter, R; Harrison, S; Natali, A; Stones, R; White, E, 2008) |
| "To examine whether cardiac hypertrophy is associated with changes in beta-adrenoceptor signal transduction mechanisms, pressure overload (PO) was induced by occlusion of the abdominal aorta and volume overload (VO) by creation of an aortocaval shunt for 4 and 24 wk in rats." | 1.34 | Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy. ( Dhalla, NS; Elimban, V; Guo, X; Saini, HK; Sethi, R; Wang, X, 2007) |
| "Isoproterenol (ISO) was given to C57BL mice with or without ARB (olmesartan) treatment and to AT1aR(-/-) mice by a subcutaneously implanted osmotic mini-pump for 11 days at a rate of 15 mg/kg/day." | 1.34 | Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice. ( Abe, Y; Fujisawa, Y; Kimura, S; Nagai, Y; Nishiyama, A; Ohmori, K; Zhang, GX, 2007) |
| "Isoproterenol-treated A/J mice demonstrated greater percent increases in echocardiographic LV mass/body weight (97 +/- 11 vs." | 1.33 | Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice. ( Ernsberger, P; Faulx, MD; Hoffman, RD; Hoit, BD; Lewis, W; Strachan, R; Vatner, D, 2005) |
| "These findings suggest that in chronic cardiac hypertrophy, contractile responses to phosphodiesterase inhibitors may be preserved despite marked reductions in inotropic responses to beta-adrenoceptor agonists." | 1.33 | Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats. ( Norton, G; Osadchii, O; Woodiwiss, A, 2005) |
| "Two murine models of cardiac hypertrophy confirmed upregulation of PLCepsilon protein expression or PLCepsilon RNA." | 1.33 | Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy. ( Blaxall, BC; Bullard, TA; Dirksen, RT; Kelley, GG; Maekawa, N; Oestreich, EA; Smrcka, AV; Vikstrom, KL; Wang, H, 2005) |
| "Three stages of cardiac hypertrophy due to volume overload were recognized during the 16-wk period." | 1.32 | Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat. ( Dhalla, NS; Liu, S; Ren, B; Sentex, E; Tappia, PS; Wang, X, 2003) |
| "Cardiac hypertrophy is often associated with an increased sympathetic drive, and both in vitro and in vivo studies have demonstrated the development of cardiomyocyte hypertrophy in response to either alpha- or beta-adrenergic stimulation." | 1.32 | Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition. ( Camihort, G; Camilión de Hurtado, MC; Cingolani, HE; Console, GM; Dumm, CG; Ennis, IL; Escudero, EM; Seidler, RW, 2003) |
| "Rats treated with isoproterenol developed myocardial hypertrophy, and NDPK in the sarcolemma rose by 60% during 14 days of treatment." | 1.32 | Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by beta-adrenergic signaling. ( Hippe, HJ; Lutz, S; Mura, RA; Niroomand, F; Tiefenbacher, C, 2003) |
| "In some models of cardiac hypertrophy, activation of activator protein 1 (AP-1) correlates with growth." | 1.32 | Transcription activator protein 1 mediates alpha- but not beta-adrenergic hypertrophic growth responses in adult cardiomyocytes. ( Best, P; Helmig, S; Piper, HM; Schlüter, KD; Taimor, G, 2004) |
| "After verifying the development of cardiac hypertrophy, we recorded continuous LV pressure-volume (P-V) loops of in situ ejecting hypertrophied rat hearts." | 1.32 | Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts. ( Ito, H; Kitagawa, Y; Takaki, M; Yamashita, D, 2004) |
| "2." | 1.32 | [Effect of zhimu and huangqi on cardiac hypertrophy and response to stimulation in mice]. ( Hou, JY; Hu, YC, 2003) |
| "Stunned myocardium is a syndrome of reversible contractile failure that frequently complicates coronary artery disease." | 1.31 | Transgenic mouse model of stunned myocardium. ( Georgakopoulos, D; Kass, DA; Kögler, H; Marbán, E; McDonough, JL; Murphy, AM; Van Eyk, JE, 2000) |
| "Although cardiac hypertrophy has been the subject of intensive investigation, regression of hypertrophy has been significantly less studied, precluding large-scale analysis of the relationship between these processes." | 1.31 | Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy. ( Bristow, J; Friddle, CJ; Koga, T; Rubin, EM, 2000) |
| "Cardiac hypertrophy was induced in rats by chronic s." | 1.31 | Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation. ( Bokník, P; Fockenbrock, M; Herzig, S; Knapp, J; Linck, B; Lüss, H; Müller, FU; Müller, T; Neumann, J; Schmitz, W; Schröder, F, 2000) |
| "To test the hypothesis that dilated cardiomyopathy (DCM) is part of the pathological spectrum of HCM, we studied chamber morphology, exercise tolerance, hemodynamics, isolated heart function, adrenergic sensitivity, and embryonic gene expression in 8- to 11-mo-old male transgenic animals." | 1.31 | Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene. ( Colon-Rivera, C; Freeman, K; Grupp, IL; Iaccarino, G; Koch, WJ; Leinwand, LA; Moore, RL; Olsson, MC; Vikstrom, KL; Weinberger, HD, 2001) |
| "V-O cardiac hypertrophy was induced in rabbits by the formation of an arterio-venous shunt between the carotid artery and jugular vein 12 to 15 weeks after the operation." | 1.31 | Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes. ( Atsumi, H; Endoh, M; Nakada, S; Sakurai, K; Sugawara, H; Tomoike, H, 2000) |
| "Isoproterenol pretreatment caused cardiac hypertrophy (29%) as shown by a significant increase in the ratio of ventricular dry weight to body weight." | 1.31 | Effects of long-term pretreatment with isoproterenol on inotropic responsiveness to alpha-adrenoceptor stimulation: study in isolated perfused rat hearts. ( Duarte, GP; Lahlou, S; Monteiro-Filho, WO; Silva, CO, 2001) |
| "Isoproterenol failed to activate ERKs in either the cultured cardiomyocytes or the hearts of mice that overexpress the dominant negative mutant of calcineurin." | 1.31 | Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin. ( Hiroi, Y; Kohmoto, O; Komuro, I; Kudoh, S; Nagai, R; Shibasaki, F; Shimoyama, M; Takahashi, T; Uozumi, H; Yao, A; Yazaki, Y; Zhu, W; Zou, Y, 2001) |
| "ACF induced cardiac hypertrophy in rats with compensated (36%) and decompensated (76%) HF." | 1.31 | Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure. ( Abassi, Z; Binah, O; Gealekman, O; Rubinstein, I; Winaver, J, 2002) |
| "Isoproterenol was continuously administered to rats at a rate of 2." | 1.30 | Cardiac beta-adrenergic signaling pathway alteration in isoproterenol-induced cardiac hypertrophy in male Sprague-Dawley rats. ( Hakamata, N; Hamada, H; Nakamura, H; Ohsuzu, F, 1997) |
| "SOP." | 1.30 | Nitric oxide inhibits isoprenaline-induced positive inotropic effects in normal, but not in hypertrophied rat heart. ( Brodde, OE; Heinroth-Hoffmann, I; Kotchi Kotchi, E; Osten, B; Preiss, M; Röhnert, P; Weisselberg, T, 1998) |
| "Cardiac fibrosis was less marked in RV." | 1.30 | Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats. ( Annoni, G; Arosio, B; Fiordaliso, F; Gagliano, N; Latini, R; Luvarà, G; Masson, S; Santambrogio, D; Vergani, C, 1998) |
| "Iso induced cardiac hypertrophy." | 1.30 | Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle. ( Kambe, F; Kamiya, K; Nishiyama, A; Seo, H; Toyama, J, 1998) |
| "Both treatments resulted in cardiac hypertrophy, but only isoproterenol induced significant increases in beta-adrenergic receptor kinase-1 protein levels and activity." | 1.30 | Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation. ( Dolber, PC; Iaccarino, G; Koch, WJ; Lefkowitz, RJ, 1999) |
| "The isoproterenol-induced increase in protein synthesis was also suppressed by inhibitors for PKA, Gi, tyrosine kinases, or Ras." | 1.30 | Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy. ( Kadowaki, T; Komuro, I; Kudoh, S; Uozumi, H; Yamazaki, T; Yazaki, Y; Zou, Y, 1999) |
| "These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor." | 1.30 | Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy. ( Ikeda, J; Miura, S; Nawata, J; Ohno, I; Shirato, K; Suzuki, J, 1999) |
| "Indapamide-treated animals had significantly greater myocardial cAMP concentrations than control animals." | 1.29 | Effect of indapamide on cyclic adenosine 3',5'-monophosphate signal transduction system in isolated adult rat cardiomyocytes from normal myocardium and cardiac hypertrophy. ( Rabkin, SW, 1993) |
| "Dahl S rats developed cardiac hypertrophy on a high-salt diet, whereas Dahl R rats did not." | 1.29 | Angiotensin II induced alteration of cyclic adenosine 3',5'-monophosphate generation in the hypertrophic myocardium of Dahl salt-sensitive rat on a high-salt diet. ( Rabkin, SW; Sunga, PS, 1994) |
| "There were differences between the cardiac hypertrophy and noncardiac hypertrophy groups with regard to the pressor response to exercise and noradrenaline (i." | 1.29 | Cardiovascular response and red cell membrane sodium transport in hypertensive cardiac hypertrophy. ( Deguchi, F; Inagaki, Y; Iwata, J; Kai, N; Saito, T; Yamamoto, K, 1993) |
| "To induce normotensive cardiac hypertrophy, male Wistar rats received injections of isoprenaline (5 mg/kg s." | 1.29 | [Recovery of healthy and hypertrophic hearts after global ischemia and graduated reperfusion]. ( Isselhard, W; Minor, T; Sturz, J, 1993) |
| "It is not clear whether regression of cardiac hypertrophy normalizes cardiac contractility." | 1.28 | Effect of enalapril on the inotropic response to isoproterenol in renal hypertensive rats. ( Fontán, M; Gómez Llambí, H; Mazzadi, A; Taquini, CM, 1992) |
| "Treatment with hydralazine decreased blood pressure in a similar way as trandolapril but did not affect either LV weight or LV Ang II." | 1.28 | Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy. ( Higaki, J; Higashimori, K; Mikami, H; Nagano, M; Nagano, N; Nakamura, F; Ogihara, T, 1992) |
| "These results confirm that cardiac hypertrophy is a heterogeneous process." | 1.28 | Cyclic AMP in myocytes isolated from hypertrophied rat hearts. ( Hilal-Dandan, R; Khairallah, PA, 1991) |
| "To study the cellular mechanisms of arrhythmias occurring in cardiac hypertrophy, we performed standard microelectrode studies on papillary muscles isolated from control (group N) and hypertrophied ferrets right ventricles." | 1.28 | Triggered activity as a possible mechanism for arrhythmias in ventricular hypertrophy. ( Baudet, S; Charpentier, F; Le Marec, H, 1991) |
| "In contrast, T3-induced cardiac hypertrophy was not accompanied by changes in Gi alpha-mRNA expression." | 1.28 | Isoprenaline-induced increase in mRNA levels of inhibitory G-protein alpha-subunits in rat heart. ( Eschenhagen, T; Mende, U; Nose, M; Schmitz, W; Scholz, H; Warnholtz, A; Wüstel, JM, 1991) |
| "The relation between cardiac hypertrophy, shunt size, myocardial contractility, capillary density, adrenergic responsiveness, and neurohumoral stimulation was evaluated in dogs with compensated and decompensated cardiac hypertrophy caused by an infrarenal aorto-caval shunt." | 1.28 | Functional and morphological characteristics of compensated and decompensated cardiac hypertrophy in dogs with chronic infrarenal aorto-caval fistulas. ( Juneau, C; Legault, F; Rakusan, K; Rose, C; Rouleau, JL, 1990) |
| "Cardiac hypertrophy is characterized by marked abnormalities in the contraction/relaxation pattern of the heart." | 1.28 | Isolated myocardial cells: a new tool for the investigation of hypertensive heart disease. ( Neyses, L; Vetter, H, 1990) |
| "Hypertensive cardiac hypertrophy of 20 patients was classified as inappropriate hypertrophy (HH-I) and appropriate hypertrophy (HH-II) according to their end-systolic wall stress, as measured by echocardiography." | 1.28 | Diastolic properties of hypertrophied hearts in essential hypertension: classification by left ventricular wall stress. ( Fujieda, K; Iida, K; Ito, I; Sugishita, Y; Yukisada, K, 1990) |
| "These findings and clinical studies of mitral regurgitation imply that for assessing resting left ventricular contractility in certain chronic conditions, the use of wall stress rather than pressure may be appropriate in the end-systolic framework." | 1.27 | Applications and limitations of end-systolic measures of ventricular performance. ( Ross, J, 1984) |
| " IPR administered to euthyroid rats in a dosage of 5 mg/kg/day for 4 days induced cardiomegaly." | 1.27 | Study of the factors influencing cardiac growth. I. Comparison of cardiomegaly induced by isoproterenol in euthyroid and thyroidectomized rats. ( Nosztray, K; Szabó, J; Szegi, J; Takács, IE, 1984) |
| "Cardiac hypertrophy was induced in rats either by isoprenaline treatment or by experimental abdominal aortic stenosis." | 1.27 | Pyrimidine nucleotide metabolism in cardiac hypertrophy. ( Aussedat, J; Olivarès, J; Ray, A; Rossi, A; Verdys, M, 1984) |
| " The chronic administration of thyroid hormone also results in cardiac hypertrophy and increased numbers of beta-adrenergic receptors in cardiac membranes." | 1.27 | Regression of thyroid hormone induced cardiac hypertrophy: effect on cardiac beta receptors and adenyl cyclase activity. ( Atkins, FL; Carney, R; Love, S, 1983) |
| "The effects of cardiac hypertrophy on the structure, function and tolerance to ischemia of rat hearts have been investigated." | 1.27 | Assessment of hemodynamic function and tolerance to ischemia in the absence or presence of calcium antagonists in hearts of isoproterenol-treated, exercise-trained, and sedentary rats. ( Brinkman, CJ; Huysmans, HA; Kappetein, AP; Los, GJ; van der Laarse, A; Weening, JJ, 1988) |
| "The effects of chronic MtTW15 pituitary adenoma implantation on beta-adrenergic responsiveness, cardiac beta-adrenoreceptors, and muscarinic receptors were studied in the rat." | 1.27 | Beta-adrenergic responsiveness and cardiac autonomic receptors after implantation of the MtTW15 pituitary adenoma in the rat. ( Baker, SP; Katovich, MJ; Nelson, CA, 1987) |
| " Chronic administration of oxfenicine to dogs for 1 year produced dose-related, nonpathological increases in relative heart weight (up to 85% at 750 mg/kg per day)." | 1.27 | Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential. ( Faccini, JM; Greaves, P; Higgins, AJ, 1985) |
| "Studies of stress-induced cardiac hypertrophy suggest that myocardial mass is regulated by the circulating level of epinephrine." | 1.27 | Catecholamine-induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant. ( Copeland, JG; Larson, DF; Russell, DH, 1985) |
| " Metoprolol, a selective beta-1 receptor antagonist, significantly inhibited the glandular enlargement induced by dobutamine or isoproterenol and produced a parallel shift in the isoproterenol dose-response curve." | 1.26 | Adrenergic beta receptors mediating submandibular salivary gland hypertrophy in the rat. ( Brenner, GM; Wulf, RG, 1981) |
| " This inhibition of cellular autophagy is interpreted as an initial anticatabolic reaction which might be responsible for the myocardial hypertrophy after chronic administration of IPR." | 1.26 | Acute effects of isoproterenol on cellular autophagy. Inhibition in myocardium but stimulation in liver parenchyma. ( Dämmrich, J; Pfeifer, U, 1981) |
| "When heart hypertrophy was more pronounced, greater losses in secretin-, as well as in D,L-isoproterenol-, glucagon-, guanine nucleotide-, and fluoride-stimulated enzyme activity developed." | 1.26 | Early decrease in secretin-, glucagon-, and isoproterenol-stimulated cardiac adenylate cyclase activity in rats treated with isoproterenol. ( Camus, JC; Chatelain, P; Christophe, J; De Neef, P; Robberecht, P, 1982) |
| "Reserpine treatment also produced stimulation of taurine influx with no effect on biosynthesis." | 1.26 | The effects of isoproterenol on taurine concentration in the rat heart. ( Chubb, J; Huxtable, R, 1978) |
| "Taurine is a modifier of calcium fluxes in the heart, as are beta-adrenergic agonists." | 1.26 | Adrenergic stimulation of taurine transport by the heart. ( Chubb, J; Huxtable, R, 1977) |
| "Development of cardiac hypertrophy is associated with depletion of endogenous catecholamine stores and increased inotropic response to exogenous catecholamines." | 1.26 | Increased number of beta-adrenergic receptors in the hypertrophied myocardium. ( Limas, CJ, 1979) |
| "Pretreatment with propranolol and pargyline protected against ISO-induced necrosis and myocardial hypertrophy, but did not influence the ISO-induced depletion of NE stores." | 1.25 | Alterations in norepinephrine pattern in the damaged myocardium in the rat. ( Bhagat, B; Dhalla, NS; Sullivan, JM, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 199 (26.01) | 18.7374 |
| 1990's | 109 (14.25) | 18.2507 |
| 2000's | 137 (17.91) | 29.6817 |
| 2010's | 229 (29.93) | 24.3611 |
| 2020's | 91 (11.90) | 2.80 |
| Authors | Studies |
|---|---|
| Bai, L | 5 |
| Kee, HJ | 4 |
| Han, X | 3 |
| Zhao, T | 1 |
| Kee, SJ | 2 |
| Jeong, MH | 4 |
| Zhang, Y | 23 |
| Shang, Z | 1 |
| Liu, A | 1 |
| Li, Y | 13 |
| Zhou, WW | 1 |
| Sun, JH | 1 |
| Yang, HX | 1 |
| Xu, GR | 1 |
| Song, QH | 1 |
| Zhang, C | 5 |
| Liu, WZ | 1 |
| Liu, XC | 1 |
| Li, AY | 1 |
| Hong, MH | 1 |
| Na, SW | 1 |
| Jang, YJ | 1 |
| Yoon, JJ | 1 |
| Lee, YJ | 2 |
| Lee, HS | 1 |
| Kim, HY | 1 |
| Kang, DG | 1 |
| Wu, XC | 2 |
| Yuan, CF | 1 |
| He, YM | 1 |
| Zhou, ZY | 1 |
| Luo, Y | 3 |
| Yang, MT | 1 |
| Li, XX | 1 |
| Liu, CQ | 2 |
| Syed, AM | 1 |
| Kundu, S | 1 |
| Ram, C | 1 |
| Kulhari, U | 1 |
| Kumar, A | 1 |
| Mugale, MN | 1 |
| Murty, US | 1 |
| Sahu, BD | 1 |
| Gao, L | 4 |
| Li, T | 3 |
| Li, S | 4 |
| Song, Z | 2 |
| Chang, Y | 1 |
| Yuan, L | 2 |
| Bi, X | 2 |
| Yu, Y | 4 |
| Yuan, J | 4 |
| Xu, S | 5 |
| Liu, F | 2 |
| Ye, J | 6 |
| Liu, P | 8 |
| Li, L | 6 |
| Fang, P | 1 |
| Chen, J | 7 |
| Tao, H | 1 |
| David, CEB | 2 |
| Lucas, AMB | 2 |
| Cunha, PLO | 1 |
| Viana, YIP | 1 |
| Yoshinaga, MY | 1 |
| Miyamoto, S | 1 |
| Filho, ABC | 1 |
| Varela, ALN | 2 |
| Kowaltowski, AJ | 2 |
| Facundo, HT | 2 |
| Hu, L | 1 |
| Wang, Z | 3 |
| Li, H | 13 |
| Wei, J | 1 |
| Tang, F | 5 |
| Wang, Q | 2 |
| Wang, J | 22 |
| Zhang, X | 12 |
| Zhang, Q | 1 |
| Gao, ZW | 1 |
| Zhuo, QY | 1 |
| Chen, MX | 1 |
| Yang, C | 4 |
| Chen, ZJ | 1 |
| Chen, Y | 6 |
| Liao, YQ | 1 |
| Wang, LL | 1 |
| Fu, D | 1 |
| Zhou, J | 4 |
| Tu, J | 2 |
| Cai, Y | 4 |
| Liu, J | 11 |
| Cai, Z | 3 |
| Wang, D | 2 |
| Ponnian, SMP | 2 |
| Saqib, F | 1 |
| Wahid, M | 1 |
| Al-Huqail, AA | 1 |
| Ahmedah, HT | 1 |
| Bigiu, N | 1 |
| Irimie, M | 1 |
| Moga, M | 1 |
| Marc Vlaic, RA | 1 |
| Pop, OL | 1 |
| Chicea, LM | 1 |
| Shervin Prince, S | 1 |
| Stanely Mainzen Prince, P | 3 |
| Berlin Grace, VM | 1 |
| Bai, C | 1 |
| Ma, Q | 1 |
| Li, Q | 5 |
| Yu, L | 1 |
| Zhen, D | 1 |
| Liu, M | 5 |
| Wei, C | 1 |
| Zheng, X | 3 |
| Su, F | 1 |
| Kang, Z | 1 |
| Li, J | 11 |
| Hao, L | 1 |
| Chen, Z | 3 |
| Zhou, H | 2 |
| Huang, X | 1 |
| Wang, S | 3 |
| Ouyang, X | 1 |
| Wang, Y | 20 |
| Cao, Q | 1 |
| Yang, L | 9 |
| Tao, Y | 1 |
| Lai, H | 1 |
| Jiang, XY | 1 |
| Guan, FF | 1 |
| Ma, JX | 1 |
| Dong, W | 1 |
| Qi, XL | 1 |
| Chen, W | 3 |
| Gao, S | 4 |
| Gao, X | 1 |
| Pan, S | 1 |
| Wang, JZ | 1 |
| Ma, YW | 1 |
| Zhang, LF | 1 |
| Lu, D | 1 |
| Lin, ZR | 1 |
| Li, ZZ | 2 |
| Cao, YJ | 1 |
| Yu, WJ | 1 |
| Ye, JT | 4 |
| Liu, PQ | 6 |
| Wang, X | 17 |
| He, K | 1 |
| Ma, L | 2 |
| Wu, L | 1 |
| Yang, Y | 6 |
| Xu, L | 1 |
| Liu, Q | 2 |
| Long, T | 1 |
| Peng, L | 1 |
| Li, F | 1 |
| Sun, Z | 1 |
| Xie, Q | 1 |
| Shaikh, F | 1 |
| Bhatt, LK | 1 |
| Li, ZY | 1 |
| Lu, GQ | 1 |
| Lu, J | 11 |
| Wang, PX | 2 |
| Zhang, XL | 1 |
| Zou, Y | 4 |
| Lunardon, G | 1 |
| de Oliveira Silva, T | 1 |
| Lino, CA | 1 |
| Lu, YW | 1 |
| Miranda, JB | 1 |
| Asprino, PF | 1 |
| de Almeida Silva, A | 1 |
| Nepomuceno, GT | 1 |
| Irigoyen, MCC | 1 |
| Carneiro-Ramos, MS | 1 |
| Takano, APC | 1 |
| Martinho, HDS | 1 |
| Barreto-Chaves, MLM | 1 |
| Wang, DZ | 2 |
| Diniz, GP | 1 |
| Lingyan, Z | 3 |
| Yihong, W | 3 |
| Youhua, W | 3 |
| Jianmei, Y | 3 |
| Jiawei, LI | 3 |
| Min, C | 3 |
| Duan, Z | 3 |
| Jiang, X | 3 |
| Zhang, K | 4 |
| Gao, C | 4 |
| Ma, W | 3 |
| Guo, X | 6 |
| Bao, G | 3 |
| Han, B | 3 |
| Hu, H | 4 |
| Zhao, Z | 4 |
| Chakrabarti, M | 4 |
| Raut, GK | 4 |
| Jain, N | 3 |
| Bhadra, MP | 5 |
| Liu, B | 7 |
| Qiu, B | 2 |
| Zhang, S | 9 |
| Abdellatif, SY | 1 |
| Fares, NH | 1 |
| Elsharkawy, SH | 1 |
| Mahmoud, YI | 1 |
| He, B | 1 |
| He, Y | 2 |
| Xia, T | 1 |
| Zeng, C | 2 |
| Li, X | 12 |
| Ding, L | 2 |
| Li, W | 3 |
| Niu, X | 1 |
| Gao, D | 1 |
| Liu, H | 3 |
| Zhou, Z | 2 |
| Deng, H | 1 |
| Tian, Z | 1 |
| Wu, Z | 3 |
| Liu, X | 6 |
| Ren, Z | 1 |
| Jiang, Z | 2 |
| Rodriguez, R | 2 |
| Harris, M | 1 |
| Murphy, E | 2 |
| Kennedy, LM | 1 |
| Guo, Z | 5 |
| Hu, YH | 1 |
| Feng, GS | 1 |
| Valenzuela Ripoll, C | 1 |
| Cai, SD | 1 |
| Wang, QQ | 1 |
| Luo, WW | 1 |
| Liang, LY | 1 |
| Wu, ZK | 1 |
| Zhang, JG | 1 |
| Javaheri, A | 1 |
| Wang, L | 9 |
| Yovas, A | 1 |
| Stanely, SP | 1 |
| He, X | 2 |
| Kim, SH | 1 |
| Jeon, MJ | 1 |
| Jeong, SM | 1 |
| Nalban, N | 1 |
| Sangaraju, R | 1 |
| Alavala, S | 1 |
| Mir, SM | 1 |
| Jerald, MK | 1 |
| Sistla, R | 1 |
| Beng, H | 1 |
| Su, H | 3 |
| Han, F | 1 |
| Fan, Z | 1 |
| Lv, N | 1 |
| Jovanović, A | 1 |
| Tan, W | 3 |
| Gu, S | 1 |
| Tian, J | 1 |
| Cao, Y | 1 |
| Jin, Z | 1 |
| Gu, B | 1 |
| Ning, Z | 1 |
| Jin, Y | 3 |
| Sun, J | 2 |
| Hao, W | 1 |
| Fillmore, N | 1 |
| Ma, H | 2 |
| Springer, D | 1 |
| Yu, ZX | 1 |
| Sadowska, A | 1 |
| Garcia, A | 1 |
| Chen, R | 1 |
| Muniz-Medina, V | 1 |
| Rosenthal, K | 1 |
| Lin, J | 2 |
| Kuruvilla, D | 1 |
| Osbourn, J | 1 |
| Karathanasis, SK | 1 |
| Walker, J | 1 |
| Zuo, Z | 1 |
| Ji, MY | 1 |
| Zhao, K | 1 |
| Su, ZP | 1 |
| Li, P | 2 |
| Hou, DR | 1 |
| Leme Goto, P | 1 |
| Cinato, M | 1 |
| Merachli, F | 1 |
| Vons, B | 1 |
| Jimenez, T | 1 |
| Marsal, D | 1 |
| Todua, N | 1 |
| Loi, H | 1 |
| Santin, Y | 1 |
| Cassel, S | 1 |
| Blanzat, M | 1 |
| Tronchere, H | 1 |
| Dejugnat, C | 1 |
| Kunduzova, O | 1 |
| Boal, F | 1 |
| Sugiyama, A | 1 |
| Okada, M | 2 |
| Yamawaki, H | 1 |
| Zhao, Y | 7 |
| Li, C | 3 |
| Xiong, HR | 1 |
| Zheng, ZW | 1 |
| Liu, R | 2 |
| Gong, W | 4 |
| Wu, YX | 1 |
| Cheng, JK | 1 |
| Tao, HQ | 1 |
| Wang, T | 4 |
| Zhai, M | 1 |
| Ponnusamy, M | 1 |
| Huang, Y | 2 |
| Liu, CY | 1 |
| Wang, M | 2 |
| Shan, C | 1 |
| Shan, PP | 1 |
| Gao, XQ | 1 |
| Wang, K | 4 |
| Chen, XZ | 1 |
| Xie, JY | 1 |
| Zhang, DY | 1 |
| Zhou, LY | 1 |
| Wen, J | 1 |
| Shen, J | 2 |
| Zhou, Y | 2 |
| Zhao, X | 1 |
| Dai, Z | 1 |
| Mei, Y | 1 |
| Ke, Q | 1 |
| Sun, X | 2 |
| Xu, Y | 3 |
| Liang, C | 2 |
| Zhang, T | 3 |
| Chen, H | 1 |
| Wu, M | 1 |
| Jiang, W | 2 |
| Zhang, J | 14 |
| Yu, C | 1 |
| Guo, D | 1 |
| Guo, R | 1 |
| Liu, N | 2 |
| Zhang, H | 3 |
| Baruscotti, M | 1 |
| Zhao, L | 3 |
| Yang, MH | 1 |
| Wang, H | 9 |
| Han, SN | 1 |
| Jia, X | 1 |
| Dai, FF | 1 |
| Zhou, MJ | 1 |
| Yin, Z | 2 |
| Wang, TQ | 1 |
| Zang, MX | 1 |
| Xue, LX | 1 |
| Qi, J | 1 |
| Tan, Y | 3 |
| Fan, D | 1 |
| Pan, W | 1 |
| Yu, J | 3 |
| Xu, W | 3 |
| Wu, J | 7 |
| Zhang, M | 4 |
| Feng, X | 2 |
| Geng, Y | 1 |
| Shen, A | 1 |
| Gao, H | 3 |
| Zhang, L | 5 |
| Liu, S | 4 |
| Zhang, N | 3 |
| Qian, H | 1 |
| Wu, S | 2 |
| Cao, L | 2 |
| Sun, Y | 3 |
| Soltani Hekmat, A | 1 |
| Javanmardi, K | 1 |
| Tavassoli, A | 1 |
| Gholampour, Y | 1 |
| Balkrishna, A | 1 |
| Rustagi, Y | 1 |
| Bhattacharya, K | 1 |
| Varshney, A | 1 |
| Althurwi, HN | 5 |
| Abdel-Kader, MS | 1 |
| Alharthy, KM | 1 |
| Salkini, MA | 1 |
| Albaqami, FF | 1 |
| Yang, J | 10 |
| Lyu, Q | 1 |
| Wu, G | 4 |
| Lin, S | 2 |
| Yang, Q | 3 |
| Hu, J | 4 |
| Manchineela, S | 1 |
| Bhukya, CK | 1 |
| Naini, R | 1 |
| Venkateshwari, A | 1 |
| Reddy, VD | 1 |
| Mendonza, JJ | 1 |
| Suresh, Y | 1 |
| Nallari, P | 1 |
| Gao, W | 3 |
| Guo, N | 2 |
| Zhao, S | 2 |
| Zhang, W | 5 |
| Yan, F | 2 |
| Liao, H | 2 |
| Chi, K | 2 |
| Gan, M | 3 |
| Fan, Y | 2 |
| Chen, L | 5 |
| Jiang, D | 2 |
| Hao, X | 1 |
| Shen, L | 3 |
| Zhu, L | 4 |
| Şengül Ayan, S | 1 |
| Sırcan, AK | 1 |
| Abewa, M | 1 |
| Kurt, A | 1 |
| Dalaman, U | 1 |
| Yaraş, N | 1 |
| Asai, K | 1 |
| Murai, K | 3 |
| Shirakabe, A | 1 |
| Kamiya, M | 1 |
| Noma, S | 1 |
| Sato, N | 1 |
| Mizuno, K | 1 |
| Shimizu, W | 1 |
| Parreira, RC | 1 |
| Gómez-Mendoza, DP | 1 |
| de Jesus, ICG | 1 |
| Lemos, RP | 1 |
| Santos, AK | 1 |
| Rezende, CP | 1 |
| Figueiredo, HCP | 1 |
| Pinto, MCX | 1 |
| Kjeldsen, F | 1 |
| Guatimosim, S | 3 |
| Resende, RR | 1 |
| Verano-Braga, T | 1 |
| Jannesar, K | 1 |
| Abbaszadeh, S | 1 |
| Malekinejad, H | 1 |
| Soraya, H | 1 |
| Hernández-Gutiérrez, S | 1 |
| Roque-Jorge, J | 1 |
| López-Torres, A | 1 |
| Díaz-Rosas, G | 1 |
| García-Chequer, AJ | 1 |
| Contreras-Ramos, A | 1 |
| Grant, MKO | 1 |
| Abdelgawad, IY | 1 |
| Lewis, CA | 1 |
| Seelig, D | 1 |
| Zordoky, BN | 3 |
| Ding, J | 1 |
| Qian, W | 2 |
| Chu, C | 1 |
| Li, K | 1 |
| Xu, G | 1 |
| Mao, Z | 1 |
| Xiao, P | 1 |
| Chen, F | 2 |
| Liu, BY | 1 |
| Liu, GL | 1 |
| Ding, W | 1 |
| Chang, WG | 1 |
| Xu, T | 1 |
| Ji, XY | 1 |
| Zheng, XX | 1 |
| Wang, JX | 1 |
| Wang, HB | 2 |
| Shuai, W | 1 |
| Liu, LB | 1 |
| Xu, M | 1 |
| Tang, QZ | 2 |
| Viswanadha, VP | 3 |
| Dhivya, V | 1 |
| Beeraka, NM | 1 |
| Huang, CY | 4 |
| Gavryushova, LV | 1 |
| Minyaeva, NN | 1 |
| Chubarev, VN | 1 |
| Mikhaleva, LM | 1 |
| Tarasov, VV | 1 |
| Aliev, G | 1 |
| Du, Z | 3 |
| Lu, Y | 6 |
| Ma, X | 1 |
| Wen, R | 2 |
| Zhou, C | 1 |
| Tu, P | 2 |
| Jiang, Y | 4 |
| Velusamy, P | 1 |
| Mohan, T | 1 |
| Ravi, DB | 1 |
| Kishore Kumar, SN | 1 |
| Srinivasan, A | 1 |
| Chakrapani, LN | 1 |
| Singh, A | 2 |
| Varadharaj, S | 1 |
| Kalaiselvi, P | 1 |
| Souza, DS | 1 |
| Barreto, TO | 1 |
| Menezes-Filho, JER | 1 |
| Heimfarth, L | 1 |
| Rhana, P | 1 |
| Rabelo, TK | 1 |
| Santana, MNS | 1 |
| Durço, AO | 1 |
| Conceição, MRL | 1 |
| Quintans-Júnior, LJ | 1 |
| Guimarães, AG | 1 |
| Cruz, JS | 1 |
| Vasconcelos, CML | 1 |
| Estrada, AC | 1 |
| Yoshida, K | 1 |
| Saucerman, JJ | 3 |
| Holmes, JW | 1 |
| Chen, X | 4 |
| Wang, WJ | 1 |
| Lai, WJ | 1 |
| Li, SH | 1 |
| Deng, YF | 1 |
| Zhou, JZ | 1 |
| Yang, SQ | 1 |
| Liu, Y | 9 |
| Shou, WN | 1 |
| Cao, DY | 1 |
| Li, XH | 1 |
| Qiu, J | 1 |
| Xiao, H | 2 |
| Zhou, S | 1 |
| Du, W | 1 |
| Mu, X | 1 |
| Shi, G | 1 |
| Tan, X | 3 |
| Han, JW | 1 |
| Kang, C | 1 |
| Kim, Y | 1 |
| Lee, MG | 1 |
| Kim, JY | 1 |
| Ni, Y | 1 |
| Deng, J | 1 |
| Bai, H | 1 |
| Chang, P | 1 |
| Zhu, X | 3 |
| Chen, XY | 1 |
| Chen, XH | 2 |
| Su, CP | 1 |
| Zhang, YL | 1 |
| Jiang, YY | 1 |
| Guo, SZ | 1 |
| Pan, R | 2 |
| Liang, T | 1 |
| Guo, J | 1 |
| Sun, T | 1 |
| Fu, X | 1 |
| Zhu, JX | 1 |
| Ling, W | 1 |
| Xue, C | 1 |
| Zhang, YS | 1 |
| Yan, C | 2 |
| Wu, MP | 1 |
| Li, SL | 1 |
| Zheng, D | 2 |
| Lyu, J | 1 |
| Guo, NN | 1 |
| Guo, YY | 2 |
| Li, LL | 1 |
| Fan, MX | 1 |
| Wang, ZH | 1 |
| Su, SA | 1 |
| Ma, Y | 1 |
| Shen, Y | 1 |
| Ji, Y | 2 |
| Xie, Y | 1 |
| Xiang, M | 1 |
| Fan, W | 2 |
| Zhang, B | 1 |
| Wu, C | 1 |
| Wu, H | 1 |
| Yang, X | 1 |
| Hu, Z | 1 |
| Wu, X | 2 |
| Guo, Y | 2 |
| Shang, D | 1 |
| Du, Y | 1 |
| Zhang, HM | 1 |
| Diaz, V | 1 |
| Walsh, ME | 1 |
| Alam, MN | 1 |
| Hossain, MM | 1 |
| Rahman, MM | 1 |
| Subhan, N | 1 |
| Mamun, MAA | 1 |
| Ulla, A | 1 |
| Reza, HM | 1 |
| Alam, MA | 1 |
| Wu, D | 2 |
| Sang, M | 1 |
| Liu, Z | 4 |
| Wu, Q | 1 |
| Yang, YH | 1 |
| Fang, HL | 1 |
| Zhao, M | 2 |
| Wei, XL | 1 |
| Yu, XJ | 1 |
| Sun, L | 1 |
| Li, DL | 1 |
| Liu, JJ | 1 |
| Zang, WJ | 1 |
| Qiao, Y | 1 |
| Zhu, B | 2 |
| Tian, A | 2 |
| Li, Z | 9 |
| Tong, YF | 1 |
| Ding, YY | 1 |
| Li, JM | 1 |
| Pan, XC | 1 |
| Lu, XL | 1 |
| Zhang, HG | 1 |
| Sun, R | 1 |
| Xiong, K | 1 |
| Shi, D | 1 |
| Xue, L | 1 |
| Hong, HQ | 1 |
| Fang, XL | 1 |
| Zhang, YH | 1 |
| Tsai, CY | 1 |
| Kuo, WW | 2 |
| Shibu, MA | 1 |
| Lin, YM | 2 |
| Liu, CN | 1 |
| Chen, YH | 1 |
| Day, CH | 1 |
| Shen, CY | 2 |
| Long, Z | 1 |
| Xu, J | 2 |
| Tan, S | 1 |
| Li, A | 2 |
| Ben-Shoshan, J | 1 |
| Jubran, A | 1 |
| Levy, R | 1 |
| Keren, G | 1 |
| Entin-Meer, M | 1 |
| Pistolozzi, M | 1 |
| Shi, X | 1 |
| Huang, D | 1 |
| Tang, J | 1 |
| Chen, M | 3 |
| Lu, Q | 1 |
| Xu, B | 2 |
| Mao, J | 1 |
| Yuan, Y | 1 |
| Peng, W | 1 |
| Xu, Z | 1 |
| Saleem, N | 1 |
| Prasad, A | 1 |
| Goswami, SK | 2 |
| Ranieri, A | 2 |
| Kemp, E | 1 |
| Burgoyne, JR | 1 |
| Avkiran, M | 2 |
| Hadzi-Petrushev, N | 1 |
| Bogdanov, J | 1 |
| Krajoska, J | 1 |
| Ilievska, J | 1 |
| Bogdanova-Popov, B | 1 |
| Gjorgievska, E | 1 |
| Mitrokhin, V | 1 |
| Sopi, R | 1 |
| Gagov, H | 1 |
| Kamkin, A | 1 |
| Mladenov, M | 1 |
| Schirmer, I | 1 |
| Bualeong, T | 1 |
| Budde, H | 1 |
| Cimiotti, D | 1 |
| Appukuttan, A | 1 |
| Klein, N | 1 |
| Steinwascher, P | 1 |
| Reusch, P | 1 |
| Mügge, A | 1 |
| Meyer, R | 1 |
| Ladilov, Y | 1 |
| Jaquet, K | 1 |
| Gao, J | 2 |
| Shi, Z | 1 |
| Wen, P | 1 |
| Ma, C | 1 |
| Xiao, XC | 1 |
| Chen, WH | 1 |
| Cao, YY | 1 |
| Lou, YJ | 1 |
| Zhai, XF | 1 |
| Li, NS | 1 |
| Bageghni, SA | 1 |
| Hemmings, KE | 1 |
| Zava, N | 1 |
| Denton, CP | 1 |
| Porter, KE | 1 |
| Ainscough, JFX | 1 |
| Drinkhill, MJ | 1 |
| Turner, NA | 1 |
| Fang, HY | 1 |
| Hung, MY | 1 |
| Pandey, S | 1 |
| Chang, CC | 1 |
| Lin, KH | 1 |
| Wang, P | 3 |
| Zhong, Y | 2 |
| Guo, K | 1 |
| Li, G | 1 |
| Zhu, M | 3 |
| McNutt, MA | 1 |
| Yin, Y | 1 |
| Tan, Z | 1 |
| Li, M | 2 |
| Li, ZM | 1 |
| Sun, SY | 1 |
| Wang, LP | 1 |
| Yang, HW | 1 |
| Fang, X | 1 |
| Hong, H | 4 |
| Ahmed, AA | 1 |
| Ahmed, AAE | 1 |
| El Morsy, EM | 1 |
| Nofal, S | 1 |
| Puhl, SL | 1 |
| Weeks, KL | 1 |
| Güran, A | 1 |
| Boknik, P | 3 |
| Kirchhefer, U | 2 |
| Müller, FU | 2 |
| Narasimhan, G | 1 |
| Carrillo, ED | 1 |
| Hernández, A | 1 |
| García, MC | 1 |
| Sánchez, JA | 1 |
| Feng, CC | 1 |
| Liao, PH | 1 |
| Tsai, HI | 1 |
| Cheng, SM | 1 |
| Yang, LY | 1 |
| PadmaViswanadha, V | 1 |
| Pan, LF | 1 |
| Chen, RJ | 1 |
| Lo, JF | 1 |
| Fan, J | 1 |
| Lei, J | 1 |
| Xu, H | 2 |
| Kapoor, I | 1 |
| Zhu, G | 1 |
| Eladwy, RA | 1 |
| Mantawy, EM | 1 |
| El-Bakly, WM | 1 |
| Fares, M | 1 |
| Ramadan, LA | 1 |
| Azab, SS | 1 |
| Zhang, HB | 1 |
| Wang, JR | 1 |
| Liu, JX | 1 |
| Li, CL | 1 |
| Hu, X | 2 |
| Ou-Yang, Q | 1 |
| Xie, X | 1 |
| Bhargava, P | 1 |
| Verma, VK | 1 |
| Malik, S | 1 |
| Khan, SI | 1 |
| Bhatia, J | 1 |
| Arya, DS | 2 |
| Imaeda, A | 1 |
| Tanaka, S | 1 |
| Tonegawa, K | 1 |
| Fuchigami, S | 1 |
| Obana, M | 1 |
| Maeda, M | 1 |
| Kihara, M | 1 |
| Kiyonari, H | 1 |
| Conway, SJ | 1 |
| Fujio, Y | 1 |
| Nakayama, H | 2 |
| Zheng, T | 1 |
| Shuai, S | 1 |
| Du, Q | 1 |
| Yang, F | 5 |
| Hou, Y | 2 |
| Zhu, P | 1 |
| Shang, L | 1 |
| Pin, L | 1 |
| Zhu, S | 1 |
| Zhong, X | 3 |
| Shun, M | 1 |
| Hou, M | 1 |
| Tripathi, D | 1 |
| Biswas, B | 1 |
| Manhas, A | 1 |
| Goyal, D | 1 |
| Gaestel, M | 1 |
| Jagavelu, K | 1 |
| Liang, J | 1 |
| Yan, W | 1 |
| Wu, F | 1 |
| Morishige, S | 1 |
| Takahashi-Yanaga, F | 1 |
| Ishikane, S | 1 |
| Arioka, M | 1 |
| Igawa, K | 1 |
| Kuroo, A | 1 |
| Tomooka, K | 1 |
| Shiose, A | 1 |
| Sasaguri, T | 1 |
| Chen, K | 1 |
| Jian, D | 1 |
| Zang, X | 1 |
| Song, W | 1 |
| Ma, J | 1 |
| Jia, Z | 2 |
| Zhang, F | 1 |
| Yao, X | 1 |
| de Lacerda Alexandre, JV | 1 |
| Araújo, MTS | 1 |
| Ponte Viana, YI | 1 |
| Coelho, BN | 1 |
| Caldas, FRL | 1 |
| Liu, ZH | 1 |
| Fan, XF | 1 |
| Gong, YS | 1 |
| Han, LP | 1 |
| Zhao, J | 2 |
| Chen, D | 1 |
| Feng, C | 1 |
| Liu, YL | 1 |
| Qu, YY | 1 |
| Chai, HJ | 1 |
| Li, R | 2 |
| Ozakca, I | 1 |
| Arioglu-Inan, E | 1 |
| Esfahani, H | 2 |
| Altan, VM | 1 |
| Balligand, JL | 2 |
| Kayki-Mutlu, G | 1 |
| Ozcelikay, AT | 1 |
| Mitsuyama, S | 2 |
| Takeshita, D | 3 |
| Obata, K | 4 |
| Zhang, GX | 6 |
| Takaki, M | 8 |
| Savergnini, SQ | 1 |
| Ianzer, D | 1 |
| Carvalho, MB | 1 |
| Ferreira, AJ | 4 |
| Silva, GA | 2 |
| Marques, FD | 2 |
| Peluso, AA | 1 |
| Beiman, M | 1 |
| Cojocaru, G | 1 |
| Cohen, Y | 1 |
| Almeida, AP | 3 |
| Rotman, G | 1 |
| Santos, RA | 4 |
| Wang, C | 3 |
| Zhu, W | 3 |
| Huang, ZP | 1 |
| Seok, HY | 1 |
| Zhang, Z | 1 |
| Kataoka, M | 1 |
| Zhu, Y | 1 |
| Cheng, S | 1 |
| Park, CS | 2 |
| Chen, S | 2 |
| Lee, H | 1 |
| Cha, H | 2 |
| Oh, JG | 1 |
| Hong, S | 1 |
| Han, P | 1 |
| Ginsburg, KS | 1 |
| Jin, S | 1 |
| Park, I | 1 |
| Singh, VP | 1 |
| Wang, HS | 1 |
| Franzini-Armstrong, C | 1 |
| Park, WJ | 2 |
| Bers, DM | 3 |
| Kranias, EG | 4 |
| Cho, C | 2 |
| Kim, DH | 2 |
| Lu, CC | 1 |
| Xu, YQ | 1 |
| Wu, JC | 1 |
| Hang, PZ | 1 |
| Wu, JW | 1 |
| Qi, JC | 1 |
| Du, ZM | 1 |
| Spindler, MJ | 1 |
| Burmeister, BT | 1 |
| Hsiao, EC | 1 |
| Salomonis, N | 1 |
| Scott, MJ | 1 |
| Srivastava, D | 1 |
| Carnegie, GK | 1 |
| Conklin, BR | 1 |
| Lu, F | 2 |
| Xing, J | 1 |
| Dong, S | 3 |
| Xu, C | 6 |
| Roy, AJ | 1 |
| Wang, YQ | 2 |
| Liu, CH | 1 |
| Zhang, JQ | 1 |
| Zhu, DN | 1 |
| Yu, BY | 1 |
| Chowdhury, D | 1 |
| Tangutur, AD | 1 |
| Khatua, TN | 1 |
| Saxena, P | 1 |
| Banerjee, SK | 1 |
| Lu, FH | 1 |
| Fu, SB | 1 |
| Leng, X | 1 |
| Zhao, YJ | 2 |
| Ren, H | 1 |
| Xu, CQ | 3 |
| Zhang, WH | 2 |
| Planavila, A | 1 |
| Redondo, I | 1 |
| Hondares, E | 1 |
| Vinciguerra, M | 1 |
| Munts, C | 1 |
| Iglesias, R | 1 |
| Gabrielli, LA | 1 |
| Sitges, M | 1 |
| Giralt, M | 1 |
| van Bilsen, M | 1 |
| Villarroya, F | 1 |
| Gravning, J | 2 |
| Ahmed, MS | 2 |
| Qvigstad, E | 1 |
| Krobert, K | 1 |
| Edvardsen, T | 1 |
| Moe, IT | 1 |
| Hagelin, EM | 1 |
| Sagave, J | 1 |
| Valen, G | 1 |
| Levy, FO | 2 |
| Osnes, JB | 1 |
| Skomedal, T | 1 |
| Attramadal, H | 2 |
| Yang, H | 1 |
| Meng, Z | 1 |
| Xing, R | 1 |
| Tian, X | 1 |
| Guo, L | 1 |
| Nie, G | 1 |
| Duan, Q | 3 |
| Chen, C | 3 |
| Ni, L | 2 |
| Yan, M | 1 |
| Cianflone, K | 1 |
| Wang, DW | 3 |
| Putinski, C | 1 |
| Abdul-Ghani, M | 1 |
| Stiles, R | 1 |
| Brunette, S | 1 |
| Dick, SA | 1 |
| Fernando, P | 2 |
| Megeney, LA | 1 |
| Chen, MS | 1 |
| Xiao, JH | 1 |
| Xu, BM | 1 |
| Wang, JL | 1 |
| Elshenawy, OH | 2 |
| El-Kadi, AO | 5 |
| McCommis, KS | 1 |
| Douglas, DL | 1 |
| Krenz, M | 2 |
| Baines, CP | 1 |
| Yang, JH | 1 |
| Polanowska-Grabowska, RK | 1 |
| Smith, JS | 1 |
| Shields, CW | 1 |
| Morais, C | 1 |
| Small, DM | 1 |
| Vesey, DA | 1 |
| Martin, J | 1 |
| Johnson, DW | 1 |
| Gobe, GC | 1 |
| Tu, Y | 2 |
| Wan, L | 1 |
| Zhao, D | 2 |
| Bu, L | 1 |
| Dong, D | 2 |
| Cheng, Z | 1 |
| Shen, B | 1 |
| Luo, YX | 1 |
| An, XZ | 1 |
| Zhang, R | 3 |
| Liu, G | 1 |
| Chen, HZ | 1 |
| Liu, DP | 1 |
| Chidiac, P | 1 |
| Sobiesiak, AJ | 1 |
| Lee, KN | 1 |
| Gros, R | 2 |
| Nguyen, CH | 1 |
| Shen, D | 1 |
| Tang, X | 3 |
| Wo, D | 1 |
| Yan, H | 1 |
| Song, R | 1 |
| Feng, J | 1 |
| Mahmud, H | 1 |
| Candido, WM | 1 |
| van Genne, L | 1 |
| Vreeswijk-Baudoin, I | 1 |
| Yu, H | 1 |
| van de Sluis, B | 1 |
| van Deursen, J | 1 |
| van Gilst, WH | 1 |
| Silljé, HH | 1 |
| de Boer, RA | 1 |
| Yu, X | 3 |
| Fu, S | 1 |
| Silva, JA | 3 |
| Santana, ET | 1 |
| Manchini, MT | 1 |
| Antônio, EL | 3 |
| Bocalini, DS | 2 |
| Krieger, JE | 2 |
| Tucci, PJ | 5 |
| Serra, AJ | 3 |
| Wang, ER | 1 |
| Jarrah, AA | 1 |
| Benard, L | 1 |
| Schwarzkopf, M | 1 |
| Hadri, L | 1 |
| Tarzami, ST | 2 |
| Rachmin, I | 1 |
| Tshori, S | 2 |
| Smith, Y | 1 |
| Oppenheim, A | 1 |
| Marchetto, S | 1 |
| Kay, G | 1 |
| Foo, RS | 1 |
| Dagan, N | 1 |
| Golomb, E | 2 |
| Gilon, D | 2 |
| Borg, JP | 1 |
| Razin, E | 2 |
| Armstrong, DW | 1 |
| Tse, MY | 1 |
| Wong, PG | 1 |
| Ventura, NM | 1 |
| Meens, JA | 1 |
| Johri, AM | 1 |
| Matangi, MF | 1 |
| Pang, SC | 1 |
| Wu, P | 2 |
| Tian, W | 2 |
| Qi, Z | 2 |
| Patel, BM | 1 |
| Desai, VJ | 1 |
| Simko, F | 1 |
| Bednarova, KR | 1 |
| Krajcirovicova, K | 1 |
| Hrenak, J | 1 |
| Celec, P | 1 |
| Kamodyova, N | 1 |
| Gajdosechova, L | 1 |
| Zorad, S | 1 |
| Adamcova, M | 1 |
| Dai, H | 1 |
| Jia, G | 1 |
| Wang, HJ | 1 |
| Wang, W | 2 |
| Cornish, KG | 1 |
| Rozanski, GJ | 1 |
| Zucker, IH | 1 |
| Ji, XX | 1 |
| Song, XL | 1 |
| Yu, XL | 1 |
| Zhu, JY | 1 |
| Zeng, S | 1 |
| Zou, J | 2 |
| Yue, Z | 1 |
| Gao, Y | 1 |
| Cao, W | 1 |
| You, XY | 1 |
| Huang, JH | 2 |
| Liu, SJ | 1 |
| Liu, SM | 1 |
| Yoshida, T | 2 |
| Yamashita, M | 1 |
| Horimai, C | 1 |
| Hayashi, M | 1 |
| Tsui, H | 1 |
| Ke, Y | 2 |
| Shi, Y | 2 |
| Davies, L | 1 |
| Cartwright, EJ | 2 |
| Venetucci, L | 1 |
| Terrar, DA | 2 |
| Huang, CL | 1 |
| Solaro, RJ | 3 |
| Lei, M | 3 |
| Lin, Y | 5 |
| Xiao, W | 3 |
| Sun, JM | 1 |
| Wang, CM | 1 |
| Hao, YY | 1 |
| Xie, YJ | 1 |
| Gu, J | 1 |
| Wang, AL | 1 |
| Parthasarathy, A | 1 |
| Gopi, V | 1 |
| Devi K M, S | 1 |
| Balaji, N | 1 |
| Vellaichamy, E | 1 |
| Moreau, S | 1 |
| DaSilva, JN | 2 |
| Valdivia, A | 1 |
| Rau, CD | 3 |
| Avetisyan, R | 1 |
| Romay, MC | 3 |
| Martin, L | 1 |
| Ren, S | 2 |
| Lusis, AJ | 4 |
| Grisanti, LA | 1 |
| Repas, AA | 1 |
| Talarico, JA | 2 |
| Gold, JI | 1 |
| Carter, RL | 1 |
| Koch, WJ | 3 |
| Tilley, DG | 2 |
| Yang, CZ | 1 |
| Tian, AJ | 1 |
| Meng, ZH | 1 |
| Wu, JM | 1 |
| Zhang, YY | 1 |
| Guo, LJ | 1 |
| Li, ZJ | 1 |
| Hemalatha, KL | 1 |
| Feng, XJ | 1 |
| Wang, JJ | 3 |
| Huang, XY | 1 |
| Perera, RK | 2 |
| Sprenger, JU | 2 |
| Steinbrecher, JH | 2 |
| Hübscher, D | 1 |
| Lehnart, SE | 2 |
| Abesser, M | 1 |
| Schuh, K | 1 |
| El-Armouche, A | 2 |
| Nikolaev, VO | 2 |
| Ren, J | 1 |
| Lu, P | 1 |
| Lu, M | 5 |
| Luan, A | 2 |
| Otsuki, Y | 1 |
| Nakamura, Y | 1 |
| Harada, S | 1 |
| Yamamoto, Y | 1 |
| Ogino, K | 1 |
| Morikawa, K | 1 |
| Ninomiya, H | 1 |
| Miyagawa, S | 1 |
| Sawa, Y | 1 |
| Hisatome, I | 1 |
| Nishimura, M | 1 |
| Kuhn, M | 2 |
| Pillai, VB | 1 |
| Samant, S | 1 |
| Sundaresan, NR | 1 |
| Raghuraman, H | 1 |
| Kim, G | 1 |
| Bonner, MY | 1 |
| Arbiser, JL | 1 |
| Walker, DI | 1 |
| Jones, DP | 1 |
| Gius, D | 1 |
| Gupta, MP | 1 |
| Maier, LS | 1 |
| Hasenfuss, G | 2 |
| Major, JL | 1 |
| Salih, M | 1 |
| Tuana, BS | 1 |
| Maayah, ZH | 2 |
| Grimm, M | 2 |
| Ling, H | 1 |
| Willeford, A | 1 |
| Pereira, L | 1 |
| Gray, CB | 1 |
| Erickson, JR | 1 |
| Sarma, S | 1 |
| Respress, JL | 1 |
| Wehrens, XH | 1 |
| Brown, JH | 1 |
| Song, S | 1 |
| Si, LY | 1 |
| Al-Rasheed, NM | 3 |
| Al-Oteibi, MM | 1 |
| Al-Manee, RZ | 1 |
| Al-Shareef, SA | 1 |
| Hasan, IH | 1 |
| Mohamad, RA | 1 |
| Mahmoud, AM | 1 |
| Ou, C | 1 |
| Huang, Z | 1 |
| Luo, C | 1 |
| Yan, G | 1 |
| Zhu, N | 1 |
| Huang, S | 1 |
| Yi, B | 1 |
| Shang, X | 1 |
| Wang, N | 2 |
| Gao, E | 2 |
| Cattin, ME | 1 |
| Weldrick, JJ | 1 |
| Roeske, CL | 1 |
| Mak, E | 1 |
| Thorn, SL | 1 |
| Burgon, PG | 1 |
| Wu, Y | 2 |
| Wang, BX | 1 |
| Mehta, G | 1 |
| Kumarasamy, S | 1 |
| Walsh, A | 1 |
| Liu, L | 3 |
| Williams, K | 1 |
| Joe, B | 1 |
| de la Serna, IL | 1 |
| Li, N | 1 |
| Cai, B | 2 |
| Zhu, J | 2 |
| Wang, B | 2 |
| Pan, Z | 1 |
| Yang, B | 2 |
| Schroeder, AM | 1 |
| Park, S | 1 |
| Jordan, MC | 2 |
| Gao, F | 1 |
| Coppola, G | 1 |
| Fishbein, MC | 2 |
| Roos, KP | 2 |
| Ghiani, CA | 1 |
| Colwell, CS | 1 |
| Streit, MR | 1 |
| Weiss, CS | 1 |
| Meyer, S | 1 |
| Ochs, MM | 1 |
| Hagenmueller, M | 1 |
| Riffel, JH | 1 |
| Buss, SJ | 1 |
| Heger, T | 1 |
| Katus, HA | 2 |
| Hardt, SE | 2 |
| An, X | 1 |
| Lu, Z | 1 |
| Bai, Y | 1 |
| Song, Y | 1 |
| Han, R | 2 |
| Mei, M | 2 |
| Zhou, M | 1 |
| Xie, J | 1 |
| Bai, J | 1 |
| Gu, R | 1 |
| Gul, R | 1 |
| Park, DR | 1 |
| Shawl, AI | 1 |
| Im, SY | 1 |
| Nam, TS | 1 |
| Lee, SH | 1 |
| Ko, JK | 1 |
| Jang, KY | 1 |
| Kim, D | 1 |
| Kim, UH | 1 |
| Mao, HP | 1 |
| Wang, XY | 1 |
| Gao, YH | 1 |
| Chang, YX | 1 |
| Niu, ZC | 1 |
| Ai, JQ | 1 |
| Gao, XM | 1 |
| Bin-Dayel, AF | 1 |
| Abdel Baky, NA | 1 |
| Fadda, LM | 1 |
| Mohammad, RA | 1 |
| Al-Mohanna, F | 1 |
| Jagadeesh, GS | 1 |
| Nagoor Meeran, MF | 1 |
| Selvaraj, P | 1 |
| Sun, D | 2 |
| Liu, C | 2 |
| Yin, Q | 1 |
| Lu, H | 1 |
| Lv, Z | 1 |
| Li, B | 2 |
| Jin, L | 3 |
| Lian, J | 2 |
| Zhou, L | 3 |
| Ma, B | 1 |
| Zou, MH | 1 |
| Xi, Y | 1 |
| Shi, S | 1 |
| Tian, Y | 3 |
| Yuan, W | 1 |
| Zeng, Q | 1 |
| Ye, X | 1 |
| Wan, Y | 1 |
| Peng, X | 1 |
| Deng, Y | 1 |
| Dai, G | 1 |
| Luo, S | 1 |
| Fan, X | 1 |
| Mo, X | 1 |
| Clouet, S | 1 |
| Di Pietrantonio, L | 1 |
| Daskalopoulos, EP | 1 |
| Horckmans, M | 1 |
| Vanorlé, M | 1 |
| Lemaire, A | 1 |
| Beauloye, C | 1 |
| Boeynaems, JM | 1 |
| Communi, D | 1 |
| Levin, MD | 1 |
| Singh, GK | 1 |
| Zhang, HX | 1 |
| Uchida, K | 1 |
| Kozel, BA | 1 |
| Stein, PK | 1 |
| Kovacs, A | 1 |
| Westenbroek, RE | 1 |
| Catterall, WA | 1 |
| Grange, DK | 1 |
| Nichols, CG | 1 |
| Scruggs, SB | 1 |
| Ping, P | 2 |
| Lou, J | 1 |
| Zhang, LL | 1 |
| Song, SY | 1 |
| Li, YC | 1 |
| Sun, F | 1 |
| Ding, XQ | 1 |
| Yu, CJ | 1 |
| Li, YY | 1 |
| Liu, MT | 1 |
| Dong, CJ | 1 |
| Chu, W | 2 |
| Zhang, ZR | 1 |
| Victorio, JA | 1 |
| Clerici, SP | 1 |
| Palacios, R | 1 |
| Alonso, MJ | 1 |
| Vassallo, DV | 3 |
| Jaffe, IZ | 1 |
| Rossoni, LV | 2 |
| Davel, AP | 2 |
| Sato, H | 1 |
| Suzuki, JI | 1 |
| Aoyama, N | 1 |
| Watanabe, R | 1 |
| Kaneko, M | 1 |
| Shiheido, Y | 1 |
| Yoshida, A | 1 |
| Wakayama, K | 1 |
| Kumagai, H | 1 |
| Ikeda, Y | 1 |
| Akazawa, H | 1 |
| Komuro, I | 4 |
| Isobe, M | 1 |
| Izumi, Y | 2 |
| Yang, Z | 1 |
| Sun, S | 1 |
| Ryu, Y | 1 |
| Piao, ZH | 1 |
| Cho, JY | 1 |
| Kim, GR | 1 |
| Choi, SY | 1 |
| Lin, MQ | 1 |
| Gan, XT | 1 |
| Rajapurohitam, V | 1 |
| Huang, CX | 1 |
| Xue, J | 1 |
| Lui, EM | 1 |
| Karmazyn, M | 2 |
| Levitan, BM | 1 |
| Manning, JR | 1 |
| Withers, CN | 1 |
| Smith, JD | 1 |
| Shaw, RM | 1 |
| Andres, DA | 1 |
| Sorrell, VL | 1 |
| Satin, J | 1 |
| Tuteryan, M | 1 |
| Santolini, M | 1 |
| Karma, A | 1 |
| Weiss, JN | 1 |
| Wang, LS | 1 |
| Lee, CT | 1 |
| Su, WL | 1 |
| Huang, SC | 1 |
| Wang, SC | 1 |
| Kumar, S | 4 |
| Jahangir Alam, M | 1 |
| Prabhakar, P | 2 |
| Ahmad, S | 1 |
| Maulik, SK | 5 |
| Sharma, M | 1 |
| Feng, Y | 2 |
| Cheng, J | 1 |
| Wei, B | 1 |
| Seldin, MM | 1 |
| Kim, ED | 1 |
| Krishnan, KC | 1 |
| Deb, A | 1 |
| El-Sherbeni, AA | 1 |
| Abdelhamid, G | 2 |
| Siraki, AG | 1 |
| Hanada, K | 1 |
| Asari, K | 1 |
| Saito, M | 1 |
| Kawana, J | 1 |
| Mita, M | 1 |
| Ogata, H | 1 |
| Monassier, L | 2 |
| Laplante, MA | 1 |
| Jaffré, F | 2 |
| Bousquet, P | 1 |
| Maroteaux, L | 2 |
| de Champlain, J | 1 |
| Trivedi, CM | 2 |
| Lu, MM | 3 |
| Epstein, JA | 3 |
| Aboutabl, ME | 1 |
| Wang, LN | 1 |
| Xi, YH | 1 |
| Li, HZ | 1 |
| Xiao, FG | 1 |
| Yang, BF | 1 |
| O'Donnell, JM | 1 |
| Fields, A | 1 |
| Xu, X | 2 |
| Chowdhury, SA | 1 |
| Geenen, DL | 3 |
| Bi, J | 1 |
| Copaja Soto, M | 1 |
| Valenzuela, R | 1 |
| Saldaña, A | 1 |
| Paz Ocaranza, M | 1 |
| Jalil, JE | 6 |
| Vio, C | 1 |
| Lijnen, P | 1 |
| Ordenes, GE | 1 |
| Vivar Sanchez, R | 1 |
| Lavandero, S | 2 |
| Díaz-Araya, G | 2 |
| Liu, YH | 1 |
| D'Ambrosio, M | 1 |
| Liao, TD | 1 |
| Peng, H | 1 |
| Rhaleb, NE | 1 |
| Sharma, U | 1 |
| André, S | 1 |
| Gabius, HJ | 1 |
| Carretero, OA | 1 |
| Shyu, KG | 1 |
| Schmechel, A | 1 |
| Höppner, G | 1 |
| Schwoerer, AP | 1 |
| Ehmke, H | 1 |
| Eschenhagen, T | 4 |
| Anderson, M | 1 |
| Moore, D | 1 |
| Larson, D | 1 |
| Cai, J | 1 |
| Yi, FF | 1 |
| Shen, DF | 1 |
| Ghosh, AK | 2 |
| Bian, ZY | 1 |
| Yan, L | 2 |
| Yang, XC | 1 |
| Yin, W | 1 |
| Zhang, P | 2 |
| Zhang, QY | 1 |
| Fan, R | 1 |
| Zhou, JJ | 1 |
| Hu, YZ | 1 |
| Guo, HT | 1 |
| Zhang, SM | 1 |
| Wang, YM | 1 |
| Kaye, AD | 1 |
| Gu, CH | 1 |
| Liu, JC | 1 |
| Cheng, L | 1 |
| Cui, Q | 1 |
| Yi, DH | 1 |
| Pei, JM | 1 |
| Liu, W | 1 |
| Zi, M | 1 |
| Jin, J | 2 |
| Prehar, S | 1 |
| Oceandy, D | 1 |
| Kimura, TE | 1 |
| Neyses, L | 2 |
| Weston, AH | 1 |
| Cheng, YS | 1 |
| Dai, DZ | 1 |
| Dai, Y | 1 |
| Gao, JP | 1 |
| Chen, CX | 1 |
| Gu, WL | 1 |
| Pandya, K | 1 |
| Porter, K | 1 |
| Rockman, HA | 2 |
| Smithies, O | 1 |
| Nakajima-Takenaka, C | 3 |
| Shimizu, J | 3 |
| Hattori, H | 1 |
| Nakashima, T | 1 |
| Kikuta, A | 1 |
| Matsuyoshi, H | 3 |
| Lin, Z | 1 |
| Murtaza, I | 1 |
| Jiao, J | 2 |
| Li, PF | 2 |
| Campreciós, G | 1 |
| Navarro, M | 1 |
| Soley, M | 1 |
| Ramírez, I | 1 |
| Ji, X | 1 |
| Takahashi, R | 1 |
| Hiura, Y | 1 |
| Hirokawa, G | 1 |
| Fukushima, Y | 1 |
| Iwai, N | 1 |
| Panek, AN | 1 |
| Posch, MG | 1 |
| Alenina, N | 1 |
| Ghadge, SK | 1 |
| Erdmann, B | 1 |
| Popova, E | 1 |
| Perrot, A | 1 |
| Geier, C | 1 |
| Dietz, R | 2 |
| Morano, RD | 1 |
| Morano, I | 1 |
| Bader, M | 3 |
| Ozcelik, C | 1 |
| Tohne, K | 1 |
| Nagai, Y | 2 |
| Nishiyama, A | 3 |
| Rodgers, BD | 2 |
| Interlichia, JP | 1 |
| Garikipati, DK | 2 |
| Mamidi, R | 1 |
| Chandra, M | 1 |
| Nelson, OL | 2 |
| Murry, CE | 1 |
| Santana, LF | 2 |
| Miller, CL | 1 |
| Oikawa, M | 1 |
| Wojtovich, AP | 1 |
| Nagel, DJ | 1 |
| Florio, V | 1 |
| Rybalkin, SD | 2 |
| Beavo, JA | 2 |
| Chen, YF | 1 |
| Li, JD | 1 |
| Blaxall, BC | 2 |
| Abe, J | 1 |
| Zhou, D | 1 |
| Valdivia, HH | 2 |
| Matkovich, SJ | 1 |
| Eschenbacher, WH | 1 |
| Dorn, LE | 1 |
| Condorelli, G | 1 |
| Diwan, A | 1 |
| Nerbonne, JM | 1 |
| Dorn, GW | 2 |
| Takimoto, E | 1 |
| Enjamoori, R | 2 |
| Jaiswal, A | 3 |
| Ray, R | 1 |
| Seth, S | 4 |
| Galindo, CL | 2 |
| Skinner, MA | 1 |
| Errami, M | 2 |
| Olson, LD | 1 |
| Watson, DA | 1 |
| McCormick, JF | 1 |
| McIver, LJ | 1 |
| Kumar, NM | 1 |
| Pham, TQ | 1 |
| Garner, HR | 2 |
| Abdellatif, M | 2 |
| Yeh, JL | 1 |
| Hsu, JH | 1 |
| Wu, PJ | 1 |
| Liou, SF | 1 |
| Liu, CP | 1 |
| Chen, IJ | 1 |
| Wu, BN | 1 |
| Dai, ZK | 1 |
| Wu, JR | 1 |
| Long, B | 1 |
| Rane, S | 1 |
| He, M | 1 |
| Sayed, D | 1 |
| Vatner, D | 2 |
| Lukowski, R | 1 |
| Loga, F | 1 |
| Leiss, V | 1 |
| Hofmann, F | 1 |
| Webb, IG | 1 |
| Nishino, Y | 1 |
| Clark, JE | 1 |
| Murdoch, C | 1 |
| Walker, SJ | 1 |
| Makowski, MR | 1 |
| Botnar, RM | 1 |
| Redwood, SR | 1 |
| Shah, AM | 1 |
| Marber, MS | 1 |
| Klaiber, M | 1 |
| Kruse, M | 1 |
| Völker, K | 1 |
| Schröter, J | 1 |
| Feil, R | 1 |
| Freichel, M | 1 |
| Gerling, A | 1 |
| Feil, S | 1 |
| Dietrich, A | 1 |
| Londoño, JE | 1 |
| Baba, HA | 1 |
| Abramowitz, J | 1 |
| Birnbaumer, L | 1 |
| Penninger, JM | 2 |
| Pongs, O | 1 |
| Santos, MH | 2 |
| Levy, RF | 1 |
| Santos, AA | 1 |
| Higuchi, ML | 2 |
| Magalhães, FC | 1 |
| Baraúna, VG | 1 |
| Kimura, S | 2 |
| Murao, K | 1 |
| Bodi, I | 2 |
| Maillet, M | 1 |
| DeSantiago, J | 1 |
| Domeier, TL | 1 |
| Mikoshiba, K | 1 |
| Lorenz, JN | 3 |
| Blatter, LA | 1 |
| Molkentin, JD | 4 |
| Dinda, AK | 3 |
| Etzion, S | 1 |
| Etzion, Y | 1 |
| DeBosch, B | 1 |
| Crawford, PA | 1 |
| Muslin, AJ | 1 |
| Drews, O | 1 |
| Tsukamoto, O | 1 |
| Liem, D | 1 |
| Streicher, J | 1 |
| Lv, R | 1 |
| Gu, YP | 1 |
| Huang, W | 1 |
| Guo, W | 1 |
| Wei, HC | 1 |
| Chen, LY | 1 |
| Ding, P | 1 |
| Huang, J | 2 |
| Battiprolu, PK | 1 |
| Hill, JA | 3 |
| Kamm, KE | 2 |
| Stull, JT | 2 |
| Hong, HM | 1 |
| Song, EJ | 1 |
| Oh, E | 1 |
| Kabir, MH | 1 |
| Lee, C | 1 |
| Yoo, YS | 1 |
| Sinisterra, RD | 1 |
| Jacoby, BA | 1 |
| Sousa, FB | 1 |
| Caliari, MV | 2 |
| Melo, MB | 2 |
| Nadu, AP | 1 |
| Souza, LE | 1 |
| Irigoyen, MC | 1 |
| Durgan, DJ | 1 |
| Tsai, JY | 1 |
| Grenett, MH | 1 |
| Pat, BM | 1 |
| Ratcliffe, WF | 1 |
| Villegas-Montoya, C | 1 |
| Garvey, ME | 1 |
| Nagendran, J | 1 |
| Dyck, JR | 1 |
| Bray, MS | 1 |
| Gamble, KL | 1 |
| Gimble, JM | 1 |
| Young, ME | 1 |
| Chen, N | 1 |
| Wang, G | 1 |
| Shan, H | 2 |
| Tang, Y | 1 |
| Le, X | 1 |
| Meng, J | 1 |
| Huang, L | 1 |
| Yu, P | 1 |
| Garlie, JB | 1 |
| Hamid, T | 1 |
| Gu, Y | 1 |
| Ismahil, MA | 1 |
| Chandrasekar, B | 2 |
| Prabhu, SD | 1 |
| Wolfram, JA | 1 |
| Liner, A | 1 |
| Richardson, SL | 1 |
| Smith, MA | 1 |
| Hoit, BD | 2 |
| Lee, HG | 1 |
| Giordano, E | 1 |
| Hillary, RA | 1 |
| Vary, TC | 1 |
| Pegg, AE | 3 |
| Sumner, AD | 1 |
| Caldarera, CM | 2 |
| Zhang, XQ | 1 |
| Song, J | 1 |
| Cheung, JY | 2 |
| Shantz, LM | 3 |
| Mullick, A | 1 |
| Tremblay, J | 1 |
| Leon, Z | 1 |
| Gros, P | 1 |
| Shibata, M | 1 |
| Ito, H | 3 |
| Buckley, MM | 2 |
| Johns, EJ | 2 |
| Song, LF | 1 |
| Qing, Y | 1 |
| Hu, XH | 1 |
| Tong, QY | 1 |
| Wu, XH | 1 |
| Rémond, MC | 1 |
| Iaffaldano, G | 1 |
| O'Quinn, MP | 1 |
| Mezentseva, NV | 1 |
| Garcia, V | 1 |
| Harris, BS | 1 |
| Gourdie, RG | 1 |
| Eisenberg, CA | 1 |
| Eisenberg, LM | 1 |
| Cai, X | 1 |
| Sun, H | 2 |
| Bai, T | 1 |
| Zhou, XW | 1 |
| Gill, DL | 1 |
| Tang, XD | 1 |
| Taglieri, DM | 1 |
| Monasky, MM | 1 |
| Knezevic, I | 1 |
| Sheehan, KA | 1 |
| Chernoff, J | 1 |
| Wolska, BM | 1 |
| Murray, DR | 1 |
| Mummidi, S | 1 |
| Valente, AJ | 1 |
| Somanna, NK | 1 |
| Delafontaine, P | 1 |
| Dinarello, CA | 1 |
| Cheng, G | 1 |
| Kasiganesan, H | 1 |
| Baicu, CF | 1 |
| Wallenborn, JG | 1 |
| Kuppuswamy, D | 1 |
| Cooper, G | 1 |
| Gong, KZ | 1 |
| Cai, YB | 1 |
| Izem-Meziane, M | 1 |
| Djerdjouri, B | 1 |
| Rimbaud, S | 1 |
| Caffin, F | 1 |
| Fortin, D | 1 |
| Garnier, A | 1 |
| Veksler, V | 1 |
| Joubert, F | 1 |
| Ventura-Clapier, R | 1 |
| Huntgeburth, M | 1 |
| Tiemann, K | 1 |
| Shahverdyan, R | 1 |
| Schlüter, KD | 8 |
| Schreckenberg, R | 1 |
| Gross, ML | 1 |
| Mödersheim, S | 1 |
| Caglayan, E | 1 |
| Müller-Ehmsen, J | 1 |
| Ghanem, A | 1 |
| Vantler, M | 1 |
| Zimmermann, WH | 2 |
| Böhm, M | 4 |
| Rosenkranz, S | 2 |
| Bass, GT | 1 |
| Ryall, KA | 1 |
| Katikapalli, A | 1 |
| Taylor, BE | 1 |
| Dang, ST | 1 |
| Acton, ST | 1 |
| Bharti, S | 1 |
| Singh, R | 1 |
| Chauhan, SS | 1 |
| Hussain, T | 1 |
| Al-Attas, OS | 1 |
| Hauton, D | 1 |
| Caldwell, GM | 1 |
| Passariello, CL | 2 |
| Gottardi, D | 1 |
| Cetrullo, S | 1 |
| Zini, M | 1 |
| Campana, G | 1 |
| Tantini, B | 1 |
| Pignatti, C | 1 |
| Flamigni, F | 1 |
| Guarnieri, C | 1 |
| Stefanelli, C | 1 |
| Råmunddal, T | 1 |
| Lindbom, M | 1 |
| Täng, MS | 1 |
| Shao, Y | 1 |
| Borén, J | 1 |
| Omerovic, E | 1 |
| Martín-Fernández, B | 1 |
| de las Heras, N | 1 |
| Miana, M | 1 |
| Ballesteros, S | 1 |
| Valero-Muñoz, M | 1 |
| Vassallo, D | 1 |
| Cachofeiro, V | 1 |
| Lahera, V | 1 |
| Singh, BK | 1 |
| Pillai, KK | 1 |
| Kohli, K | 1 |
| Haque, SE | 1 |
| Jackson, MF | 1 |
| Luong, D | 1 |
| Vang, DD | 1 |
| Stanton, JB | 1 |
| Somvanshi, RK | 1 |
| Qiu, X | 1 |
| Kumar, U | 1 |
| Dias-Peixoto, MF | 1 |
| Almeida, PW | 1 |
| Braga, VB | 1 |
| Coutinho, DC | 1 |
| Melo, DS | 1 |
| Gomes Filho, A | 1 |
| Greco, L | 1 |
| Campagnole-Santos, MJ | 1 |
| Lima, RF | 1 |
| Wong, TM | 3 |
| von Lueder, TG | 1 |
| How, OJ | 1 |
| Vinge, LE | 1 |
| Krobert, KA | 1 |
| Larsen, TS | 1 |
| Smiseth, OA | 1 |
| Aasum, E | 1 |
| Rocha-Resende, C | 1 |
| Roy, A | 1 |
| Resende, R | 1 |
| Ladeira, MS | 1 |
| Lara, A | 1 |
| de Morais Gomes, ER | 1 |
| Prado, VF | 1 |
| Guatimosim, C | 1 |
| Prado, MA | 1 |
| Goyal, BR | 1 |
| Mehta, AA | 1 |
| Larocca, TJ | 1 |
| Jeong, D | 2 |
| Kohlbrenner, E | 1 |
| Lee, A | 1 |
| Hajjar, RJ | 4 |
| Verma, SK | 1 |
| Krishnamurthy, P | 1 |
| Barefield, D | 1 |
| Singh, N | 1 |
| Gupta, R | 1 |
| Lambers, E | 1 |
| Thal, M | 1 |
| Mackie, A | 1 |
| Hoxha, E | 1 |
| Ramirez, V | 1 |
| Qin, G | 1 |
| Sadayappan, S | 1 |
| Kishore, R | 1 |
| Haines, CD | 1 |
| Harvey, PA | 1 |
| Leinwand, LA | 2 |
| Vidal, M | 1 |
| Wieland, T | 1 |
| Lohse, MJ | 3 |
| Lorenz, K | 1 |
| Zhou, X | 2 |
| Xing, S | 1 |
| Qiao, G | 1 |
| Gava, AL | 2 |
| Balarini, CM | 1 |
| Peotta, VA | 2 |
| Abreu, GR | 1 |
| Cabral, AM | 4 |
| Vasquez, EC | 4 |
| Meyrelles, SS | 3 |
| Kwon, EJ | 1 |
| Kritzer, MD | 1 |
| Michel, JJ | 1 |
| Le, A | 1 |
| Thakur, H | 1 |
| Gayanilo, M | 1 |
| Negro, A | 1 |
| Danial, JB | 1 |
| Oskouei, B | 1 |
| Sanders, M | 1 |
| Hare, JM | 2 |
| Hanauer, A | 1 |
| Dodge-Kafka, K | 1 |
| Kapiloff, MS | 1 |
| Sankar, V | 1 |
| Pangayarselvi, B | 1 |
| Prathapan, A | 1 |
| Raghu, KG | 1 |
| Qin, M | 1 |
| Liu, T | 1 |
| Yu, S | 1 |
| Huang, C | 1 |
| Szeto, C | 1 |
| Tang, M | 1 |
| Fu, Q | 1 |
| Makarewich, C | 1 |
| Ai, X | 1 |
| Tang, A | 1 |
| Wang, F | 1 |
| Ge, XJ | 1 |
| Kunapuli, SP | 1 |
| Xiang, KY | 1 |
| Tse, MM | 1 |
| Hammock, BD | 1 |
| Roy, SJ | 1 |
| Mainzen Prince, PS | 1 |
| Sumita Yoshikawa, W | 1 |
| Nakamura, K | 1 |
| Miura, D | 1 |
| Hashimoto, K | 1 |
| Kataoka, N | 1 |
| Toyota, H | 1 |
| Okuyama, H | 1 |
| Miyoshi, T | 1 |
| Morita, H | 1 |
| Fukushima Kusano, K | 1 |
| Matsuo, T | 1 |
| Kajiya, F | 1 |
| Yagi, N | 1 |
| Ohe, T | 1 |
| Al-Mazroua, HA | 1 |
| Korashy, HM | 1 |
| Lv, Q | 1 |
| Temple, J | 1 |
| Dzhura, I | 1 |
| Trimble, R | 1 |
| Roden, DM | 1 |
| Passier, R | 1 |
| Olson, EN | 2 |
| Colbran, RJ | 1 |
| Anderson, ME | 1 |
| Ozaki, M | 1 |
| Kawashima, S | 1 |
| Yamashita, T | 1 |
| Hirase, T | 1 |
| Ohashi, Y | 1 |
| Inoue, N | 1 |
| Hirata, K | 1 |
| Yokoyama, M | 2 |
| Odashiro, K | 1 |
| Hiramatsu, S | 1 |
| Yanagi, N | 1 |
| Arita, T | 1 |
| Maruyama, T | 1 |
| Kaji, Y | 1 |
| Harada, M | 1 |
| Ren, B | 1 |
| Sentex, E | 1 |
| Tappia, PS | 1 |
| Dhalla, NS | 5 |
| Shi, YR | 1 |
| Bu, DF | 2 |
| Qi, YF | 3 |
| Jiang, HF | 1 |
| Pang, YZ | 3 |
| Tang, CS | 4 |
| Du, JB | 1 |
| Borges, JC | 1 |
| Gomes, MA | 1 |
| Lomez, ES | 1 |
| Leite, KM | 1 |
| Araujo, RC | 1 |
| Pesquero, JB | 1 |
| Pesquero, JL | 1 |
| Novotny, J | 1 |
| Hrbasová, M | 1 |
| Kolár, F | 2 |
| Svoboda, P | 1 |
| Ennis, IL | 1 |
| Escudero, EM | 1 |
| Console, GM | 1 |
| Camihort, G | 1 |
| Dumm, CG | 1 |
| Seidler, RW | 1 |
| Camilión de Hurtado, MC | 1 |
| Cingolani, HE | 2 |
| Braun, M | 1 |
| Simonis, G | 1 |
| Birkner, K | 1 |
| Pauke, B | 1 |
| Strasser, RH | 1 |
| Tomita, H | 2 |
| Nazmy, M | 1 |
| Kajimoto, K | 1 |
| Yehia, G | 1 |
| Molina, CA | 1 |
| Sadoshima, J | 4 |
| Miura, S | 2 |
| Ohno, I | 2 |
| Suzuki, J | 2 |
| Suzuki, K | 1 |
| Okada, S | 1 |
| Okuyama, A | 1 |
| Nawata, J | 2 |
| Ikeda, J | 2 |
| Shirato, K | 2 |
| Oudit, GY | 1 |
| Crackower, MA | 1 |
| Eriksson, U | 1 |
| Sarao, R | 1 |
| Kozieradzki, I | 1 |
| Sasaki, T | 1 |
| Irie-Sasaki, J | 1 |
| Gidrewicz, D | 1 |
| Rybin, VO | 1 |
| Wada, T | 1 |
| Steinberg, SF | 2 |
| Backx, PH | 1 |
| Kook, H | 1 |
| Lepore, JJ | 1 |
| Gitler, AD | 1 |
| Wing-Man Yung, W | 1 |
| Mackay, J | 1 |
| Zhou, R | 1 |
| Ferrari, V | 1 |
| Gruber, P | 1 |
| GOODWIN, JF | 1 |
| TAFUR, E | 1 |
| COHEN, LS | 1 |
| LEVINE, HD | 1 |
| ROE, BB | 1 |
| BRUNS, DL | 1 |
| DEBONO, AH | 1 |
| PROCTOR, E | 1 |
| BROCK, R | 1 |
| Fernández-Velasco, M | 1 |
| Goren, N | 1 |
| Benito, G | 1 |
| Blanco-Rivero, J | 1 |
| Boscá, L | 1 |
| Delgado, C | 1 |
| Nienaber, JJ | 1 |
| Tachibana, H | 1 |
| Naga Prasad, SV | 1 |
| Esposito, G | 1 |
| Mao, L | 1 |
| Ocaranza, MP | 1 |
| Carreño, JE | 1 |
| Muñoz, D | 1 |
| Riveros, JP | 1 |
| Lutz, S | 1 |
| Mura, RA | 1 |
| Hippe, HJ | 1 |
| Tiefenbacher, C | 1 |
| Niroomand, F | 1 |
| Kedzierski, RM | 1 |
| Grayburn, PA | 1 |
| Kisanuki, YY | 1 |
| Williams, CS | 1 |
| Hammer, RE | 1 |
| Richardson, JA | 3 |
| Schneider, MD | 1 |
| Yanagisawa, M | 1 |
| Roman, BB | 1 |
| Goldspink, PH | 1 |
| Spaite, E | 1 |
| Urboniene, D | 1 |
| McKinney, R | 1 |
| Buttrick, PM | 3 |
| Taimor, G | 6 |
| Best, P | 1 |
| Helmig, S | 1 |
| Piper, HM | 8 |
| Kitagawa, Y | 2 |
| Yamashita, D | 1 |
| Hu, YC | 1 |
| Hou, JY | 1 |
| Liao, Y | 1 |
| Asakura, M | 1 |
| Takashima, S | 1 |
| Ogai, A | 1 |
| Asano, Y | 1 |
| Shintani, Y | 1 |
| Minamino, T | 1 |
| Asanuma, H | 1 |
| Sanada, S | 1 |
| Kim, J | 1 |
| Kitamura, S | 1 |
| Tomoike, H | 2 |
| Hori, M | 1 |
| Kitakaze, M | 1 |
| Callebert, J | 1 |
| Sarre, A | 1 |
| Etienne, N | 1 |
| Nebigil, CG | 1 |
| Launay, JM | 1 |
| Christe, M | 1 |
| Jin, N | 1 |
| Gould, KE | 1 |
| Iversen, PW | 1 |
| Kadambi, V | 1 |
| Zuckerman, SH | 1 |
| Bloem, LJ | 1 |
| Pasumarthi, KB | 1 |
| Nakajima, H | 1 |
| Nakajima, HO | 1 |
| Soonpaa, MH | 2 |
| Field, LJ | 2 |
| Robbins, J | 1 |
| Faulx, MD | 1 |
| Ernsberger, P | 1 |
| Hoffman, RD | 1 |
| Lewis, W | 1 |
| Strachan, R | 1 |
| Minhas, KM | 1 |
| Khan, SA | 1 |
| Raju, SV | 1 |
| Phan, AC | 1 |
| Gonzalez, DR | 1 |
| Skaf, MW | 1 |
| Lee, K | 1 |
| Tejani, AD | 1 |
| Saliaris, AP | 2 |
| Barouch, LA | 1 |
| O'Donnell, CP | 1 |
| Emala, CW | 1 |
| Berkowitz, DE | 1 |
| Hohimer, AR | 1 |
| Davis, LE | 1 |
| Hatton, DC | 1 |
| Woldbaek, PR | 1 |
| Sande, JB | 1 |
| Strømme, TA | 1 |
| Lunde, PK | 1 |
| Djurovic, S | 1 |
| Lyberg, T | 1 |
| Christensen, G | 1 |
| Tønnessen, T | 1 |
| Freund, C | 1 |
| Schmidt-Ullrich, R | 1 |
| Baurand, A | 1 |
| Dunger, S | 1 |
| Schneider, W | 1 |
| Loser, P | 1 |
| El-Jamali, A | 1 |
| Scheidereit, C | 1 |
| Bergmann, MW | 1 |
| Osadchii, O | 1 |
| Norton, G | 1 |
| Woodiwiss, A | 1 |
| Geng, B | 1 |
| Pan, CS | 2 |
| Chang, JK | 1 |
| Zhou, YZ | 1 |
| Zhu, SJ | 1 |
| Yu, LJ | 1 |
| McQueen, AP | 1 |
| Zhang, D | 1 |
| Hu, P | 1 |
| Swenson, L | 1 |
| Zaha, VG | 1 |
| Hoffman, JL | 1 |
| Yun, UJ | 1 |
| Chakrabarti, G | 1 |
| Albertine, KH | 1 |
| Abel, ED | 1 |
| Litwin, SE | 1 |
| Scholz, PM | 4 |
| Weiss, HR | 5 |
| Oestreich, EA | 1 |
| Maekawa, N | 1 |
| Bullard, TA | 1 |
| Vikstrom, KL | 2 |
| Dirksen, RT | 1 |
| Kelley, GG | 1 |
| Smrcka, AV | 1 |
| Kizaki, K | 1 |
| Ito, R | 1 |
| Yoshioka, K | 1 |
| Hashizume, K | 1 |
| Mutoh, K | 1 |
| Hara, Y | 1 |
| Weil, J | 1 |
| Zolk, O | 1 |
| Griepentrog, J | 1 |
| Wenzel, U | 1 |
| Zhang, LK | 1 |
| Palfi, A | 1 |
| Toth, A | 1 |
| Hanto, K | 1 |
| Deres, P | 1 |
| Szabados, E | 1 |
| Szereday, Z | 1 |
| Kulcsar, G | 1 |
| Kalai, T | 1 |
| Hideg, K | 1 |
| Gallyas, F | 1 |
| Sumegi, B | 1 |
| Toth, K | 1 |
| Halmosi, R | 1 |
| Campos, LA | 1 |
| Iliescu, R | 1 |
| Fontes, MA | 1 |
| Schlegel, WP | 1 |
| Baltatu, OC | 1 |
| Zhong, W | 1 |
| Mao, S | 1 |
| Tobis, S | 1 |
| Angelis, E | 1 |
| de Alborán, IM | 1 |
| MacLellan, WR | 1 |
| Beeri, R | 1 |
| Nechushtan, H | 1 |
| Kaluzhny, D | 1 |
| Pikarsky, E | 1 |
| Jaehnig, EJ | 1 |
| Heidt, AB | 1 |
| Greene, SB | 1 |
| Cornelissen, I | 1 |
| Black, BL | 1 |
| Fan, GC | 1 |
| Yuan, Q | 1 |
| Song, G | 1 |
| Chen, G | 1 |
| Qian, J | 1 |
| Ashraf, M | 1 |
| Sethi, R | 1 |
| Saini, HK | 1 |
| Elimban, V | 1 |
| Shan, D | 1 |
| Su, Y | 1 |
| Jing, Y | 1 |
| Antoons, G | 2 |
| Volders, PG | 1 |
| Stankovicova, T | 1 |
| Bito, V | 1 |
| Stengl, M | 1 |
| Vos, MA | 1 |
| Sipido, KR | 1 |
| Zhang, YG | 1 |
| Li, YG | 1 |
| Liu, BG | 1 |
| Wei, RH | 1 |
| Wang, DM | 1 |
| Tan, XR | 1 |
| Ohmori, K | 1 |
| Fujisawa, Y | 1 |
| Abe, Y | 1 |
| Krenek, P | 1 |
| Klimas, J | 1 |
| Kroslakova, M | 1 |
| Gazova, A | 1 |
| Plandorova, J | 1 |
| Kucerova, D | 1 |
| Fecenkova, A | 1 |
| Svec, P | 1 |
| Kyselovic, J | 1 |
| Tamura, Y | 1 |
| Taniguchi, S | 1 |
| Uesato, S | 1 |
| Stoller, D | 1 |
| Kakkar, R | 1 |
| Smelley, M | 1 |
| Chalupsky, K | 1 |
| Earley, JU | 1 |
| Shi, NQ | 1 |
| Makielski, JC | 1 |
| McNally, EM | 1 |
| Oliveira, TL | 1 |
| Castro, MC | 1 |
| Castro, CH | 1 |
| Gava, E | 1 |
| Kitten, GT | 1 |
| Xu, XL | 1 |
| Ji, H | 1 |
| Gu, SY | 1 |
| Shao, Q | 1 |
| Huang, QJ | 1 |
| Cheng, YP | 1 |
| Tassa, AT | 1 |
| Dimaio, JM | 1 |
| Morisco, C | 2 |
| Marrone, C | 1 |
| Galeotti, J | 1 |
| Shao, D | 1 |
| Vatner, DE | 3 |
| Vatner, SF | 5 |
| Itoh, K | 1 |
| Minakawa, M | 1 |
| Ono, Y | 1 |
| Tsushima, T | 1 |
| Fukui, K | 1 |
| Fukuda, I | 1 |
| Kim, T | 1 |
| Thu, VT | 1 |
| Han, IY | 1 |
| Youm, JB | 1 |
| Kim, E | 1 |
| Kang, SW | 1 |
| Kim, YW | 1 |
| Lee, JH | 1 |
| Joo, H | 1 |
| Shelton, JM | 2 |
| Flanagan, ET | 1 |
| Aherne, CM | 1 |
| Lainis, F | 1 |
| Sattar, M | 1 |
| Stones, R | 1 |
| Natali, A | 1 |
| Billeter, R | 1 |
| Harrison, S | 1 |
| White, E | 1 |
| Ihara, SS | 1 |
| Bombig, MT | 1 |
| Zimmer, HG | 5 |
| Newman, WH | 2 |
| Ellison, DM | 1 |
| Brenner, GM | 1 |
| Wulf, RG | 1 |
| Richichi, I | 1 |
| Raisaro, A | 1 |
| Guagliumi, G | 1 |
| Desperati, M | 1 |
| Dämmrich, J | 2 |
| Pfeifer, U | 2 |
| Gerlach, E | 2 |
| Simpson, P | 2 |
| Ibel, H | 2 |
| Steinkopff, G | 2 |
| Rossi, A | 3 |
| Olivares, J | 3 |
| Aussedat, J | 4 |
| Ray, A | 3 |
| Raymondjean, M | 1 |
| Kneip, B | 1 |
| Kruh, J | 1 |
| Clarke, K | 1 |
| Ward, LC | 1 |
| Taylor, PB | 7 |
| Tang, Q | 3 |
| Harris, P | 1 |
| Palileo, EV | 1 |
| Ashley, WW | 1 |
| Swiryn, S | 1 |
| Bauernfeind, RA | 1 |
| Strasberg, B | 1 |
| Petropoulos, AT | 1 |
| Rosen, KM | 1 |
| McGrath, A | 1 |
| Savion, S | 1 |
| Sung, R | 1 |
| Stephens, M | 1 |
| Blayney, L | 1 |
| Henderson, A | 1 |
| Bartolome, JV | 1 |
| Trepanier, PA | 1 |
| Chait, EA | 1 |
| Slotkin, TA | 4 |
| Perin, A | 1 |
| Sessa, A | 1 |
| Desiderio, MA | 1 |
| Sreter, FA | 1 |
| Faris, R | 1 |
| Balogh, I | 1 |
| Somogyi, E | 1 |
| Sotonyi, P | 1 |
| Tarazi, RC | 4 |
| Corder, DW | 1 |
| Heyliger, CE | 1 |
| Beamish, RE | 1 |
| Petkov, O | 2 |
| Hemwall, EL | 1 |
| Duthinh, V | 1 |
| Houser, SR | 2 |
| Ross, J | 2 |
| Botham, MJ | 1 |
| Lemmer, JH | 1 |
| Gerren, RA | 1 |
| Long, RW | 1 |
| Behrendt, DM | 1 |
| Gallagher, KP | 1 |
| Szabó, J | 6 |
| Nosztray, K | 5 |
| Takács, IE | 2 |
| Szegi, J | 4 |
| Genovese, A | 3 |
| Chiariello, M | 2 |
| Bozzaotre, M | 1 |
| Latte, S | 1 |
| De Alfieri, W | 1 |
| Condorelli, M | 4 |
| Wyse, RK | 1 |
| Jones, M | 2 |
| Welham, KC | 1 |
| de Leval, MR | 1 |
| Iida, K | 5 |
| Sugishita, Y | 5 |
| Matsuda, M | 1 |
| Yamaguchi, T | 1 |
| Ajisaka, R | 2 |
| Matsumoto, R | 1 |
| Fujita, T | 2 |
| Ito, I | 5 |
| Verdys, M | 2 |
| Cluzeaud, F | 1 |
| Perennec, J | 1 |
| de Amoral, E | 1 |
| Willemin, M | 1 |
| Hatt, PY | 1 |
| Tse, J | 4 |
| Wrenn, RW | 1 |
| Kuo, JF | 3 |
| Tanaka, M | 1 |
| Tsuchihashi, Y | 1 |
| Katsume, H | 2 |
| Ijichi, H | 2 |
| Ibata, Y | 2 |
| Bobik, A | 1 |
| Korner, P | 1 |
| Chatelain, P | 1 |
| Robberecht, P | 1 |
| De Neef, P | 1 |
| Camus, JC | 1 |
| Christophe, J | 1 |
| Lakatta, EG | 3 |
| Yin, FC | 1 |
| Atkins, FL | 1 |
| Carney, R | 1 |
| Love, S | 1 |
| Ayobe, MH | 4 |
| Raum, WJ | 1 |
| Laks, MM | 1 |
| Garner, D | 1 |
| Ikuhara, MH | 1 |
| Swerdloff, RS | 1 |
| Homcy, CJ | 1 |
| Sit, SP | 1 |
| Manders, WT | 2 |
| Volpe, M | 1 |
| Trimarco, B | 1 |
| Mele, A | 1 |
| Cuocolo, A | 1 |
| De Luca, N | 1 |
| Ricciardelli, B | 1 |
| Webb, JG | 1 |
| Koschine, H | 1 |
| Zeppilli, P | 1 |
| Pirrami, MM | 1 |
| Sassara, M | 1 |
| Fenici, R | 1 |
| Ferro, G | 1 |
| Cacciapuoti, AA | 2 |
| Bartolome, J | 1 |
| Huguenard, J | 1 |
| Deshaies, Y | 2 |
| Willemot, J | 2 |
| Leblanc, J | 2 |
| Manohar, M | 2 |
| Thurmon, JC | 1 |
| Tranquilli, WJ | 1 |
| Devous, MD | 1 |
| Theodorakis, MC | 1 |
| Shawley, RV | 1 |
| Feller, DL | 1 |
| Benson, JG | 1 |
| Bisgard, GE | 1 |
| Bullard, V | 1 |
| Rankin, JH | 1 |
| Hotujac, L | 1 |
| Dürrigl, A | 1 |
| Baldwin, KM | 1 |
| Ernst, SB | 1 |
| Mullin, WJ | 1 |
| Schrader, LF | 1 |
| Herrick, RE | 1 |
| Zhou, XJ | 1 |
| Long, CS | 1 |
| Hartogensis, WE | 1 |
| Simpson, PC | 2 |
| Rabkin, SW | 3 |
| Abassi, ZA | 1 |
| Cuda, G | 1 |
| Stylianou, M | 1 |
| Panchal, VR | 1 |
| Trachewsky, D | 1 |
| Keiser, HR | 1 |
| Sunga, PS | 2 |
| Clarke, MS | 1 |
| Caldwell, RW | 1 |
| Chiao, H | 1 |
| Miyake, K | 1 |
| McNeil, PL | 1 |
| Lappi, SE | 1 |
| Seidler, FJ | 2 |
| Boluyt, MO | 2 |
| Long, X | 1 |
| Mende, U | 3 |
| Schmitz, W | 5 |
| Crow, MT | 1 |
| Weber, M | 1 |
| Mészáros, J | 6 |
| Pásztor, B | 1 |
| Decker, RS | 2 |
| Decker, ML | 1 |
| Behnke-Barclay, MM | 1 |
| Janes, DM | 1 |
| Clark, WA | 3 |
| Inoko, M | 1 |
| Kihara, Y | 1 |
| Morii, I | 1 |
| Fujiwara, H | 1 |
| Sasayama, S | 3 |
| Omura, T | 2 |
| Kim, S | 2 |
| Takeuchi, K | 4 |
| Iwao, H | 1 |
| Takeda, T | 3 |
| Brand, T | 1 |
| Sharma, HS | 1 |
| Schaper, W | 1 |
| Mäkynen, H | 1 |
| Arvola, P | 1 |
| Vapaatalo, H | 1 |
| Pörsti, I | 1 |
| Kim, KK | 1 |
| Daud, AI | 1 |
| Koh, GY | 1 |
| Kim, JS | 1 |
| Alpert, NR | 2 |
| Mulieri, LA | 2 |
| Holubarsch, C | 1 |
| Harmsen, E | 1 |
| Schoemaker, R | 1 |
| Ruzicka, M | 1 |
| Leenen, FH | 2 |
| Saito, T | 1 |
| Kai, N | 1 |
| Yamamoto, K | 1 |
| Iwata, J | 1 |
| Deguchi, F | 1 |
| Inagaki, Y | 1 |
| Minor, T | 1 |
| Isselhard, W | 1 |
| Sturz, J | 1 |
| Nieto, JL | 1 |
| Díaz-Laviada, I | 1 |
| Guillén, A | 1 |
| García-Barreno, P | 1 |
| Haro, A | 1 |
| Kimura, H | 1 |
| Miyamoto, A | 1 |
| Ohshika, H | 2 |
| Noda, N | 1 |
| Hayashi, H | 1 |
| Satoh, H | 1 |
| Terada, H | 1 |
| Hirano, M | 1 |
| Kobayashi, A | 1 |
| Yamazaki, N | 1 |
| Póvoa, R | 1 |
| Manzoli, MT | 1 |
| Ferreira, C | 2 |
| Murad, N | 3 |
| Simões, M | 1 |
| Luna, B | 1 |
| Gillis, AM | 1 |
| Mathison, HJ | 1 |
| Patel, C | 1 |
| Lester, WM | 1 |
| Tang, L | 2 |
| Cerbai, E | 2 |
| Barbieri, M | 1 |
| Mugelli, A | 2 |
| Ryder, KO | 2 |
| Hart, G | 3 |
| Coutinho, JJ | 1 |
| Bryant, SM | 3 |
| Gómez, AM | 1 |
| Cheng, H | 1 |
| Lederer, MR | 1 |
| Cannell, MB | 1 |
| McCune, SA | 1 |
| Altschuld, RA | 1 |
| Lederer, WJ | 1 |
| Bailey, BA | 1 |
| Dipla, K | 1 |
| Yamazaki, T | 2 |
| Kudoh, S | 3 |
| Mizuno, T | 1 |
| Hiroi, Y | 2 |
| Shiojima, I | 1 |
| Takano, H | 1 |
| Kinugawa, Ki | 1 |
| Kohmoto, O | 2 |
| Takahashi, T | 3 |
| Yazaki, Y | 3 |
| Naim, KL | 1 |
| Rabindranauth, P | 1 |
| Arthur, GD | 1 |
| Belcastro, AN | 1 |
| Bowman, JC | 1 |
| Jiang, T | 1 |
| Fishman, GI | 1 |
| Hakamata, N | 1 |
| Hamada, H | 1 |
| Ohsuzu, F | 1 |
| Nakamura, H | 1 |
| Buus, NH | 1 |
| Terp, K | 1 |
| Baandrup, U | 1 |
| Mulvany, MJ | 1 |
| Nyborg, NC | 1 |
| Sumida, E | 2 |
| Nohara, M | 1 |
| Muro, A | 1 |
| Kaku, H | 1 |
| Koga, Y | 1 |
| Toshima, H | 1 |
| Imaizumi, T | 1 |
| Kotchi Kotchi, E | 1 |
| Weisselberg, T | 1 |
| Röhnert, P | 1 |
| Preiss, M | 1 |
| Heinroth-Hoffmann, I | 2 |
| Osten, B | 1 |
| Brodde, OE | 1 |
| Communal, C | 2 |
| Ribuot, C | 2 |
| Durand, A | 2 |
| Demenge, P | 2 |
| Masson, S | 2 |
| Arosio, B | 2 |
| Luvarà, G | 1 |
| Gagliano, N | 2 |
| Fiordaliso, F | 2 |
| Santambrogio, D | 2 |
| Vergani, C | 2 |
| Latini, R | 2 |
| Annoni, G | 2 |
| Grupp, IL | 2 |
| Walsh, RA | 1 |
| Boivin, GP | 1 |
| Rindt, H | 1 |
| Goldberg, Y | 2 |
| Schäfer, M | 2 |
| Kambe, F | 1 |
| Kamiya, K | 1 |
| Seo, H | 1 |
| Toyama, J | 1 |
| Iaccarino, G | 2 |
| Dolber, PC | 1 |
| Lefkowitz, RJ | 1 |
| Burtea, C | 1 |
| Gatina, R | 1 |
| Stoian, G | 1 |
| Mardare, M | 1 |
| Dumitru, IF | 1 |
| Dragomir, CT | 1 |
| Uozumi, H | 2 |
| Kadowaki, T | 1 |
| McMartin, L | 1 |
| Summers, RJ | 1 |
| Pino, R | 1 |
| Rodriguez, ML | 1 |
| Saadane, N | 2 |
| Alpert, L | 2 |
| Chalifour, LE | 2 |
| Shipsey, SJ | 1 |
| Takemoto, Y | 1 |
| Yoshiyama, M | 1 |
| Komatsu, R | 1 |
| Yoshikawa, J | 1 |
| Murphy, AM | 1 |
| Kögler, H | 1 |
| Georgakopoulos, D | 1 |
| McDonough, JL | 1 |
| Kass, DA | 1 |
| Van Eyk, JE | 1 |
| Marbán, E | 1 |
| Yoshida, H | 1 |
| Szymanska, G | 1 |
| Strömer, H | 1 |
| Silverman, M | 1 |
| Belu-John, Y | 1 |
| Morgan, JP | 2 |
| Calvillo, L | 1 |
| D'Aquila, S | 1 |
| Frischkopf, K | 2 |
| Flesch, M | 1 |
| Leone, RJ | 1 |
| Straznicka, M | 1 |
| Friddle, CJ | 1 |
| Koga, T | 1 |
| Rubin, EM | 1 |
| Bristow, J | 1 |
| Knollmann, BC | 1 |
| Knollmann-Ritschel, BE | 1 |
| Weissman, NJ | 1 |
| Jones, LR | 1 |
| Morad, M | 1 |
| Brooks, WW | 1 |
| Bing, OH | 1 |
| Malhotra, A | 1 |
| Satoh, N | 1 |
| Colucci, WS | 1 |
| Conrad, CH | 1 |
| Inamoto, S | 1 |
| Murao, S | 1 |
| Kitazawa, S | 1 |
| Maeda, S | 1 |
| Mitarai, S | 2 |
| Reed, TD | 1 |
| Yatani, A | 3 |
| Mackintosh, CA | 1 |
| Feith, DJ | 2 |
| Fockenbrock, M | 1 |
| Herzig, S | 1 |
| Knapp, J | 2 |
| Linck, B | 2 |
| Lüss, H | 2 |
| Müller, T | 2 |
| Schröder, F | 1 |
| Neumann, J | 2 |
| Di Fusco, F | 1 |
| Hashim, S | 1 |
| Anand-Srivastava, MB | 1 |
| Hammerschmidt, S | 1 |
| Bell, M | 1 |
| Büchler, N | 1 |
| Wahn, H | 1 |
| Remkes, H | 1 |
| Neubauer, S | 1 |
| Sato, Y | 1 |
| Kiriazis, H | 1 |
| Schmidt, AG | 1 |
| Hahn, H | 1 |
| Ferguson, DG | 1 |
| Sako, H | 1 |
| Honda, R | 2 |
| Mesnard-Rouiller, L | 1 |
| Frank, KF | 1 |
| Beyermann, B | 1 |
| Fujimori, K | 1 |
| Freeman, K | 1 |
| Colon-Rivera, C | 1 |
| Olsson, MC | 1 |
| Moore, RL | 2 |
| Weinberger, HD | 1 |
| Sugawara, H | 1 |
| Sakurai, K | 1 |
| Atsumi, H | 1 |
| Nakada, S | 1 |
| Endoh, M | 1 |
| Tymitz, KM | 1 |
| Lalli, MJ | 1 |
| Schlüter, K | 1 |
| Zebrowski, DC | 1 |
| Meyer, TE | 1 |
| Chung, ES | 1 |
| Perlini, S | 1 |
| Norton, GR | 1 |
| Woodiwiss, AJ | 1 |
| Lorbar, M | 1 |
| Fenton, RA | 1 |
| Dobson, JG | 1 |
| De Windt, LJ | 1 |
| Lim, HW | 1 |
| Bueno, OF | 1 |
| Liang, Q | 1 |
| Delling, U | 1 |
| Braz, JC | 1 |
| Glascock, BJ | 1 |
| Kimball, TF | 1 |
| del Monte, F | 1 |
| Silva, CO | 1 |
| Monteiro-Filho, WO | 1 |
| Duarte, GP | 1 |
| Lahlou, S | 1 |
| Iwata, M | 1 |
| Yoshikawa, T | 1 |
| Baba, A | 1 |
| Anzai, T | 1 |
| Nakamura, I | 1 |
| Wainai, Y | 1 |
| Ogawa, S | 1 |
| Meyer, M | 1 |
| Trost, SU | 1 |
| Bluhm, WF | 1 |
| Knot, HJ | 1 |
| Swanson, E | 1 |
| Dillmann, WH | 1 |
| Sears, CE | 1 |
| Rigg, L | 1 |
| Casadei, B | 1 |
| Yao, A | 1 |
| Shimoyama, M | 1 |
| Shibasaki, F | 1 |
| Nagai, R | 1 |
| Fabiano de Franco, M | 1 |
| Brodde, O | 1 |
| Gallego, M | 1 |
| Espiña, L | 1 |
| Vegas, L | 1 |
| Echevarria, E | 1 |
| Iriarte, MM | 1 |
| Casis, O | 1 |
| Ver Heyen, M | 1 |
| Heymans, S | 1 |
| Reed, T | 1 |
| Periasamy, M | 1 |
| Awede, B | 1 |
| Lebacq, J | 1 |
| Vangheluwe, P | 1 |
| Dewerchin, M | 1 |
| Collen, D | 1 |
| Sipido, K | 1 |
| Carmeliet, P | 1 |
| Wuytack, F | 1 |
| White, R | 1 |
| Yuan, B | 1 |
| Antos, CL | 1 |
| McKinsey, TA | 1 |
| Frey, N | 1 |
| Kutschke, W | 1 |
| McAnally, J | 1 |
| Gealekman, O | 1 |
| Abassi, Z | 1 |
| Rubinstein, I | 1 |
| Winaver, J | 1 |
| Binah, O | 1 |
| Shizukuda, Y | 1 |
| Shan, J | 1 |
| Yu, XC | 1 |
| Fung, ML | 1 |
| Petrashevskaya, NN | 1 |
| Rubio, M | 1 |
| Schwartz, A | 2 |
| Bhagat, B | 1 |
| Sullivan, JM | 1 |
| Pagano, VT | 2 |
| Inchiosa, MA | 3 |
| Quinones, MA | 1 |
| Gaasch, WH | 1 |
| Cole, JS | 1 |
| Alexander, JK | 1 |
| Miyagishima, Y | 1 |
| Kannengiesser, GJ | 1 |
| Lubbe, WF | 1 |
| Opie, LH | 1 |
| Huxtable, R | 5 |
| Chubb, J | 5 |
| Bressler, R | 1 |
| Collins, P | 1 |
| Billings, CG | 1 |
| Barer, GR | 1 |
| Daly, JJ | 1 |
| Jolly, A | 1 |
| Yates, JC | 1 |
| Malik, AB | 2 |
| Geha, AS | 2 |
| Rau, E | 1 |
| Meyer, DK | 1 |
| Irmer, M | 1 |
| Köhler, G | 1 |
| Friedrichs, H | 1 |
| Eschenbruch, E | 1 |
| Döring, HJ | 1 |
| Hein, B | 3 |
| Hein, R | 2 |
| Janke, J | 3 |
| Bronnimann, D | 1 |
| Franklin, D | 1 |
| Kemper, WS | 1 |
| McKown, D | 1 |
| Hollander, W | 1 |
| Prusty, S | 1 |
| Kirkpatrick, B | 1 |
| Paddock, J | 1 |
| Nagraj, S | 1 |
| Swanson, CT | 1 |
| Draisey, TF | 1 |
| Csáky, L | 2 |
| Iazigian, A | 1 |
| Lapohos, E | 1 |
| Szabó, S | 1 |
| Ensslen, R | 1 |
| Schwarz, F | 3 |
| Thormann, J | 3 |
| Schlepper, M | 2 |
| Sesto, M | 2 |
| Langebartels, F | 2 |
| Abe, T | 2 |
| Sugiki, K | 1 |
| Wada, J | 1 |
| O'Keefe, DD | 1 |
| Hoffman, JI | 2 |
| Cheitlin, R | 1 |
| O'Neill, MJ | 1 |
| Allard, JR | 1 |
| Shapkin, E | 1 |
| Flameng, W | 1 |
| Hehrlein, F | 1 |
| Griffin, WS | 1 |
| Wildenthal, K | 1 |
| Revis, NW | 2 |
| Cameron, AJ | 2 |
| Harri, MN | 1 |
| Sakellariou, G | 1 |
| Atsalakis, E | 1 |
| Vrettos, I | 1 |
| Sakellariou, B | 1 |
| Volonakis, M | 1 |
| Polverino, W | 1 |
| Szöör, A | 2 |
| Byus, CV | 1 |
| Chubb, JM | 1 |
| Huxtable, RJ | 1 |
| Russell, DH | 3 |
| Brackett, NL | 1 |
| Powell, JR | 1 |
| Baste, CA | 1 |
| Priest, RE | 1 |
| Limas, CJ | 1 |
| Witchitz, S | 1 |
| Haiat, R | 1 |
| Tarrade, T | 1 |
| Chiche, P | 1 |
| Hammond, HK | 1 |
| Roth, DA | 1 |
| Insel, PA | 1 |
| Ford, CE | 1 |
| White, FC | 1 |
| Maisel, AS | 1 |
| Ziegler, MG | 1 |
| Bloor, CM | 1 |
| Robbins, RJ | 1 |
| Swain, JL | 1 |
| Lévai, G | 2 |
| Yurenev, AP | 1 |
| Parfyonova, EV | 1 |
| Krasnikova, TL | 1 |
| Aripova, NA | 1 |
| Gierschik, P | 1 |
| Knorr, A | 1 |
| Larisch, K | 1 |
| Weismann, K | 1 |
| Erdmann, E | 2 |
| Trindade, JD | 1 |
| Cihák, R | 1 |
| Pelouch, V | 1 |
| Procházka, J | 1 |
| Ostádal, B | 2 |
| Widimský, J | 1 |
| Shimizu, M | 1 |
| Sasaki, H | 1 |
| Sanjo, J | 1 |
| Ogawa, K | 1 |
| Mizokami, T | 1 |
| Yagi, T | 1 |
| Kato, H | 1 |
| Hamaya, K | 1 |
| Namiki, A | 1 |
| Isogai, Y | 1 |
| Erokhina, IL | 1 |
| Gómez Llambí, H | 4 |
| Mazzadi, A | 2 |
| Fontán, M | 3 |
| Taquini, CM | 3 |
| Suzuki, Y | 3 |
| Nagano, M | 1 |
| Higaki, J | 1 |
| Nakamura, F | 1 |
| Higashimori, K | 1 |
| Nagano, N | 1 |
| Mikami, H | 1 |
| Ogihara, T | 1 |
| Hilal-Dandan, R | 1 |
| Khairallah, PA | 2 |
| Ikawa, H | 1 |
| Suzuki, A | 1 |
| Kolarova, R | 2 |
| Popova, N | 1 |
| Foster, KA | 1 |
| Hock, CE | 1 |
| Reibel, DK | 1 |
| Bouanani, N | 1 |
| Corsin, A | 1 |
| Gilson, N | 1 |
| Crozatier, B | 2 |
| Kuwajima, I | 1 |
| Hoshino, S | 1 |
| Kanemaru, A | 1 |
| Shimozawa, T | 1 |
| Matsushita, S | 1 |
| Kuramoto, K | 1 |
| Gallo, A | 2 |
| Rudnick, SJ | 1 |
| LaPres, JJ | 1 |
| Lesch, M | 1 |
| Charpentier, F | 1 |
| Baudet, S | 1 |
| Le Marec, H | 1 |
| Yelamarty, RV | 1 |
| Misawa, H | 1 |
| Scaduto, RC | 1 |
| Pawlush, DG | 1 |
| Elensky, M | 1 |
| Ezzaher, A | 1 |
| el Houda Bouanani, N | 1 |
| Su, JB | 1 |
| Hittinger, L | 3 |
| Wright, CC | 1 |
| Kedem, J | 1 |
| Rodriquez, E | 1 |
| Wong, J | 1 |
| Mackenzie, JW | 1 |
| Prodanov, K | 1 |
| Tsakova, L | 1 |
| Balutsov, M | 1 |
| Patel, MB | 1 |
| Stewart, JM | 1 |
| Loud, AV | 1 |
| Anversa, P | 1 |
| Fiegel, L | 1 |
| Hintze, TH | 1 |
| Nose, M | 1 |
| Scholz, H | 2 |
| Warnholtz, A | 1 |
| Wüstel, JM | 1 |
| Saito, D | 2 |
| Tani, H | 2 |
| Kusachi, S | 2 |
| Uchida, S | 1 |
| Ohbayashi, N | 1 |
| Marutani, M | 1 |
| Maekawa, K | 1 |
| Tsuji, T | 2 |
| Haraoka, S | 1 |
| Ondrejicková, O | 1 |
| Dzurba, A | 2 |
| Sedlák, J | 1 |
| Tokárová, J | 1 |
| Macicková, T | 1 |
| Benes, L | 1 |
| Scamps, F | 1 |
| Mayoux, E | 1 |
| Charlemagne, D | 1 |
| Vassort, G | 1 |
| Shannon, R | 1 |
| Legault, F | 1 |
| Rouleau, JL | 1 |
| Juneau, C | 1 |
| Rose, C | 1 |
| Rakusan, K | 4 |
| Iwasaki, T | 1 |
| Takino, Y | 1 |
| Suzuki, T | 1 |
| Cimini, CM | 1 |
| Chou, HT | 1 |
| Yokota, Y | 1 |
| Fukuzaki, H | 1 |
| Mill, JG | 1 |
| Stefanon, I | 1 |
| Leite, CM | 1 |
| Silver, MA | 1 |
| Pick, R | 3 |
| Brilla, CG | 1 |
| Janicki, JS | 3 |
| Weber, KT | 4 |
| Vetter, H | 1 |
| Gwathmey, JK | 1 |
| Kŏrge, P | 1 |
| Männik, G | 1 |
| Allard, MF | 2 |
| DeVenny, MF | 1 |
| Doss, LK | 2 |
| Grizzle, WE | 1 |
| Bishop, SP | 2 |
| Kuraja, I | 1 |
| Massadi, A | 1 |
| Agnoletti, G | 1 |
| Panzali, AF | 1 |
| Cornacchiari, A | 1 |
| De Giuli, F | 1 |
| Ferrari, R | 1 |
| Yukisada, K | 4 |
| Fujieda, K | 1 |
| Toraason, M | 1 |
| Luken, ME | 1 |
| Krueger, JA | 1 |
| Agabiti-Rosei, E | 2 |
| Muiesan, ML | 2 |
| Romanelli, G | 1 |
| Beschi, M | 1 |
| Castellano, M | 1 |
| Muiesan, G | 2 |
| Chevalier, B | 1 |
| Mansier, P | 1 |
| Callens-el Amrani, F | 1 |
| Swynghedauw, B | 1 |
| Helbing, RK | 2 |
| Rourke, S | 1 |
| Churchill, D | 1 |
| Doering, CW | 1 |
| Shroff, SG | 1 |
| Abrahams, C | 1 |
| Benjamin, IJ | 1 |
| Tan, LB | 1 |
| Cho, K | 1 |
| Shannon, RP | 1 |
| Kohin, S | 1 |
| Lader, AS | 1 |
| Patrick, TA | 1 |
| Kelly, P | 1 |
| Honda, M | 2 |
| Morioka, S | 2 |
| Yamada, S | 2 |
| Ohoka, M | 2 |
| Tanabe, K | 1 |
| Matsuno, Y | 1 |
| Murakami, Y | 1 |
| Kobayashi, S | 1 |
| Ishinaga, Y | 1 |
| Moriyama, K | 2 |
| Hou, QC | 1 |
| Yamori, Y | 1 |
| Yamada, N | 1 |
| Shimizu, A | 1 |
| Hina, K | 1 |
| Watanabe, H | 1 |
| Ueeda, M | 1 |
| Mima, T | 1 |
| Thollon, C | 2 |
| Kreher, P | 2 |
| Vescovo, G | 2 |
| Harding, SE | 2 |
| Dalla Libera, L | 1 |
| Pessina, AC | 1 |
| Poole-Wilson, PA | 2 |
| Jones, SM | 1 |
| Bishopric, NH | 1 |
| Ordahl, CP | 1 |
| Beuckelmann, D | 1 |
| Diet, F | 1 |
| Feiler, G | 1 |
| Jeppsson, AB | 1 |
| Waldeck, B | 1 |
| Widmark, E | 1 |
| Pickett, S | 1 |
| Lee, JC | 1 |
| Kuribayashi, T | 1 |
| Furukawa, K | 1 |
| Yasuda, M | 2 |
| Oku, H | 2 |
| Hirota, K | 1 |
| Kajino, H | 1 |
| Nishikimi, T | 2 |
| Kawarabayashi, T | 1 |
| Yoshimura, T | 1 |
| Jett, GK | 1 |
| Jett, MD | 1 |
| Bosco, P | 1 |
| van Rijk-Swikker, GL | 1 |
| Clark, RE | 1 |
| Sabh, AR | 2 |
| Saleh, AM | 2 |
| Abdel Tawab, S | 2 |
| Komatsu, H | 1 |
| Blanchard, EM | 1 |
| Knufman, NM | 1 |
| van der Laarse, A | 2 |
| Vliegen, HW | 1 |
| Brinkman, CJ | 2 |
| Grisk, A | 1 |
| Hoffmann, U | 1 |
| Möritz, KU | 1 |
| Los, GJ | 1 |
| Kappetein, AP | 1 |
| Weening, JJ | 1 |
| Huysmans, HA | 1 |
| Fouad, FM | 1 |
| Shimamatsu, K | 1 |
| Hanna, MM | 1 |
| Gende, OA | 1 |
| Mattiazzi, A | 1 |
| Camilion, MC | 1 |
| Pedroni, P | 1 |
| Taquini, C | 1 |
| Nelson, CA | 1 |
| Katovich, MJ | 1 |
| Baker, SP | 1 |
| Higgins, AJ | 1 |
| Faccini, JM | 1 |
| Greaves, P | 1 |
| Middleton, KM | 1 |
| Henderson, AH | 1 |
| Lewis, MJ | 1 |
| Verdetti, J | 1 |
| Tisné-Versailles, J | 1 |
| Constantin, M | 1 |
| Lamar, JC | 1 |
| Pourrias, B | 1 |
| Ziegelhöffer, A | 1 |
| Okolicány, J | 1 |
| Monosíková, R | 1 |
| Holec, V | 1 |
| Larson, DF | 1 |
| Copeland, JG | 1 |
| Befeler, B | 1 |
| Ross, MD | 1 |
| Wells, DE | 1 |
| Castellanos, A | 1 |
| Myerburg, RJ | 1 |
| Mathur, PP | 1 |
| Blundell, PE | 1 |
| Tobin, JR | 1 |
| Swan, HJ | 1 |
| Tietzová, H | 1 |
| Poupa, O | 4 |
| Turek, Z | 3 |
| Stanton, HC | 4 |
| Epstein, EJ | 1 |
| Doukas, NG | 1 |
| Coulshed, N | 1 |
| Brown, AK | 1 |
| Bowman, Z | 2 |
| Dines, DE | 1 |
| Parkin, TW | 1 |
| Tourniaire, A | 1 |
| Deyrieux, F | 1 |
| Blum, J | 1 |
| Tartulier, M | 1 |
| Marcano, BA | 1 |
| Moss, AJ | 1 |
| Iakovleva, AI | 1 |
| Sorokina, MN | 1 |
| Frank, MJ | 1 |
| Levinson, GE | 1 |
| Ueda, H | 1 |
| Machida, K | 1 |
| Nakanishi, A | 1 |
| Yasuda, H | 1 |
| Brenner, G | 1 |
| Mayfield, ED | 1 |
| Mueller, RA | 1 |
| Axelrod, J | 1 |
| Bartosová, D | 1 |
| Chvapil, M | 1 |
| Korecký, B | 1 |
| Vízek, M | 2 |
| Hultgren, HN | 1 |
| Hubis, H | 1 |
| Shumway, N | 1 |
| Jain, V | 1 |
| Subramanian, S | 1 |
| Lambert, EC | 1 |
| Bache, RJ | 1 |
| Harley, A | 1 |
| Greenfield, JC | 1 |
| Cooper, CM | 1 |
| Bensaïd, J | 1 |
| Castan, R | 1 |
| Sozutek, Y | 1 |
| Scebat, L | 1 |
| Lenègre, J | 1 |
| Kubo, S | 1 |
| Kusukawa, R | 1 |
| Somerville, J | 1 |
| Bonham-Carter, RE | 1 |
| Masáreová, E | 1 |
| Inczinger, F | 1 |
| Bózner, A | 1 |
| Kölbel, F | 2 |
| Sonka, J | 2 |
| Jirásek, A | 1 |
| Kubelka, J | 1 |
| Pfitzer, P | 1 |
| Knieriem, HJ | 2 |
| Dietrich, H | 1 |
| Herbertz, G | 1 |
| Chan, TS | 1 |
| Potter, RT | 1 |
| el-Sherif, N | 1 |
| Gordon, AL | 1 |
| Lehr, D | 1 |
| Williams, RG | 1 |
| Ellison, RC | 1 |
| Nadas, AS | 1 |
| Völker, W | 1 |
| Strauer, BE | 1 |
| Riecker, G | 1 |
| Fleckenstein, A | 1 |
| Eckardt, K | 1 |
| Ludin, HJ | 1 |
| O'Kane, HO | 1 |
| Leonteva, TA | 1 |
| Semenova, LA | 1 |
| Lin, YC | 1 |
| Uemura, N | 1 |
| Tanaka, H | 1 |
| Niimura, T | 1 |
| Hashiguchi, N | 1 |
| Yoshimura, M | 1 |
| Terashi, S | 1 |
| Kanehisa, T | 1 |
| Archie, JP | 1 |
| Fixler, DE | 1 |
| Ullyot, DJ | 1 |
| Buckberg, GD | 1 |
| Talner, NS | 1 |
| Michaëlsson, M | 1 |
| Engle, MA | 1 |
| Sigel, H | 1 |
| Bennaceur, M | 1 |
| Cauwel, G | 1 |
| Guy, CR | 1 |
| Eliot, RS | 1 |
| Cohen, J | 1 |
| Meerson, FZ | 1 |
| Bischoff, KO | 2 |
| Meesmann, W | 2 |
| Wild, U | 1 |
| Wood, WG | 1 |
| Lindenmayer, GE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Prospective, Non-Randomized, Multi-Center Observational Study to Establish a Physical Baseline Profile for Individual Study Subjects Using Various Modalities and Identify Deviations Via Longitudinal Monitoring That May Develop Over Time[NCT05687578] | 10,000 participants (Anticipated) | Observational | 2023-03-29 | Enrolling by invitation | |||
| A Feasibility Study of Circulating microRNAs as Disease Markers in Pediatric Cancers[NCT01541800] | 20 participants (Anticipated) | Observational | 2010-03-31 | Recruiting | |||
| A Longitudinal Study of Biomarkers in Pediatric Patients With Central Nervous System Tumors[NCT01595126] | 100 participants (Anticipated) | Observational | 2011-12-31 | Recruiting | |||
| Anxiety-mediated Impairments in Large Elastic Artery Function and the Autonomic Nervous System[NCT03109795] | Phase 4 | 30 participants (Actual) | Interventional | 2017-04-10 | Terminated (stopped due to Funding ended) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for isoproterenol and Cardiomegaly
| Article | Year |
|---|---|
PRKCE gene encoding protein kinase C-epsilon-Dual roles at sarcomeres and mitochondria in cardiomyocytes.
Topics: Arachidonic Acid; Cardiomegaly; Cardiotonic Agents; Enzyme Activation; Gene Expression; Humans; Isop | 2016 |
Regression of left ventricular hypertrophy by medical treatment: present status and possible implications.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cardiomegaly; Catecholamines; Coronary Circulation | 1983 |
Myocardial aging: functional alterations and related cellular mechanisms.
Topics: Adenosine Triphosphate; Aging; Animals; Calcium; Cardiac Glycosides; Cardiomegaly; Coronary Circulat | 1982 |
Mechanical and neurohumoral regulation of adult cardiocyte growth.
Topics: Animals; Biomarkers; Cardiomegaly; Cats; Cells, Cultured; Heart; Isoproterenol; Muscle Proteins; Myo | 1995 |
Optimization of myocardial function.
Topics: Animals; Body Temperature Regulation; Cardiomegaly; Guinea Pigs; Humans; Isoproterenol; Muscle Contr | 1993 |
Type I cyclic AMP-dependent protein kinase as a positive effector of growth.
Topics: Animals; Cardiomegaly; Cell Cycle; Chromatography, Agarose; Cyclic AMP; Enzyme Activation; Growth; I | 1978 |
Adrenergic activity and myocardial anatomy and function in essential hypertension.
Topics: Animals; Antihypertensive Agents; Cardiomegaly; Catecholamines; Heart; Hemodynamics; Humans; Hyperte | 1985 |
[Morphological principles of cardiac hypertrophy].
Topics: Adult; Anemia, Hypochromic; Animals; Cardiomegaly; Cardiomyopathies; Cardiomyopathy, Hypertrophic; C | 1972 |
The pathophysiology of congestive heart failure in infancy.
Topics: Acid-Base Equilibrium; Arteriovenous Malformations; Blood Chemical Analysis; Blood Gas Analysis; Blo | 1972 |
Congenital complete heart block: an international study of the natural history.
Topics: Adams-Stokes Syndrome; Adolescent; Adult; Bradycardia; Cardiomegaly; Child; Child, Preschool; Digita | 1972 |
The pathophysiologic vulnerability of the subendocardium of the left ventricle.
Topics: Arrhythmias, Cardiac; Capillaries; Cardiomegaly; Coronary Disease; Coronary Vessels; Endocardium; He | 1973 |
2 trials available for isoproterenol and Cardiomegaly
| Article | Year |
|---|---|
Reversal of cardiac hypertrophy by long-term treatment with calcium antagonists in hypertensive patients.
Topics: Adult; Blood Pressure; Calcium Channel Blockers; Cardiomegaly; Catecholamines; Female; Heart; Heart | 1988 |
[Congenital familial atrioventricular heart block (apropos of 3 cases in brothers)].
Topics: Adams-Stokes Syndrome; Adolescent; Adult; Bradycardia; Cardiomegaly; Clinical Trials as Topic; Elect | 1973 |
752 other studies available for isoproterenol and Cardiomegaly
| Article | Year |
|---|---|
Protocatechuic acid attenuates isoproterenol-induced cardiac hypertrophy via downregulation of ROCK1-Sp1-PKCγ axis.
Topics: Animals; Cardiomegaly; Cell Culture Techniques; Cell Line; Cell Survival; Dactinomycin; Down-Regulat | 2021 |
Angiotensin-(3-7) alleviates isoprenaline-induced cardiac remodeling via attenuating cAMP-PKA and PI3K/Akt signaling pathways.
Topics: Angiotensin II; Animals; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Cyclic AMP; Cyclic AM | 2021 |
Modified citrus pectin prevents isoproterenol-induced cardiac hypertrophy associated with p38 signalling and TLR4/JAK/STAT3 pathway.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cardiovascular Agents; Disease Models, Animal; Gal | 2021 |
Betulinic Acid Improves Cardiac-Renal Dysfunction Caused by Hypertrophy through Calcineurin-NFATc3 Signaling.
Topics: Animals; Betulinic Acid; Biomarkers; Calcineurin; Cardiomegaly; Fibrosis; Heart; Heart Ventricles; I | 2021 |
[Chikusetsu saponin Ⅳa ameliorates myocardial hypertrophy of rats through regulating expression of miR199a-5p/Atg5].
Topics: Animals; Cardiomegaly; Isoproterenol; Myocardium; Myocytes, Cardiac; Oleanolic Acid; Rats; Saponins | 2021 |
Aloin alleviates pathological cardiac hypertrophy via modulation of the oxidative and fibrotic response.
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Cardiomegaly; Cathartics; Emodin; Fibrosis; Isoprot | 2022 |
Schisandrin A protects against isoproterenol‑induced chronic heart failure via miR‑155.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cyclooctanes; Echocardiography; Heart Failure; Hea | 2022 |
MiRNA-339-5p promotes isoproterenol-induced cardiomyocyte hypertrophy by targeting VCP to activate the mTOR signaling.
Topics: Animals; Biological Phenomena; Cardiomegaly; Isoproterenol; MicroRNAs; Myocytes, Cardiac; Rats; TOR | 2022 |
Protective effect of sinomenine on isoproterenol-induced cardiac hypertrophy in mice.
Topics: Animals; Cardiomegaly; Fibrosis; Isoproterenol; Mice; Morphinans; NF-kappa B; Stroke Volume; Superox | 2021 |
Calorie restriction changes lipidomic profiles and maintains mitochondrial function and redox balance during isoproterenol-induced cardiac hypertrophy.
Topics: Caloric Restriction; Cardiomegaly; Humans; Hydrogen Peroxide; Isoproterenol; Lipidomics; Mitochondri | 2022 |
Icariin inhibits isoproterenol-induced cardiomyocyte hypertropic injury through activating autophagy via the AMPK/mTOR signaling pathway.
Topics: AMP-Activated Protein Kinases; Animals; Animals, Newborn; Apoptosis; Autophagy; Cardiomegaly; Cardio | 2022 |
Metabolomics and integrated network pharmacology analysis reveal attenuates cardiac hypertrophic mechanisms of HuoXin pill.
Topics: Animals; Cardiomegaly; Drugs, Chinese Herbal; Isoproterenol; Metabolomics; Network Pharmacology; Pho | 2022 |
Smilax glabra Roxb. flavonoids protect against pathological cardiac hypertrophy by inhibiting the Raf/MEK/ERK pathway: In vivo and in vitro studies.
Topics: Animals; Cardiomegaly; Flavonoids; Isoproterenol; MAP Kinase Signaling System; Mitogen-Activated Pro | 2022 |
Preventive effects of (-) epicatechin on tachycardia, cardiac hypertrophy, and nuclear factor- κB inflammatory signaling pathway in isoproterenol-induced myocardial infarcted rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Body Weight; Cardiomegaly; Catechin; Isoproterenol; | 2022 |
Metabolomics based mechanistic insights to vasorelaxant and cardioprotective effect of ethanolic extract of Citrullus lanatus (Thunb.) Matsum. & Nakai. seeds in isoproterenol induced myocardial infraction.
Topics: Animals; Cardiomegaly; Chromatography, Liquid; Citrullus; Ethanol; Humans; Isoproterenol; Metabolomi | 2022 |
Valencene post-treatment exhibits cardioprotection via inhibiting cardiac hypertrophy, oxidative stress, nuclear factor- κB inflammatory pathway, and myocardial infarct size in isoproterenol-induced myocardial infarcted rats; A molecular study.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Biomarkers; Body Weight; Cardiomegaly; Inflammation | 2022 |
Combination of 1,8-cineole and beta-caryophyllene synergistically reverses cardiac hypertrophy in isoprenaline-induced mice and H9c2 cells.
Topics: Animals; Cardiomegaly; Eucalyptol; Isoproterenol; Mice; Polycyclic Sesquiterpenes; Proto-Oncogene Pr | 2022 |
Analysis of Therapeutic Targets of A Novel Peptide Athycaltide-1 in the Treatment of Isoproterenol-Induced Pathological Myocardial Hypertrophy.
Topics: Animals; Cardiomegaly; Heart; Isoproterenol; Myocardium; Peptides; Rats | 2022 |
Pirfenidone attenuates cardiac hypertrophy against isoproterenol by inhibiting activation of the janus tyrosine kinase-2/signal transducer and activator of transcription 3 (JAK-2/STAT3) signaling pathway.
Topics: Animals; Cardiomegaly; Isoproterenol; Mice; Myocytes, Cardiac; Pyridones; Signal Transduction; STAT3 | 2022 |
Syringic acid mitigates isoproterenol-induced cardiac hypertrophy and fibrosis by downregulating Ereg.
Topics: Animals; Cardiomegaly; Fibrosis; Gallic Acid; Isoproterenol; Mice; Myocardium | 2022 |
Cardiac-specific Trim44 knockout in rat attenuates isoproterenol-induced cardiac remodeling via inhibition of AKT/mTOR pathway.
Topics: Animals; Cardiomegaly; Isoproterenol; Myocytes, Cardiac; Proto-Oncogene Proteins c-akt; Rats; TOR Se | 2023 |
GDH promotes isoprenaline-induced cardiac hypertrophy by activating mTOR signaling via elevation of α-ketoglutarate level.
Topics: Animals; Cardiomegaly; Glucose; Glutamate Dehydrogenase; Glutamates; Isoproterenol; Ketoglutaric Aci | 2022 |
Puerarin attenuates isoproterenol‑induced myocardial hypertrophy via inhibition of the Wnt/β‑catenin signaling pathway.
Topics: Cardiomegaly; Humans; Isoflavones; Isoproterenol; RNA, Messenger; Wnt Signaling Pathway | 2022 |
Ectopic Acsl6 Overexpression Partially Improves Isoproterenol-Induced Cardiac Hypertrophy In Vivo and Cardiomyocyte Hypertrophy In Vitro.
Topics: Animals; Cardiomegaly; Coenzyme A Ligases; Isoproterenol; Mice; Rats | 2022 |
Cardioprotective Effect of Polymyxin-B and Dantrolene Combination on Isoproterenol-Induced Hypertrophic Cardiomyopathy in Rats, via Attenuation of Calmodulin-Dependent Protein Kinase II.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Cardiomyopathy, Hypertrop | 2022 |
SZC-6, a small-molecule activator of SIRT3, attenuates cardiac hypertrophy in mice.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Isoproterenol; Mice; Myocytes, Cardiac; Rats; | 2023 |
Set7 deletion attenuates isoproterenol-induced cardiac fibrosis and delays cardiac dysfunction.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Fibrosis; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Mi | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Protective efficacy of Shenge San on mitochondria in H9c2 cardiomyocytes.
Topics: AMP-Activated Protein Kinases; Cardiomegaly; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; | 2022 |
Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
Topics: Animals; Autophagy; Cardiomegaly; fms-Like Tyrosine Kinase 3; Isoproterenol; Ligands; Mice; Mice, In | 2022 |
Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
Topics: Animals; Autophagy; Cardiomegaly; fms-Like Tyrosine Kinase 3; Isoproterenol; Ligands; Mice; Mice, In | 2022 |
Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
Topics: Animals; Autophagy; Cardiomegaly; fms-Like Tyrosine Kinase 3; Isoproterenol; Ligands; Mice; Mice, In | 2022 |
Activation of FMS-like tyrosine kinase 3 protects against isoprenaline-induced cardiac hypertrophy by improving autophagy and mitochondrial dynamics.
Topics: Animals; Autophagy; Cardiomegaly; fms-Like Tyrosine Kinase 3; Isoproterenol; Ligands; Mice; Mice, In | 2022 |
Prohibitin1 maintains mitochondrial quality in isoproterenol-induced cardiac hypertrophy in H9C2 cells.
Topics: Animals; Cardiomegaly; Cell Line; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; Oxidative | 2023 |
Prohibitin1 maintains mitochondrial quality in isoproterenol-induced cardiac hypertrophy in H9C2 cells.
Topics: Animals; Cardiomegaly; Cell Line; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; Oxidative | 2023 |
Prohibitin1 maintains mitochondrial quality in isoproterenol-induced cardiac hypertrophy in H9C2 cells.
Topics: Animals; Cardiomegaly; Cell Line; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; Oxidative | 2023 |
Prohibitin1 maintains mitochondrial quality in isoproterenol-induced cardiac hypertrophy in H9C2 cells.
Topics: Animals; Cardiomegaly; Cell Line; Humans; Isoproterenol; Mitochondria; Myocytes, Cardiac; Oxidative | 2023 |
Effect of Hesperetin on Isoprenaline-induced Hypertrophy of H9C2 Cardiomyocytes.
Topics: Autophagy; Cardiomegaly; Humans; Isoproterenol; Myocytes, Cardiac; RNA, Messenger | 2022 |
Effect of Hesperetin on Isoprenaline-induced Hypertrophy of H9C2 Cardiomyocytes.
Topics: Autophagy; Cardiomegaly; Humans; Isoproterenol; Myocytes, Cardiac; RNA, Messenger | 2022 |
Effect of Hesperetin on Isoprenaline-induced Hypertrophy of H9C2 Cardiomyocytes.
Topics: Autophagy; Cardiomegaly; Humans; Isoproterenol; Myocytes, Cardiac; RNA, Messenger | 2022 |
Effect of Hesperetin on Isoprenaline-induced Hypertrophy of H9C2 Cardiomyocytes.
Topics: Autophagy; Cardiomegaly; Humans; Isoproterenol; Myocytes, Cardiac; RNA, Messenger | 2022 |
Calanus oil attenuates isoproterenol-induced cardiac hypertrophy by regulating myocardial remodeling and oxidative stress.
Topics: Anti-Inflammatory Agents; Antioxidants; Cardiomegaly; Humans; Isoproterenol; Myocardium; Oxidative S | 2023 |
Naringenin Attenuates Isoprenaline-Induced Cardiac Hypertrophy by Suppressing Oxidative Stress through the AMPK/NOX2/MAPK Signaling Pathway.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Isoproterenol; Mice; Mice, Inbred C57BL; Myocy | 2023 |
GRK2 participation in cardiac hypertrophy induced by isoproterenol through the regulation of Nrf2 signaling and the promotion of NLRP3 inflammasome and oxidative stress.
Topics: Animals; Cardiomegaly; G-Protein-Coupled Receptor Kinase 2; Inflammasomes; Isoproterenol; NF-E2-Rela | 2023 |
Trim65 attenuates isoproterenol-induced cardiac hypertrophy by promoting autophagy and ameliorating mitochondrial dysfunction via the Jak1/Stat1 signaling pathway.
Topics: Animals; Autophagy; Cardiomegaly; Isoproterenol; Mice; Mice, Inbred C57BL; Mitochondria; Myocytes, C | 2023 |
OGFOD1 modulates the transcriptional and proteomic landscapes to alter isoproterenol-induced hypertrophy susceptibility.
Topics: Animals; Cardiomegaly; Heart; Humans; Isoproterenol; Mice; Myocytes, Cardiac; Nuclear Proteins; Prot | 2023 |
JMJD6 protects against isoproterenol-induced cardiac hypertrophy via inhibition of NF-κB activation by demethylating R149 of the p65 subunit.
Topics: Animals; Cardiomegaly; Heart Failure; Histones; Isoproterenol; Myocytes, Cardiac; NF-kappa B; Rats; | 2023 |
Protective effects of β-caryophyllene on mitochondrial damage and cardiac hypertrophy pathways in isoproterenol-induced myocardial infarcted rats.
Topics: Animals; Antioxidants; Biomarkers; Body Weight; Cardiomegaly; Isoproterenol; Mitochondria, Heart; My | 2023 |
Protocatechuic acid prevents isoproterenol-induced heart failure in mice by downregulating kynurenine-3-monooxygenase.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Kynurenine; Kynurenine 3-Monooxygenase; Mice; M | 2023 |
Arbutin Attenuates Isoproterenol-Induced Cardiac Hypertrophy by Inhibiting TLR-4/NF-κB Pathway in Mice.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Arbutin; Atrial Natriuretic Factor; Cardiomegaly; C | 2020 |
Isosteviol prevents the development of isoprenaline‑induced myocardial hypertrophy.
Topics: Animals; Apoptosis; Calcium; Cardiomegaly; Diterpenes, Kaurane; Isoproterenol; Male; Membrane Potent | 2019 |
UBE3A alleviates isoproterenol-induced cardiac hypertrophy through the inhibition of the TLR4/MMP-9 signaling pathway.
Topics: Cardiomegaly; Cell Line; Gene Knockdown Techniques; Humans; Isoproterenol; Matrix Metalloproteinase | 2020 |
Human Relaxin-2 Fusion Protein Treatment Prevents and Reverses Isoproterenol-Induced Hypertrophy and Fibrosis in Mouse Heart.
Topics: Animals; Cardiomegaly; Fibrosis; Isoproterenol; Male; Mice; Mice, Inbred C57BL; Myocardium | 2019 |
CD47 Deficiency Attenuates Isoproterenol-Induced Cardiac Remodeling in Mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; CD47 Antigen; Isoproterenol; Male; Mice; Mice, Inbred C57 | 2019 |
In vitro and in vivo cardioprotective and metabolic efficacy of vitamin E TPGS/Apelin.
Topics: Animals; Apelin; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cell Hypoxia; Cell Line; Diabetic Card | 2020 |
Canstatin suppresses isoproterenol-induced cardiac hypertrophy through inhibition of calcineurin/nuclear factor of activated T-cells pathway in rats.
Topics: Animals; Calcineurin; Calcium; Cardiomegaly; Collagen Type IV; Dose-Response Relationship, Drug; Hea | 2020 |
[Expression and bioinformatics analysis of miRNA in ISO-induced rat cardiac hypertrophy].
Topics: Animals; Cardiomegaly; Computational Biology; Isoproterenol; Male; MicroRNAs; Myocardium; Random All | 2019 |
[Effects of chrysanthemum flower extract on cardiac hypertrophy induced by isoprenaline in mice].
Topics: Animals; Cardiomegaly; Chrysanthemum; Flowers; Isoproterenol; Mice; Plant Extracts | 2019 |
NFATc3-dependent expression of miR-153-3p promotes mitochondrial fragmentation in cardiac hypertrophy by impairing mitofusin-1 expression.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Gene Expression Regulation; GTP Phosphohydrolases; Isopro | 2020 |
Pyrroloquinoline quinone attenuates isoproterenol hydrochloride‑induced cardiac hypertrophy in AC16 cells by inhibiting the NF‑κB signaling pathway.
Topics: Cardiomegaly; Cell Line; Humans; Isoproterenol; Myocytes, Cardiac; NF-kappa B; PQQ Cofactor; Signal | 2020 |
STVNa Attenuates Isoproterenol-Induced Cardiac Hypertrophy Response through the HDAC4 and Prdx2/ROS/Trx1 Pathways.
Topics: Animals; Cardiomegaly; Diterpenes, Kaurane; Heart Failure; Histone Deacetylases; Humans; Isoproteren | 2020 |
LncRNA-Mhrt regulates cardiac hypertrophy by modulating the miR-145a-5p/KLF4/myocardin axis.
Topics: Animals; Base Sequence; Cardiomegaly; Cells, Cultured; Chlorocebus aethiops; COS Cells; Extracellula | 2020 |
iTRAQ‑based quantitative proteomics analysis of the potential application of secretoneurin gene therapy for cardiac hypertrophy induced by DL‑isoproterenol hydrochloride in mice.
Topics: Animals; Blotting, Western; Cardiomegaly; Echocardiography; Genetic Therapy; Hemodynamics; Hypertrop | 2020 |
Aliskiren attenuates cardiac dysfunction by modulation of the mTOR and apoptosis pathways.
Topics: Amides; Angiotensin II; Animals; Apoptosis; Blotting, Western; Cardiomegaly; Disease Models, Animal; | 2020 |
High content screening identifies licoisoflavone A as a bioactive compound of Tongmaiyangxin Pills to restrain cardiomyocyte hypertrophy via activating Sirt3.
Topics: Acetylation; Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Drug Ev | 2020 |
Circular RNA expression in isoproterenol hydrochloride-induced cardiac hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Gene Expression Profiling; Gene Expression Regulat | 2020 |
Songling Xuemaikang Capsule inhibits isoproterenol-induced cardiac hypertrophy via CaMKIIδ and ERK1/2 pathways.
Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Capsules; Cardiomegaly; Cardiotonic Age | 2020 |
SIRT3 inhibits cardiac hypertrophy by regulating PARP-1 activity.
Topics: Acetylation; Animals; Atrial Natriuretic Factor; Cardiomegaly; Cardiotonic Agents; Cell Line; Isopro | 2020 |
Selective targeting of ubiquitination and degradation of PARP1 by E3 ubiquitin ligase WWP2 regulates isoproterenol-induced cardiac remodeling.
Topics: Animals; Cardiomegaly; Fibrosis; Heart Failure; Humans; Isoproterenol; Leupeptins; Lysine; Male; Mic | 2020 |
Angiotensin (1-7) and Apelin co-therapy: New strategy for heart failure treatment of rats.
Topics: Adrenergic beta-Agonists; Angiotensin I; Animals; Apelin; Cardiomegaly; Heart Failure; Hemodynamics; | 2020 |
Application of Zebrafish Model in the Suppression of Drug-Induced Cardiac Hypertrophy by Traditional Indian Medicine Yogendra Ras.
Topics: Animals; Antioxidants; Biomarkers; C-Reactive Protein; Cardiomegaly; Disease Models, Animal; Erythro | 2020 |
Cymbopogon Proximus Essential Oil Protects Rats against Isoproterenol-Induced Cardiac Hypertrophy and Fibrosis.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Collagen Type I; Collagen Type III; Cymbopogon; Fi | 2020 |
Taurine attenuates isoproterenol-induced H9c2 cardiomyocytes hypertrophy by improving antioxidative ability and inhibiting calpain-1-mediated apoptosis.
Topics: Animals; Apoptosis; Apoptotic Protease-Activating Factor 1; Atrial Natriuretic Factor; bcl-2-Associa | 2020 |
Imine stilbene analog ameliorate isoproterenol-induced cardiac hypertrophy and hydrogen peroxide-induced apoptosis.
Topics: Animals; Apoptosis; Cardiomegaly; Hydrogen Peroxide; Imines; Isoproterenol; Molecular Docking Simula | 2020 |
Carboxypeptidase A4 promotes cardiomyocyte hypertrophy through activating PI3K-AKT-mTOR signaling.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Carboxypeptidases A; Cardiomegaly; Case-Contr | 2020 |
The Expression of microRNA in Adult Rat Heart with Isoproterenol-Induced Cardiac Hypertrophy.
Topics: Aging; Animals; Atrial Natriuretic Factor; Base Sequence; Cardiomegaly; Gene Expression Regulation, | 2020 |
Mathematical model of the ventricular action potential and effects of isoproterenol-induced cardiac hypertrophy in rats.
Topics: Action Potentials; Animals; Cardiomegaly; Heart Ventricles; Ion Channels; Isoproterenol; Kinetics; M | 2020 |
Effect of Gonadectomy and Angiotensin II Receptor Blockade in a Mouse Model of Isoproterenol-induced Cardiac Diastolic Dysfunction.
Topics: Angiotensin Receptor Antagonists; Animals; Cardiomegaly; Castration; Diastole; Disease Models, Anima | 2021 |
Cardiomyocyte Proteome Remodeling due to Isoproterenol-Induced Cardiac Hypertrophy during the Compensated Phase.
Topics: Actins; Animals; Cardiomegaly; Gene Expression Regulation; Isoproterenol; Male; Mice; Mice, Inbred C | 2020 |
HTR2A promotes the development of cardiac hypertrophy by activating PI3K-PDK1-AKT-mTOR signaling.
Topics: 3-Phosphoinositide-Dependent Protein Kinases; Animals; Animals, Newborn; Cardiomegaly; Humans; Isopr | 2020 |
Cardioprotective effects of memantine in myocardial ischemia: Ex vivo and in vivo studies.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Isoproterenol; Lipid Peroxidation; Male; Malondialdehyde; | 2020 |
Role of sodium tetraborate as a cardioprotective or competitive agent: Modulation of hypertrophic intracellular signals.
Topics: Animals; Apoptosis; Borates; Cardiomegaly; Cardiotonic Agents; Cell Proliferation; Cells, Cultured; | 2020 |
Lack of sexual dimorphism in a mouse model of isoproterenol-induced cardiac dysfunction.
Topics: Animals; Biomarkers; Cardiomegaly; Disease Models, Animal; Echocardiography; Female; Heart Diseases; | 2020 |
Swietenine extracted from Swietenia relieves myocardial hypertrophy induced by isoprenaline in mice.
Topics: Animals; Cardiomegaly; Cell Enlargement; Cell Line; Cell Survival; Heart; Isoproterenol; Limonins; M | 2020 |
Baicalein attenuates cardiac hypertrophy in mice via suppressing oxidative stress and activating autophagy in cardiomyocytes.
Topics: Animals; Animals, Newborn; Autophagy; Cardiomegaly; Cardiotonic Agents; Catalase; Flavanones; Forkhe | 2021 |
Deletion of Microfibrillar-Associated Protein 4 Attenuates Left Ventricular Remodeling and Dysfunction in Heart Failure.
Topics: Adrenergic beta-Agonists; Animals; Aorta; Biomechanical Phenomena; Cardiomegaly; Carrier Proteins; C | 2020 |
The protective effect of piperine against isoproterenol-induced inflammation in experimental models of myocardial toxicity.
Topics: Adrenergic beta-Agonists; Alkaloids; Animals; Benzodioxoles; Cardiomegaly; Cytokines; Endothelium; F | 2020 |
The cardiac protection of Baoyuan decoction via gut-heart axis metabolic pathway.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Drugs, Chinese Herbal; Dysbiosis; Feces; Gastrointestinal | 2020 |
Targeting the Nrf2/ARE Signalling Pathway to Mitigate Isoproterenol-Induced Cardiac Hypertrophy: Plausible Role of Hesperetin in Redox Homeostasis.
Topics: Animals; Antioxidants; Biomarkers; Cardiomegaly; Cell Line; Cell Nucleus; Cytoprotection; Gene Expre | 2020 |
Myocardial hypertrophy is prevented by farnesol through oxidative stress and ERK1/2 signaling pathways.
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Apoptosis Regulatory Proteins; Blood Pressure; Card | 2020 |
A multiscale model of cardiac concentric hypertrophy incorporating both mechanical and hormonal drivers of growth.
Topics: Biomechanical Phenomena; Cardiomegaly; Computer Simulation; Constriction, Pathologic; Hormones; Huma | 2021 |
α-Galactosylceramide and its analog OCH differentially affect the pathogenesis of ISO-induced cardiac injury in mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cytokines; Fibrosis; Galactosylceramides; Glycolipids; In | 2020 |
Bone marrow mesenchymal stem cells inhibit cardiac hypertrophy by enhancing FoxO1 transcription.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Cell Membrane; Cell Proliferation; Down-Regula | 2021 |
Isoproterenol-induced hypertrophy of neonatal cardiac myocytes and H9c2 cell is dependent on TRPC3-regulated Ca
Topics: Animals; Animals, Newborn; Calcium; Calcium Channels, L-Type; Cardiomegaly; Isoproterenol; Mice, Kno | 2020 |
MBNL1 regulates isoproterenol-induced myocardial remodelling in vitro and in vivo.
Topics: 3' Untranslated Regions; Animals; Animals, Newborn; Apoptosis; Base Sequence; Cardiomegaly; Disease | 2021 |
Echinacoside reverses myocardial remodeling and improves heart function via regulating SIRT1/FOXO3a/MnSOD axis in HF rats induced by isoproterenol.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Line; Forkhead Box Protein O3; Glycogen; Glycosides; Heart Fa | 2021 |
Vasonatrin peptide, a synthetic natriuretic peptide, attenuates myocardial injury and oxidative stress in isoprenaline-induced cardiomyocyte hypertrophy.
Topics: Animals; Animals, Newborn; Atrial Natriuretic Factor; Cardiomegaly; Cardiotonic Agents; Cyclic GMP; | 2021 |
Deciphering the effective combinatorial components from Si-Miao-Yong-An decoction regarding the intervention on myocardial hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cell Line; Drugs, Chinese Herbal; Extracellular Si | 2021 |
Pinoresinol diglucoside (PDG) attenuates cardiac hypertrophy via AKT/mTOR/NF-κB signaling in pressure overload-induced rats.
Topics: Animals; Animals, Newborn; Aorta, Abdominal; Cardiomegaly; Constriction, Pathologic; Disease Models, | 2021 |
Higenamine attenuates cardiac fibroblast abstract and fibrosis via inhibition of TGF-β1/Smad signaling.
Topics: Actins; Adrenergic beta-Agonists; Alkaloids; Animals; Aorta; Apoptosis; Cardiomegaly; Fibrinolytic A | 2021 |
Mouse strain-specific responses of mitochondrial respiratory function and cardiac hypertrophy to isoproterenol treatment.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Mice; Mitochondria; Myocytes, Cardiac | 2021 |
Piezo1-Mediated Mechanotransduction Promotes Cardiac Hypertrophy by Impairing Calcium Homeostasis to Activate Calpain/Calcineurin Signaling.
Topics: Adrenergic beta-Agonists; Animals; Calcineurin; Calcium; Calcium Signaling; Calpain; Cardiomegaly; H | 2021 |
Plantago asiatica L. seeds extract protects against cardiomyocyte injury in isoproterenol- induced cardiac hypertrophy by inhibiting excessive autophagy and apoptosis in mice.
Topics: Animals; Apoptosis; Autophagy; Cardiomegaly; Cell Line; Isoproterenol; Mice; Mice, Inbred C57BL; Myo | 2021 |
KLF15 protects against isoproterenol-induced cardiac hypertrophy via regulation of cell death and inhibition of Akt/mTOR signaling.
Topics: Animals; Apoptosis; Cardiomegaly; DNA-Binding Proteins; Gene Expression Regulation; Isoproterenol; K | 2017 |
Moderate lifelong overexpression of tuberous sclerosis complex 1 (TSC1) improves health and survival in mice.
Topics: Adiposity; Animals; Brain; Cardiomegaly; Female; Isoproterenol; Longevity; Male; Mechanistic Target | 2017 |
Astaxanthin Prevented Oxidative Stress in Heart and Kidneys of Isoproterenol-Administered Aged Rats.
Topics: Animals; Antioxidants; Cardiomegaly; Heart; Isoproterenol; Kidney; Lipid Peroxidation; Male; Myocard | 2018 |
Stachydrine ameliorates isoproterenol-induced cardiac hypertrophy and fibrosis by suppressing inflammation and oxidative stress through inhibiting NF-κB and JAK/STAT signaling pathways in rats.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Cardiomegaly; Cytokines; Isoproterenol; Janus Kinas | 2017 |
Specific α7 nicotinic acetylcholine receptor agonist ameliorates isoproterenol-induced cardiac remodelling in mice through TGF-β1/Smad3 pathway.
Topics: alpha7 Nicotinic Acetylcholine Receptor; Animals; Benzamides; Bridged Bicyclo Compounds; Cardiomegal | 2017 |
PEG-coated gold nanoparticles attenuate β-adrenergic receptor-mediated cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Fibrosis; Gold; Heart; Interleukin-6; Isoproterenol | 2017 |
Cyclin-Dependent Kinase Inhibitor p21WAF1/CIP1 Facilitates the Development of Cardiac Hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Calcineurin; Cardiomegaly; Cell Line; Cyclin-Dependent Kinase In | 2017 |
Senescence as a novel mechanism involved in β-adrenergic receptor mediated cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cellular Senescence; Cyclin-Dependent Kinase Inhibitor Proteins; GATA4 Transc | 2017 |
G3BP2 is involved in isoproterenol-induced cardiac hypertrophy through activating the NF-κB signaling pathway.
Topics: Animals; Cardiomegaly; Cell Nucleus; Disease Models, Animal; Gene Knockdown Techniques; GTP-Binding | 2018 |
E2/ER β inhibit ISO-induced cardiac cellular hypertrophy by suppressing Ca2+-calcineurin signaling.
Topics: Animals; Calcineurin; Calcineurin Inhibitors; Calcium; Calcium-Calmodulin-Dependent Protein Kinase T | 2017 |
Hydrogen inhibits isoproterenol‑induced autophagy in cardiomyocytes in vitro and in vivo.
Topics: Animals; Autophagy; Cardiomegaly; Cell Line; Cells, Cultured; Hydrogen; Isoproterenol; Male; Mice; M | 2017 |
Increased CD11b+ cells and Interleukin-1 (IL-1) alpha levels during cardiomyopathy induced by chronic adrenergic activation.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiomyopathies; CD11b Antigen; Interleukin-1alpha | 2017 |
Alterations in NO/ROS ratio and expression of Trx1 and Prdx2 in isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cell Survival; Cells, Cultured; Isoproterenol; Nitric Oxide; Peroxiredoxins; | 2017 |
ClC-3 chloride channel is involved in isoprenaline-induced cardiac hypertrophy.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Line; Chloride Channels; Dependovirus; Disease Models, | 2018 |
Palmatine attenuates isoproterenol-induced pathological hypertrophy via selectively inhibiting HDAC2 in rats.
Topics: Animals; Atrial Natriuretic Factor; Berberine Alkaloids; Cardiomegaly; Cardiotonic Agents; Histone D | 2017 |
Apocynin prevents isoproterenol-induced cardiac hypertrophy in rat.
Topics: Acetophenones; Adrenergic beta-Agonists; Animals; Biomarkers; Body Weight; Cardiomegaly; Echocardiog | 2018 |
β-Adrenergic regulation of cardiac type 2A protein phosphatase through phosphorylation of regulatory subunit B56δ at S573.
Topics: Adenoviridae; Adrenergic beta-Agonists; Amino Acid Sequence; Animals; Cardiomegaly; Disease Models, | 2018 |
Comparative study of the antioxidant properties of monocarbonyl curcumin analogues C66 and B2BrBC in isoproteranol induced cardiac damage.
Topics: Animals; Antioxidants; Cardiomegaly; Curcumin; Isoproterenol; Lipid Peroxidation; Male; Myocardium; | 2018 |
Soluble adenylyl cyclase: A novel player in cardiac hypertrophy induced by isoprenaline or pressure overload.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Cardiomegaly; Isoproterenol; Mice; Pressure; R | 2018 |
Analyzing gene expression profiles with preliminary validations in cardiac hypertrophy induced by pressure overload.
Topics: Animals; Cardiomegaly; Databases, Genetic; Disease Models, Animal; Gene Expression Profiling; Gene E | 2018 |
[Protective effect of Dendrobium candidum on isoproterenol induced cardiac hypertrophy in rats].
Topics: Animals; Cardiomegaly; Dendrobium; Drugs, Chinese Herbal; Female; Isoproterenol; Male; Myocardium; R | 2018 |
Cardiac fibroblast-specific p38α MAP kinase promotes cardiac hypertrophy via a putative paracrine interleukin-6 signaling mechanism.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Fibroblasts; Interleukin-6; Isoproterenol; MAP Kina | 2018 |
17β-Estradiol and/or estrogen receptor alpha signaling blocks protein phosphatase 1 mediated ISO induced cardiac hypertrophy.
Topics: Animals; Calcium; Cardiomegaly; Cell Enlargement; Cell Line; Estradiol; Estrogen Receptor alpha; Iso | 2018 |
JMJD3 inhibition protects against isoproterenol-induced cardiac hypertrophy by suppressing β-MHC expression.
Topics: Animals; Animals, Newborn; Benzazepines; Cardiomegaly; Demethylation; Gene Knockdown Techniques; His | 2018 |
PTENα regulates mitophagy and maintains mitochondrial quality control.
Topics: Animals; Autophagy; Carbonyl Cyanide m-Chlorophenyl Hydrazone; Cardiomegaly; Gene Deletion; HEK293 C | 2018 |
A Novel Class of tRNA-Derived Small Non-Coding RNAs Respond to Myocardial Hypertrophy and Contribute to Intergenerational Inheritance.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Female; Gene Expression Profiling; Gene Regulatory Ne | 2018 |
PARP1 interacts with HMGB1 and promotes its nuclear export in pathological myocardial hypertrophy.
Topics: Active Transport, Cell Nucleus; Angiotensin II; Animals; Cardiomegaly; Cell Nucleus; HMGB1 Protein; | 2019 |
Protocatechuic aldehyde protects against isoproterenol-induced cardiac hypertrophy via inhibition of the JAK2/STAT3 signaling pathway.
Topics: Animals; Benzaldehydes; Cardiomegaly; Cardiotonic Agents; Catechols; Cells, Cultured; Isoproterenol; | 2018 |
Dimethyl fumarate interferes with MyD88-dependent toll-like receptor signalling pathway in isoproterenol-induced cardiac hypertrophy model.
Topics: Animals; Cardiomegaly; Dimethyl Fumarate; Disease Models, Animal; Extracellular Signal-Regulated MAP | 2018 |
Role of type 2A phosphatase regulatory subunit B56α in regulating cardiac responses to β-adrenergic stimulation in vivo.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Disease Models, Animal; Dobutamine; Female; Heart R | 2019 |
Topics: Animals; Cardiomegaly; Disease Models, Animal; Drugs, Chinese Herbal; Humans; Isoproterenol; Male; M | 2019 |
Protective Action of Diazoxide on Isoproterenol-Induced Hypertrophy Is Mediated by Reduction in MicroRNA-132 Expression.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cardiovascular Agents; Cells, Cultured; Cyclic AMP Response | 2018 |
Tumorous imaginal disc 1 (TID1) inhibits isoproterenol-induced cardiac hypertrophy and apoptosis by regulating c-terminus of hsc70-interacting protein (CHIP) mediated degradation of Gαs.
Topics: Animals; Apoptosis; Cardiomegaly; HSP40 Heat-Shock Proteins; Humans; Isoproterenol; Male; Rats; Sign | 2018 |
Galectin-1 attenuates cardiomyocyte hypertrophy through splice-variant specific modulation of Ca
Topics: 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl e | 2019 |
Mechanistic insights to the cardioprotective effect of blueberry nutraceutical extract in isoprenaline-induced cardiac hypertrophy.
Topics: Animals; Blueberry Plants; Cardiomegaly; Cardiotonic Agents; Catalase; Dietary Supplements; Fibrosis | 2018 |
Curcumin alleviates isoproterenol-induced cardiac hypertrophy and fibrosis through inhibition of autophagy and activation of mTOR.
Topics: Animals; Autophagy; Beclin-1; Cardiomegaly; Curcumin; Fibrosis; Isoproterenol; Male; Myocardium; Rat | 2018 |
AdipoRon prevents l-thyroxine or isoproterenol-induced cardiac hypertrophy through regulating the AMPK-related pathway.
Topics: AMP-Activated Protein Kinases; Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Gene E | 2019 |
Hesperidin regresses cardiac hypertrophy by virtue of PPAR-γ agonistic, anti-inflammatory, antiapoptotic, and antioxidant properties.
Topics: Animals; Anti-Inflammatory Agents; Antioxidants; Apoptosis; Cardiomegaly; Cardiotonic Agents; Gene E | 2019 |
Myofibroblast β2 adrenergic signaling amplifies cardiac hypertrophy in mice.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Cardiomegaly; Cyclic AMP-Dependent Protein Kinases; Is | 2019 |
Genistein reverses isoproterenol-induced cardiac hypertrophy by regulating miR-451/TIMP2.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Female; Genistein; HeLa Cells; Humans; Isoprotereno | 2019 |
Acupuncture at PC6 prevents cardiac hypertrophy in isoproterenol-treated mice.
Topics: Acupuncture Points; Acupuncture Therapy; Animals; Atrial Natriuretic Factor; Cardiomegaly; Disease M | 2019 |
Chrysophanol attenuated isoproterenol-induced cardiac hypertrophy by inhibiting Janus kinase 2/signal transducer and activator of transcription 3 signaling pathway.
Topics: Animals; Animals, Newborn; Anthraquinones; Cardiomegaly; Cardiomyopathies; Isoproterenol; Janus Kina | 2019 |
Plantamajoside attenuates isoproterenol-induced cardiac hypertrophy associated with the HDAC2 and AKT/ GSK-3β signaling pathway.
Topics: Animals; Cardiomegaly; Catechols; Cell Line; Cell Survival; Disease Models, Animal; Glucosides; Glyc | 2019 |
Proinflammatory Effect of Endothelial Microparticles Is Mitochondria Mediated and Modulated Through MAPKAPK2 (MAPK-Activated Protein Kinase 2) Leading to Attenuation of Cardiac Hypertrophy.
Topics: Adenosine Triphosphate; Analysis of Variance; Animals; Blotting, Western; Cardiomegaly; Cell-Derived | 2019 |
Soluble epoxide hydrolase inhibitor, TUPS, attenuates isoproterenol/angiotensin II-induced cardiac hypertrophy through mammalian target of rapamycin-mediated autophagy inhibition.
Topics: Angiotensin II; Animals; Autophagy; Beclin-1; Cardiomegaly; Cell Line; Cell Survival; Epoxide Hydrol | 2019 |
2,5-Dimethylcelecoxib prevents isoprenaline-induced cardiomyocyte hypertrophy and cardiac fibroblast activation by inhibiting Akt-mediated GSK-3 phosphorylation.
Topics: Animals; Animals, Newborn; Cardiomegaly; Disease Models, Animal; Fibroblasts; Glycogen Synthase Kina | 2019 |
Protective effect of histone methyltransferase NSD3 on ISO-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cell Line; Gene Expression Regulation, Enzymologic; Histone-Lysine N-Methyltr | 2019 |
Dissection of mechanisms of Chinese medicinal formula Si-Miao-Yong-an decoction protects against cardiac hypertrophy and fibrosis in isoprenaline-induced heart failure.
Topics: Animals; Cardiomegaly; Cell Line; Doxorubicin; Drugs, Chinese Herbal; Fibrosis; Heart Failure; Isopr | 2020 |
Diazoxide Modulates Cardiac Hypertrophy by Targeting H2O2 Generation and Mitochondrial Superoxide Dismutase Activity.
Topics: Animals; Cardiomegaly; Diazoxide; Drug Evaluation, Preclinical; Hydrogen Peroxide; Ion Transport; Is | 2020 |
SIRT1 activation attenuates cardiac fibrosis by endothelial-to-mesenchymal transition.
Topics: Animals; Cardiomegaly; Cell Line; Cell Nucleus; Collagen; Down-Regulation; Endothelium; Fibrosis; Is | 2019 |
Troxerutin attenuates isoproterenol-induced cardiac hypertrophy via the LKB1/AMPK/mTOR pathway.
Topics: AMP-Activated Protein Kinases; Animals; Anticoagulants; Cardiomegaly; Hydroxyethylrutoside; Isoprote | 2021 |
[Oxidative stress and calcium/calmodulin-dependent protein kinase II contribute to the development of sustained β adrenergic receptor-stimulated cardiac hypertrophy in rats].
Topics: Acetylcysteine; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Isoproter | 2013 |
Nebivolol prevents desensitization of β-adrenoceptor signaling and induction of cardiac hypertrophy in response to isoprenaline beyond β1-adrenoceptor blockage.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor | 2013 |
Left ventricular mechanical and energetic changes in long-term isoproterenol-induced hypertrophied hearts of SERCA2a transgenic rats.
Topics: Animals; Cardiomegaly; Isoproterenol; Male; Oxygen Consumption; Rats; Rats, Transgenic; Sarcoplasmic | 2013 |
The novel Mas agonist, CGEN-856S, attenuates isoproterenol-induced cardiac remodeling and myocardial infarction injury in rats.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; CHO Cells; Collagen; Cricetinae; Cricetulus; Fibronectins | 2013 |
Choline protects against cardiac hypertrophy induced by increased after-load.
Topics: Animals; Calcineurin; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Choline; Down-Regulation; G | 2013 |
MicroRNA-22 regulates cardiac hypertrophy and remodeling in response to stress.
Topics: Amino Acid Sequence; Animals; Calcineurin; Cardiomegaly; Cardiomyopathy, Dilated; Disease Models, An | 2013 |
Cardioprotective effect of calcitriol on myocardial injury induced by isoproterenol in rats.
Topics: Animals; bcl-2-Associated X Protein; Blotting, Western; Body Weight; Calcitriol; Cardiomegaly; Caspa | 2013 |
Targeted ablation of the histidine-rich Ca(2+)-binding protein (HRC) gene is associated with abnormal SR Ca(2+)-cycling and severe pathology under pressure-overload stress.
Topics: Animals; Calcium Signaling; Calcium-Binding Proteins; Cardiac Pacing, Artificial; Cardiomegaly; Dise | 2013 |
Vitexin protects against cardiac hypertrophy via inhibiting calcineurin and CaMKII signaling pathways.
Topics: Animals; Animals, Newborn; Apigenin; Calcineurin; Calcineurin Inhibitors; Calcium-Calmodulin-Depende | 2013 |
AKAP13 Rho-GEF and PKD-binding domain deficient mice develop normally but have an abnormal response to β-adrenergic-induced cardiac hypertrophy.
Topics: A Kinase Anchor Proteins; Animals; Breeding; Cardiomegaly; Electrocardiography; Embryo, Mammalian; F | 2013 |
Exogenous hydrogen sulfide prevents cardiomyocyte apoptosis from cardiac hypertrophy induced by isoproterenol.
Topics: Animals; Animals, Newborn; Apoptosis; Benzimidazoles; Carbocyanines; Cardiomegaly; Cardiotonic Agent | 2013 |
Preventive effects of p-coumaric acid on cardiac hypertrophy and alterations in electrocardiogram, lipids, and lipoproteins in experimentally induced myocardial infarcted rats.
Topics: Animals; Cardiomegaly; Cholesterol; Coumaric Acids; Electrocardiography; Fatty Acids, Nonesterified; | 2013 |
Protective effects and active ingredients of yi-qi-fu-mai sterile powder against myocardial oxidative damage in mice.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Creatine Kinase; Drugs, Chinese Herbal; Isoproterenol; L- | 2013 |
A proteomic view of isoproterenol induced cardiac hypertrophy: prohibitin identified as a potential biomarker in rats.
Topics: Animals; Biomarkers; Cardiomegaly; Disease Models, Animal; Gene Expression Profiling; Gene Expressio | 2013 |
Role of the calcium-sensing receptor in cardiomyocyte apoptosis via the sarcoplasmic reticulum and mitochondrial death pathway in cardiac hypertrophy and heart failure.
Topics: Animals; Aorta, Thoracic; Apoptosis; Benzamides; Calcium; Cardiomegaly; Cyclohexylamines; Cytochrome | 2013 |
Fibroblast growth factor 21 protects against cardiac hypertrophy in mice.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cardiotonic Agents; Fetus; Fibroblast Growth Factors; Gene | 2013 |
Connective tissue growth factor/CCN2 attenuates β-adrenergic receptor responsiveness and cardiotoxicity by induction of G protein-coupled receptor kinase-5 in cardiomyocytes.
Topics: Adrenergic Agonists; Animals; Arrestins; beta-Arrestins; Calcium-Binding Proteins; Cardiomegaly; Cel | 2013 |
No overt structural or functional changes associated with PEG-coated gold nanoparticles accumulation with acute exposure in the mouse heart.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiotoxins; Disease Models, Animal; Drug Delivery | 2013 |
Chronic inhibition of cGMP-specific phosphodiesterase 5 suppresses endoplasmic reticulum stress in heart failure.
Topics: Animals; Aorta; Apoptosis; Calcium-Binding Proteins; Cardiomegaly; Constriction; Cyclic GMP-Dependen | 2013 |
Intrinsic-mediated caspase activation is essential for cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Animals, Newborn; Apoptosis; Bronchodilator Agents; Cardiomegaly; Caspase 3 | 2013 |
Upregulation of TRPC1 contributes to contractile function in isoproterenol-induced hypertrophic myocardium of rat.
Topics: Animals; Blotting, Western; Calcium; Cardiomegaly; Isoproterenol; Male; Myocardial Contraction; Myoc | 2013 |
Fenofibrate modulates cytochrome P450 and arachidonic acid metabolism in the heart and protects against isoproterenol-induced cardiac hypertrophy.
Topics: 8,11,14-Eicosatrienoic Acid; Animals; Arachidonic Acid; Cardiomegaly; Cytochrome P-450 CYP2J2; Cytoc | 2014 |
Cardiac-specific hexokinase 2 overexpression attenuates hypertrophy by increasing pentose phosphate pathway flux.
Topics: Adrenergic alpha-Agonists; Animals; Animals, Newborn; Cardiomegaly; Cell Death; Cells, Cultured; Deh | 2013 |
PKA catalytic subunit compartmentation regulates contractile and hypertrophic responses to β-adrenergic signaling.
Topics: Adrenergic beta-Agonists; Animals; Animals, Newborn; Calcium; Calcium Signaling; Cardiomegaly; Catal | 2014 |
Fibronectin and transforming growth factor beta contribute to erythropoietin resistance and maladaptive cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cell Line; Erythropoietin; Fibronectins; Isoproterenol; Rats; Recombinant Pro | 2014 |
In vitro and in vivo direct monitoring of miRNA-22 expression in isoproterenol-induced cardiac hypertrophy by bioluminescence imaging.
Topics: Animals; Cardiomegaly; Green Fluorescent Proteins; Isoproterenol; Luciferases, Firefly; Luminescent | 2014 |
Overexpression of mitofilin in the mouse heart promotes cardiac hypertrophy in response to hypertrophic stimuli.
Topics: Animals; Cardiomegaly; Constriction, Pathologic; Heart; Humans; Isoproterenol; Male; Mice; Mice, Tra | 2014 |
The eIF2B-interacting domain of RGS2 protects against GPCR agonist-induced hypertrophy in neonatal rat cardiomyocytes.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cell Size; Cells, Cultured; Cyclic AMP; Eukaryotic Initiati | 2014 |
Chlorogenic acid prevents isoproterenol-induced hypertrophy in neonatal rat myocytes.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cells, Cultured; Chlorogenic Acid; Isoproterenol; Myocytes, | 2014 |
Cardiac function and architecture are maintained in a model of cardiorestricted overexpression of the prorenin-renin receptor.
Topics: Animals; Blood Pressure; Blotting, Western; Cardiomegaly; Creatine Kinase; Echocardiography; Gene Ex | 2014 |
Calcium sensing receptor promotes cardiac fibroblast proliferation and extracellular matrix secretion.
Topics: Animals; Calcium Signaling; Cardiomegaly; Cell Proliferation; Extracellular Matrix; Extracellular Ma | 2014 |
Exercise training can prevent cardiac hypertrophy induced by sympathetic hyperactivity with modulation of kallikrein-kinin pathway and angiogenesis.
Topics: Animals; Apoptosis; Capillaries; Cardiomegaly; Fibrillar Collagens; Isoproterenol; Kallikreins; Kini | 2014 |
Deletion of CXCR4 in cardiomyocytes exacerbates cardiac dysfunction following isoproterenol administration.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Chemokine CXCL12; De | 2014 |
Erbin is a negative modulator of cardiac hypertrophy.
Topics: Animals; Biomarkers; Cardiomegaly; Carrier Proteins; Disease Progression; Down-Regulation; Extracell | 2014 |
Gestational hypertension and the developmental origins of cardiac hypertrophy and diastolic dysfunction.
Topics: Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; Cardiomegaly; Female; Fibrosis; GATA T | 2014 |
Exercise protects against chronic β-adrenergic remodeling of the heart by activation of endothelial nitric oxide synthase.
Topics: Animals; Cardiomegaly; Fibrosis; Heart; Hemodynamics; Isoproterenol; Mice; Mice, Inbred C57BL; Myoca | 2014 |
Beneficial role of tamoxifen in experimentally induced cardiac hypertrophy.
Topics: Animals; Blood Pressure; C-Reactive Protein; Cardiomegaly; Disease Models, Animal; Female; Heart Rat | 2014 |
Melatonin reduces cardiac remodeling and improves survival in rats with isoproterenol-induced heart failure.
Topics: Animals; Cardiomegaly; Heart Failure; Isoproterenol; Male; Melatonin; Rats; Rats, Wistar | 2014 |
Astragalus polysaccharide inhibits isoprenaline-induced cardiac hypertrophy via suppressing Ca²⁺-mediated calcineurin/NFATc3 and CaMKII signaling cascades.
Topics: Animals; Animals, Newborn; Astragalus Plant; Atrial Natriuretic Factor; Calcineurin; Calcium; Calciu | 2014 |
Cardiac sympathetic afferent denervation attenuates cardiac remodeling and improves cardiovascular dysfunction in rats with heart failure.
Topics: Adrenergic beta-Agonists; Afferent Pathways; Animals; Apoptosis; Blotting, Western; Cardiomegaly; Ca | 2014 |
Effects and mechanism of action of ligustrazine on isoprenaline-induced cardiomyocyte hypertrophy.
Topics: Animals; Calcium Channel Blockers; Calcium Signaling; Cardiomegaly; Cardiotonic Agents; Cells, Cultu | 2014 |
Rapamycin attenuated cardiac hypertrophy induced by isoproterenol and maintained energy homeostasis via inhibiting NF-κB activation.
Topics: Animals; Blotting, Western; Cardiomegaly; Cells, Cultured; Energy Metabolism; Homeostasis; Isoproter | 2014 |
HMGA1 is a new target of miR-195 involving isoprenaline-induced cardiomyocyte hypertrophy.
Topics: 3' Untranslated Regions; Animals; Base Sequence; Cardiomegaly; Cells, Cultured; Down-Regulation; HMG | 2014 |
Kruppel-like factor 4 protein regulates isoproterenol-induced cardiac hypertrophy by modulating myocardin expression and activity.
Topics: Angiotensin II; Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Cardiomegaly; Cell Line | 2014 |
Tumor suppressor gene ING3 induces cardiomyocyte hypertrophy via inhibition of AMPK and activation of p38 MAPK signaling.
Topics: AMP-Activated Protein Kinases; Angiotensin II; Animals; Animals, Newborn; Aorta, Abdominal; Cardiome | 2014 |
Pak1 is required to maintain ventricular Ca²⁺ homeostasis and electrophysiological stability through SERCA2a regulation in mice.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiac Pacing, Artificial; Cardiomegaly; Cells, Culture | 2014 |
Polyamine depletion attenuates isoproterenol-induced hypertrophy and endoplasmic reticulum stress in cardiomyocytes.
Topics: Acetyltransferases; Animals; Apoptosis; Atrial Natriuretic Factor; bcl-2-Associated X Protein; Cardi | 2014 |
Reduction of isoproterenol-induced cardiac hypertrophy and modulation of myocardial connexin43 by a KATP channel agonist.
Topics: Animals; Cardiomegaly; Connexin 43; Disease Models, Animal; Gene Expression; Heart Ventricles; Immun | 2015 |
Aminoguanidine inhibits ventricular fibrosis and remodeling process in isoproterenol-induced hypertrophied rat hearts by suppressing ROS and MMPs.
Topics: Animals; Antioxidants; Cardiomegaly; Fibrosis; Guanidines; Heart Ventricles; Isoproterenol; Male; Ma | 2014 |
N-[(11)C]-methyl-hydroxyfasudil is a potential biomarker of cardiac hypertrophy.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Biomarkers; Cardiomegaly; Cell Nucleus; Cell | 2015 |
Mapping genetic contributions to cardiac pathology induced by Beta-adrenergic stimulation in mice.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Chromosome Mapping; Female; Fibrosis; Genetic Loci; | 2015 |
Temporal and gefitinib-sensitive regulation of cardiac cytokine expression via chronic β-adrenergic receptor stimulation.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Chemokine CCL2; ErbB Re | 2015 |
[Establishment of a FVB/N mouse model of cardiac hypertrophy by isoprenaline].
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Isoproterenol; Mice; Mice, Inbred Strains | 2014 |
Antihyperlipidaemic, antihypertrophic, and reducing effects of zingerone on experimentally induced myocardial infarcted rats.
Topics: Animals; Cardiomegaly; Guaiacol; Hyperlipidemias; Hypolipidemic Agents; Isoproterenol; Male; Myocard | 2015 |
The orphan receptor NOR1 participates in isoprenaline-induced cardiac hypertrophy by regulating PARP-1.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; DNA-Binding Proteins; Gene Knock- | 2015 |
Microdomain switch of cGMP-regulated phosphodiesterases leads to ANP-induced augmentation of β-adrenoceptor-stimulated contractility in early cardiac hypertrophy.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; B | 2015 |
Nitric oxide synthase inhibition abolishes exercise-mediated protection against isoproterenol-induced cardiac hypertrophy in female mice.
Topics: Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Echocardiography; Enzyme Inhibitors; | 2015 |
Astragaloside IV protects against isoproterenol-induced cardiac hypertrophy by regulating NF-κB/PGC-1α signaling mediated energy biosynthesis.
Topics: Animals; Atrial Natriuretic Factor; Cardiomegaly; Down-Regulation; Energy Metabolism; Gene Knockdown | 2015 |
Adipose stem cell sheets improved cardiac function in the rat myocardial infarction, but did not alter cardiac contractile responses to β-adrenergic stimulation.
Topics: Adipocytes; Animals; Atrial Natriuretic Factor; Atrial Remodeling; Bucladesine; Cardiomegaly; Cell D | 2015 |
Cardiac actions of atrial natriuretic peptide: new visions of an old friend.
Topics: 3',5'-Cyclic-AMP Phosphodiesterases; Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; C | 2015 |
Honokiol blocks and reverses cardiac hypertrophy in mice by activating mitochondrial Sirt3.
Topics: Acetylation; Adenosine Triphosphatases; Animals; Biphenyl Compounds; Cardiomegaly; Cardiotonic Agent | 2015 |
Astragalus polysaccharide attenuates isoproterenol-induced cardiac hypertrophy by regulating TNF-α/PGC-1α signaling mediated energy biosynthesis.
Topics: Animals; Animals, Newborn; Astragalus propinquus; Cardiomegaly; Cells, Cultured; Drugs, Chinese Herb | 2015 |
In vivo model with targeted cAMP biosensor reveals changes in receptor-microdomain communication in cardiac disease.
Topics: Adrenergic beta-Agonists; Animals; Biosensing Techniques; Calcium-Binding Proteins; Cardiomegaly; Ce | 2015 |
Interplay between the E2F pathway and β-adrenergic signaling in the pathological hypertrophic response of myocardium.
Topics: Animals; Calcium-Binding Proteins; Cardiomegaly; Cardiomyopathy, Dilated; Cell Survival; Cyclic AMP- | 2015 |
Early Changes in Cytochrome P450s and Their Associated Arachidonic Acid Metabolites Play a Crucial Role in the Initiation of Cardiac Hypertrophy Induced by Isoproterenol.
Topics: Adrenergic beta-Antagonists; Animals; Arachidonic Acids; Cardiomegaly; Cell Line; Cytochrome P-450 E | 2015 |
CaMKIIδ mediates β-adrenergic effects on RyR2 phosphorylation and SR Ca(2+) leak and the pathophysiological response to chronic β-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calcium Signaling; Calcium-Binding Proteins; Calcium-Cal | 2015 |
Klotho ameliorated isoproterenol-induced pathological changes in cardiomyocytes via the regulation of oxidative stress.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Gene Expression Regulation; Glucuronidase; Heart Fa | 2015 |
Simvastatin prevents isoproterenol-induced cardiac hypertrophy through modulation of the JAK/STAT pathway.
Topics: Animals; Biomarkers; Cardiomegaly; Creatine Kinase, MB Form; Cytoprotection; Disease Models, Animal; | 2015 |
Puerarin prevents cardiac hypertrophy induced by pressure overload through activation of autophagy.
Topics: Adenine; AMP-Activated Protein Kinases; Animals; Autophagy; Cardiomegaly; Carrier Proteins; Disease | 2015 |
Orphan Nuclear Receptor Nur77 Inhibits Cardiac Hypertrophic Response to Beta-Adrenergic Stimulation.
Topics: Adrenergic alpha-1 Receptor Agonists; Animals; Cardiomegaly; Cells, Cultured; Endothelin-1; GATA4 Tr | 2015 |
Deletion of MLIP (muscle-enriched A-type lamin-interacting protein) leads to cardiac hyperactivation of Akt/mammalian target of rapamycin (mTOR) and impaired cardiac adaptation.
Topics: Adaptation, Physiological; Animals; Cardiomegaly; Carrier Proteins; Co-Repressor Proteins; Female; G | 2015 |
[The effect of relgulation of PPAR-α on cardiac hypertrophy and the relationship between the effect of PPAR-α with PI3K/Akt/mTOR pathway].
Topics: Atrial Natriuretic Factor; Cardiomegaly; Cells, Cultured; Fenofibrate; Humans; Isoproterenol; Myocyt | 2015 |
MITF interacts with the SWI/SNF subunit, BRG1, to promote GATA4 expression in cardiac hypertrophy.
Topics: Angiotensin II; Animals; Aorta; Base Sequence; Binding Sites; Cardiomegaly; Cell Line; Constriction, | 2015 |
MicroRNA regulation of unfolded protein response transcription factor XBP1 in the progression of cardiac hypertrophy and heart failure in vivo.
Topics: Animals; Cardiomegaly; Cell Line; Disease Progression; DNA-Binding Proteins; Heart Failure; Humans; | 2015 |
Mesenchymal Stem Cells and Cardiomyocytes Interplay to Prevent Myocardial Hypertrophy.
Topics: Animals; Bone Marrow Cells; Calcineurin; Calcium Signaling; Cardiomegaly; Coculture Techniques; Isop | 2015 |
Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease.
Topics: Adrenergic beta-Agonists; Aging; Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Fibrosis; | 2016 |
Cardiac Effects of Attenuating Gsα - Dependent Signaling.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Size; Cyclic AMP; Gene Expression; GTP-Binding | 2016 |
Speckle Tracking Based Strain Analysis Is Sensitive for Early Detection of Pathological Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Early Diagnosis; Echocardiography; Heart; Isoproteren | 2016 |
Astragaloside IV improves the isoproterenol-induced vascular dysfunction via attenuating eNOS uncoupling-mediated oxidative stress and inhibiting ROS-NF-κB pathways.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Astragalus propinquus; Cardiomegaly; Cytokines; Humans; Is | 2016 |
Overexpression of microRNA-99a Attenuates Cardiac Hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Cell Enlargement; Cells, Cultured; Disease Models, Animal; Ge | 2016 |
Nicotinic Acid Adenine Dinucleotide Phosphate (NAADP) and Cyclic ADP-Ribose (cADPR) Mediate Ca2+ Signaling in Cardiac Hypertrophy Induced by β-Adrenergic Stimulation.
Topics: ADP-ribosyl Cyclase 1; Animals; Calcium Signaling; Cardiomegaly; Cyclic ADP-Ribose; Isoproterenol; M | 2016 |
Danhong injection attenuates isoproterenol-induced cardiac hypertrophy by regulating p38 and NF-κb pathway.
Topics: Animals; Cardiomegaly; Carthamus tinctorius; Cell Line; Flowers; Gene Expression Regulation; Isoprot | 2016 |
Effect of aliskiren and carvedilol on expression of Ca(2+)/calmodulin-dependent protein kinase II δ-subunit isoforms in cardiac hypertrophy rat model.
Topics: Amides; Animals; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Carbazoles; Cardiomegaly; Carve | 2016 |
Protective Effects of 7-Hydroxycoumarin on Dyslipidemia and Cardiac Hypertrophy in Isoproterenol-Induced Myocardial Infarction in Rats.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Dyslipidemias; Hydroxymethylglutaryl CoA Reductases | 2016 |
SIRT6 suppresses isoproterenol-induced cardiac hypertrophy through activation of autophagy.
Topics: Animals; Animals, Newborn; Autophagy; Cardiomegaly; Cells, Cultured; Forkhead Box Protein O3; Isopro | 2016 |
Downregulation of β-Adrenoceptors in Isoproterenol-Induced Cardiac Remodeling through HuR.
Topics: 3' Untranslated Regions; Animals; Cardiomegaly; Cells, Cultured; Down-Regulation; ELAV-Like Protein | 2016 |
Endoplasmic Reticulum Stress is Involved in DFMO Attenuating Isoproterenol-Induced Cardiac Hypertrophy in Rats.
Topics: Acetyltransferases; Animals; Antineoplastic Agents; Apoptosis; Atrial Natriuretic Factor; bcl-2-Asso | 2016 |
Deregulation of XBP1 expression contributes to myocardial vascular endothelial growth factor-A expression and angiogenesis during cardiac hypertrophy in vivo.
Topics: Aged; Animals; Capillaries; Cardiomegaly; Cell Line; Dependovirus; Endoplasmic Reticulum Stress; Fem | 2016 |
Suppression of calcium‑sensing receptor ameliorates cardiac hypertrophy through inhibition of autophagy.
Topics: AMP-Activated Protein Kinases; Animals; Autophagy; Calcium; Calcium-Calmodulin-Dependent Protein Kin | 2016 |
Cardiac Specific Overexpression of hHole Attenuates Isoproterenol-Induced Hypertrophic Remodeling through Inhibition of Extracellular Signal-Regulated Kinases (ERKs) Signalling.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Fibrosis; Humans; Intracellular Signaling Peptides an | 2016 |
Loss of Mouse P2Y6 Nucleotide Receptor Is Associated with Physiological Macrocardia and Amplified Pathological Cardiac Hypertrophy.
Topics: Animals; Cardiomegaly; Hyperplasia; Isoproterenol; Male; Mice; Mice, Knockout; Myocardial Ischemia; | 2016 |
K(ATP) channel gain-of-function leads to increased myocardial L-type Ca(2+) current and contractility in Cantu syndrome.
Topics: Animals; Calcium Channels, L-Type; Calcium Signaling; Cardiomegaly; Female; Heart Ventricles; Humans | 2016 |
Protective effects of Astragalus polysaccharides against endothelial dysfunction in hypertrophic rats induced by isoproterenol.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Astragalus propinquus; Cardiomegaly; Cells, Cultured; Endo | 2016 |
Type III Transforming Growth Factor-β Receptor Drives Cardiac Hypertrophy Through β-Arrestin2-Dependent Activation of Calmodulin-Dependent Protein Kinase II.
Topics: Analysis of Variance; Animals; beta-Arrestin 2; Biopsy, Needle; Calcium-Calmodulin-Dependent Protein | 2016 |
Spironolactone Prevents Endothelial Nitric Oxide Synthase Uncoupling and Vascular Dysfunction Induced by β-Adrenergic Overstimulation: Role of Perivascular Adipose Tissue.
Topics: Adipose Tissue; Analysis of Variance; Animals; Cardiomegaly; Disease Models, Animal; Isoproterenol; | 2016 |
Inhibition of Cardiomyocytes Hypertrophy by Resveratrol Is Associated with Amelioration of Endoplasmic Reticulum Stress.
Topics: Animals; Animals, Newborn; Antioxidants; Apoptosis; Atrial Natriuretic Factor; bcl-2-Associated X Pr | 2016 |
A Periodontal pathogen Porphyromonas gingivalis deteriorates Isoproterenol-Induced myocardial remodeling in mice.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Disease Models, Animal; Heart; Isoproterenol; Mice, | 2017 |
The poly(ADP-ribosyl)ation of FoxO3 mediated by PARP1 participates in isoproterenol-induced cardiac hypertrophy.
Topics: Adenoviridae; Animals; Animals, Newborn; Benzamides; Benzimidazoles; Cardiomegaly; Echocardiography; | 2016 |
Gallic acid prevents isoproterenol-induced cardiac hypertrophy and fibrosis through regulation of JNK2 signaling and Smad3 binding activity.
Topics: Animals; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Fibrosis; Gallic Acid; Gene Expressi | 2016 |
North American ginseng (Panax quinquefolius) suppresses β-adrenergic-dependent signalling, hypertrophy, and cardiac dysfunction.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Dose-Response Relationship, Drug; Isoproterenol; Ma | 2016 |
Rad-deletion Phenocopies Tonic Sympathetic Stimulation of the Heart.
Topics: Animals; Calcium Channels, L-Type; Cardiomegaly; Case-Control Studies; Echocardiography, Stress; Gen | 2016 |
Systems Genetics Approach Identifies Gene Pathways and Adamts2 as Drivers of Isoproterenol-Induced Cardiac Hypertrophy and Cardiomyopathy in Mice.
Topics: ADAMTS Proteins; Animals; Cardiomegaly; Cardiomyopathies; Cardiotonic Agents; Catecholamines; Gene E | 2017 |
Delonix regia Leaf Extract (DRLE): A Potential Therapeutic Agent for Cardioprotection.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Creatine Kinase; Fabaceae; Female; Heart; Heart Injuries; | 2016 |
Proteomic analysis of the protective effects of aqueous bark extract of Terminalia arjuna (Roxb.) on isoproterenol-induced cardiac hypertrophy in rats.
Topics: Animals; Cardiomegaly; Isoproterenol; Male; Phytotherapy; Plant Bark; Plant Extracts; Proteomics; Ra | 2017 |
CaMKII inhibition reduces isoproterenol-induced ischemia and arrhythmias in hypertrophic mice.
Topics: Animals; Arrhythmias, Cardiac; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; Car | 2017 |
A systems genetics approach identifies
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cell Size; Cells, Cultured; Gene Expression Profiling; Ge | 2017 |
The role of cytochrome P450 1B1 and its associated mid-chain hydroxyeicosatetraenoic acid metabolites in the development of cardiac hypertrophy induced by isoproterenol.
Topics: Animals; Cardiomegaly; Cell Line; Cytochrome P-450 CYP1B1; Gene Expression Regulation, Enzymologic; | 2017 |
Comparison of pharmacodynamics between carvedilol and metoprolol in rats with isoproterenol-induced cardiac hypertrophy: effects of carvedilol enantiomers.
Topics: Adenylyl Cyclases; Adrenergic alpha-Antagonists; Adrenergic beta-Antagonists; Animals; Blood Pressur | 2008 |
Serotonin 5-HT(2B) receptor blockade prevents reactive oxygen species-induced cardiac hypertrophy in mice.
Topics: Angiotensin II; Animals; Cardiomegaly; Disease Models, Animal; Echocardiography, Doppler; Indoles; I | 2008 |
Transgenic overexpression of Hdac3 in the heart produces increased postnatal cardiac myocyte proliferation but does not induce hypertrophy.
Topics: Animals; Animals, Newborn; Cardiomegaly; Cardiotonic Agents; Cell Proliferation; Cyclin-Dependent Ki | 2008 |
Modulation of cytochrome P450 gene expression and arachidonic acid metabolism during isoproterenol-induced cardiac hypertrophy in rats.
Topics: Animals; Arachidonic Acid; Cardiomegaly; Cytochrome P-450 Enzyme System; Gene Expression Profiling; | 2008 |
L-arginine inhibits isoproterenol-induced cardiac hypertrophy through nitric oxide and polyamine pathways.
Topics: Adrenergic beta-Agonists; Animals; Arginine; Atrial Natriuretic Factor; Biogenic Polyamines; Blood P | 2008 |
Limited functional and metabolic improvements in hypertrophic and healthy rat heart overexpressing the skeletal muscle isoform of SERCA1 by adenoviral gene transfer in vivo.
Topics: Adenosine Triphosphate; Adenoviridae; Adrenergic beta-Agonists; Animals; Calcium-Binding Proteins; C | 2008 |
Early expression of monocyte chemoattractant protein-1 correlates with the onset of isoproterenol-induced cardiac fibrosis in rats with distinct angiotensin-converting enzyme polymorphism.
Topics: Animals; Cardiomegaly; Cell Proliferation; Chemokine CCL2; Collagen; Endothelin-1; Fibroblasts; Fibr | 2008 |
N-acetyl-seryl-aspartyl-lysyl-proline prevents cardiac remodeling and dysfunction induced by galectin-3, a mammalian adhesion/growth-regulatory lectin.
Topics: Animals; Anti-Inflammatory Agents; Blood Pressure; Body Weight; Cardiac Output; Cardiomegaly; Cardio | 2009 |
Serotonin 5-HT2B receptor in cardiac fibroblast contributes to cardiac hypertrophy: a new therapeutic target for heart failure?
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Cardiomegaly; Cytokines; Drug Deli | 2009 |
Treatment with atorvastatin partially protects the rat heart from harmful catecholamine effects.
Topics: Adrenergic beta-Agonists; Animals; Atorvastatin; Atrial Natriuretic Factor; Cardiomegaly; Cell Membr | 2009 |
Comparison of isoproterenol and dobutamine in the induction of cardiac hypertrophy and fibrosis.
Topics: Animals; Cardiac Output; Cardiomegaly; Cardiotonic Agents; Dobutamine; Echocardiography; Endomyocard | 2008 |
Targeted expression of receptor-associated late transducer inhibits maladaptive hypertrophy via blocking epidermal growth factor receptor signaling.
Topics: Adenoviridae; Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Collagen; Disease Models, Anim | 2009 |
Stimulation of kappa-opioid receptor reduces isoprenaline-induced cardiac hypertrophy and fibrosis.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 2009 |
Cardiac-specific deletion of mkk4 reveals its role in pathological hypertrophic remodeling but not in physiological cardiac growth.
Topics: Adaptation, Physiological; Animals; Apoptosis; Blood Pressure; Cardiomegaly; Disease Models, Animal; | 2009 |
Stress-induced cardiac insufficiency relating to abnormal leptin and FKBP12.6 is ameliorated by CPU0213, an endothelin receptor antagonist, which is not affected by the CYP3A suppressing effect of erythromycin.
Topics: Animals; Cardiomegaly; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Cytochrome P-45 | 2009 |
Effect of sodium houttuyfonate on myocardial hypertrophy in mice and rats.
Topics: Alkanes; Angiotensin II; Animals; Captopril; Cardiomegaly; Cyclic AMP; Dose-Response Relationship, D | 2009 |
Decreased beta-adrenergic responsiveness following hypertrophy occurs only in cardiomyocytes that also re-express beta-myosin heavy chain.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiomyopathies; Disease Models, Animal; Isoproter | 2009 |
Effects of formaldehyde on cardiovascular system in in situ rat hearts.
Topics: Animals; Calcium; Cardiomegaly; Excitation Contraction Coupling; Formaldehyde; Heart; Heart Rate; Is | 2009 |
miR-23a functions downstream of NFATc3 to regulate cardiac hypertrophy.
Topics: Aldosterone; Animals; Base Sequence; Calcineurin; Cardiomegaly; Cell Line; Disease Models, Animal; G | 2009 |
Acute and chronic adrenergic stimulation of submandibular salivary glands. Effects on the endocrine function of epidermal growth factor in mice.
Topics: Adrenergic alpha-Agonists; Animals; Atrial Natriuretic Factor; Cardiomegaly; Epidermal Growth Factor | 2009 |
Plasma miR-208 as a biomarker of myocardial injury.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Heart Injuries; Isoproterenol; Kidney; Male; Mic | 2009 |
Plasma miR-208 as a biomarker of myocardial injury.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Heart Injuries; Isoproterenol; Kidney; Male; Mic | 2009 |
Plasma miR-208 as a biomarker of myocardial injury.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Heart Injuries; Isoproterenol; Kidney; Male; Mic | 2009 |
Plasma miR-208 as a biomarker of myocardial injury.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Heart Injuries; Isoproterenol; Kidney; Male; Mic | 2009 |
Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload.
Topics: Angiotensin II; Animals; Base Sequence; Calcium; Cardiomegaly; Connective Tissue Growth Factor; DNA | 2009 |
Left ventricular function of isoproterenol-induced hypertrophied rat hearts perfused with blood: mechanical work and energetics.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Blotting, Western; Calcium-Binding Proteins; Card | 2009 |
Myostatin represses physiological hypertrophy of the heart and excitation-contraction coupling.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiomegaly; Cell Differentiation; Cell Line; Cell Prol | 2009 |
Role of Ca2+/calmodulin-stimulated cyclic nucleotide phosphodiesterase 1 in mediating cardiomyocyte hypertrophy.
Topics: Angiotensin II; Animals; Calcium; Calcium Signaling; Calmodulin; Cardiomegaly; Cardiotonic Agents; C | 2009 |
Inpp5f is a polyphosphoinositide phosphatase that regulates cardiac hypertrophic responsiveness.
Topics: Animals; Cardiomegaly; Cell Size; Disease Models, Animal; Gene Expression Regulation; Humans; Inosit | 2009 |
Take it to heart: myostatin inhibition, mighty mouse and the quest for a competitive edge.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiomegaly; Cell Differentiation; Cell Line; Cell Prol | 2009 |
MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overloaded adult hearts.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Diastole; Electrocardiography; Fibrosis; Gene Expression | 2010 |
Controlling myocyte cGMP: phosphodiesterase 1 joins the fray.
Topics: Angiotensin II; Animals; Calcium; Calcium Signaling; Calmodulin; Cardiomegaly; Cardiotonic Agents; C | 2009 |
Catecholamine-induced myocardial fibrosis and oxidative stress is attenuated by Terminalia arjuna (Roxb.).
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Captopril; Cardiomegaly; Fibrosis; Heart; Isoproter | 2009 |
Transcriptional profile of isoproterenol-induced cardiomyopathy and comparison to exercise-induced cardiac hypertrophy and human cardiac failure.
Topics: Analysis of Variance; Animals; Cardiomegaly; Cell Size; Cluster Analysis; Disease Models, Animal; Ge | 2009 |
The role of microRNA-133 in cardiac hypertrophy uncovered.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Diastole; Electrocardiography; Fibrosis; Gene Expression | 2010 |
KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways.
Topics: Animals; Calcineurin; Cardiomegaly; Cyclic GMP; Cyclic GMP-Dependent Protein Kinases; Disease Models | 2010 |
miR-9 and NFATc3 regulate myocardin in cardiac hypertrophy.
Topics: Aldosterone; Animals; Base Sequence; Cardiomegaly; Gene Expression; Humans; In Vitro Techniques; Iso | 2010 |
An antagonism between the AKT and beta-adrenergic signaling pathways mediated through their reciprocal effects on miR-199a-5p.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Hypoxia; Cells, Cultured; Hypoxia-Inducible Fa | 2010 |
Cardiac hypertrophy is not amplified by deletion of cGMP-dependent protein kinase I in cardiomyocytes.
Topics: Animals; Base Sequence; Cardiomegaly; Cells, Cultured; Cyclic GMP-Dependent Protein Kinase Type I; C | 2010 |
Constitutive glycogen synthase kinase-3alpha/beta activity protects against chronic beta-adrenergic remodelling of the heart.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Apoptosis; Cardiomegaly; Disease Models, Animal; Enz | 2010 |
Novel insights into the mechanisms mediating the local antihypertrophic effects of cardiac atrial natriuretic peptide: role of cGMP-dependent protein kinase and RGS2.
Topics: Adrenergic beta-Agonists; Angiotensin II; Animals; Atrial Natriuretic Factor; Calcium; Cardiomegaly; | 2010 |
Exercise training inhibits inflammatory cytokines and more than prevents myocardial dysfunction in rats with sustained beta-adrenergic hyperactivity.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Cardiomegaly; Cardiomyopathies; Cardiotonic Ag | 2010 |
Effects of angiotensin type I receptor blockade on the cardiac Raf/MEK/ERK cascade activated via adrenergic receptors.
Topics: Adrenergic beta-Agonists; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; | 2010 |
The IP3 receptor regulates cardiac hypertrophy in response to select stimuli.
Topics: Age Factors; Angiotensin II; Animals; Arrhythmias, Cardiac; Calcineurin; Calcium Signaling; Cardiome | 2010 |
Peripheral benzodiazepine receptor ligand Ro5-4864 inhibits isoprenaline-induced cardiac hypertrophy in rats.
Topics: Animals; Antioxidants; Benzodiazepinones; Cardiomegaly; Disease Models, Animal; Dose-Response Relati | 2010 |
Akt2 deficiency promotes cardiac induction of Rab4a and myocardial β-adrenergic hypersensitivity.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomegaly; Cells, Cultured; Enzyme Induction; Gene Expressi | 2010 |
Effect of U50,488H, a κ-opioid receptor agonist on myocardial α-and β-myosin heavy chain expression and oxidative stress associated with isoproterenol-induced cardiac hypertrophy in rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Animals; A | 2010 |
Differential regulation of proteasome function in isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cyclic AMP-Dependent Protein Kinases; Hydrolysis; Isoproterenol; Male; Mice; | 2010 |
[Dynamic study on inhibition of qi-benefiting, blood-activating recipe on myocardial hypertrophy induced by ISO in rats].
Topics: Animals; Atrial Natriuretic Factor; Cardiac Output; Cardiomegaly; Drug Combinations; Drugs, Chinese | 2010 |
Cardiac myosin light chain kinase is necessary for myosin regulatory light chain phosphorylation and cardiac performance in vivo.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Echocardiography; Female; Gene Expression Regulation, Enz | 2010 |
Endothelin-1- and isoproterenol-induced differential protein expression and signaling pathway in HL-1 cardiomyocytes.
Topics: Amino Acid Sequence; Animals; Cardiomegaly; Cardiotonic Agents; Cell Line; Electrophoresis, Gel, Two | 2011 |
An oral formulation of angiotensin-(1-7) produces cardioprotective effects in infarcted and isoproterenol-treated rats.
Topics: Administration, Oral; Analysis of Variance; Angiotensin I; Animals; Blood Pressure; Cardiomegaly; Ca | 2011 |
Evidence suggesting that the cardiomyocyte circadian clock modulates responsiveness of the heart to hypertrophic stimuli in mice.
Topics: Aging; Animals; Body Temperature; Cardiomegaly; Cardiotonic Agents; Circadian Clocks; CLOCK Proteins | 2011 |
Tanshinone IIA protects against cardiac hypertrophy via inhibiting calcineurin/NFATc3 pathway.
Topics: Abietanes; Animals; Atrial Natriuretic Factor; Calcineurin; Calcium Signaling; Cardiomegaly; Drugs, | 2011 |
Antioxidant and cardioprotective effects of Danshensu (3-(3, 4-dihydroxyphenyl)-2-hydroxy-propanoic acid from Salvia miltiorrhiza) on isoproterenol-induced myocardial hypertrophy in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Antioxidants; Arrhythmias, Cardiac; Cardiomegaly; | 2011 |
Tumor necrosis factor receptor 2 signaling limits β-adrenergic receptor-mediated cardiac hypertrophy in vivo.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Cardiomegaly; Echocardiography; Enzyme-Linked | 2011 |
The role of E2F1 in the development of hypertrophic cardiomyopathy.
Topics: Angiotensin II; Animals; Apoptosis; Atrial Natriuretic Factor; Cardiomegaly; Cardiomyopathy, Hypertr | 2011 |
Overexpression of ornithine decarboxylase decreases ventricular systolic function during induction of cardiac hypertrophy.
Topics: Action Potentials; Animals; Cardiomegaly; Chromatography, High Pressure Liquid; Heart Ventricles; Is | 2012 |
A novel role for the fifth component of complement (C5) in cardiac physiology.
Topics: Animals; Base Sequence; Cardiomegaly; Complement C5; DNA Primers; Gene Expression Regulation; Isopro | 2011 |
NHE-1 participates in isoproterenol-induced downregulation of SERCA2a and development of cardiac remodeling in rat hearts.
Topics: Animals; Calcium Signaling; Calcium-Binding Proteins; Cardiomegaly; Collagen; Disease Models, Animal | 2011 |
Impact of L-NAME on the cardiopulmonary reflex in cardiac hypertrophy.
Topics: Animals; Baroreflex; Blood Pressure; Blood Volume; Caffeine; Cardiomegaly; Disease Models, Animal; D | 2011 |
[The antagonistic effect of PI3K-gamma inhibitor AS605240 on cardiac hypertrophy and cardiac fibrosis induced by isoproterenol in rats].
Topics: Animals; Cardiomegaly; Fibrosis; Isoproterenol; Male; Myocardium; Proteasome Endopeptidase Complex; | 2011 |
GATA6 reporter gene reveals myocardial phenotypic heterogeneity that is related to variations in gap junction coupling.
Topics: Adherens Junctions; Animals; beta-Galactosidase; Cardiomegaly; Cell Communication; Cells, Cultured; | 2011 |
Protein kinase D3 is a pivotal activator of pathological cardiac hypertrophy by selectively increasing the expression of hypertrophic transcription factors.
Topics: Animals; Animals, Newborn; Cardiomegaly; Isoproterenol; Myocytes, Cardiac; Protein Kinase C; Protein | 2011 |
Ablation of p21-activated kinase-1 in mice promotes isoproterenol-induced cardiac hypertrophy in association with activation of Erk1/2 and inhibition of protein phosphatase 2A.
Topics: Animals; Calcium; Cardiomegaly; Disease Models, Animal; Echocardiography; Enzyme Activation; Extrace | 2011 |
β2 adrenergic activation induces the expression of IL-18 binding protein, a potent inhibitor of isoproterenol induced cardiomyocyte hypertrophy in vitro and myocardial hypertrophy in vivo.
Topics: Adrenergic beta-2 Receptor Agonists; Animals; Cardiomegaly; CCAAT-Enhancer-Binding Proteins; Cyclic | 2012 |
Cytoskeletal role in protection of the failing heart by β-adrenergic blockade.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2012 |
Identification of proteins responding to adrenergic receptor subtype-specific hypertrophy in cardiomyocytes by proteomic approaches.
Topics: Acetylcysteine; Animals; Cardiomegaly; Cells, Cultured; Disease Models, Animal; Electrophoresis, Gel | 2011 |
Catecholamine-induced cardiac mitochondrial dysfunction and mPTP opening: protective effect of curcumin.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Catecholamines; Curc | 2012 |
Transforming growth factor β₁ oppositely regulates the hypertrophic and contractile response to β-adrenergic stimulation in the heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angio | 2011 |
Automated image analysis identifies signaling pathways regulating distinct signatures of cardiac myocyte hypertrophy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Adhesion; Cell Enla | 2012 |
Phosphorylation of Akt/GSK-3β/eNOS amplifies 5-HT2B receptor blockade mediated anti-hypertrophic effect in rats.
Topics: Animals; Cardiomegaly; Drug Evaluation, Preclinical; Drug Synergism; Glycogen Synthase Kinase 3; Gly | 2012 |
Cardiac lipoprotein lipase activity in the hypertrophied heart may be regulated by fatty acid flux.
Topics: Angiopoietin-Like Protein 4; Angiopoietins; Animals; Biological Transport; Cardiomegaly; Cardiotonic | 2012 |
Evidence that AMP-activated protein kinase can negatively modulate ornithine decarboxylase activity in cardiac myoblasts.
Topics: AMP-Activated Protein Kinases; Animals; Cardiomegaly; Down-Regulation; Eflornithine; Gene Expression | 2012 |
Overexpression of apolipoprotein B attenuates pathologic cardiac remodeling and hypertrophy in response to catecholamines and after myocardial infarction in mice.
Topics: Animals; Apolipoproteins B; Cardiomegaly; Echocardiography; Heart; Humans; Isoproterenol; Male; Mice | 2012 |
Spironolactone prevents alterations associated with cardiac hypertrophy produced by isoproterenol in rats: involvement of serum- and glucocorticoid-regulated kinase type 1.
Topics: Aldosterone; Animals; Blood Pressure; Cardiomegaly; Fibrosis; Heart; Immediate-Early Proteins; Infla | 2012 |
Effect of Cissampelos pareira root extract on isoproterenol-induced cardiac dysfunction.
Topics: Animals; Calcineurin; Cardiomegaly; Isoproterenol; L-Lactate Dehydrogenase; Male; Oxidative Stress; | 2013 |
The aging myostatin null phenotype: reduced adiposity, cardiac hypertrophy, enhanced cardiac stress response, and sexual dimorphism.
Topics: Adipose Tissue, Brown; Adiposity; Aging; Animals; Bone Density; Cardiomegaly; Cardiotonic Agents; Fe | 2012 |
Isoproterenol induced hypertrophy and associated signaling pathways are modulated by somatostatin in H9c2 cells.
Topics: Animals; Cardiomegaly; Cell Line; Isoproterenol; Myocytes, Cardiac; Rats; Signal Transduction; Somat | 2013 |
The cardiac expression of Mas receptor is responsive to different physiological and pathological stimuli.
Topics: Angiotensin I; Animals; Cardiomegaly; Desoxycorticosterone; Hypertension; Isoproterenol; Male; Motor | 2012 |
The function of calcineurin and ERK1/2 signal in the antihypertrophic effects of kappa-opioid receptor stimulation on myocardial hypertrophy induced by isoprenaline.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Calcineurin; Calcium Signaling; Cardiomegaly; | 2012 |
Cardiomyocyte-restricted inhibition of G protein-coupled receptor kinase-3 attenuates cardiac dysfunction after chronic pressure overload.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Cardiomegaly; Endomyocardial Fibrosis; G-Prote | 2012 |
Non-neuronal cholinergic machinery present in cardiomyocytes offsets hypertrophic signals.
Topics: Acetylcholine; Acetylcholinesterase; Animals; Atropine; Cardiomegaly; Cell Movement; Cells, Cultured | 2012 |
Beneficial role of spironolactone, telmisartan and their combination on isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Algorithms; Angiotensin II Type 1 Receptor Blockers; Animals; Benzimidazol | 2012 |
CXCR4 gene transfer prevents pressure overload induced heart failure.
Topics: Animals; Blotting, Western; Calcineurin; Calcium Channels, L-Type; Cardiomegaly; Chemokine CXCL12; E | 2012 |
Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Disease Susceptibility; Fibrosis; Interleukin-10; Iso | 2012 |
Estrogens mediate cardiac hypertrophy in a stimulus-dependent manner.
Topics: Animals; Aromatase; Blotting, Western; Cardiomegaly; Echocardiography; Estrogens; Female; Heart; Iso | 2012 |
Genistein prevents isoproterenol-induced cardiac hypertrophy in rats.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Catalase; Disease Models, Animal; Enzyme Inhibitors; Fibr | 2012 |
β-Adrenergic receptor stimulation causes cardiac hypertrophy via a Gβγ/Erk-dependent pathway.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Chlorocebus aethiops; COS Cells; Extracellular Sign | 2012 |
β-adrenoceptor regulates miRNA expression in rat heart.
Topics: Animals; Cardiomegaly; Gene Expression Profiling; Gene Expression Regulation; Hemodynamics; Isoprote | 2012 |
Baroreflex control of renal sympathetic nerve activity in mice with cardiac hypertrophy.
Topics: Animals; Arterial Pressure; Baroreflex; Cardiomegaly; Disease Models, Animal; Isoproterenol; Kidney; | 2012 |
AAV-mediated knock-down of HRC exacerbates transverse aorta constriction-induced heart failure.
Topics: Animals; Aorta; Calcium; Calcium-Binding Proteins; Cardiomegaly; Carrier Proteins; Constriction; Cyt | 2012 |
Anchored p90 ribosomal S6 kinase 3 is required for cardiac myocyte hypertrophy.
Topics: A Kinase Anchor Proteins; Adaptor Proteins, Signal Transducing; Animals; Animals, Newborn; Binding S | 2013 |
Desmodium gangeticum (Linn.) DC. exhibits antihypertrophic effect in isoproterenol-induced cardiomyoblasts via amelioration of oxidative stress and mitochondrial alterations.
Topics: Adrenergic beta-Agonists; Animals; Antioxidants; Cardiomegaly; Cardiovascular Agents; Cell Line; Cel | 2013 |
Effect of isoprenaline chronic stimulation on APD restitution and ventricular arrhythmogenesis.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Cardiac Pacing, Artificial; Cardiomegaly; Card | 2013 |
Cardiotoxic and cardioprotective features of chronic β-adrenergic signaling.
Topics: Adrenergic beta-Antagonists; Animals; Apoptosis; Calcium; Calcium-Calmodulin-Dependent Protein Kinas | 2013 |
Soluble epoxide hydrolase inhibitor, TUPS, protects against isoprenaline-induced cardiac hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Body Weight; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytoch | 2013 |
Protective effects of sinapic acid on cardiac hypertrophy, dyslipidaemia and altered electrocardiogram in isoproterenol-induced myocardial infarcted rats.
Topics: Animals; Antioxidants; Cardiomegaly; Coumaric Acids; Dyslipidemias; Electrocardiography; Hydroxymeth | 2013 |
Increased passive stiffness of cardiomyocytes in the transverse direction and residual actin and myosin cross-bridge formation in hypertrophied rat hearts induced by chronic β-adrenergic stimulation.
Topics: Actins; Adrenergic beta-Agonists; Animals; Cardiomegaly; Cells, Cultured; Diacetyl; Disease Models, | 2013 |
Downregulation of the cardiotrophin-1 gene expression by valsartan and spironolactone in hypertrophied heart rats in vivo and rat cardiomyocyte H9c2 cell line in vitro: a novel mechanism of cardioprotection.
Topics: Animals; Blotting, Western; Cardiomegaly; Cardiotonic Agents; Cell Line; Cytokines; Disease Models, | 2013 |
Effects of taurine on myocardial cGMP/cAMP ratio, antioxidant ability, and ultrastructure in cardiac hypertrophy rats induced by isoproterenol.
Topics: Animals; Antioxidants; Cardiomegaly; Creatine Kinase, MB Form; Cyclic AMP; Cyclic GMP; Glutathione; | 2013 |
Calmodulin kinase II and arrhythmias in a mouse model of cardiac hypertrophy.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Arrhythmias, Cardiac; Benzylamines; Calcium Ch | 2002 |
Overexpression of endothelial nitric oxide synthase attenuates cardiac hypertrophy induced by chronic isoproterenol infusion.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Isoproterenol; Mice; Mice, Transgenic; Muscle Cells | 2002 |
Arrhythmogenic and inotropic effects of interferon investigated in perfused and in vivo rat hearts: influences of cardiac hypertrophy and isoproterenol.
Topics: Animals; Arrhythmias, Cardiac; Cardiomegaly; Drug Synergism; Heart Block; Humans; In Vitro Technique | 2002 |
Characterization of cardiac hypertrophy and heart failure due to volume overload in the rat.
Topics: Animals; Arteries; Cardiac Output, Low; Cardiomegaly; Coronary Circulation; Heart; Hemodynamics; Hyp | 2003 |
Dysfunction of myocardial taurine transport and effect of taurine supplement in rats with isoproterenol-induced myocardial injury.
Topics: Animals; Biological Transport, Active; Carboxy-Lyases; Cardiomegaly; Isoproterenol; Male; Myocardium | 2002 |
Tonin in rat heart with experimental hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin II; Animals; Atrial Natriuretic Factor; Cardiomegaly; Disease | 2003 |
Cardiomegaly induced by pressure overload in newborn rats is accompanied by altered expression of the long isoform of G(s)alpha protein and deranged signaling of adenylyl cyclase.
Topics: Adenylyl Cyclases; Aging; Animals; Animals, Newborn; Cardiomegaly; Cardiotonic Agents; Colforsin; Fl | 2003 |
Regression of isoproterenol-induced cardiac hypertrophy by Na+/H+ exchanger inhibition.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Hydrogen-Ion Concentration; Isoproterenol; Male; My | 2003 |
Regulation of protein kinase C isozyme and calcineurin expression in isoproterenol induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Calcineurin; Cardiomegaly; Isoenzymes; Isoprot | 2003 |
Inducible cAMP early repressor (ICER) is a negative-feedback regulator of cardiac hypertrophy and an important mediator of cardiac myocyte apoptosis in response to beta-adrenergic receptor stimulation.
Topics: Adenoviridae; Adrenergic beta-Agonists; Animals; Animals, Newborn; Apoptosis; Cardiomegaly; Cell Siz | 2003 |
Inhibition of matrix metalloproteinases prevents cardiac hypertrophy induced by beta-adrenergic stimulation in rats.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Insulin-Like Growth Factor I; Isoproterenol; Male; Matrix | 2003 |
Phosphoinositide 3-kinase gamma-deficient mice are protected from isoproterenol-induced heart failure.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Catalytic Domain; Disease Models, Animal; Fibrosis; | 2003 |
Cardiac hypertrophy and histone deacetylase-dependent transcriptional repression mediated by the atypical homeodomain protein Hop.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cell Line; Gene Expression Regulation; Hemodynamics; Hist | 2003 |
CARDIAC FUNCTION IN PRIMARY MYOCARDIAL DISORDERS. I.
Topics: Angiocardiography; Blood Pressure Determination; Cardiac Catheterization; Cardiac Surgical Procedure | 1964 |
THE APEX CARDIOGRAM IN LEFT VENTRICULAR OUTFLOW TRACT OBSTRUCTION.
Topics: Aortic Valve Stenosis; Cardiomegaly; Carotid Arteries; Electrocardiography; Heart Rate; Humans; Isop | 1964 |
THE ARTIFICIAL CARDIAC PACEMAKER. INDICATIONS FOR IMPLANTATION.
Topics: Adams-Stokes Syndrome; Arrhythmias, Cardiac; Atrioventricular Block; Bradycardia; Brugada Syndrome; | 1964 |
DYNAMIC OBSTRUCTION OF THE LEFT VENTRICLE; ITS PRODUCTION AND ABOLITION BY DRUGS IN NORMAL ANIMALS.
Topics: Aminophylline; Aortic Valve Stenosis; Calcium Chloride; Cardiomegaly; Diagnosis, Differential; Dogs; | 1965 |
Regional distribution of hyperpolarization-activated current (If) and hyperpolarization-activated cyclic nucleotide-gated channel mRNA expression in ventricular cells from control and hypertrophied rat hearts.
Topics: Action Potentials; Animals; Aortic Valve Stenosis; Cardiomegaly; Cell Size; Cesium; Cyclic Nucleotid | 2003 |
Inhibition of receptor-localized PI3K preserves cardiac beta-adrenergic receptor function and ameliorates pressure overload heart failure.
Topics: Animals; beta-Adrenergic Receptor Kinases; Cardiomegaly; Cyclic AMP-Dependent Protein Kinases; Enzym | 2003 |
Polymorphism in gene coding for ACE determines different development of myocardial fibrosis in rats.
Topics: Animals; Cardiomegaly; Cell Division; Female; Fibrosis; Genotype; Heart; Isoproterenol; Male; Matrix | 2004 |
Plasma membrane-associated nucleoside diphosphate kinase (nm23) in the heart is regulated by beta-adrenergic signaling.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Adult; Aged; Animals; Card | 2003 |
Cardiomyocyte-specific endothelin A receptor knockout mice have normal cardiac function and an unaltered hypertrophic response to angiotensin II and isoproterenol.
Topics: Angiotensin II; Animals; Base Sequence; Cardiomegaly; DNA; Female; Heart; Isoproterenol; Male; Mice; | 2003 |
Inhibition of PKC phosphorylation of cTnI improves cardiac performance in vivo.
Topics: Animals; Calcium; Cardiomegaly; Cardiotonic Agents; Coronary Circulation; Cyclic AMP; Cyclic AMP-Dep | 2004 |
Transcription activator protein 1 mediates alpha- but not beta-adrenergic hypertrophic growth responses in adult cardiomyocytes.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Division; Cells, Cu | 2004 |
Phosphorylation of eukaryotic translation initiation factor 2Bepsilon by glycogen synthase kinase-3beta regulates beta-adrenergic cardiac myocyte hypertrophy.
Topics: Adenoviridae; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Animals, Newborn; Atri | 2004 |
Reversible effects of isoproterenol-induced hypertrophy on in situ left ventricular function in rat hearts.
Topics: Adrenergic beta-Agonists; Animals; Blotting, Western; Cardiac Catheterization; Cardiomegaly; Electro | 2004 |
[Effect of zhimu and huangqi on cardiac hypertrophy and response to stimulation in mice].
Topics: Anemarrhena; Animals; Astragalus propinquus; Cardiomegaly; Cardiotonic Agents; Cold Temperature; Dru | 2003 |
Celiprolol, a vasodilatory beta-blocker, inhibits pressure overload-induced cardiac hypertrophy and prevents the transition to heart failure via nitric oxide-dependent mechanisms in mice.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Celiprol | 2004 |
Involvement of the serotonin 5-HT2B receptor in cardiac hypertrophy linked to sympathetic stimulation: control of interleukin-6, interleukin-1beta, and tumor necrosis factor-alpha cytokine production by ventricular fibroblasts.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2004 |
Decreased baroreflex sensitivity in isoproterenol-treated mice with cardiac hypertrophy.
Topics: Animals; Baroreflex; Blood Pressure; Body Weight; Bronchodilator Agents; Cardiomegaly; Disease Model | 2004 |
Transgenic mice with cardiac-specific over-expression of MLK7 have increased mortality when exposed to chronic beta-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Fibrosis; Gene Expression Regulation; Heart Failure | 2004 |
Targeted expression of cyclin D2 results in cardiomyocyte DNA synthesis and infarct regression in transgenic mice.
Topics: Age Factors; Animals; Animals, Newborn; Cardiomegaly; Coronary Disease; Cyclin D1; Cyclin D2; Cyclin | 2005 |
Impact of beta-myosin heavy chain expression on cardiac function during stress.
Topics: Animals; Body Weight; Cardiac Output, Low; Cardiomegaly; Cardiotonic Agents; Chronic Disease; Dobuta | 2004 |
Strain-dependent beta-adrenergic receptor function influences myocardial responses to isoproterenol stimulation in mice.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Cardiomegaly; Echocardiography; Heart; Isoprot | 2005 |
Leptin repletion restores depressed {beta}-adrenergic contractility in ob/ob mice independently of cardiac hypertrophy.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Age Factors; Animals; Blotting, Western; Calcium; Cardi | 2005 |
Repeated daily injections and osmotic pump infusion of isoproterenol cause similar increases in cardiac mass but have different effects on blood pressure.
Topics: Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal; Infusion Pumps; Infusions, Intravenou | 2005 |
Daily administration of interleukin-18 causes myocardial dysfunction in healthy mice.
Topics: Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; Calcium; Calcium-Binding Proteins; Cal | 2005 |
Requirement of nuclear factor-kappaB in angiotensin II- and isoproterenol-induced cardiac hypertrophy in vivo.
Topics: Angiotensin II; Animals; Apoptosis; Cardiomegaly; I-kappa B Proteins; Interleukin-6; Isoproterenol; | 2005 |
Inotropic responses to phosphodiesterase inhibitors in cardiac hypertrophy in rats.
Topics: 8-Bromo Cyclic Adenosine Monophosphate; Amrinone; Animals; Blood Pressure; Cardiomegaly; Cardiotonic | 2005 |
Effect of relaxin on myocardial ischemia injury induced by isoproterenol.
Topics: Animals; Cardiomegaly; Creatine Kinase; Disease Models, Animal; Endothelins; Gene Expression; Heart; | 2005 |
[PTEN negatively regulates isoproterenol-induced cardiac hypertrophy and effects of captopril on PTEN expression].
Topics: Animals; Captopril; Cardiomegaly; Disease Models, Animal; Gene Expression Regulation; Isoproterenol; | 2005 |
Contractile dysfunction in hypertrophied hearts with deficient insulin receptor signaling: possible role of reduced capillary density.
Topics: Animals; Apoptosis; Capillaries; Cardiomegaly; Cardiotonic Agents; Coronary Circulation; Diabetes Co | 2005 |
Functional interaction of a beta-adrenergic agonist and cyclic GMP phosphodiesterase inhibitor in control and hypertrophic cardiomyocytes.
Topics: 3',5'-Cyclic-GMP Phosphodiesterases; Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Enlargeme | 2006 |
Phospholipase C epsilon modulates beta-adrenergic receptor-dependent cardiac contraction and inhibits cardiac hypertrophy.
Topics: Animals; Calcium; Cardiomegaly; Heart Failure; Humans; Isoproterenol; Male; Mice; Mice, Inbred C57BL | 2005 |
Induction of heparanase gene expression in ventricular myocardium of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Blotting, Northern; Cardiomegaly; Disease Models, Animal; Drug Administration Schedule; Enz | 2005 |
Alterations of the preproenkephalin system in cardiac hypertrophy and its role in atrioventricular conduction.
Topics: Adrenergic beta-Agonists; Animals; Animals, Newborn; Atrioventricular Node; Blotting, Northern; Card | 2006 |
Cardioprotective effects of ghrelin and des-octanoyl ghrelin on myocardial injury induced by isoproterenol in rats.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Fibrosis; Ghrelin; Growth Hormone; Isoproterenol; Male; M | 2006 |
PARP inhibition prevents postinfarction myocardial remodeling and heart failure via the protein kinase C/glycogen synthase kinase-3beta pathway.
Topics: Animals; Cardiomegaly; Collagen Type III; Electrocardiography; Enzyme Inhibitors; Glycogen Synthase | 2006 |
Enhanced isoproterenol-induced cardiac hypertrophy in transgenic rats with low brain angiotensinogen.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Angiotensinogen; Animals; Animals, Geneticall | 2006 |
Hypertrophic growth in cardiac myocytes is mediated by Myc through a Cyclin D2-dependent pathway.
Topics: Animals; Apoptosis; Cardiomegaly; Cell Cycle; Cell Enlargement; Cell Proliferation; Cells, Cultured; | 2006 |
Transcription factor MITF regulates cardiac growth and hypertrophy.
Topics: Animals; Body Weight; Cardiomegaly; Cell Enlargement; Cell Line; Extracellular Signal-Regulated MAP | 2006 |
Increased susceptibility to isoproterenol-induced cardiac hypertrophy and impaired weight gain in mice lacking the histidine-rich calcium-binding protein.
Topics: Animals; Calcium; Calcium-Binding Proteins; Cardiomegaly; Genetic Predisposition to Disease; Isoprot | 2006 |
Small heat-shock protein Hsp20 attenuates beta-agonist-mediated cardiac remodeling through apoptosis signal-regulating kinase 1.
Topics: Adrenergic beta-Agonists; Animals; Apoptosis; Cardiomegaly; Cardiotonic Agents; Cells, Cultured; Dow | 2006 |
Dependence of changes in beta-adrenoceptor signal transduction on type and stage of cardiac hypertrophy.
Topics: Adenylyl Cyclases; Animals; Calcium; Cardiomegaly; Cardiotonic Agents; Isoproterenol; Male; Myocytes | 2007 |
kappa-opioid receptor stimulation inhibits cardiac hypertrophy induced by beta1-adrenoceptor stimulation in the rat.
Topics: 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer; Adrenergic | 2007 |
Window Ca2+ current and its modulation by Ca2+ release in hypertrophied cardiac myocytes from dogs with chronic atrioventricular block.
Topics: Adrenergic beta-Agonists; Animals; Buffers; Calcium; Calcium Channels, L-Type; Cardiomegaly; Chronic | 2007 |
Urotensin II accelerates cardiac fibrosis and hypertrophy of rats induced by isoproterenol.
Topics: Angiotensin II; Animals; Cardiomegaly; Cell Proliferation; Collagen; Fibroblasts; Fibrosis; Hydroxyp | 2007 |
Role of AT1 receptor in isoproterenol-induced cardiac hypertrophy and oxidative stress in mice.
Topics: Adrenergic beta-Agonists; Angiotensins; Animals; Antioxidants; Blotting, Western; Cardiomegaly; Coll | 2007 |
Increased expression of endothelial nitric oxide synthase and caveolin-1 in the aorta of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Acetylcholine; Animals; Aorta; Blood Pressure; Cardiomegaly; Caveolin 1; Disease Models, Animal; Dos | 2006 |
Effects of a novel histone deacetylase inhibitor, N-(2-aminophenyl) benzamide, on a reversible hypertrophy induced by isoproterenol in in situ rat hearts.
Topics: Analysis of Variance; Animals; Benzamides; Cardiac Catheterization; Cardiac Output; Cardiomegaly; Co | 2007 |
Mice lacking sulfonylurea receptor 2 (SUR2) ATP-sensitive potassium channels are resistant to acute cardiovascular stress.
Topics: Acute Disease; Adrenergic beta-Agonists; Animals; ATP-Binding Cassette Transporters; Calcium Channel | 2007 |
Isoproterenol-induced impairment of heart function and remodeling are attenuated by the nonpeptide angiotensin-(1-7) analogue AVE 0991.
Topics: Angiotensins; Animals; Cardiomegaly; Collagen; Disease Models, Animal; Extracellular Matrix; Fibrone | 2007 |
Cardioprotective effects of Astragali Radix against isoproterenol-induced myocardial injury in rats and its possible mechanism.
Topics: Animals; Astragalus Plant; Cardiomegaly; Cardiomyopathies; Cardiotonic Agents; Carrier Proteins; Cyc | 2008 |
Doxycycline attenuates isoproterenol- and transverse aortic banding-induced cardiac hypertrophy in mice.
Topics: Animals; Aorta; Cardiomegaly; Disease Models, Animal; Doxycycline; Isoproterenol; Male; Mice; Mice, | 2008 |
Endocytosis machinery is required for beta1-adrenergic receptor-induced hypertrophy in neonatal rat cardiac myocytes.
Topics: Adrenergic beta-1 Receptor Agonists; Adrenergic beta-Agonists; Animals; Animals, Newborn; Arrestins; | 2008 |
Role of oxidative stress in hypertrophied myoblasts stimulated by isoproterenol.
Topics: Animals; Apoptosis; Cardiomegaly; Cells, Cultured; Extracellular Signal-Regulated MAP Kinases; Gluco | 2008 |
Does strong hypertrophic condition induce fast mitochondrial DNA mutation of rabbit heart?
Topics: Amino Acid Substitution; Animals; Cardiomegaly; Cytochromes b; DNA, Mitochondrial; Electron Transpor | 2008 |
Myosin regulatory light chain phosphorylation attenuates cardiac hypertrophy.
Topics: Age Factors; Animals; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinase Type 2; Cardiomegaly; | 2008 |
Impact of cardiac hypertrophy on arterial and cardiopulmonary baroreflex control of renal sympathetic nerve activity in anaesthetized rats.
Topics: Animals; Baroreflex; Blood Pressure; Body Weight; Caffeine; Cardiomegaly; Central Nervous System Sti | 2008 |
Voluntary exercise-induced changes in beta2-adrenoceptor signalling in rat ventricular myocytes.
Topics: Animals; Calcium; Cardiomegaly; Cardiotonic Agents; Female; Isoproterenol; Myocytes, Cardiac; Physic | 2008 |
Exercise training prevents beta-adrenergic hyperactivity-induced myocardial hypertrophy and lesions.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Heart Failure; In Situ Nick-End Labeling; Isoproter | 2008 |
Correlation between haemodynamic and metabolic changes in three models of experimental cardiac hypertrophy.
Topics: Adenine Nucleotides; Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Constriction; Cyclic A | 1984 |
A differential effect of ouabain and beta-agonists on contractility and lactic acid production in the hypertrophied heart.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Dogs; Hemodynamics; Isoproterenol; Lactates; Myocar | 1980 |
Adrenergic beta receptors mediating submandibular salivary gland hypertrophy in the rat.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Dose-Response Relationship, Drug; Hypertrophy; Isop | 1981 |
[Pharmacological tests in the polycardiography of valve defects].
Topics: Amyl Nitrite; Angiotensins; Cardiomegaly; Heart Valve Diseases; Heart Valve Prosthesis; Humans; Isop | 1980 |
Acute effects of isoproterenol on cellular autophagy. Inhibition in myocardium but stimulation in liver parenchyma.
Topics: Animals; Autophagy; Cardiomegaly; Heart; Isoproterenol; Liver; Male; Microscopy, Electron; Myocardiu | 1981 |
Some metabolic features of the development of experimentally induced cardiac hypertrophy.
Topics: Adenine Nucleotides; Adrenergic beta-Antagonists; Animals; Cardiomegaly; Cyclic AMP; Female; Isoprot | 1982 |
Norepinephrine-stimulated hypertrophy of cultured rat myocardial cells is an alpha 1 adrenergic response.
Topics: Adrenergic alpha-Antagonists; Animals; Cardiomegaly; Isoproterenol; Myocardium; Norepinephrine; Phen | 1983 |
Studies on the hexose monophosphate shunt in the myocardium during development of hypertrophy.
Topics: Adenine Nucleotides; Animals; Cardiomegaly; Female; Glucosephosphate Dehydrogenase; Hexosephosphates | 1980 |
Changes in myocardial pyrimidine nucleotide levels following repeated injections of isoproterenol in rats.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Cardiomegaly; DNA; Female; Heart; Isoprotereno | 1981 |
Early molecular events in rat heart after administration of triiodothyronine and isoproterenol.
Topics: Animals; Cardiomegaly; Heart; Isoproterenol; Kinetics; Male; Myocardium; Poly A; Polyribosomes; Prot | 1983 |
Protein synthesis in the early stages of cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Female; Isoproterenol; Kinetics; Myocardium; Protein Biosynthesis; Puromycin; | 1983 |
Development of isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Body Water; Body Weight; Cardiomegaly; DNA; Female; Half-Life; Hemodynamics; Hydroxyproline | 1984 |
Regression of isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; DNA; DNA-Directed RNA Polymerases; Female; Hydroxyproline; Isoproterenol; Myo | 1984 |
Polyamine metabolism in myocardial hypertrophy.
Topics: Cardiomegaly; Diet; Humans; Isoproterenol; Myocardium; Ornithine Decarboxylase; Physical Exertion; P | 1982 |
Exercise provocable right ventricular outflow tract tachycardia.
Topics: Adolescent; Adult; Anti-Arrhythmia Agents; Bundle-Branch Block; Cardiomegaly; Electric Stimulation; | 1982 |
Myocyte hypertrophy in neonatal rat heart cultures and its regulation by serum and by catecholamines.
Topics: Animals; Blood Physiological Phenomena; Cardiomegaly; Catecholamines; Cell Division; Cells, Cultured | 1982 |
Cardiac hypertrophy and its regression in rat: comparison of morphological changes in response to aortic constriction, iron deficiency anaemia and isoprenaline.
Topics: Anemia, Hypochromic; Animals; Aorta, Abdominal; Body Water; Cardiomegaly; Constriction; Isoprotereno | 1982 |
Role of polyamines in isoproterenol-induced cardiac hypertrophy: effects of alpha-difluoromethylornithine, an irreversible inhibitor of ornithine decarboxylase.
Topics: Animals; Cardiomegaly; Eflornithine; Isoproterenol; Male; Ornithine; Ornithine Decarboxylase Inhibit | 1982 |
Polyamine levels and diamine oxidase activity in hypertrophic heart of spontaneously hypertensive rats and of rats treated with isoproterenol.
Topics: Amine Oxidase (Copper-Containing); Animals; Cardiomegaly; Hypertension; Isoproterenol; Male; Muscle | 1983 |
Changes in myosin isozyme distribution induced by low doses of isoproterenol.
Topics: Adenosine Triphosphatases; Animals; Cardiomegaly; Isoenzymes; Isoproterenol; Myosins; Rats; Rats, In | 1982 |
Defect in the adrenergic receptor-adenylate cyclase system during development of catecholamine-induced cardiomyopathy.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Dihydroalprenolol; Dihydroergotoxine; Epinephrine; Isoprot | 1984 |
Some functional changes in experimentally induced cardiac overload.
Topics: Aminooxyacetic Acid; Animals; Atropine; Cardiomegaly; Disease Models, Animal; Drug Combinations; Ele | 1983 |
Comparison of slow response action potentials from normal and hypertrophied myocardium.
Topics: Action Potentials; Animals; Cardiomegaly; Cats; Isoproterenol; Isotonic Solutions; Papillary Muscles | 1984 |
Applications and limitations of end-systolic measures of ventricular performance.
Topics: Animals; Cardiomegaly; Chronic Disease; Dogs; Heart Diseases; Heart Function Tests; Heart Ventricles | 1984 |
Coronary vasodilator reserve in young dogs with moderate right ventricular hypertrophy.
Topics: Animals; Cardiomegaly; Coronary Circulation; Coronary Vessels; Dogs; Hemodynamics; Isoproterenol; Va | 1984 |
Study of the factors influencing cardiac growth. I. Comparison of cardiomegaly induced by isoproterenol in euthyroid and thyroidectomized rats.
Topics: Animals; Cardiomegaly; Heart; Hypothyroidism; Isoproterenol; Oxygen Consumption; Rats; Thyroidectomy | 1984 |
Adrenergic activity as a modulating factor in the genesis of myocardial hypertrophy in the rat.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Heart Rate; Hydroxyproline; Isoproterenol; Male; | 1984 |
Cardiac performance and myocardial blood flow in pigs with compensated right ventricular hypertrophy.
Topics: Animals; Cardiomegaly; Coronary Circulation; Heart; Heart Function Tests; Hemodynamics; Isoprotereno | 1984 |
[Pathophysiology of asymmetric septal hypertrophy with special reference to the response to isoproterenol administration].
Topics: Adult; Aged; Cardiomegaly; Cardiomyopathy, Hypertrophic; Echocardiography; Female; Heart Septum; Hum | 1984 |
Pyrimidine nucleotide metabolism in cardiac hypertrophy.
Topics: Adenosine Triphosphate; Animals; Aorta, Abdominal; Cardiomegaly; Constriction; Female; Isoproterenol | 1984 |
Myocardial cell nucleus in cardiac overloading in the rat.
Topics: Animals; Cardiomegaly; Cell Nucleolus; Cell Nucleus; Chromatin; DNA; Isoproterenol; Microscopy, Elec | 1984 |
Thyroxine-induced changes in characteristics and activities of beta-adrenergic receptors and adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate systems in the heart may be related to reputed catecholamine supersensitivity in hyperthyroidism.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Cyclic AMP; Cyclic GMP; Dihydroalprenolol; Fluorides; Hear | 1980 |
Comparison of cardiac lesions induced in rats by isoproterenol and by repeated stress of restraint and water immersion with special reference to etiology of cardiomyopathy.
Topics: Adrenal Glands; Animals; Cardiomegaly; Cardiomyopathies; Catecholamines; Heart; Immersion; Isoproter | 1980 |
Cardiac beta adrenoceptors and adenylate cyclase in normotensive and renal hypertensive rabbits during changes in autonomic activity.
Topics: Adenosine Triphosphatases; Adenylyl Cyclases; Animals; Autonomic Nervous System; Blood Pressure; Car | 1981 |
Early decrease in secretin-, glucagon-, and isoproterenol-stimulated cardiac adenylate cyclase activity in rats treated with isoproterenol.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Glucagon; Heart; Isoproterenol; Male; Myocardium; Rats; Ra | 1982 |
Regression of thyroid hormone induced cardiac hypertrophy: effect on cardiac beta receptors and adenyl cyclase activity.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Cell Membrane; Dihydroalprenolol; Isoproterenol; Kinetics; | 1983 |
Reversal of changes in myocardial beta-receptors and inotropic responsiveness with regression of cardiac hypertrophy in renal hypertensive rats (RHR).
Topics: Animals; Captopril; Cardiomegaly; Hypertension, Renal; Isoproterenol; Male; Myocardial Contraction; | 1984 |
Norepinephrine increases beta-receptors and adenylate cyclase in canine myocardium.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Cyclic AMP; Dogs; Heart; Isoproterenol; Male; Myocardium; | 1984 |
Effects of pressure overload, left ventricular hypertrophy on beta-adrenergic receptors, and responsiveness to catecholamines.
Topics: Animals; Body Weight; Cardiomegaly; Dogs; Female; Hemodynamics; Isoproterenol; Male; Myocardial Cont | 1984 |
Relationships between left ventricular mass and clinical, biohumoral and hemodynamic parameters in human hypertension.
Topics: Adolescent; Adult; Age Factors; Animals; Cardiomegaly; Catecholamines; Echocardiography; Heart Rate; | 1984 |
Beta-adrenoceptors and responsiveness in cardiac hypertrophy associated with renal hypertension in renovascular hypertensive rats.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Dose-Response Relationship, Drug; Heart; Heart Rate; | 1984 |
Adaptation of left ventricle to chronic pressure overload: response to inotropic drugs.
Topics: Animals; Calcium; Cardiac Volume; Cardiomegaly; Dogs; Dose-Response Relationship, Drug; Heart; Isopr | 1980 |
Is the ATP decline a signal for stimulating protein synthesis in isoproterenol-induced cardiac hypertrophy?
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Cardiomegaly; Female; Heart; Isoproterenol; My | 1980 |
T wave abnormalities in top-ranking athletes: effects of isoproterenol, atropine, and physical exercise.
Topics: Adolescent; Adult; Atropine; Bradycardia; Cardiomegaly; Electrocardiography; Humans; Hyperventilatio | 1980 |
Increased myocardial pyrimidine nucleotide synthesis in isoproterenol-induced cardiac hypertrophy in rats.
Topics: Animals; Cardiomegaly; Cytosine Nucleotides; Female; Isoproterenol; Myocardium; Phosphates; Pyrimidi | 1980 |
Myocardial hypertrophy in the rat. Correlation between two experimental models.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Heart; Hypoxia; Isoproterenol; Male; Myocardial Infar | 1980 |
Role of ornithine decarboxylase in cardiac growth and hypertrophy.
Topics: Animals; Carboxy-Lyases; Cardiomegaly; Eflornithine; Heart; Isoproterenol; Male; Myocardium; Ornithi | 1980 |
Early metabolic alterations during the development of experimentally induced cardiac hypertrophy.
Topics: Adenosine Triphosphate; Amino Acids; Animals; Blood Pressure; Cardiomegaly; Energy Metabolism; Isopr | 1980 |
Protein synthesis, amino acid uptake, and pools during isoproterenol-induced hypertrophy of the rat heart and tibialis muscle.
Topics: Amino Acids; Animals; Cardiomegaly; Hypertrophy; Isoproterenol; Male; Muscular Diseases; Protein Bio | 1981 |
Regional myocardial blood flow and coronary vascular reverse in unanesthetized vascular reserve in unanesthetized young calves with severe concentric right ventricular hypertrophy.
Topics: Animals; Blood Flow Velocity; Body Weight; Cardiomegaly; Cattle; Coronary Circulation; Heart Septum; | 1981 |
Blood flow in the hypertrophied right ventricular myocardium of unanesthetized ponies.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Coronary Circulation; Disease Models, Animal; He | 1981 |
The effect of magnesium aspartate hydrochloride on isoprenaline-induced cardiomegaly.
Topics: Animals; Aspartic Acid; Cardiomegaly; Heart; Isoproterenol; Magnesium; Male; Organ Size; Rats; Rats, | 1981 |
Exercise capacity and cardiac function of rats with drug-induced cardiac enlargement.
Topics: Actomyosin; Adenosine Triphosphatases; Animals; Body Weight; Cardiac Output; Cardiomegaly; Female; I | 1982 |
Induction of hypertrophic responsiveness to isoproterenol by TGF-beta in adult rat cardiomyocytes.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cattle; Cells, Cultured; Culture Media; Isoproteren | 1995 |
Beta-adrenergic stimulation of cardiac non-myocytes augments the growth-promoting activity of non-myocyte conditioned medium.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Betaxolol; Cardiomegaly; Cell Division; Cells, Cultured; Cultu | 1993 |
Effect of indapamide on cyclic adenosine 3',5'-monophosphate signal transduction system in isolated adult rat cardiomyocytes from normal myocardium and cardiac hypertrophy.
Topics: 1-Methyl-3-isobutylxanthine; Angiotensin II; Animals; Binding, Competitive; Carbachol; Cardiomegaly; | 1993 |
Angiotensin II maintains, but does not mediate, isoproterenol-induced cardiac hypertrophy in rats.
Topics: Actins; Angiotensin II; Animals; Base Sequence; Biphenyl Compounds; Blood Pressure; Captopril; Cardi | 1994 |
Angiotensin II induced alteration of cyclic adenosine 3',5'-monophosphate generation in the hypertrophic myocardium of Dahl salt-sensitive rat on a high-salt diet.
Topics: 1-Methyl-3-isobutylxanthine; Adenylate Cyclase Toxin; Angiotensin II; Animals; Cardiomegaly; Cell Si | 1994 |
Contraction-induced cell wounding and release of fibroblast growth factor in heart.
Topics: Animals; Cardiomegaly; Cattle; Cell Membrane; Enzyme-Linked Immunosorbent Assay; Fibroblast Growth F | 1995 |
Beta-adrenergic control of c-fos expression in fetal and neonatal rat tissues: relationship to cell differentiation and teratogenesis.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Animals, Newborn; Cardiomegaly; Cell Differ | 1995 |
Isoproterenol infusion induces alterations in expression of hypertrophy-associated genes in rat heart.
Topics: Animals; Base Sequence; Cardiomegaly; Gene Expression; Heart; Isoproterenol; Male; Molecular Sequenc | 1995 |
Parathyroid hormone induces protein kinase C but not adenylate cyclase in adult cardiomyocytes and regulates cyclic AMP levels via protein kinase C-dependent phosphodiesterase activity.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Cell Membrane; Cells, Cultured; Cyclic AMP; Electrophoresi | 1995 |
Effect of ouabain in catecholamine-induced cardiac hypertrophy.
Topics: Action Potentials; Animals; Cardiomegaly; Electrocardiography; Electrophysiology; Heart; Isoproteren | 1995 |
Transition from compensatory hypertrophy to dilated, failing left ventricles in Dahl salt-sensitive rats.
Topics: Animals; Blood Pressure; Calcium; Cardiomegaly; Disease Models, Animal; Echocardiography; Heart Fail | 1994 |
Transforming growth factor beta 1 and extracellular matrix gene expression in isoprenaline induced cardiac hypertrophy: effects of inhibition of the renin-angiotensin system.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Benzimidazoles; Biphenyl Compounds; Blotting, Nor | 1994 |
Expression of nuclear proto-oncogenes in isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Blotting, Northern; Cardiomegaly; Cell | 1993 |
High calcium diet effectively opposes the development of deoxycorticosterone-salt hypertension in rats.
Topics: Acetylcholine; Animals; Blood Pressure; Calcium; Calcium, Dietary; Cardiomegaly; Desoxycorticosteron | 1994 |
Tumor suppressor gene expression during normal and pathologic myocardial growth.
Topics: Animals; Antigens, Polyomavirus Transforming; Blotting, Northern; Blotting, Western; Body Weight; Ca | 1994 |
Impairment of the Bezold-Jarisch reflex in conscious rats with myocardial hypertrophy.
Topics: Animals; Baroreflex; Blood Pressure; Body Weight; Cardiomegaly; Heart Rate; Isoproterenol; Male; Org | 1994 |
Sensitivity to ischaemic ATP breakdown in different models of cardiac hypertrophy in rats.
Topics: Adenosine Triphosphate; Animals; Cardiomegaly; Coronary Circulation; Hyperemia; Hypertension; Isopro | 1994 |
Cardiovascular response and red cell membrane sodium transport in hypertensive cardiac hypertrophy.
Topics: Biological Transport; Blood Pressure; Cardiomegaly; Cardiovascular System; Erythrocyte Membrane; Fem | 1993 |
[Recovery of healthy and hypertrophic hearts after global ischemia and graduated reperfusion].
Topics: Adenine Nucleotides; Animals; Cardiomegaly; Heart Function Tests; Isoproterenol; Male; Myocardial Re | 1993 |
Cardiac beta-adrenoceptors, G-proteins and adenylate cyclase regulation during myocardial hypertrophy.
Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Animals; Carbachol; Cardiomegaly; Cholera Toxin; Colfors | 1993 |
Down-regulation of beta-adrenoceptors and loss of Gs alpha subunit levels in ventricular myocardium of rats treated with isoproterenol.
Topics: Animals; Cardiomegaly; Down-Regulation; GTP-Binding Proteins; Heart Ventricles; Isoproterenol; Male; | 1993 |
Ca2+ transients and cell shortening in diabetic rat ventricular myocytes.
Topics: Animals; Biological Transport; Calcium; Cardiomegaly; Cardiomyopathies; Cell Size; Diabetes Mellitus | 1993 |
[Myocardial hypertrophy due to isoproterenol. The preventive action of verapamil].
Topics: Analysis of Variance; Animals; Calcium Channel Blockers; Cardiomegaly; Cardiotonic Agents; Drug Eval | 1995 |
Quinidine pharmacodynamics in normal and isoproterenol-induced hypertrophied blood-perfused working rabbit hearts.
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Cardiomegaly; Electrocardiography; Heart; Hemody | 1996 |
Altered contractile function in isoproterenol-induced hypertrophied rat heart.
Topics: Actin Cytoskeleton; Animals; Calcium; Cardiomegaly; Female; Heart; Isoproterenol; Myocardial Contrac | 1996 |
Occurrence and properties of the hyperpolarization-activated current If in ventricular myocytes from normotensive and hypertensive rats during aging.
Topics: Aging; Animals; Cardiomegaly; Electric Conductivity; Electrophysiology; Hypertension; Isoproterenol; | 1996 |
Transient outward current in catecholamine-induced cardiac hypertrophy in the rat.
Topics: 4-Aminopyridine; Action Potentials; Animals; Cardiomegaly; Electric Conductivity; Isoproterenol; Kin | 1996 |
Force-frequency response in isoproterenol-induced hypertrophied rat heart.
Topics: Action Potentials; Animals; Calcium; Cardiomegaly; Female; Isoproterenol; Myocardial Contraction; Ra | 1996 |
L-type calcium current in catecholamine-induced cardiac hypertrophy in the rat.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Calcium Channels; Cardiomegaly; Catecholamines | 1997 |
Defective excitation-contraction coupling in experimental cardiac hypertrophy and heart failure.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calcium Channel Blockers; Calcium Channels; Calcium Chan | 1997 |
Cellular basis of contractile derangements of hypertrophied feline ventricular myocytes.
Topics: Actin Cytoskeleton; Animals; Calcium; Cardiomegaly; Cats; Colforsin; Fluorescent Dyes; Hemodynamics; | 1997 |
Protein kinase A and protein kinase C synergistically activate the Raf-1 kinase/mitogen-activated protein kinase cascade in neonatal rat cardiomyocytes.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Animals, Newborn; Bucladesine; Calcium; Calcium-Calmodulin-Dep | 1997 |
Basal muscarinic activity does not impede beta-adrenergic activation in rabbit hearts in controls or thyroxine-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Atropine; Body Weight; Cardiomegaly; Cyclic AMP; Cyclic GMP; Isop | 1997 |
A calcium stimulated cysteine protease involved in isoproterenol induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Calpain; Cardiomegaly; Cyclic AMP; Cysteine Endopeptidas | 1997 |
Expression of protein kinase C beta in the heart causes hypertrophy in adult mice and sudden death in neonates.
Topics: Age Factors; Animals; Animals, Newborn; Body Weight; Calcium; Cardiomegaly; Death, Sudden; Female; I | 1997 |
Cardiac beta-adrenergic signaling pathway alteration in isoproterenol-induced cardiac hypertrophy in male Sprague-Dawley rats.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Blood Pressure; Cardiomegaly; Catecholamines; | 1997 |
Pharmacological characterization of coronary small arteries from pigs with chronic ischaemic myocardial remodelling.
Topics: Acetylcholine; Animals; Bradykinin; Cardiomegaly; Cardiotonic Agents; Chronic Disease; Coronary Vess | 1998 |
Altered calcium handling in compensated hypertrophied rat cardiomyocytes induced by pressure overload.
Topics: Adrenergic beta-Agonists; Animals; Calcium; Cardiomegaly; Cells, Cultured; Colforsin; Heart; Hemodyn | 1998 |
Nitric oxide inhibits isoprenaline-induced positive inotropic effects in normal, but not in hypertrophied rat heart.
Topics: Adrenergic beta-Agonists; Animals; Aorta, Abdominal; Cardiomegaly; Cardiotonic Agents; Heart Ventric | 1998 |
Myocardial beta-adrenergic reactivity in volume overload-induced cardiac hypertrophy in the rat.
Topics: Adrenergic beta-Agonists; Animals; Cardiac Volume; Cardiomegaly; Catecholamines; Dose-Response Relat | 1998 |
Remodelling of cardiac extracellular matrix during beta-adrenergic stimulation: upregulation of SPARC in the myocardium of adult rats.
Topics: Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; Cardiomegaly; Collagen; Extracellular | 1998 |
Overexpression of alpha1B-adrenergic receptor induces left ventricular dysfunction in the absence of hypertrophy.
Topics: Adrenergic alpha-1 Receptor Antagonists; Animals; Blood Pressure; Calcium; Cardiomegaly; Cells, Cult | 1998 |
Intracellular signaling leads to the hypertrophic effect of neuropeptide Y.
Topics: Androstadienes; Animals; Aprotinin; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; Cell | 1998 |
Myocardial beta-adrenergic reactivity in pressure overload-induced cardiac hypertrophy in the rat.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Catecholamines; Decerebrate State; Dose-Response Re | 1998 |
Role of phosphatidylinositol 3-kinase activation in the hypertrophic growth of adult ventricular cardiomyocytes.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Androstadienes; Animals; Cardiomegaly; Cells, C | 1998 |
Effects of thyroid status on expression of voltage-gated potassium channels in rat left ventricle.
Topics: Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Amino Acid Sequence; Animals; Autoradiography | 1998 |
Bbeta-adrenergic receptor kinase-1 levels in catecholamine-induced myocardial hypertrophy: regulation by beta- but not alpha1-adrenergic stimulation.
Topics: Adenylyl Cyclases; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; beta-Adrenergic Rec | 1999 |
Spin-spin relaxation times in myocardial hypertrophy induced by endocrine agents in rat.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Estradiol; Female; Hormones; Hydrocortisone; Isopro | 1998 |
Both Gs and Gi proteins are critically involved in isoproterenol-induced cardiomyocyte hypertrophy.
Topics: Animals; beta-Adrenergic Receptor Kinases; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegal | 1999 |
Developed pressure data may provide misinformation when used alone to evaluate systolic function in isovolumetric left ventricle preparations.
Topics: Animals; Blood Pressure Determination; Cardiomegaly; Cardiotonic Agents; Isoproterenol; Myocardial C | 1999 |
Functional analysis of desensitization of the beta-adrenoceptor signalling pathway in rat cardiac tissues following chronic isoprenaline infusion.
Topics: Adrenergic beta-Agonists; Animals; Bucladesine; Cardiomegaly; Colforsin; Dose-Response Relationship, | 1999 |
Modulation of the pacemaker current If by beta-adrenoceptor subtypes in ventricular myocytes isolated from hypertensive and normotensive rats.
Topics: Action Potentials; Adenosine; Adrenergic alpha-1 Receptor Agonists; Adrenergic beta-1 Receptor Antag | 1999 |
Expression of immediate early genes, GATA-4, and Nkx-2.5 in adrenergic-induced cardiac hypertrophy and during regression in adult mice.
Topics: Animals; Antihypertensive Agents; Atrial Natriuretic Factor; Cardiomegaly; DNA-Binding Proteins; GAT | 1999 |
Normal regional distribution of membrane current density in rat left ventricle is altered in catecholamine-induced hypertrophy.
Topics: Action Potentials; Analysis of Variance; Animals; Biological Transport, Active; Calcium; Cardiomegal | 1999 |
Overexpression of insulin-like growth factor-I in hearts of rats with isoproterenol-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Angiotensin Receptor Antagonists; Animals; Antihypertensive Agents; Benzim | 1999 |
Increased JNK, AP-1 and NF-kappa B DNA binding activities in isoproterenol-induced cardiac remodeling.
Topics: Animals; Blood Pressure; Cardiomegaly; Cell Nucleus; DNA-Binding Proteins; Echocardiography; Gene Ex | 1999 |
Transgenic mouse model of stunned myocardium.
Topics: Actin Cytoskeleton; Adrenergic beta-Agonists; Animals; Calcium; Cardiomegaly; Dilatation, Pathologic | 2000 |
Na(+)/H(+) exchange inhibition attenuates hypertrophy and heart failure in 1-wk postinfarction rat myocardium.
Topics: Adrenergic beta-Agonists; Animals; Cardiac Output, Low; Cardiomegaly; Guanidines; Hemodynamics; Isop | 2000 |
Altered phosphorylation of sarcoplasmic reticulum contributes to the diminished contractile response to isoproterenol in hypertrophied rat hearts.
Topics: Animals; Blotting, Western; Calcium; Cardiomegaly; Cardiotonic Agents; Electrophoresis, Polyacrylami | 1999 |
Altered molecular response to adrenoreceptor-induced cardiac hypertrophy in Egr-1-deficient mice.
Topics: Actins; Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Atrial Natriuretic Factor; Car | 2000 |
Left ventricular response to beta-adrenergic stimulation in aging rats.
Topics: Adaptation, Physiological; Adrenergic beta-Agonists; Aging; Analysis of Variance; Animals; Atrial Na | 2000 |
Central role for ornithine decarboxylase in beta-adrenoceptor mediated hypertrophy.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Animals, Genetically Modified; Atrial Natri | 2000 |
Cyclic GMP attenuates cyclic AMP-stimulated inotropy and oxygen consumption in control and hypertrophic hearts.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Cyclic AMP; Cyclic GMP; Isoproterenol; Molsidomine; Myoca | 2000 |
Expression profiling reveals distinct sets of genes altered during induction and regression of cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Gene Expression Profiling; Gene Expression Regulation; Isopro | 2000 |
Remodelling of ionic currents in hypertrophied and failing hearts of transgenic mice overexpressing calsequestrin.
Topics: Action Potentials; Animals; Calcium Channels, L-Type; Calcium Signaling; Calsequestrin; Cardiomegaly | 2000 |
Altered inotropic responsiveness and gene expression of hypertrophied myocardium with captopril.
Topics: Adrenergic beta-Agonists; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Calcium | 2000 |
Isoproterenol-induced myocardial injury resulting in altered S100A4 and S100A11 protein expression in the rat.
Topics: Amino Acid Sequence; Animals; Cardiomegaly; Cloning, Molecular; COS Cells; DNA, Complementary; Heart | 2000 |
Changes in ionic currents and beta-adrenergic receptor signaling in hypertrophied myocytes overexpressing G alpha(q).
Topics: 4-Aminopyridine; Action Potentials; Animals; Calcium Channels, L-Type; Cardiomegaly; Cells, Cultured | 2000 |
Hypertrophic effect of selective beta(1)-adrenoceptor stimulation on ventricular cardiomyocytes from adult rat.
Topics: Adrenergic beta-Antagonists; Animals; Cardiomegaly; Cardiotonic Agents; Heart Ventricles; Hypertroph | 2000 |
Overexpression of antizyme in the hearts of transgenic mice prevents the isoprenaline-induced increase in cardiac ornithine decarboxylase activity and polyamines, but does not prevent cardiac hypertrophy.
Topics: Animals; Biogenic Polyamines; Cardiomegaly; Heart; Isoproterenol; Mice; Mice, Transgenic; Myocardium | 2000 |
Protein phosphatase activity is increased in a rat model of long-term beta-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Analysis of Variance; Animals; Calcium-Binding Proteins; Cardiomegaly; Dis | 2000 |
Volume overload cardiac hypertrophy exhibits decreased expression of g(s)alpha and not of g(i)alpha in heart.
Topics: Adenylyl Cyclases; Animals; Aorta, Thoracic; Arteriovenous Shunt, Surgical; Blood Pressure; Blotting | 2000 |
Acute changes of myocardial creatine kinase gene expression under beta-adrenergic stimulation.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Creatine Kinase; Gene Expression Regulation, Enzymo | 2000 |
Rescue of contractile parameters and myocyte hypertrophy in calsequestrin overexpressing myocardium by phospholamban ablation.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Atrial Natriuretic Factor; Calcium-Binding Proteins; Calseques | 2001 |
Progression from hypertrophic to dilated cardiomyopathy in mice that express a mutant myosin transgene.
Topics: Adrenergic beta-Agonists; Animals; beta-Adrenergic Receptor Kinases; Cardiomegaly; Cardiomyopathy, D | 2001 |
Differential alteration of cardiotonic effects of EMD 57033 and beta-adrenoceptor agonists in volume-overload rabbit ventricular myocytes.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cardiotonic Agents; Disease Models, Animal; Dobutam | 2000 |
Enhanced Ca2+ channel currents in cardiac hypertrophy induced by activation of calcineurin-dependent pathway.
Topics: Animals; Blotting, Western; Calcineurin; Calcineurin Inhibitors; Calcium; Calcium Channels; Cardiome | 2001 |
Hypertrophy-associated gene induction after beta-adrenergic stimulation in adult cardiomyocytes.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cells, Cultured; Gene Expression Profiling; Heart V | 2001 |
Beta-adrenergic cardiac hypertrophy is mediated primarily by the beta(1)-subtype in the rat heart.
Topics: Adrenergic beta-1 Receptor Antagonists; Adrenergic beta-2 Receptor Antagonists; Adrenergic beta-Agon | 2001 |
Antiadrenergic effects of adenosine in pressure overload hypertrophy.
Topics: Adenosine; Adrenergic Antagonists; Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; C | 2001 |
Targeted inhibition of calcineurin attenuates cardiac hypertrophy in vivo.
Topics: A Kinase Anchor Proteins; Adaptor Proteins, Signal Transducing; Adenoviridae; Animals; Blood Pressur | 2001 |
Effects of long-term pretreatment with isoproterenol on inotropic responsiveness to alpha-adrenoceptor stimulation: study in isolated perfused rat hearts.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animals; Body Weig | 2001 |
Autoimmunity against the second extracellular loop of beta(1)-adrenergic receptors induces beta-adrenergic receptor desensitization and myocardial hypertrophy in vivo.
Topics: Adrenergic beta-Agonists; Amino Acid Sequence; Animals; beta-Adrenergic Receptor Kinases; Binding, C | 2001 |
Impaired sarcoplasmic reticulum function leads to contractile dysfunction and cardiac hypertrophy.
Topics: Animals; Atrial Natriuretic Factor; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Cardiotonic | 2001 |
Nitric oxide does not modulate the hyperpolarization-activated current, I(f), in ventricular myocytes from spontaneously hypertensive rats.
Topics: Adenylyl Cyclases; Adrenergic beta-Agonists; Amphotericin B; Analysis of Variance; Animals; Arrhythm | 2001 |
Isoproterenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
Topics: Adaptor Proteins, Signal Transducing; Adaptor Proteins, Vesicular Transport; Adrenergic beta-Agonist | 2001 |
Targeted overexpression of ornithine decarboxylase enhances beta-adrenergic agonist-induced cardiac hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Atenolol; Blotting, Southern; Cadaverine; Cardiomegaly; Hypertrop | 2001 |
[Functional characterization of myocardial hypertrophy induced by isoproterenol and its regression].
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Isoproterenol; Male; Rats; Rats, Wistar | 2001 |
Enhanced protein phosphorylation in hypertensive hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Calcium-Binding Proteins; Calmodulin; Cardiomegaly; Hypertension; | 2001 |
Spironolactone and captopril attenuates isoproterenol-induced cardiac remodelling in rats.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Captopril; Cardiomegaly; Collagen | 2001 |
Replacement of the muscle-specific sarcoplasmic reticulum Ca(2+)-ATPase isoform SERCA2a by the nonmuscle SERCA2b homologue causes mild concentric hypertrophy and impairs contraction-relaxation of the heart.
Topics: Alternative Splicing; Animals; Calcium; Calcium-Binding Proteins; Calcium-Transporting ATPases; Card | 2001 |
Isoproterenol-induced cardiac hypertrophy: role of circulatory versus cardiac renin-angiotensin system.
Topics: Adrenergic beta-Agonists; Angiotensin I; Angiotensin II; Animals; Antihypertensive Agents; Blood Pre | 2001 |
Activated glycogen synthase-3 beta suppresses cardiac hypertrophy in vivo.
Topics: Animals; Calcineurin; Calcium-Calmodulin-Dependent Protein Kinases; Cardiomegaly; DNA-Binding Protei | 2002 |
Role of myocardial inducible nitric oxide synthase in contractile dysfunction and beta-adrenergic hyporesponsiveness in rats with experimental volume-overload heart failure.
Topics: Adrenergic beta-Agonists; Amidines; Animals; Arteriovenous Fistula; Benzylamines; Calcium; Cardiac V | 2002 |
Isoprotrenol activates extracellular signal-regulated protein kinases in cardiomyocytes through calcineurin.
Topics: Adrenergic beta-Agonists; Age Factors; Animals; Animals, Newborn; Calcineurin; Cardiomegaly; Enzyme | 2002 |
Attenuated "cross talk" between kappa-opioid receptors and beta-adrenoceptors in the heart of chronically hypoxic rats.
Topics: Adenosine Diphosphate Ribose; Adenylyl Cyclases; Adrenergic beta-Agonists; Animals; Calcium Signalin | 2002 |
Cardiac function and electrical remodeling of the calcineurin-overexpressed transgenic mouse.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Calcineurin; Cardiomegaly; Isoproterenol; Mice | 2002 |
Alterations in norepinephrine pattern in the damaged myocardium in the rat.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Isoproterenol; Male; Monoamine Oxidase; Myocardium; Necrosi | 1975 |
Cardiomegaly produced by chronic beta-adrenergic stimulation in the rat: comparison with alpha-adrenergic effects.
Topics: Actomyosin; Adenosine Triphosphatases; Adrenergic beta-Agonists; Adrenergic beta-Antagonists; Animal | 1977 |
Echocardiographic determination of left ventricular stress-velocity relations.
Topics: Adolescent; Adult; Aged; Angiocardiography; Aortic Valve Insufficiency; Aortic Valve Stenosis; Cardi | 1975 |
[Catecholamine in the myocardium; a fluorescence histochemical study].
Topics: Animals; Atrioventricular Node; Cardiomegaly; Catecholamines; Dogs; Heart Atria; Heart Block; Heart | 1975 |
Experimental myocardial infarction with left ventricular failure in the isolated perfused rat heart. Effects of isoproterenol and pacing.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiomegaly; Disease Models, Animal; Heart; Heart Failure; | 1975 |
Changes in taurine concentration in heart and skeletal muscle during atrophy and hypertrophy.
Topics: Amino Acids; Animals; Atrophy; Cardiomegaly; Hypertension; Hypertrophy; Isoproterenol; Male; Muscle | 1975 |
Quantitation of isoprenaline-induced changes in the ventricular myocardium.
Topics: Animals; Body Weight; Cardiomegaly; Collagen; Dose-Response Relationship, Drug; Heart; Heart Ventric | 1975 |
Induction of necrosis and failure in the isolated perfused rat heart with oxidized isoproterenol.
Topics: Animals; Cardiomegaly; Drug Stability; Heart; Heart Diseases; Isoproterenol; Male; Microscopy, Elect | 1975 |
Role of adrenergic mechanisms in the development of cardiac hypertrophy.
Topics: Animals; Aorta, Abdominal; Blood Pressure; Cardiomegaly; Female; Heart; Heart Rate; Isoproterenol; M | 1975 |
Studies on protein metabolism during isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Isoproterenol; Kinetics; Muscle Proteins; Myocardium; Rats | 1975 |
A diurnal rhythm of incorporation of L-[3H] leucine in myocardium of the rat.
Topics: Animals; Body Weight; Cardiomegaly; Circadian Rhythm; Heart; Heart Ventricles; In Vitro Techniques; | 1975 |
Attenuation of beta-adrenergic cardiac responses in chronically hypoxic rats with right ventricular hypertrophy.
Topics: Animals; Cardiomegaly; Erythrocyte Count; Heart; Heart Ventricles; Hematocrit; Hemoglobins; Hypoxia; | 1975 |
Restriction of beta-adrenergic responsiveness in hypertrophied hearts of chronically isoproterenol-treated rats.
Topics: Adenosine Triphosphate; Animals; Biological Transport, Active; Calcium; Cardiomegaly; Heart; Isoprot | 1975 |
Regulation of taurine in the hypertrophying heart.
Topics: Animals; Cardiomegaly; Cystine; Isoproterenol; Male; Rats; Taurine; Time Factors | 1976 |
Taurine and isoproterenol toxicity.
Topics: Animals; Cardiomegaly; Glycine; Isoproterenol; Male; Myocardium; Organ Size; Rats; Serine; Taurine; | 1976 |
Dynamic changes in left ventricular wall thickness and their use in analyzing cardiac function in the conscious dog.
Topics: Animals; Aortic Valve Stenosis; Biomechanical Phenomena; Cardiomegaly; Coronary Disease; Dogs; Heart | 1976 |
Role of hypertension in ischemic heart disease and cerebral vascular disease in the cynomolgus monkey with coarctation of the aorta.
Topics: Animals; Aortic Coarctation; Blood Pressure; Cardiomegaly; Cardiovascular Diseases; Cerebral Arterie | 1977 |
Quantitative histological changes in isoproterenol induced cardiac growth.
Topics: Animals; Body Weight; Cardiomegaly; Female; Heart; Hyperplasia; Isoproterenol; Myocardium; Organ Siz | 1977 |
Experimental cardiac hypertrophy induced by isoproterenol in the rat.
Topics: Animals; Cardiomegaly; DNA; Heart; Isoproterenol; Male; Muscle Proteins; Myocardium; Organ Size; Rat | 1975 |
Protein fractions and antigens of the heart muscle in isoproterenol induced cardiac hypertrophy.
Topics: Animals; Antigens; Cardiomegaly; Disease Models, Animal; Heart Ventricles; Isoproterenol; Muscle Pro | 1976 |
[Left ventricular ejection and ejection reserve during isoproterenol infusion in hypertrophic obstructive cardiomyopathy (author's transl)].
Topics: Adult; Cardiac Catheterization; Cardiomegaly; Cardiomyopathies; Female; Heart Ventricles; Hemodynami | 1977 |
Prevention of isoproterenol-induced cardiac hypertrophy by beta-blocking agents in the rat.
Topics: Animals; Cardiomegaly; DNA; Isoproterenol; Muscle Proteins; Myocardium; Oxprenolol; Propranolol; Rat | 1976 |
[Determinants of left ventricular hypertrophy, function and contractile reserve in aortic valve disease (author's transl)].
Topics: Adolescent; Adult; Aortic Valve Insufficiency; Aortic Valve Stenosis; Cardiac Output; Cardiomegaly; | 1978 |
The effects of isoproterenol on taurine concentration in the rat heart.
Topics: Amino Acids; Animals; Biological Transport; Cardiomegaly; Heart; Isoproterenol; Male; Myocardium; Ra | 1978 |
[Effects of isoproterenol and 1-norepinephrine on the left ventricular hypertrophied heart (author's transl)].
Topics: Animals; Cardiomegaly; Coronary Circulation; Death, Sudden; Dogs; Heart; Isoproterenol; Myocardium; | 1978 |
Coronary blood flow in experimental canine left ventricular hypertrophy.
Topics: Adenosine; Animals; Blood Flow Velocity; Cardiomegaly; Coronary Circulation; Dogs; Heart Rate; Isopr | 1978 |
Recovery from myocardial failure after aortic valve replacement.
Topics: Adult; Angiocardiography; Aortic Valve Insufficiency; Aortic Valve Stenosis; Cardiac Catheterization | 1978 |
Myofibrillar alkaline protease activity in rat heart and its responses to some interventions that alter cardiac size.
Topics: Animals; Autolysis; Cardiomegaly; Cathepsins; Diabetes Mellitus, Experimental; Growth; Isoproterenol | 1978 |
The relationship between fibrosis and lactate dehydrogenase isoenzymes in the experimental hypertrophic heart of rabbits.
Topics: Animals; Aortic Coarctation; Cardiomegaly; Collagen; Hydroxyproline; Isoenzymes; Isoproterenol; L-La | 1978 |
Metabolic and cardiovascular responses to prolonged noradrenaline load and their antagonism by beta blockade in the rat.
Topics: Adipose Tissue, Brown; Adrenal Glands; Alprenolol; Animals; Blood Pressure; Body Temperature; Body W | 1978 |
Alterations in the cardiovascular system that occur in advanced age.
Topics: Adult; Aged; Aging; Blood Pressure; Cardiomegaly; Cardiovascular Physiological Phenomena; Chemorecep | 1979 |
Characterization of the decreased ATPase activity of rat cardiac actomyosin in isoproterenol-induced cardiac hypertrophy.
Topics: Actomyosin; Adenosine Triphosphatases; Animals; Calcium; Cardiomegaly; Depression, Chemical; Isoprot | 1979 |
[Severe diphtheria with acute myocardial infarction (author's transl)].
Topics: Cardiomegaly; Child; Diphtheria; Diphtheria Antitoxin; Female; Humans; Hydrocortisone; Isoproterenol | 1979 |
Metabolism of lipids in experimental hypertrophic hearts of rabbits.
Topics: Animals; Cardiomegaly; Carnitine; Cholesterol; Fatty Acids; Fatty Acids, Nonesterified; Isoprotereno | 1979 |
[Myocardial hypertrophy in the course of experimental infarct in the rat].
Topics: Animals; Cardiomegaly; Isoproterenol; Myocardial Infarction; Myocardium; Radioisotopes; Rats; Thalli | 1979 |
ATPase activity of sulfhydryl-modified cardiac myosin from normal and isoproterenol-treated rats.
Topics: Adenosine Triphosphatases; Animals; Calcium-Transporting ATPases; Cardiomegaly; Ethylmaleimide; Hydr | 1979 |
Increase in type I adenosine 3',5'-monophosphate-dependent protein kinase during isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Body Weight; Cardiomegaly; Cyclic AMP; Enzyme Activation; Isoproterenol; Male; Myocardium; | 1976 |
Adrenergic stimulation of taurine transport by the heart.
Topics: Alanine; Animals; Biological Transport; Cardiomegaly; Cyclic AMP; Heart; Isoproterenol; Kinetics; My | 1977 |
Alterations in activities of cyclic nucleotide systems and in beta-adrenergic receptor-mediated activation of cyclic AMP-dependent protein kinase during progression and regression of isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Cyclic AMP; Cyclic GMP; Enzyme Activation; Isoproterenol; Male; Nucleotides, | 1978 |
Studies on adenosine triphosphatase activity of rat cardiac myosin in isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Isoproterenol; Male; Molecular Conform | 1977 |
Isoproterenol-induced cardiac hypertrophy: modifications in characteristics of beta-adrenergic receptor, adenylate cyclase, and ventricular contraction.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Cyclic AMP; Isoproterenol; Male; Myocardial Contraction; M | 1979 |
Increased number of beta-adrenergic receptors in the hypertrophied myocardium.
Topics: Alprenolol; Animals; Binding, Competitive; Cardiomegaly; Dihydroalprenolol; Isoproterenol; Male; Rat | 1979 |
[Cardiovascular complications during treatment by verapamil. A propos of 6 cases].
Topics: Adrenergic beta-Antagonists; Adult; Aged; Arrhythmias, Cardiac; Cardiomegaly; Female; Glucagon; Hear | 1975 |
Myocardial beta-adrenergic receptor expression and signal transduction after chronic volume-overload hypertrophy and circulatory congestion.
Topics: Adenylyl Cyclases; Animals; Blood Volume; Cardiomegaly; Catecholamines; Coronary Circulation; Female | 1992 |
C-myc protooncogene modulates cardiac hypertrophic growth in transgenic mice.
Topics: Actins; Adenylyl Cyclases; Animals; Cardiomegaly; Fibrosis; Heart; Isomerism; Isoproterenol; Mice; M | 1992 |
Sodium-pump injury and arrhythmogenic transient depolarizations in catecholamine-induced cardiac hypertrophy.
Topics: Action Potentials; Animals; Body Weight; Cardiomegaly; Colforsin; Electric Stimulation; Heart; Isopr | 1992 |
Catecholamine-induced cardiac hypertrophy uncouples beta-adrenoceptors from slow calcium channels.
Topics: Action Potentials; Adenylyl Cyclases; Animals; Calcium Channels; Cardiomegaly; Colforsin; Electric S | 1992 |
Alteration of beta-adrenoceptor function in hypertensive patients with different degrees of left ventricular hypertrophy.
Topics: Adult; Blood Pressure; Cardiomegaly; Colforsin; Humans; Hypertension; Isoproterenol; Lymphocytes; Ma | 1992 |
Role of altered G-protein expression in the regulation of myocardial adenylate cyclase activity and force of contraction in spontaneous hypertensive cardiomyopathy in rats.
Topics: Adenylate Cyclase Toxin; Adenylyl Cyclases; Animals; Carbachol; Cardiomegaly; Cell Membrane; GTP-Bin | 1992 |
Cardiovascular effects on conscious rats of pretreatment with isoproterenol for 3 days.
Topics: Analysis of Variance; Animals; Blood Pressure; Cardiomegaly; Consciousness; Heart Rate; Isoprotereno | 1992 |
Functional changes in the right and left ventricle during development of cardiac hypertrophy and after its regression.
Topics: Animals; Cardiomegaly; Collagen; Disease Models, Animal; Heart Ventricles; Isoproterenol; Male; Rats | 1992 |
Effect of captopril on isoproterenol-induced cardiac hypertrophy and polyamine contents.
Topics: Animals; Blood Pressure; Body Weight; Captopril; Cardiomegaly; DNA; Heart; Heart Rate; Isoproterenol | 1992 |
[The capacity for reactive DNA synthesis of the myocytes in the heart conduction system in experimental and clinical myocardial pathology].
Topics: Adult; Aged; Animals; Autoradiography; Cardiomegaly; Cell Nucleus; Cytophotometry; DNA; Female; Hear | 1992 |
Effect of enalapril on the inotropic response to isoproterenol in renal hypertensive rats.
Topics: Animals; Body Weight; Cardiomegaly; Enalapril; Hypertension, Renovascular; Isoproterenol; Male; Musc | 1992 |
[Cardiac performance in elderly hypertensives with left ventricular hypertrophy].
Topics: Aged; Aged, 80 and over; Cardiomegaly; Echocardiography; Exercise Test; Female; Heart; Humans; Hyper | 1992 |
Role of cardiac angiotensin II in isoproterenol-induced left ventricular hypertrophy.
Topics: Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Body Weight; Card | 1992 |
Cyclic AMP in myocytes isolated from hypertrophied rat hearts.
Topics: Animals; Calcium; Cardiomegaly; Cyclic AMP; Heart; In Vitro Techniques; Isoproterenol; Male; Microsc | 1991 |
Effects of aging and drugs on myocardial beta-adrenergic receptors in M-SHRSP and SHRSP.
Topics: 5'-Nucleotidase; Aging; Animals; Cardiomegaly; Cerebrovascular Disorders; Disease Susceptibility; Do | 1991 |
Reversal of angiotensin II effect on the cyclic adenosine 3',5' monophosphate response to isoprenaline in cardiac hypertrophy.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Cyclic AMP; Heart; Isoproterenol; Male; Myoc | 1991 |
Changes in the enzyme activity of the myocardium and participation of the alpha-adrenergic and M-cholinergic systems in experimental isoprenaline myocardial hypertrophy.
Topics: Animals; Atropine; Blood Pressure; Cardiomegaly; Enzyme Activation; Indicators and Reagents; Isoprot | 1991 |
Altered responsiveness of hypertrophied rat hearts to alpha- and beta-adrenergic stimulation.
Topics: Adrenergic alpha-Agonists; Adrenergic beta-Agonists; Animals; Blood Pressure; Calcium; Cardiomegaly; | 1991 |
Beta-adrenoceptors and adenylate cyclase activity in hypertrophied and failing rabbit left ventricle.
Topics: Adenylyl Cyclases; Adrenergic beta-Antagonists; Animals; Binding, Competitive; Cardiomegaly; Colfors | 1991 |
Cardiac performance in elderly hypertensive patients with left ventricular hypertrophy: responses to isometric exercise and beta-agonists.
Topics: Aged; Blood Pressure; Cardiomegaly; Echocardiography; Exercise; Heart Rate; Humans; Hypertension; Is | 1991 |
Improvement of cardiac contractile response to beta-adrenergic stimulation in normal and two-kidney, one-clip hypertensive rats treated with nitrendipine.
Topics: Animals; Blood Pressure; Body Weight; Cardiomegaly; Heart; Hypertension, Renal; Isoproterenol; Male; | 1991 |
Hypertrophy of isolated adult feline heart cells following beta-adrenergic-induced beating.
Topics: 1-Methyl-3-isobutylxanthine; Animals; Calcium; Cardiomegaly; Cats; Cells, Cultured; Colforsin; Cultu | 1991 |
Triggered activity as a possible mechanism for arrhythmias in ventricular hypertrophy.
Topics: Action Potentials; Animals; Arrhythmias, Cardiac; Cardiac Pacing, Artificial; Cardiomegaly; Ferrets; | 1991 |
Altered Ca2+ dynamics in single cardiac myocytes from renovascular hypertensive rats.
Topics: Analysis of Variance; Animals; Calcium; Calcium Channel Blockers; Cardiomegaly; Cells, Cultured; Fur | 1991 |
Increased negative inotropic effect of calcium-channel blockers in hypertrophied and failing rabbit heart.
Topics: Animals; Calcium Channel Blockers; Cardiac Pacing, Artificial; Cardiomegaly; Coronary Circulation; D | 1991 |
Relationship between adenylate cyclase activity and regional myocardial energetics in experimental left ventricular hypertrophy.
Topics: Adenylyl Cyclases; Animals; Cardiomegaly; Colforsin; Coronary Circulation; Dogs; Energy Metabolism; | 1991 |
[Dynamic biochemical, metrometric and histomorphological studies in isoproterenol-induced myocardial hypertrophy and its regression in rats].
Topics: Animals; Body Weight; Cardiomegaly; Connective Tissue; Disease Models, Animal; Heart; Isoproterenol; | 1991 |
Altered function and structure of the heart in dogs with chronic elevation in plasma norepinephrine.
Topics: Animals; Cardiomegaly; Dogs; Hemodynamics; Isoproterenol; Microscopy, Electron; Myocardial Contracti | 1991 |
Isoprenaline-induced increase in mRNA levels of inhibitory G-protein alpha-subunits in rat heart.
Topics: Animals; Autoradiography; Blotting, Northern; Cardiomegaly; GTP-Binding Proteins; Heart Diseases; He | 1991 |
Oxygen metabolism of the hypertrophic right ventricle in open chest dogs.
Topics: Animals; Cardiomegaly; Coronary Vessels; Disease Models, Animal; Dogs; Female; Isoproterenol; Male; | 1991 |
Processes linked to the formation of reactive oxygen species are not necessarily involved in the development of isoproterenol-induced hypertrophy of the heart. The effect of stobadine.
Topics: Animals; Anti-Arrhythmia Agents; Body Weight; Carbolines; Cardiomegaly; Catalase; Free Radical Scave | 1991 |
Calcium current in single cells isolated from normal and hypertrophied rat heart. Effects of beta-adrenergic stimulation.
Topics: Action Potentials; Adrenergic beta-Agonists; Animals; Calcium; Cardiomegaly; Differential Threshold; | 1990 |
Reduced subendocardial coronary reserve. A potential mechanism for impaired diastolic function in the hypertrophied and failing heart.
Topics: Animals; Cardiomegaly; Coronary Circulation; Dogs; Heart Failure; Isoproterenol; Myocardial Contract | 1990 |
Functional and morphological characteristics of compensated and decompensated cardiac hypertrophy in dogs with chronic infrarenal aorto-caval fistulas.
Topics: Adaptation, Physiological; Animals; Aorta; Arteriovenous Shunt, Surgical; Biomechanical Phenomena; C | 1990 |
Effects of isoproterenol on the developing heart in rats.
Topics: Animals; Animals, Newborn; Cardiomegaly; Catecholamines; Female; Fetal Heart; Heart; Heart Septum; H | 1990 |
Isoproterenol and myocardial O2 supply/consumption in hypertension-induced myocardial hypertrophy.
Topics: Animals; Biological Availability; Cardiac Output; Cardiomegaly; Coronary Circulation; Endocardium; H | 1990 |
Left ventricular reserve of the hypertrophied heart in patients with systemic hypertension and hypertrophic cardiomyopathy--relation to age and left ventricular relative wall thickness.
Topics: Adolescent; Adult; Age Factors; Cardiomegaly; Cardiomyopathy, Hypertrophic; Echocardiography; Female | 1990 |
Changes in performance of the surviving myocardium after left ventricular infarction in rats.
Topics: Animals; Blood Pressure; Calcium; Cardiomegaly; Disease Models, Animal; Female; Heart; Isoproterenol | 1990 |
Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis.
Topics: Animals; Cardiomegaly; Collagen; Disease Models, Animal; Fibrosis; Heart; Ischemia; Isoproterenol; K | 1990 |
Isolated myocardial cells: a new tool for the investigation of hypertensive heart disease.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Heart Rate; Hypertension; Isoproterenol; Myo | 1990 |
Intracellular calcium related to force development in twitch contraction of mammalian myocardium.
Topics: Actin Cytoskeleton; Aequorin; Animals; Caffeine; Calcium; Cardiomegaly; Ferrets; Hyperthyroidism; Is | 1990 |
The effect of regular physical exercise on sensitivity to ischaemia in the rat's heart.
Topics: Adenine Nucleotides; Adenosine Triphosphate; Animals; Cardiomegaly; Coronary Disease; Glycogen; Hear | 1990 |
Alterations in dietary sodium affect isoproterenol-induced cardiac hypertrophy.
Topics: Aldosterone; Animals; Body Water; Cardiomegaly; Diet, Sodium-Restricted; Isoproterenol; Male; Organ | 1990 |
[Effect of alpha methyldopa on heart in renovascular hypertension].
Topics: Animals; Blood Pressure; Cardiomegaly; Heart Rate; Hypertension, Renovascular; Isoproterenol; Male; | 1990 |
Effects of prolonged infusions of atrial natriuretic peptide and isoproterenol on the mechanical and endocrine function of isolated atria.
Topics: Animals; Atrial Function; Atrial Natriuretic Factor; Cardiomegaly; Exocytosis; Heart Atria; Heart Fa | 1990 |
Diastolic properties of hypertrophied hearts in essential hypertension: classification by left ventricular wall stress.
Topics: Adult; Cardiomegaly; Diastole; Echocardiography; Female; Hemodynamics; Humans; Hypertension; Isoprot | 1990 |
Ultrastructural and electrophysiological alterations during the development of catecholamine-induced cardiac hypertrophy and failure.
Topics: Action Potentials; Animals; Body Weight; Cardiomegaly; Disease Models, Animal; Heart Failure; Isopro | 1990 |
Cooperative action of insulin and catecholamines on stimulation of ornithine decarboxylase activity in neonatal rat heart cells.
Topics: Animals; Blood Proteins; Calcimycin; Cardiomegaly; Catecholamines; Cells, Cultured; Cyclic AMP; Drug | 1990 |
Mechanical and non-mechanical factors in hypertensive hypertrophy, their clinical roles.
Topics: Biomechanical Phenomena; Blood Pressure; Cardiomegaly; Humans; Hypertension; Isoproterenol; Myocardi | 1990 |
Verapamil does not prevent isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Calcium Channels; Cardiomegaly; Isoproterenol; Male; Myocardium; Rats; Verapamil | 1990 |
Hypertrophy and dysfunction of parotid gland induced by chronic stimulation of beta 1-adrenergic receptors.
Topics: Adrenergic beta-Agonists; Amylases; Animals; Cardiomegaly; Cyclic AMP; Dobutamine; Hypertrophy; Isop | 1985 |
Study of the factors influencing cardiac growth. II. Digitoxin treatment and isoproterenol-induced cardiac hypertrophy in the rat.
Topics: Animals; Body Weight; Cardiomegaly; Digitoxin; Heart Ventricles; Isoproterenol; Male; Myocardium; Or | 1985 |
Beta-adrenergic system is modified in compensatory pressure cardiac overload in rats: physiological and biochemical evidence.
Topics: Animals; Binding Sites; Cardiac Pacing, Artificial; Cardiomegaly; Colforsin; Coronary Circulation; I | 1989 |
Effect of catecholamine-induced cardiac hypertrophy on the force-interval relationship.
Topics: Animals; Cardiomegaly; Female; Heart Atria; Heart Ventricles; Isoproterenol; Myocardial Contraction; | 1989 |
Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle.
Topics: Animals; Azo Compounds; Birefringence; Cardiomegaly; Collagen; Isoproterenol; Male; Microscopy, Pola | 1989 |
Fibrosis-induced reduction of endomyocardium in the rat after isoproterenol treatment.
Topics: Animals; Cardiomegaly; Collagen; Elasticity; Endomyocardial Fibrosis; Heart; Isoproterenol; Male; Mi | 1989 |
Isoproterenol-induced myocardial fibrosis in relation to myocyte necrosis.
Topics: Animals; Antibodies, Monoclonal; Autoradiography; Cardiomegaly; DNA; DNA Replication; Fibrosis; Hear | 1989 |
Isoproterenol-induced alterations in myocardial blood flow, systolic and diastolic function in conscious dogs with heart failure.
Topics: Animals; Cardiomegaly; Coronary Circulation; Diastole; Disease Models, Animal; Dogs; Female; Heart F | 1989 |
Study of cardiac hypertrophy--humoral factors that stimulate protein metabolism of cultured rat heart cells.
Topics: Angiotensin II; Animals; Biological Factors; Cardiomegaly; Cells, Cultured; Chromatography, High Pre | 1989 |
Development of the linkage of beta-adrenergic receptors to cardiac hypertrophy and heart rate control: neonatal sympathectomy with 6-hydroxydopamine.
Topics: Animals; Animals, Newborn; Body Weight; Cardiomegaly; Heart Rate; Hydroxydopamines; Isoproterenol; O | 1989 |
Study of the pathogenesis of cardiac hypertrophy--biochemical differences of cultured heart cells from normotensive and spontaneously hypertensive rats.
Topics: Angiotensin II; Animals; Cardiomegaly; Cells, Cultured; Hypertension; Isoproterenol; Leucine; Myocar | 1989 |
Coronary flow reserve and oxygen metabolism of the right ventricle.
Topics: Animals; Cardiomegaly; Coronary Circulation; Coronary Disease; Dogs; Female; Heart Ventricles; Isopr | 1989 |
Altered electrical response to caffeine exposure in hypertrophied rat myocardium.
Topics: Action Potentials; Animals; Caffeine; Cardiomegaly; Coronary Vessels; Electrophysiology; Female; Iso | 1989 |
Contractile abnormalities of single right ventricular myocytes isolated from rats with right ventricular hypertrophy.
Topics: Animals; Cardiomegaly; In Vitro Techniques; Isoproterenol; Myocardial Contraction; Myosins; Rats; Ra | 1989 |
Isoproterenol sensitivity of isolated cardiac myocytes from rats with monocrotaline-induced right-sided hypertrophy and heart failure.
Topics: Animals; Calcium-Transporting ATPases; Cardiomegaly; Catecholamines; Cells, Cultured; Disease Models | 1989 |
Induction of the skeletal alpha-actin gene in alpha 1-adrenoceptor-mediated hypertrophy of rat cardiac myocytes.
Topics: Actins; Animals; Cardiomegaly; Cells, Cultured; Dose-Response Relationship, Drug; Isoproterenol; Myo | 1987 |
Properties of cardiac alpha- and beta-adrenoceptors in spontaneously hypertensive rats.
Topics: Aging; Animals; Cardiomegaly; Electric Stimulation; Hypertension; In Vitro Techniques; Isoproterenol | 1988 |
Further studies on the cardiomegaly induced by beta-adrenoceptor agonists.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Cardiomegaly; Ethanolamines; Guinea Pigs; Isoprotere | 1986 |
Phosphorylation of ribosomal and ribosome-associated proteins in isoproterenol-induced cardiac hypertrophy.
Topics: Animals; Cardiomegaly; Isoproterenol; Kinetics; Leucine; Male; Phosphates; Phosphorus Radioisotopes; | 1985 |
[Responses of hypertensive-hypertrophied ventricle to beta-adrenergic stimulation in man].
Topics: Adult; Cardiomegaly; Cardiomyopathy, Hypertrophic; Humans; Hypertension; Isoproterenol; Middle Aged; | 1985 |
Regional differences of myocyte hypertrophy and three-dimensional deformation of the heart.
Topics: Animals; Aorta; Blood Pressure; Body Weight; Cardiomegaly; Heart; Heart Rate; Isoproterenol; Ligatio | 1986 |
[Left ventricular function in essential hypertension during isoproterenol infusion].
Topics: Adult; Aged; Blood Pressure; Cardiomegaly; Echocardiography; Heart; Heart Rate; Humans; Hypertension | 1985 |
Left ventricular outflow tract obstruction following mitral valve replacement: effect of strut height and orientation.
Topics: Animals; Bioprosthesis; Cardiac Output; Cardiomegaly; Equipment Design; Heart Rate; Heart Valve Pros | 1986 |
The protective effect of vitamin E in stress-induced myocardial lesion in rats.
Topics: Animals; Cardiomegaly; Electrocardiography; Heart Rate; Isoproterenol; L-Lactate Dehydrogenase; Orga | 1985 |
The effect of vitamin E and inderal on cardiac lesions induced by adrenergic-mediated stresses.
Topics: Animals; Cardiomegaly; Electrocardiography; Heart Rate; Immersion; Isoproterenol; L-Lactate Dehydrog | 1985 |
Intracellular turnover and cardiac hypertrophy.
Topics: Animals; Autophagy; Cardiomegaly; Heart; Isoproterenol; Male; Microscopy, Electron; Phagocytosis; Pr | 1986 |
Cardiac function of patients with essential hypertension during exercise and isoproterenol infusion.
Topics: Adult; Aged; Cardiomegaly; Echocardiography; Electrocardiography; Exercise Test; Female; Hemodynamic | 1987 |
The effects of acute and chronic inotropic interventions on tension independent heat of rabbit papillary muscle.
Topics: Animals; Cardiomegaly; Cardiotonic Agents; Heart; In Vitro Techniques; Isoproterenol; Myocardial Con | 1987 |
Quantification of myocardial necrosis and cardiac hypertrophy in isoproterenol-treated rats.
Topics: Animals; Aspartate Aminotransferases; Cardiomegaly; Cardiomyopathies; Creatine Kinase; DNA; Isoprote | 1987 |
Catecholamine induced cardiac hypertrophy.
Topics: Animals; Body Weight; Cardiomegaly; Chromatin; DNA Damage; DNA-Directed RNA Polymerases; Female; Hem | 1987 |
Classification of hypertrophied hearts in essential hypertension: evaluation by left ventricular wall stress and adrenergic responses.
Topics: Adult; Aged; Cardiomegaly; Echocardiography; Female; Hemodynamics; Humans; Hypertension; Isoproteren | 1988 |
Subacute effects of propranolol and B 24/76 on isoproterenol-induced rat heart hypertrophy in correlation with blood pressure.
Topics: Animals; Blood Pressure; Cardiomegaly; Isoenzymes; Isoproterenol; Myosins; Ornithine Decarboxylase; | 1988 |
Assessment of hemodynamic function and tolerance to ischemia in the absence or presence of calcium antagonists in hearts of isoproterenol-treated, exercise-trained, and sedentary rats.
Topics: Animals; Cardiomegaly; Cardioplegic Solutions; Creatine Kinase; Diltiazem; Fibrosis; Heart Arrest, I | 1988 |
Impaired inotropic responses to alpha-adrenergic stimulation in experimental left ventricular hypertrophy.
Topics: Animals; Cardiomegaly; Disease Models, Animal; Heart Ventricles; Hypertension, Renal; Isoproterenol; | 1985 |
Renal hypertension impairs inotropic isoproterenol effect without beta-receptor changes.
Topics: Animals; Calcium Chloride; Cardiomegaly; Hypertension, Renovascular; Isoproterenol; Male; Myocardial | 1985 |
Increased sensitivity to alpha-adrenoceptor stimulation but intact purinergic and muscarinergic effects in prehypertensive cardiac hypertrophy of spontaneously hypertensive rats.
Topics: Adenosine; Animals; Carbachol; Cardiomegaly; Hypertension; In Vitro Techniques; Isoproterenol; Male; | 1986 |
Beta-adrenergic responsiveness and cardiac autonomic receptors after implantation of the MtTW15 pituitary adenoma in the rat.
Topics: Adenoma; Animals; Cardiomegaly; Drinking; Guanylyl Imidodiphosphate; Heart Rate; Hypothyroidism; Iso | 1987 |
Coronary hyperemia and cardiac hypertrophy following inhibition of fatty acid oxidation. Evidence of a regulatory role for cytosolic phosphorylation potential.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiomegaly; Coronary Circulation; Creatine | 1985 |
Catecholamine-induced necrosis and hypertrophy. Hemodynamic factors.
Topics: Animals; Blood Pressure; Cardiomegaly; Catecholamines; Dobutamine; Dopamine; Heart Rate; Heart Ventr | 1985 |
[Absence, in the hypertrophied rat heart caused by aortocaval fistula, of several metabolic and electrophysiological changes seen in other models of hypertrophy].
Topics: Action Potentials; Adenosine Triphosphate; Animals; Aorta, Abdominal; Aortic Valve Stenosis; Cardiom | 1985 |
Cardiotoxicity of high doses of isoproterenol on cardiac haemodynamics and metabolism in SHR and WKY rats.
Topics: Animals; Cardiomegaly; Dose-Response Relationship, Drug; Energy Metabolism; Heart Diseases; Hemodyna | 1985 |
[Changes in the activity of Ca2+ stimulated membrane ATPase and calcium binding in the myocardium in cardiac hypertrophy in rats induced by catecholamines].
Topics: Animals; Calcium; Calcium-Transporting ATPases; Cardiomegaly; Cell Membrane; Isoproterenol; Male; My | 1985 |
Catecholamine-induced cardiac hypertrophy in a denervated, hemodynamically non-stressed heart transplant.
Topics: Animals; Body Weight; Cardiomegaly; Catecholamines; Cattle; Dose-Response Relationship, Drug; Heart; | 1985 |
Angina pectoris induced by dumping syndrome in idiopathic hypertrophic subaortic stenosis.
Topics: Adrenergic beta-Antagonists; Amyl Nitrite; Angina Pectoris; Aortography; Bundle-Branch Block; Cardia | 1973 |
Cardiovascular effects of a newer antiarrhythmic agent, disopyramide phosphate.
Topics: Adrenergic beta-Antagonists; Animals; Anti-Arrhythmia Agents; Blood Pressure; Cardiomegaly; Catheter | 1972 |
Effect of right ventricular hypertrophy on infundibular pressure gradients in dogs.
Topics: Animals; Arteriovenous Fistula; Blood Pressure; Cardiomegaly; Dogs; Heart; Heart Rate; Hemodynamics; | 1965 |
Cardiomegaly after repeated application of isoprenalin in the rat.
Topics: Animals; Body Weight; Cardiomegaly; Isoproterenol; Male; Organ Size; Rats | 1965 |
Estimation of grossly detectable isoproterenol-induced myocardiopathies in rats using the ridit transformation.
Topics: Animals; Cardiomegaly; Cardiomyopathies; Female; Isoproterenol; Necrosis; Organ Size; Rats; Statisti | 1966 |
Right ventricular systolic pressure gradients in aortic valve disease.
Topics: Adult; Amyl Nitrite; Aortic Valve Insufficiency; Aortic Valve Stenosis; Blood Pressure; Blood Pressu | 1967 |
Studies on isoproterenol-induced cardiomegaly in rats.
Topics: Animals; Cardiomegaly; Female; Isoproterenol; Propranolol; Rats; Submandibular Gland | 1967 |
Reversal of electrocardiogram to normal in chronic obstructive pulmonary disease with emphysema.
Topics: Breathing Exercises; Cardiomegaly; Diet Therapy; Electrocardiography; Heart Failure; Humans; Isoprot | 1967 |
[Idiopathic myocardiopathy without obstructive or constrictive complications, well tolerated for 24 years].
Topics: Adult; Bundle-Branch Block; Cardiac Catheterization; Cardiomegaly; Cardiomyopathies; Electrocardiogr | 1967 |
Spurious heart disease in athletic children.
Topics: Adolescent; Blood Pressure; Bradycardia; Cardiac Catheterization; Cardiac Output; Cardiomegaly; Diag | 1968 |
[A chronic model of necrotic cardiopathy induced by repeated administration of isadrin to experimental animals].
Topics: Animals; Cardiomegaly; Isoproterenol; Models, Biological; Myocardial Infarction; Myocardium; Rabbits | 1967 |
An index of the contractile state of the myocardium in man.
Topics: Adolescent; Adult; Cardiac Catheterization; Cardiomegaly; Digitalis Glycosides; Dye Dilution Techniq | 1968 |
Left ventricular performance during the infusion of isoproterenol in patients with valvular heart diseases and idiopathic cardiomegaly.
Topics: Adolescent; Adult; Aortic Valve Insufficiency; Blood Pressure; Cardiac Catheterization; Cardiomegaly | 1968 |
Studies on isoproterenol-induced cardiomegaly in rats.
Topics: Amino Acids; Animals; Blood Pressure; Calcium; Carbon Isotopes; Cardiac Catheterization; Cardiomegal | 1969 |
Abnormal cardiac norepinephrine storage in isoproterenol-treated rats.
Topics: Animals; Cardiomegaly; Desoxycorticosterone; Heart; Hypertension; Hypotension; Isoproterenol; Male; | 1968 |
The growth of the muscular and collagenous parts of the rat heart in various forms of cardiomegaly.
Topics: Anemia, Hypochromic; Animals; Cardiomegaly; Collagen; Hydroxyproline; Hypertension; Hypertrophy; Hyp | 1969 |
Cardiac function following prosthetic aortic valve replacement.
Topics: Aortic Valve; Aortic Valve Insufficiency; Aortic Valve Stenosis; Blood Pressure; Cardiomegaly; Elect | 1969 |
Concomitant development of infundibular pulmonary stenosis and spontaneous closure of ventricular septal defect. An unusual variant in the natural history of ventricular septal defect.
Topics: Angiocardiography; Blood Pressure; Cardiac Catheterization; Cardiomegaly; Child; Cineangiography; El | 1969 |
Evaluation of thoracic impedance plethysmography as an indicator of stroke volume in man.
Topics: Adult; Aorta, Thoracic; Cardiac Catheterization; Cardiac Output; Cardiomegaly; Electric Conductivity | 1969 |
Effects of monoamine oxidase inhibitors on isoproterenol-induced cardiomegaly in rats.
Topics: Animals; Carbon Isotopes; Cardiomegaly; DNA; Female; Glycine; Isocarboxazid; Isoniazid; Isoprotereno | 1970 |
Cardiomegaly in rats after repeated administration of isoprenaline and thyroidin.
Topics: Age Factors; Animals; Cardiomegaly; Heart; Injections, Subcutaneous; Isoproterenol; Male; Organ Size | 1968 |
[Pharmacodynamic effect of a beta-blocking agent, trasicor, in normal subjects and in subjects with valvular cardiopathy].
Topics: 1-Propanol; Adolescent; Adult; Aortic Valve Insufficiency; Blood Pressure; Cardiomegaly; Female; Hea | 1969 |
Hemodynamic and angiocardiographic studies on cardiodynamics. Experimental mitral insufficiency.
Topics: Angiocardiography; Animals; Aorta; Blood Pressure; Cardiac Catheterization; Cardiac Output; Cardiome | 1970 |
The heart in lentiginosis.
Topics: Adolescent; Angiocardiography; Autopsy; Blood Pressure; Body Weight; Cardiac Catheterization; Cardio | 1972 |
Experimental cardiomegalies and "cardiomegalies" in free-living animals.
Topics: Animals; Birds; Body Weight; Cardiomegaly; Coronary Vessels; Fishes; Heart; Heart Diseases; Isoprote | 1969 |
[Influencing of the isoprenaline necrosis of the myocardium by ATP-Spofa administration].
Topics: Adenosine Triphosphate; Animals; Cardiomegaly; Disease Models, Animal; Female; Heart; Isoproterenol; | 1971 |
[Isoproterenol cardiomegaly and dehydroepiandosterone].
Topics: Animals; Cardiomegaly; Dehydroepiandrosterone; Estradiol; Heart; Isoproterenol; Male; Rats; Seminal | 1972 |
[Cardiac hypertrophy induced by isoproterenol (morphometric, electron-microscopic, autoradiographic, cytophotometric and biochemical findings)].
Topics: Animals; Autoradiography; Cardiomegaly; Cell Nucleus; Chromatin; DNA; Edema; Glycogen; Histocytochem | 1972 |
Congenital intraventricular trifascicular block.
Topics: Adams-Stokes Syndrome; Atropine; Bradycardia; Bundle-Branch Block; Cardiac Catheterization; Cardiome | 1973 |
Dehydroepiandrosterone-sulphate in isoproterenol cardiomegaly.
Topics: Animals; Cardiomegaly; Dehydroepiandrosterone; Heart; Isoproterenol; Kidney; Liver; Male; Organ Size | 1972 |
A suggested mechanism for Mobitz type II block based on concealed atrial reciprocation.
Topics: Adult; Arrhythmia, Sinus; Cardiomegaly; Electrocardiography; Heart Block; Humans; Injections, Intrav | 1972 |
Isoproterenol-induced cardiomegaly: assessment of myocardial protein content, actomyosin ATPase and heart rate.
Topics: Actomyosin; Adenosine Triphosphatases; Animals; Blood Pressure; Cardiomegaly; Disease Models, Animal | 1972 |
Development of left ventricular outflow obstruction in idiopathic hypertrophic subaortic stenosis. Report of a case.
Topics: Adolescent; Angiocardiography; Cardiac Catheterization; Cardiomegaly; Cardiomyopathy, Hypertrophic; | 1973 |
[Maximal contraction velocity (V max ) of the hypertrophied left ventricle in the guinea pig in Goldblatt's hypertension].
Topics: Animals; Cardiomegaly; Guinea Pigs; Heart Ventricles; Hypertension, Renal; Isoproterenol | 1972 |
[Reduction of the isoproterenol-induced 45 Ca ++ -net uptake and energy rich phosphate metabolism of the hypertrophied myocardium in the rat].
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Isotopes; Cardiomegaly; Heart; Isoproterenol; Phos | 1972 |
Response of the hypertrophied heart to stress.
Topics: Animals; Blood Flow Velocity; Blood Gas Analysis; Blood Pressure; Cardiac Output; Cardiac Volume; Ca | 1973 |
Comparative morphological study of some experimental models of myocardial hypertrophy.
Topics: Animals; Aortic Valve Stenosis; Cardiomegaly; Disease Models, Animal; Isoproterenol; Male; Mice; Myo | 1971 |
Hemodynamics in the rat with isoproterenol induced cardiac hypertrophy.
Topics: Animals; Blood Pressure; Body Temperature; Cardiac Output; Cardiomegaly; Female; Heart; Heart Rate; | 1973 |
Electrophysiological and histological abnormalities of the heart in myotonic dystrophy.
Topics: Adams-Stokes Syndrome; Adult; Biopsy; Cardiomegaly; Cell Nucleus; Electrocardiography; Heart; Heart | 1973 |
Regional myocardial blood flow in lambs with concentric right ventricular hypertrophy.
Topics: Animals; Blood Pressure; Cardiac Output; Cardiac Volume; Cardiomegaly; Coronary Circulation; Coronar | 1974 |
[Restriction of beta-adrenergic myocardial reactions (45 Ca-uptake, ATP utilization) in cardiomegaly induced by isoproterenol].
Topics: Adenosine Triphosphate; Animals; Calcium; Calcium Radioisotopes; Cardiomegaly; Isoproterenol; Myocar | 1973 |
Role of endocrine factors in the pathogenesis of cardiac hypertrophy.
Topics: Acromegaly; Animals; Body Weight; Cardiomegaly; Catecholamines; Disease Models, Animal; Growth Hormo | 1974 |
Development of modern components of the mechanism of cardiac hypertrophy.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Cardiomegaly; Cardiomyopathies; Cold Tempera | 1974 |
[Contractility and elevated catecholamine sensitivity of pressure-produced hypertrophied heart].
Topics: Animals; Aortic Coarctation; Cardiomegaly; Catecholamines; Dogs; Dose-Response Relationship, Drug; H | 1974 |
[Dosis-effect curve of isoproterenol (IP) and noradrenaline (NA) in reference to contractility of the hypertrophic heart due to pressure].
Topics: Blood Pressure; Cardiomegaly; Dose-Response Relationship, Drug; Heart; Humans; Isoproterenol; Norepi | 1974 |
Myocardial synthesis of ribonucleic acid. I. Stimulation by isoproterenol.
Topics: Animals; Cardiomegaly; Heart; Isoproterenol; Male; Myocardium; Rats; Rats, Inbred Strains; RNA | 1971 |